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Abstract 
Synthesis of indoles, biindoles, indole alkaloids, 
pyrroloindoles and benzimidazoles from aromatic nitro 
compounds and a study of the chemoselectivity in the 
Kosugi-Migita-Stille coupling 
Nurul Hoda Ansari 
 
Total syntheses of the three naturally occurring indole alkaloids alocasin A, scalaridine A and hyrtinadine 
A-B have been accomplished using three palladium catalyzed reactions, an alkyne hydrostannylation, a 
Kosugi-Migita-Stille coupling and a reductive N-heterocyclization as the key steps. A palladium 
catalyzed double reductive cyclization of 1,4-, 1,3-, and 2,3-bis(2-nitroaryl)-1,3-butadienes to afford 2,2’-
, 2,3’-, and 3,3’-biindoles, respectively, has been developed. In an attempt to synthesize indolo[2,3-b]-and 
indolo[3,2-b]-indoles from the reductive cyclizations of 1,1’-, and 1,2’-bis(2-nitroaryl)ethenes 
respectively, nonselective product formation was observed giving rise to carbon monoxide insertion 
product as the sole or the major reaction product. The reductive cyclization strategy was extended to 
achieve the expedient synthesis of three naturally occurring polybrominated biindoles; 2,2’,5,5’-
tetrabromo-3,3’-bi-1H-indole, 2,2’,6,6’-tetrabromo-3,3’-bi-1H-indole and 2,2’,5,5’,6,6’-hexabromo-3,3’-
bi-1H-indole. In addition, palladium catalyzed, carbon monoxide mediated, double reductive N-
heterocyclization of dialkenyldinitrobenzenes to the highly functionalized and highly elusive novel non-
symmetrical pyrroloindoles has been developed for the first time. The methodology presents the first 
common synthetic routes to all isomeric pyrroloindoles which are of interest in a number of applications 
in addition to their presence as a core moiety in bioactive natural products. The highly functionalized 
isomeric cyclization precursors were prepared through the use of Kosugi-Migita-Stille coupling. The 
generally mild reaction conditions offer significant improvements over the previously reported synthetic 
routes. A facile base-mediated cyclization of enamines derived from the condensation of 2-nitroanilines 
with α-branched aldehydes, in the presence of a carbon-based electrophile, to give N-alkoxy-substituted 
benzimidazoles with or without an oxygenate side chain in the 2-position has also been developed. 
Finally, the chemoselectivity of Kosugi-Migita-Stille couplings of all isomeric permuatations of 
bromphenyl- and bromonitrophenyl trifluoromethanesulfonates was examined in order to compare and 
contrast the reactivity of C-Br and C-OTf bonds under three different reaction conditions. To the best of 
our knowledge, the study presented here represents the first of its kind. 
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Chapter 1 Short syntheses of the indole alkaloids alocasin A, scalaridine A and hyrtinadine 
A-B 
1.A Introduction 
A number of bisindole alkaloids have been isolated from marine sponges and tunicates. Specific examples 
include hemacanthins,
1
 dragmacidins,
2
 topsentins (spongetins),
1c-e,3
 nortopsentins
4
 and rhopaladins.
5
 
These metabolites possess diverse bioactivities such as cytotoxic,
1f,g,2d,3a,4
 antiviral,
1g,2b,4
 antifungal,
7
 
antibacterial
7
 and antiplasmodial
8
 activities. The common feature of these alkaloids is the presence of a 
pyrazinone/imidazole or a reduced derivative linker either attached directly to the 3 positions of the two 
indoles or attached via a carbonyl carbon and/or methine. Hydroxylation in the 6 or 7 position can also be 
found in some of the metabolites. 
Alocasin A was recently isolated from the dried rhizomes of the herbaceous plant Alocasia macrorrhiza, 
collected in the People Republic of China (Fig. 1.1).
9
 This is the only heterocycle-linked bisindole 
isolated from a terrestrial source. The presence of hydroxyl groups in the two 5-positions is also unusual 
for this type of bisindoles, but can be found in hyrtinadine A isolated from the marine sponge Hyrtios 
sp.
10
 and scalaridine A and hyrtinadine B isolated from the marine sponge Scalarispongia sp.
11
 
Hyrtinadine A and scalaridine A are the only examples of pyrimidine and pyridine linked bisindole 
alkaloids respectively. The structures of these natural products are depicted in Figure 1.1. 
Figure 1.1 structures of alocasin A, scalaridine A, and hyrtinadine A-B 
 
 
The structure elucidation of alocasin A, scalaridine A and hyrtinadine A-B was achieved using 
spectroscopic techniques. 
2 
 
Total syntheses of alocasin A, scalaridine A and hyrtinadine A using cross-coupling strategy have 
recently been reported. In the syntheses of the pyrazine, pyridine and pyrimidine linked bisindoles, a one 
pot double Suzuki-Miyaura cross coupling of 1-t-butoxycarbonyl-5-methoxy-3-boryl indole with 2,5-
dibromopyrazine (alocasin A, Scheme 1.1),
12
 3,5-dibromopyridine (scalaridine A, Scheme 1.2)
13
 and 2-
iodo-5-bromopyrimidine (hyrtinadine A, Scheme 1.3)
14
 were used as the key step. In another synthesis of 
hyrtinadine A, a palladium catalyzed double cross coupling of a triindolylindium reagent and 2-chloro-4-
bromopyrimidine was used (Scheme 1.4).
15
 Synthesis of hyrtinadine B has not been reported to date. 
Scheme 1.1 Sperry’s synthesis of alocasin A 
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Scheme 1.2 Sperry’s synthesis of scalaridine A 
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Scheme 1.3 Tasch’s synthesis of hyrtinadine A 
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Scheme 1.4 Mosquera’s synthesis of scalaridine A 
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1.B Results and Discussion 
The objective of this work was to develop short and efficient synthetic routes to all the four natural 
products namely alocasin A, scalaridine A, hyrtinadine A and hyrtinadine B using a late stage palladium 
catalyzed reductive N-heterocyclization as the key indole forming step. This methodology has been 
emerging as a powerful tool for the synthesis of a wide variety of substituted indoles.
16
 A number of 
naturally occurring indole alkaloids have been synthesized including tjipanazoles,
17
 murrayaquinone,
18
 
bauerine A,
19
 carbazole alkaloids,
20
 mushroom metabolites,
21
 and the tetracyclic alkaloid ht-13-B
22
 using 
this reaction as the key indole forming step. The originally proposed plan was to use vinylstannane 4 as 
the common intermediate in the Kosugi-Migita-Stille cross coupling to assemble the reductive cyclization 
4 
 
precursors. Although the plan worked well for alocasin A, it proved problematic for the remaining three 
natural products calling for a change in the synthetic strategy. 
Alocasin A was synthesized in 6 steps from 4-benzyloxy-2-bromo-1-nitrobenzene (1) using a palladium 
catalyzed reaction in five of the steps (Scheme 1.5). The synthesis commenced with a Sonogashira 
coupling of 1 with trimethylsilylethyne followed by a tetrabutylammonium fluoride (TBAF) mediated 
deprotection affording products 2 and 3 respectively, in high isolated yields. Use of highly α-
regioselective palladium catalyzed hydrostannylation of ortho-substituted arylakynes reported by Alami 
et al
23
 gave rise to the expected vinylstannane 4 in excellent yield.
24
 Palladium catalyzed reactions of 
halopyrazines
25
 including Sonogashira,
26
 Suzuki-Miyaura,
27
 Negishi,
28
 and Kosugi-Migita-Stille
29
 cross 
couplings have been reported. A double Suzuki-Miyaura cross coupling of 2,5-dibromopyrazine (5) with 
3-borylated indoles was used to prepare 2,5-bisindolopyrazines.
14,30
 A sequential Suzuki-Miyaura and 
Kosugi-Migita-Stille cross coupling of 2,5-dibromo-3-methoxypyrazine was used in the total synthesis of 
bisindolopyrazine alkaloid dragmacidin D.
31
 In the present synthesis of alocasin A, the central pyrazine 
nucleus was installed by a one-pot double Kosugi-Migita-Stille cross coupling of vinylstannane 4 with 5 
in a relatively low isolated yield along with the dimer 7 in 40% yield resulting from the dimerization of 4. 
The two products were readily separated by chromatography on a silica gel. Cross coupling of related 
styryltin derivatives with aryl bromides and iodides have been reported.
32
   
A double palladium catalyzed reductive N-heterocyclization of 6 using a 
bis(dibenzylideneactone)palladium-1,3-bis(diphenylphosphino)propane-1,10-phenanthroline catalyst 
system in the presence of carbon monoxide (pCO=6 atm, 120 °C) in N,N-dimethylformamide, furnished 
protected dibenzyloxyalocasin A 8 in excellent isolated yield. The benzyl groups were smoothly 
reomoved by hydrogenolysis using Pd/C-H2 (10% Pd, pH2=4 atm) in ethanol at 60 °C affording the 
naturally occurring bisindolopyrazine alocasin A. Thus the synthesis of this natural product was 
completed in six steps in 21% overall yield starting from 1. The NMR, IR, HRMS, and melting point 
were compared with the literature reported data and all corroborated the originally proposed structure. It 
should be noted that all transformations from 6 to alocasin A involved reactions at two different centers 
making a total of nine connections/disconnections with an 84% average yield per step (Scheme 1.5). 
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Scheme 1.5 Synthesis of alocasin A 
 
 
Excited by the successful synthesis of alocasin A, a similar sequence of Kosugi-Migita-Stille cross 
coupling of 3,5-dibromopyridine (9) was envisioned for the synthesis of scalaridine A. While 9 has been 
utilized in cross coupling reactions with aryltin reagents,
33
 the use of vinyl tin reagents has not been 
reported. Disappointingly, all attempted cross coupling reactions of 4 with 9 using a number of 
palladium-based catalysts failed to give the desired coupling product. The only product obtained from 
these reactions was the homocoupling product 7 derived from the dimerization of 4. Low yields in 
addition to a preference for cine-substitution
34
 have been observed in palladium catalyzed cross couplings 
using 1-trimethylstannyl-1-phenylethene and 2- and 3-bromopyridines (Scheme 1.6).
35
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Scheme 1.6 Attempted cross coupling of 4 with 3,5-dibromopyridine (9) 
 
 
Thus, a slightly different strategy was pursued for the synthesis of scalaridine A where the polarity of the 
coupling partners was reversed, that is, a Kosugi-Migita-Stille coupling of heteroaryl vinylstannane with 
an aryl halide. Hydrostannation of ethyne-substituted heterocycles are relatively rare in the literature. A 
single example of a copper catalyzed, α-regioselective hydrostannation, of 2-ethynylpyridine using 
hexamethylditin was reported by Yoshida et al.
32
 A palladium catalyzed hydrostannation of an N-
protected 3-ethynylindole also gave exclusively α-stannylated product.36 In contrast, palladium catalyzed 
hydrostannation of 2-ethynylpyridine with an ionic liquid supported stannane was shown to be relatively 
unselective having an α/β-ratio of 38:62.37 
In our case, palladium catalyzed hydrostannylation of 3,5-diethynylpyridine (10) gratifyingly furnished 
11 with exclusive α-selectivity. Subsequent Kosugi-Migita-Stille coupling of 11 with 4-benzyloxy-2-
iodo-1-nitrobenzene (12) gave the expected product 13. Reductive cyclization followed by debenzylation 
afforded scalaridine A. Synthetic scalaridine A was spectroscopically and thermally identical to sample 
obtained from natural sources (
1
H NMR, 
13
C NMR, IR, HRMS, mp). Starting from 10, the overall yield 
was 13% in four synthetic transformations (Scheme 1.7). 
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Scheme 1.7 Synthesis of scalaridine A 
 
 
2,5-Dichloropyrimidine  has been shown to participate in Kosugi-Migita-Stille cross coupling reactions 
with vinylstannanes, reacting first in the 2-position then in the 5-position.
38
 However, the related 
compound 2,5-dibromopyrimidine (15) proved to be problematic substrate in cross coupling reactions. 
Attempted coupling of 4 with 15 gave three identifiable products, destannylated product 16, an 
inseparable mixture of homocoupling product 7 and an unknown impurity, and the monocoupled, 
debrominated pyrimidine 17. The site of cross coupling was determined to be the 2-position based on 
1
H 
NMR wherein  a doublet resonance at δ 8.65 ppm integrating to two protons and a triplet at δ 7.10 ppm 
integrating to one proton with a coupling constant of J=5.2 Hz was observed. Similar chemical shifts and 
coupling constants have been reported for related 2-substituted pyrimidines (Scheme 1.8).
3
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Scheme 1.8 Attemepted cross coupling of 4 with 2,5-dibromopyrimidine (15) 
 
 
Here as well the reductive cyclization precursor was prepared by Kosugi-Migita-Stille coupling by 
reversing the polarity of the coupling partners. Double Sonogashira coupling
40
 of 2,5-dibromopyrimidine 
(15) with trimethylsilylethyne gave the expected product 18, which was used for desilylation using 
potassium carbonate in methanol/diethyl ether to give 2,5-diethynylpyrimidine (19). Palladium catalyzed 
hydrostannylation of 19 afforded the divinyltin-substituted pyrimidine 20, again with excellent α-
regioselectivity. The subsequent steps, Kosugi-Migita-Stille coupling of 20 with 12, reductive N-
heterocyclization, and debenzylation proceeded eventually to give hyrtinadine A. The spectroscopic data 
(
1
H and 
13
C NMRs, HRMS) and melting point were fully consistent with those of the natural hyrtinadine 
A. The overall yield of hyrtinadine A starting from 15 was 12% in six steps (Scheme 1.9). 
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Scheme 1.9 Synthesis of hyrtinadine A 
 
 
Finally, 5-ethynylpyrimidine (23) served as the starting material for the synthesis of the fourth alkaloid 
hyrtinadine B. Following same sequence of reactions used in the synthesis of hyrtinadine A, (1) palladium 
catalyzed hydrostannylation, (2) cross coupling, (3) reductive cyclization, and (4) debenzylation gave 
hyrtinadine B in 28% overall yield in four steps. The spectroscopic data of the synthetic sample matched 
with those of the isolated compound (Scheme 1.10). 
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Scheme 1.10 Synthesis of hyrtinadine B 
 
 
1.C Conclusion 
Expedient synthetic routes to four naturally occurring indole alkaloids, alocasin A, scalaridine A and 
hyrtinadine A-B have been developed. The overall yields were 21% (six steps), 13% (four steps), 12% 
(six steps), and 28% (four steps) respectively. Three palladium catalyzed reactions, namely, an alkyne 
hydrostannylation, a Kosugi-Migita-Stille cross coupling and a reductive N-heterocyclizations are the key 
steps in the syntheses. Results from the palladium catalyzed hydrostannylations of heteroarylethynes 
indicates that an ortho-substituent is not a requirement for high α-regioselectivity when ethynyl 
substituted heterocycles are used. 
11 
 
Chapter 2 Double palladium catalyzed reductive cyclizations. Synthesis of 2,2’-, 2,3’-, and 
3,3’-bi-1H-indoles, indolo[3,2-b]indoles, and indolo[2,3-b]indoles 
2.A Introduction 
Indoles and carbazoles can be synthesized by the reductive cyclization of 2-nitrostyrenes and 2-
nitrobiphenyls using a number of reagents. Cadogan
43
 and Sundberg
44
 employed trialkyl phosphites or 
triphenylphsophine as reducing agents at elevated temperatures to carry out such transformations. More 
recently, however, reductive cyclizations using transition metal catalysts in the presence of carbon 
monoxide as the ultimate reducing agent have been developed. In fact, palladium complexes are the most 
commonly employed catalysts for effecting reductive cyclizations, and this facile method has been used 
in the total synthesis of a number of indole alkaloids.
45
 Therefore, we envisioned this methodology as an 
expedient pathway for the synthesis of a wide variety of compounds containing two indole units. Five 
different substrates in total, three bis(2-nitrophenyl)butadienes and two bis(2-nitrophenyl)ethenes were 
selected as biindole precursors (Figure 2.1). The formation of 2,2’-, 3,3’-, and 2,3’-biindoles from 1,4-, 
2,3-, and 1,3-bis(2-nitroaryl)-1,3-butadienes, respectively, was anticipated via a cyclization onto each of 
the two carbon-carbon double bonds of the butadienes (A-C, Figure 2.1). In related reactions, successful 
reductive cyclyzations of 1,2-bis(2-nitroaryl)ethenes and 1,1-bis(2-nitroaryl)ethenes onto a shared olefin 
was hypothesized to furnish indolo[3,2-b]indoles and indolo[2,3-b]indoles respectively (D-E, Figure 2.1). 
We disclose herein a short and efficient synthetic sequences to a variety of biindoles using a double 
reductive cyclization of 1,4-, 2,3-, and 1,3-bis(2-nitroaryl)-1,3-butadienes as the ultimate and key step 
leading to both the indole rings. Also disclosed are the nonselective reactions of 1,2-bis(2-
nitroaryl)ethenes and 1,1-bis(2-nitroaryl)ethenes forming a mixture of products. 
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Figure 2.1 Possible cyclizations (A-E) of bis(2-nitrophenyl)butadienes and –ethenes.  
 
 
2.B Results and Discussion 
The first biindole that was chosen for synthesis was 2,2’-bi-1H-indole (38). The cyclization precursor, 
1,4-bis(2-nitrophenyl)-1,3-butadiene (33), was prepared following the procedure of Lowinger et al
46 
via a 
Wittig reaction of 2-nitrocinnamaldehyde (31) with 2-nitrobenzyl triphenylphosphonium bromide in the 
presence of a base. To our delight, subjecting compound 33 to our standard condition of reductive N-
heterocyclization using a bis(dibenzylideneacetone)palladium-1,3-bis(diphenyl)propane-1,10-
phenanthroline catalyst symtem, in the presence of carbon monoxide (pCO=6 atm, 120 °C) in N,N’-
dimethylformamide, afforded compound 38
47
 in good isolated yield. 
A number of synthetic pathways to access 2,2’-biindoles have been reported in the literature. For instance, 
the parent compound 38 has been accessed by iridium,
48
 gold
49
 and base
50
 catalyzed cyclization of the 
13 
 
diamine corresponding to 33, Cadogan-Sunderberg type cyclizations using triphenylpshophine
51
 or 
tripheylphosphite,
52
 and double Madelung cyclization.
53
 Pertinent to the current methodology, Cenini et 
al. reported a Pd(TMB)2-TMphenanthroline
54
 catalyzed carbon monoxide (pCO=40 atm, 140 °C) 
mediated cyclization of 33 to give 38 (40%) in addition to the monocyclized product 2-(2-
nitrophenyl)indole (26%).
55
 A related reaction has also been described by Davies et al. using a palladium 
catalyzed route without any experimental details or yields.
56 
Excited by the above result, four additional substrates (34-37), in 55-75% yields, were prepared by the 
treatment of the Wittig salts (28-30) with 31 or 5-bromo-2-nitrocinnamaldehyde (32) in the presence of a 
base. 5-Bromo-2-nitrocinnamaldehyde, in turn, was obtained by the reaction of 5-bromo-2-
nitrobenzaldehyde with (formylmethyl)triphenylphosphonium chloride in the presence of 4-(N,N-
dimethylamino)pyridine (DMAP). Dienal 43 was also isolated resulting from two consecutive Wittig 
reactions in addition to 32 (Scheme 2.1). The dienes (34-37) were smoothly transformed to the 
corresponding 2,2’-bi-1H-indoles (39-42) under the same conditions. A good to excellent yield of product 
was observed for all substrates examined (Table 2.1). 
 
Table 2.1 Synthesis of 2,2’-bi-1H-indoles 
R NO2 NO2
Pd(dba)2, dppp
1,10-phen, DMF
CO (6 atm), 120 °C
1
2
PPh3Br
CHOR'
R NO2
1
2
O2N
R'1'
2'
N
H
H
N
R R'1
1'
2
2'
NaOEt
EtOH, rt
+
 
Phosphane Aldehyde Diene
a,b
 2,2’-Bi-1H-indole
a
 
27 (R=H) 31 (R’=H) 33 (R=R’=H) 38 (R=R’=H, 73%) 
28 (R=6-Cl) 31  34 (R=6-Cl, R’=H, 55%) 39 (R=4-Cl, R’=H, 94%) 
29 (R=3-OMe) 31  35 (R=3-OMe, R’=H, 64%) 40 (R=7-OMe, R’=H, 93%) 
30 (R=4-Br) 31 36 (R=4-Br, R’=H, 73%) 41 (R=6-Br, R’=H, 74%) 
30  32 (R’=5-Br) 37 (R=4-Br, R’=5-Br, 75%) 42 (R=6- Br, R’=5-Br, 71%) 
a
Isolated yield of pure product after chromatography. 
b
Mixtures of EE/ZZ isomers obtained for 35-37. 
 
Scheme 2.1 Synthesis of 5-bromo-2-nitrocinnamaldehyde (32) 
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After the successful synthesis of 2,2’-bi-1H-indoles, double cyclization of 2,3-bis(2-nitrophenyl)-1,3-
butadienes to give 3,3’-bi-1H-indoles was examined next, and the results are summarized in Table 2.2, 
Scheme 2.2, and Scheme 2.3. The parent cyclization precursor 2,3-bis(2-nitrophenyl)-1,3-butadiene (52) 
has previously been prepared using a palladium catalyzed double cross coupling of 2-nitrophenylboronic 
acid with 1,4-bis(carbonyloxy)-2-butyne.
57
 We have recently reported the formation of 7, a substituted 
analogue of 52, as a side product in Kosugi-Migita-Stille reaction of 4 with an aryl bromide.
58
 It seemed 
plausible that homocoupling of 4, and related alkenyltin reagents, would be the major reaction path in the 
absence of a cross-coupling partner. In order to examine this idea, tributyl(1-(2-nitrophenyl)tin (48) was 
prepared from 1-ethynyl-2-nitrobenzene (44) in excellent isolated yield using the regioselective palladium 
catalyzed hydrostannation developed by Alami and coworkers.
23b
 As expected, the β-isomer was not 
detected by 
1
H NMR of the crude reaction mixture. To our delight, palladium catalyzed homocoupling of 
48 proceeded smoothly in DMF to give dimer 52. Reductive cyclization of 52 resulted in the formation of 
3,3’-bi-1H-indole (56)59 as the sole product (Table 2.2). 
3,3-Biindoles are relatively rare in nature, but a handful examples of halogenated and/or sulfur containing 
alkaloids have been isolated from algae.
60-63
 In addition, the unsubstituted 3,3’-biindole 56 was isolated 
from a terrestrial fungus.
64
 Recent synthesis of 3,3’-biindoles include, for example, a Masuda indole 
borylation-Suzuki arylation sequence,
65
 a tellurium tetrachloride
66
 mediated and palladium catalyzed 
oxidative dimerizations of indoles.
67
 
To briefly examine the ease of synthesis of 3,3’-biindoles by reductive N-heterocyclization, four 
additional 1-(2-nitrophenyl)ethenyl)tin derivatives (4, 49-51) were prepared in a similar fashion to 48 
(Table 2.2). Although palladium catalyzed homocoupling of 4 gave the expected product 7 in good yield, 
the yield of chloro-substituted dimer 53 remained low and we were compelled to look for an alternative 
pathway. Homocoupling of organotin reagents have been reported using an excess of CuCl in DMF,
68
 an 
excess of Cu(NO3)2 in THF,
69
 or a catalytic amount of CuCl2 in the presence of 0.5 equivalent of iodine in 
DMF.
70
 After several trials for the preparation of reductive cyclization precursors using the literature 
conditions, a combination of 2.5 equivalent of CuCl in DMF at ambient temperature was found to work 
well for our substrates (49-51) giving excellent yields of porducts (Table 2.2). These precursors (7, 53-55) 
were successfully converted to expected 3,3’-biindoles (57-60) in 64-100% isolated yields. The results are 
summarized in Table 2.2 below. 
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Table 2.2 Synthesis of 3,3’-bi-1H-indoles 
R NO2 R NO2
SnBu3
PdCl2(PPh3)2, THF
Bu3SnH, rt
PdCl2(PPh3)2, CuI
PPh3, DMF, rt
CuCl, DMF, rt
or,
Pd(dba)2, dppp
1,10-phen, DMF
CO (6 atm), 120 °C
O2N
NO2R
R
R
N
H
H
N
R
1
2
 
Alkyne Vinyltin
a
 Diene
a
 3,3’-Bi-1H-indole
a
 
44 (R=H) 48 (95%) 52 (67%
b
) 56 (R=H, 89%) 
3 (R=5-OBn) 4 (96%) 7 (78%
b
) 57 (R=5,5’-OBn, 87%) 
45 (R=4-Cl) 49 (96%) 53 (36%
b
, 80%
c
) 58 (R=6,6’-diCl, 100%) 
46 (R=4-CO2Me) 50 (78%) 54 (92%
c
) 59 (R=6,6’-diCO2Me, 100%) 
47 (R=4-OMe)  51 (90%) 55 (98%
c
) 60 (R=6,6’-diOMe, 64%) 
a
Isolated yield of product after chromatography. 
b
PdCl2(PPh3)2 used. 
c
CuCl used. 
As an example of pyridine-linked biindole, 4,4’-diaza-3,3’-bi-1H-indole (64) was synthesized using 
hydrostannation, dimerization, cyclization sequence discussed above. Thus, 64 was prepared in three 
steps from the previously reported 2-ethynyl-3-nitropyridine (Scheme 2.2). 
 
Scheme 2.2 Synthesis of 4,4’-diaza-3,3’-bi-1H-indole (64) 
 
An unsymmetrical biindole 68 was also synthesized (Scheme 2.3). Treatment of 65 with HBr in 3-
pentanone as a solvent furnished vinyl bromide 66
71
 in 57% yield. The vinyl bromide was then subjected 
to Kosugi-Migita-Stille coupling with ethenyltin 48 to give 2,3-bis(2-nitrophenyl)-1,3-butadiene (67). Tin 
impurities from the cross coupling were removed by chromatography using a 9:1 SiO2/K2CO3 stationary 
phase as described by Harrowven et al.
72
 Double reductive cyclization smoothly converted 67 to the 
desired 3,3’-biindole in quantitative yield (Scheme 2.3).73 
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Scheme 2.3 Synthesis of unsymmetrical 3,3’-bi-1H-indole 68 
 
 
The third permutation of the double cyclization of substituted 1,3-butadienes is the synthesis of 2,3’-bi-
1H-indoles from 1,3-bis(2-nitrophenyl)-1,3-butadienes (Table 2.3). Synthesis of 2,3-bi-1H-indoles have 
previously been reported via the Fischer indole,
74
 acid mediated reaction of 3-bromoindole with indole,
75
 
and Lewis acid mediated dimerization to give 2,3-dihydro-2,3’-bisindole, followed by oxidation.76 To 
date, only four natural products containing a 2,3’-bisindole have been isolated.77 All four natural 
compounds are connected by an ethylene bridge between the 2 and 3’ carbons of the respective indoles. 
The parent cyclization precursor 71 was prepared in moderate yield by the treatment of the Wittig salt 
with 2-(2-nitrophenyl)-2-propenal (70)
78
 under basic conditions. Three additional substrates (72-74) were 
also synthesized in a similar fashion. Low to moderate yields of produtcs were isolated. Treatment of (71-
74) with carbon monoxide under palladium catalyzed conditions gave the anticipated 2,3’-bi-1H-indoles 
(75-78) in 61-72% yields. The results are summarized in Table 2.3. 
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Table 2.3 Synthesis of 2,3’-bi-1H-indoles 
R
PPh3Br
NO2 O2N
OHC
+
R NO2
NO2
R
N
H
NHNaOEt
EtOH
Pd(dba)2, dppp
1,10-phen, DMF
CO (6 atm), 120 °C
1
3
 
                                                                                                   
Phosphane Aldehyde Diene
a
   2,3’-Bi-1H-indole
a
 
27 (R=H) 70 71 (R=H, 41%) 75 (R=H, 61%) 
29 (R=3-OMe) 70 72 (R=3-OMe, 38%) 76 (R=7-OMe, 72%) 
30 (R=4-Br) 70 73 (R=4-Br, 21%) 77 (R=6-Br, 66%) 
69 (R=5-Br) 70 74 (R=5-Br, 22%) 78 (R=5-Br, 67%) 
a
Isolated yield of pure product after chromatography 
The fourth variation of the double cyclization is the cyclization of the two adjacent nitro-groups onto a 
shared olefin bond with the anticipated formation of indolo[3,2-b]indole. In this case, subjecting the 
known parent compound 1,2-bis(2-nitrophenyl)ethene (79)
79
 to the palladium catalyzed reductive 
cyclization conditions for 56 h did not furnish the double cyclization product indolo[3,2-b]indole (80)
80
 
but gave two isomeric tetracyclic compounds indolo[1,2-c]quinazolin-6(5H)-one (81) and 5,11-dihyro-
6H-indolo[3,2-c]quinoline-6-one (82). The products were analyzed by 2D NMR experiments and by 
comparison of analytical data with literature reported values. It should be noted that Nishiyama et al. have 
reported a reductive cyclization, related to the transition metal catalyzed reactions. For example, treatment 
of 79 with a catalytic amount of selenium (40 mol%) under 30 atm of carbon monoxide at 100 ˚C gave 81 
in 60% yield.
81
 In this catalytic process, carbon monoxide insertion to form an isocyanate was suggested 
as plausible intermediate that ultimately reacts with the indole N-H giving rise to the insertion product. 
Isocyanate 83 has previously been reported as an intermediate in a Curtius rearrangement of the 
corresponding acid, affording a 1:1 mixture of 81 and 82.
82
 Compound 82 was not observed in the 
selenium catalyzed reactions (Scheme 2.4). Products derived from insertion of carbon monoxide have 
been isolated in a few additional cases of transition metal catalyzed reductive cyclizations aromatic nitro 
compounds.
83
 An example is the rhodium catalyzed reductive cyclization of 84 that gave, in addition to 
indole 85 as the major product, quinolinone 86 and amine 87 (Scheme 2.5).
84
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Scheme 2.4 Reductive cyclization of 79 
 
Scheme 2.5 Reductive cyclization of 84
84
  
 
The formation of indolo[1,2-c]quinazolin-6(5H)-one encouraged us to evaluate the palladium catalyzed 
pathway of 1,2-bis(2-nitrophenyl)ethenes as a general methodology toward these compounds. Two 
additional substrates 88 and 91 were prepared by Wittig reactions of 28 and 29 with 2-nitrobenzaldehyde. 
From the reductive cyclization of chloro-substituted alkene 88, both indolo[3,2-b]indole (90) and 
indolo[1,2-c]quinazolin-6(5H)-one (89) were isolated. The former compound 90 represents the first case 
of the formation of an indolo[3,2-b]indole from a transition metal catalyzed reductive cyclization, 
although as a minor product (Scheme 2.6). In contrast, the methoxy substituted substrate 91 did not 
participate in a double cyclization as readily as 79 and 88. In this case, two monocyclized products 92 and 
93 were isolated in 10% and 74% respectively, together with a negligible amount of indolo[3,2-
c]quinolin-6-one (94) (Scheme 2.7). Monocyclized indole 93 was hypothesized to be intermediate 
precursor to the tetracyclic compound 94; however, only a miniscule amount of 94 (2%) was isolated 
from an attempted cyclization of 93 under identical reaction conditions. Although all starting material was 
consumed in the reaction, no other side products were identified (Scheme 2.7). 
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Scheme 2.6 Reductive cyclization of 88 
 
Scheme 2.7 Reductive cyclization of 91 
 
 
Finally, the feasibility of palladium catalyzed double reductive N-heterocyclization of 1,1-bis(2-
nitrophenyl)alkenes for the formation of indolo[2,3-b]indoles was also studied. The reductive cyclization 
precursor 95 was prepared by the Kosugi-Migita-Stille cross coupling of 1-iodo-2-nitrobenzene in good 
yield.
85
 As observed in the previous palladium catalyzed reactions involving tin compound 48, dimer 52 
was also isolated in low yield (11%). When subjected to palladium catalyzed reductive cyclization, 
compound 95 gave the anticipated product indolo[2,3-b]indole (96), although in a very low isolated yield 
together with the indolo[2,3-c]quinolinone (97) as the major product (Scheme 2.8). Cadogan-Sundberg 
type cyclizations of 3-(2-nitrophenyl)indoles using triphenylphosphine
86
 or triethyl phosphite
87
 to afford 
indolo[3,2-b]indoles have been reported. 
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Scheme 2.8 Synthesis of indolo[2,3-b]indole (96) and indolo[2,3-c]quinlinone (97) 
 
 
The reaction pathway seen in Scheme 2.8 represents a very short and efficient route to access indolo[2,3-
c]quinolin-6-one starting from a symmetrical substrate like 95. A number of methodologies have been 
developed for the construction of the indoloquinoline-6-one skeleton. For example, cyclizations of N-
arylindole-2-carboxamides utilizing a Heck reaction,
88
 photochemical cyclizations of indole-2-carboxylic 
acid arylamides,
89
 and 3-(2-azidophenyl)-N-phenylacrylamides,
90
 oxidative cyclizations of 3-arylindole-2-
carboxamides,
91
 and a platinum catalyzed reduction of ethyl 3-(2-nitrophenyl)-1H-indole-2-
carboxylates.
92
 
The unsymmetrical compound 99 containing a methoxy group meta to one of the nitro groups and a 
benzyloxy group para to the second nitro group was also synthesized by the Kosugi-Migita-Stille 
coupling of 4 with 98 (Scheme 2.9). Compound 99 was subjected to the cyclization conditions, and three 
different products were obtained after chromatography, an indolo[2,3-b]indole (100) and two isomeric 
indolo[2,3-c]quinolin-6-ones 101 and 102 in an approximately 1:1:1 ratio. The structures of the isomeric 
tetracycles (101-102) were elucidated using 2D NMR experiments (Scheme 2.9). It becomes clear that 
while the use of an unsymmetrical substrate will furnish two isomeric indolo[2,3-c]quinolin-6-ones, the 
methodology presented here may be of synthetic value employing symmetrical 1,1-bis(2-nitroaryl)alkenes 
as the starting materials. 
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Scheme 2.9 Reductive cyclization of 99 
 
 
2.C Conclusion 
A palladium catalyzed, carbon monoxide mediated, double reductive N-heterocyclization of 1,4-, 1,3-, 
and 2,3-bis(2-nitroaryl)-1,3-butadienes to afford 2,2’-, 2,3’-, and 3,3’-biindoles, respectively, have been 
developed. The methodology presented here clearly demonstrates potentially useful routes to access these 
ring systems. On the basis of the results in Schemes 2.4-2.8 and from the selenium catalyzed reactions 
reported in the literature, it appears that general syntheses of indolo[3,2-b]indoles and indolo[2,3-
b]indoles via a palladium catalyzed carbon monoxide mediated reductive cyclizations of 1,2-bis(2-
nitroaryl)ethenes or 1,1-bis(2-nitroaryl)ethenes, respectively are not feasible. Products derived from 
carbon monoxide insertion and/or monocyclized products are the predominant products observed in these 
reactions. 
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Chapter 3 Syntheses of three naturally occurring polybrominated 3,3’-bi-1H-indoles 
3.A Introduction 
Halogen and/ or sulfur containing 3,3’-bi-1H-indoles are relatively rare in nature. A small number of such 
indole alkaloids have been isolated mainly from marine algae and also from a terrestrial fungus. In 1982, 
Norton et al isolated 2,2’,5,5’-tetrabromo-3,3’-bi-1H-indole (103) from Rivularia firma (Fig. 3.1).109 This 
was the first alkaloid of this family to be isolated and characterized. The related isomeric alkaloid 
2,2’,6,6’-tetrabromo-3,3’-bi-1H-indole (104) was later isolated from the same species.110 More recently 
was isolated 2,2’,5,5’,6,6’-hexabromo-3,3’-bi-1H-indole (105) from the red alga Laurentia similis.111 
Compound 105 has been shown to be a protein tyrosine phospholipase 1B inhibitor.
112
 
In addition to the polyhalogenated indoles 103-105, sulfur containing alkaloids 106,
60a
 107-108,
60b
 109
60c 
also exist in the nature and they are all produced by the red alga Laurencia brongniartii. The only 
example of a 3,3’-bi-1H-indole from a terrestrial source is the parent compound isolated from the fungus 
Gliocladium catenulatum.
64
 The polyfunctionalized biindole 110 was isolated from the green alga 
Chaetomorpha basiretorsa Setchell.
63
 To the best of our knowledge, the synthesis of none of these 
polyhalogenated alkaloids has been reported to date. 
 
Figure 3.1 Naturally occurring polyhalogenated 3,3’-bi-1H-indoles 
N
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              103 (R=Br, R’=H)             106 (R=R’=SMe) 110  
              104 (R=H, R’=Br)             107 (R=SMe, R’=SOMe) 
              105 (R=R’=Br)             108 (R=R’=SOMe) 
            109 (R=Br, R’=SMe) 
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We have recently disclosed palladium catalyzed double reductive cyclization of 2,3-bis(2-nitrophenyl)-
1,3-butadienes for the synthesis of a variety of 3,3’-biindoles (Scheme 3.1).113 For instance, reductive 
cyclization of 2,3-bis(2-nitrophenyl)-1,3-butadiene (52) gave the parent 3,3’-bi-1H-indole (56) in 
excellent isolated yield. Herein are described synthetic routes to biindoles 103-105 based on this 
methodology. 
 
Scheme 3.1 Palladium catalyzed double reductive cyclization to 3,3’-biindoles 
 
                        
3.B Results and Discussion 
Biindole 120 has previously been prepared by a palladium catalyzed oxidative dimerization of 5-
bromoindole (Scheme 3.2),
67
 reductive cyclization
73
 and a two-step procedure employing a nucleophilic 
addition of 5-bromoindole to 5-bromoisatine followed by borane reduction of the intermediate (Scheme 
3.3).
114
  
 
Scheme 3.2 Palladium catalyzed oxidative dimerization of 5-bromoindole 
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Scheme 3.3 Two common routes to 16 
 
We hypothesized that comounds 103 and 104 can be derived from compound 111 by the introduction of 
extra bromine atoms. Accordingly, our synthesis commenced with the known compound 5-bromo-2-
nitro-1-iodobenzene (112) as the starting point for the synthesis of alkaloids 103 and 104. Sonogashira 
coupling of 112 with trimethylsilylethyne at ambient temperature gave 113. The silyl group was smoothly 
removed using potassium carbonate in a methanol-diethyl ether solvent system to afford 114. Treatment 
of 114 with tributyltin hydride in the presence of bis(triphenylphosphine)palladium dichloride in THF 
furnished the required vinyl tin derivative 115 with excellent α-selectivity (Scheme 3.4). No trace of the 
β-isomer was observed by 1H NMR of the crude reaction mixture.23b Tin compound 115 was smoothly 
transformed into the reductive cyclization precursor 116 using an excess of copper chloride. Once in 
hand, diene 116 was dissolved in N,N-dimethylformamide (DMF) and subjected to carbon monoxide-
mediated reductive cyclization (pCO = 6 atm, 120 °C) in the presence of a palladium catalyst system 
consisting of bis(dibenzylideneacetone)palladium - 1,3-bis(diphenyl)propane - 1,10-phenanthroline to 
give 5,5’-dibromo-3,3’-bi-1H-indole 111. The 1H NMR and 13C NMR data recorded for 111 were in 
complete accordance with the reported values. 
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Scheme 3.4 Synthesis of precursor 111 
 
 
3-Substituted indoles have been selectively brominated in the 2-position using NBS. For example, 
bromination of 3-methylindole using NBS in carbon tetrachloride (CCl4) gave 2-bromo-3-methylindole in 
97% yield.
115
 
 
Scheme 3.5 Bromination of 3-methylindole                     
 
  
 
 
 
N
H
N
H
Br
NBS, CCl4
97%
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Based on this result, biindole 111 was treated with 2.0 equivalents of NBS in CCl4 affording the naturally 
occurring tetrabrominated alkaloid 103 in 59% yield after chromatographic purification. Reactions of 111 
with 4-6 equivalents of NBS in CCl4 were not clean and afforded a number of inseparable products with 
low mass balance. However, replacing CCl4 with a 1: 1 mixture of tetrahydrofuran and dichloromethane 
as the solvent system gave 105 in 46% isolated yield upon treatment with six equivalents of NBS. All 
analytical data for 103
109
 and 105
111
 were in complete agreement with the data reported for the isolated 
natural products.  
 
Scheme 3.6 Synthesis of 2,2’,5,5’-tetrabromo- and 2,2’,5,5’,6,6’-hexabromobiindoles 
 
 
A synthetic sequence similar to the one depicted in Scheme 3.6 was used to prepare the remaining 
2,2’,6,6’-tetrabrominated alkaloid 104. 1-(4-Bromo-2-nitrophenyl)ethyne (117) served as the starting 
point for the synthesis of 104 (Scheme 3.7). Both the regioselective palladium catalyzed 
hydrostannylation of 117 furnishing vinyl tin 118 and the subsequent copper mediated coupling affording 
dimer 119 proceeded uneventfully. Reductive cyclization of 119 afforded 6,6’-dibromo-3,3’-biindole 
(120) in 64% isolated yield. Compound 120 has previously been prepared via a palladium catalyzed 
oxidative dimerization of 6-bromoindole.
67
 
Similar to the synthesis of 103, biindole 120 was treated with 2.0 equivalents of NBS in CCl4 affording 
the tetrabrominated biindole alkaloid 104 in 59% yield after chromatographic purification. All analytical 
data were in complete agreement with the data reported for isolated 104.
109
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Scheme 3.7 Synthesis of 2,2’,6,6’-tetrabromo-bi-1H-indole 
 
 
Biindole 120 was percieved to be a suitable precursor to the hexabromo substituted natural product 105. 
In the event, treatment of 120 with 5 equivalents of NBS in a THF-dichloromethane solvent mixture gave 
a separable mixture of the expected product 105 along with a significant amount of 2,2’,5,6,6’-
pentabromo-bi-1H-indole 121 (Scheme 3.8). Disappointingly, increasing the amount of NBS to eight 
equivalents gave roughly the same product ratio but in a much diminished yield (Scheme 3.8). In 
addition, an attempted bromination of the isolated pentabromobiindole 121 using three equivalents of 
NBS was unsuccessful. The starting material was recoved in high yield (94%) after chromatography. 
 
Scheme 3.8 Polybromination of 120  
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Reports for direct 2,6-dibromination and 2,5,6-tribromination of 3-substituted indoles can be found in the 
literature.  For example, 2,6-dibromination of 3-cyanomethylindole using NBS-SiO2 in dichloromethane 
gave 2,6-dibromo-3-cyanomethylindole (81%), 2,5-dibromo-3-cyanomethylindole (3%), and 2,4-
dibromo-3-cyanomethylindole (5%).
116 
3-Methylindole afforded selectively 2,6-dibromo-3-methylindole 
using NBS-SiO2 in dichloromethane
117
 and 3-phenylindole using NBS in acetic acid furnished a 6:1 ratio 
of 2,6-dibromo-3-phenylindole and 2,5-dibromo-3-phenylindole.
118
 In contrast, a 3:4 ratio of 2,6: 2,5-
dibromination was observed from brominations of methyltryptophan employing NBS in 
AcOH/HCOOH.
119
 Tribromination of 3-methylindole with bromine in acetic anhydride gave 2,5,6-
tribromo-3-methyl-N-acetylindole.
120
 Based on these previously reported brominations, polybrominations 
of the parent 3,3’-biindole 56 to give either 104 or 105, depending on the stoichiometry of the reagents, 
were also pursued. Thus, 3,3’-biindole 56 was treated with 4.0, 5.1, and 8.0 equivalents of NBS in 
THF/dichloromethane (Scheme 3.9). The brominations proved to be substantially more difficult and only 
low yields of product(s) were obtained. Using 4.0 equivalents of NBS gave a mixture of 104 and 121 both 
in 8% isolated yield. Increasing the amount of NBS to 5.1 equivalents eliminated the formation of 
biindole 104 but gave instead pentabrominated and hexabrominated compounds 121 and 105, 
respectively. Finally, treatment of 56 with 8.0 equivalents of NBS gave 105 in 16% yield. No other 
products were isolated from the three reactions of 56.  
 
Scheme 3.9 Bromination of 3,3-bi-1H-indole 56 
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3.C Conclusion 
The naturally occurring polybrominated indoles 2,2’,5,5’-tetrabromo-3,3’-bi-1H-indole, 2,2’,6,6’-
tetrabromo-3,3’-bi-1H-indole, and 2,2’,5,5’,6,6’-hexabromo-3,3’-bi-1H-indole were synthesized for the 
first time using a palladium catalyzed, carbon monoxide mediated, double N-heterocyclization of 2,3-
bis(2-nitro-4(or 5)-bromophenyl)-1,4-butadienes as the key indolization step. The synthetically derived 
compounds were in all aspects identical to the biindoles isolated from the natural sources. 
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Chapter 4 A facile base-mediated synthesis of N-alkoxy-substituted benzimidazoles 
4.A Introduction 
Benzimidazoles are a large class of heterocyclic aromatic compounds consisting of a benzene ring fused 
to imidazole. The benzo derivative of imidazole is referred to as benzimidazole. The parent compound of 
the series is commonly called benzimidazole although other name such as 1,3-benzodiazole is often used. 
Our group has reported the synthesis of a series of N-substituted 2-nitrobenzenamines. We were 
proposing to use compound 123 as a precursor to quinolines via the palladium catalyzed, carbon 
monoxide, mediated reductive N-heterocyclization. With this in mind, compound 122 was dissolved in 
dimethylsulfoxide (DMSO) and the solution was added to a suspension of sodium hydride (NaH) in 
DMSO at an ambient temperature. After stirring the mixture for 1 h, the resulting solution was cooled to 0 
o
C and methyl iodide (MeI) was added. After slowly warming to ambient temperature over 1 h, the 
reaction mixture was worked up and purified. To our surprise, the expected N-methylated product 123 
was not observed in the crude; instead 1-methoxybenzimidazole (124), 1-methoxy-2-(2-methoxy-2-
propyl)benzimidazole (125), and 1-methoxy-2-(2-hydroxy-2-propyl)benzimidazole (126) were obtained 
in 5%, 57%, and 15% yield, respectively (Scheme 4.1). Cyclization of N-phenacyl-2-nitroaniline
121 
and N-
benzyl-2-nitroanilines to give N-oxygenated benzimidazoles
122
 has been reported. 
Scheme 4.1 Formation of benzimidazoles 124-126 from enamine 122 
 
The formation of the observed products in the preceding reaction can be accounted for based on the 
methodologies developed by Gardiner et al for the formation of 2-substituted N-alkoxybenzimidazoles 
from 2-nitrobenzeneamines and organic halides in the presence of a base and by Popov and Kryshtalyuk 
for the formation of 2-substituted N-hydroxybenzimidazoles from 2-nitrobenzeneamines (Scheme 
4.2).
123,124
 N-alkoxybenzimidazles can also be prepared from N-hydroxybenzimidazoles either via a 
Williamson type ether synthesis
125
 or by a Mitsunobu reaction
126 
with an alcohol. The reaction of 122 to 
give 124-126 differs in that either a loss of or oxygenation of the side chain is observed. The formation of 
compounds 125 and 126 was particularly interesting in the sense that no synthetic routes to N-alkoxy-2-
(alkoxyalkyl)benzimidazoles or N-alkoxy-2-(hydroxyalkyl)benzimidazoles have been reported to date. 
This chapter presents detailed studies of the scope and limitation of the base mediated cyclization of 
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enamines to give N-oxygenated benzimidazoles. A plausible mechanism has also been included. N-
Oxygenated benzimidazoles have been shown to exhibit anti-protozoa
127
 and anti-HIV activities.
123d
 
Scheme 4.2 Formation of 2-ethenyl-N-propoxybenzimidazole
123f
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4.B Results and Discussion 
In the reaction above, 3 equivalents of base and 3.2 equivalents of MeI were used to give rise to products 
124-126. With the hope to control the selectivity of the reaction, we carried out a screening of the reaction 
conditions by varying the amounts of base and the electrophiles. We chose compound 127 for this 
purpose because it contains a methoxy group on the aromatic ring that may be useful to determine the 
product ratios in the crude reaction. As can be seen in table 4.1 (entries 1-3), increasing the amount of 
MeI while keeping the amount of base the same did not improve the reaction in favor of any of the 
products and the starting material was recovered in each case. Products 128 and 130 were inseparable by 
column chromatography; the approximate ratios of these products were determined by 
1
H NMR. 
Gratifyingly, a significant improvement was observed when the amount of base was increased to 2.10 
equivalents with 1.05 equivalents of MeI (table 4.1, entry 4). However, a mixture of products was 
observed upon increasing the amount of MeI while keeping the amount of base the same (table 4.1, 
entries 5-6). Finally, using 3.15 equivalents of both NaH and MeI resulted in a clean conversion of 127 to 
129 with only trace amounts of the other two benzimidazoles observed in the 
1
H NMR of the crude 
reaction mixture. Other possible solvents were also examined for the cyclization, however only a low 
yield of 129 was obtained. So, we concluded that DMF, NMP, and MeCN were not a good suit to this 
reaction. 
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Table 4.1 Condition screening   
a) Isolated yields of products after chromatography unless stated as ~%. The ~% are yields calculated 
from the 
1
H NMR spectrum of an inseparable mixture. b) The starting material was recovered in 48% 
yield. c) Trace amount of the compound was observed in the 
1
H NMR of the crude reaction mixture. d) 
The starting material was recovered in 40% yield. e) The starting material was recovered in 35% yield. 
Based on the results from table 4.1, we devised two set of reaction conditions. Experiments using 3.15 
equivalents of both NaH and MeI to afford dimethylated benzimidazoles are referred to as Conditions A 
(See Table 4.1, entry 7); reactions using 2.1 equivalents of NaH and 1.05 equivalents of MeI to give 
monomethylated benzimidazoles as the major product are referred to as Conditions B (See Table 4.1, 
entry 4). The scope and limitation of the cyclization to give N-oxygenated benzimidazoles were probed 
using fifteen different enamines in total and the results are summarized in Table 4.2. Ten of the enamines 
were previously reported and five new were prepared by condensation of the appropriately substituted 2-
nitroaniline with an aldehyde in dichloromethane or benzene in the presence of molecular sieves. 
Enamines derived from condensation of 2-nitroanilines bearing a substituent in the 4- or 5- position and 
3-methylpropanal were selected in order to evaluate the effects of electronic properties and the relative 
position of the substituent on the benzene ring in a systematic fashion without a significant steric 
 
Entry Eq. NaH Eq. MeI Solvent Alkoxybenzimidazoles
a
 
1
b
 1.05 1.05 DMSO 128
c
 -- -- 
2
d
 1.05 2.10 DMSO 128 (1%) -- 130 (34%) 
3
e
 1.05 3.17 DMSO 128 (3%) -- 130 (30%) 
4 2.10 1.05 DMSO 128 (2%) 129 tr. 130 (74%) 
5 2.10 2.10 DMSO 128 (5%) 129 (17%) 130 (56%) 
6 2.10 3.16 DMSO 128 (7%) 129 (18%) 130 (46%) 
7 3.15 3.15 DMSO 128
c
 129 (69%) 130
c
 
8 3.75 3.33 DMSO 128 (5%) 129 (64%) 130 (2%) 
9 5.0 5.0 DMSO 128
c
 129 (65%) -- 
10 3.74 3.20 DMF 128 (21%) 129 (8%) -- 
11 3.75 3.32 NMP 128
c
 129 (2(%) -- 
12 3.74 3.20 MeCN 128 (65%) 129 (13%) -- 
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contribution (Table 4.2, entries 1-25). The enamines were tested under both Conditions A and Conditions 
B and the results are summarized in Table 4.2. Although we initially considered acetonitrile and ratio of 
the reagents (Table 4.1, entry 12) to be plausible pathways for the synthesis of 2H-N-
alkoxybenzimidazoles, complex mixtures of products in inferior yields were obtained when applied to 
other enamines. 
As can be seen in Table 4.1, all substrates except 4-nitro-substituted enamine 144 furnished N-
methoxybenzimidazoles under Condition A. Enamines 127, 131, 133, and 136 containing methoxy-, 
chloro-, bromo- and fluoro-substituent respectively at the 4-position gave good to excellent yields (69-
94%) of dimethylated benzimidazoles as the sole product isolated after chromatography (Table 4.2, 
entries 1-8). In each of these reactions, an immediate color change to deep purple was observed upon 
mixing the enamine with the base in DMSO. In most cases, the purple color rapidly changed to brown or 
orange-brown within two minutes. The appearance of brown color was an indicative of a resting state of 
the reaction and no further reaction would occur until MeI had been added. For example, addition of MeI 
either after 2 minutes or 9 h of stirring at ambient temperature gave almost identical isolated yield of 
product 129 (entries 2-3). Similar color changes were observed for all substrate types although longer 
times were required in some cases before the purple color would disappear. 
Apart from the selectivity observed for the first four substrates in Table 4.2, the rest of enamines gave 
either 2H-unsubstituted N-methoxybenzimidazoles, mixtures of N-methoxybenzimidazoles, or N-
methylation of the starting material. The parent substrates 122, 138 and 153 gave rise to mixtures of three 
benzimidazoles when MeI was added at 0 °C (entries 9, 11, 24). In contrast monoalkylated 
benzimidazoles were not observed when MeI was added at ambient temperature (entries 10, 12, 15). The 
reason for this product distribution is not clear. 
Two substrates containing an electron withdrawing group at the 4-position of the aromatic ring were also 
examined (Table 4.2, entries 13-16). Reaction of ester functionalized substrate 142 gave N-methylation 
product in 62% isolated yield when MeI was added at ambient temperature. In this reaction no sign of 
benzimidazoles was observed in the crude. However, when MeI was added after mixing the reaction 
mixture for 24 h at ambient temperature, N-methoxybenzimidazole was isolated as the only product in 
good yield. No trace of a 2-substituted product was observed in the crude reaction mixture. Reaction of 
144 in a similar fashion gave N-methylated product in 85% isolated yield as the sole product. Extending 
the reaction time for the nitro analog 144 prior to addition of MeI did give neither benzimidazole, or any 
other product nor was the starting material observed in the crude reaction mixture. N-methylation was not 
limited to substrates containing electron withdrawing groups on the aromatic ring, but it was observed 
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with 5-methoxy- and 5-chloro-substituted enamines 145 and 147 when insufficient time was given before 
the mixing of MeI. 
Two additional enamines 157 and 160 were also tested. The methoxy-substituted enamine 157 behaved 
similar to 127, affording the dialkylated produt 158. In addition, a minor amount of the monoalkylated 
product 159 was isolated upon addition of MeI at ambient temperature (entry 27). Enamine 160 proved to 
be remarkably sensitive to temperature. All three N-oxygenated benzimidazoles were obtained in low 
yield at 0 °C. In contrast, only 134 was obtained when the reaction was carried out at ambient 
temperature. 
Table 4.2 Base-mediated synthesis of benzimidazoles under Condition A 
Entry 
H
N
NO2R
1
2
4
5
 
Enamine 
Condition A 
 
Alkoxybenzimidazoles
b 
 
∑ (%)c Time/Tempa 
N
N
OMe
R
 
 
% Yield 
N
N
OMe
R
OMe
 
% Yield 
N
N
OMe
R
OH
 
% Yield 
1 127(R=4-OMe) 1 h-0 °C 128
d
 129 (71)  71 
2 127 2 min-rt  129 (71)  71 
3 127 9 h-rt 128
d
 129 (69)  69 
4 131 (R=4-Cl) 1 h-0 °C  132 (86)  86 
5 131 1 h-rt  132 (94)  94 
6 133 (R=4-Br) 1 h-0 °C 134
d
 135 (78)  78 
7 133 4 min-rt 134
d
 135 (93)  93 
8 136 (R=4-F) 1 h-rt  137 (75)  75 
9 138 (R=4-Me) 1 h-0 °C 139 (28) 140 (52) 141 (5) 85 
10 138 1 h-rt 139 (27) 140 (68)  95 
11 122 (R=H) 1 h-0 °C 124 (5) 125 (57) 126 (15) 77 
12 122 1 h-rt 124 (31) 125 (34)  65 
13 142 (R=4-CO2Me) 10 min-rt
f
    - 
14 142  24 h-rt 143 (74)   74 
15 23 (R=4-NO2) 1 h-0 °C
g
    - 
16 144 24 h-rt    - 
17 145 (R=5-OMe) 1 h-rt
i
    - 
35 
 
18 145
j
 24 h-rt 146 (51)   51 
19 147 (R=5-Cl) 6 min-rt
k
 149 (9)   9 
20 147 1 h-0 °C 148 (56) 149 (27)  83 
21 147 1 h-rt 148 (52) 149 (31)  83 
22 150 (R=5-Br) 10 min-rt 151 (67) 152 (28)  95 
23 150 1 h-rt 151 (55) 152 (29)  84 
24 153 (R=5-Me) 1 h-0 °C 154 (21) 155 (22) 156 (20) 63 
25 153 10 min-rt 154 (31) 155 (26)  57 
 
H
N
NO2R  
157 (R=4-OMe)   
N
N
OMe
OMe
R  
158 
N
N
OMe
OHR
 
159 
 
26 157 1 h-0 °C 128
d
 158 (78)  78 
27 157 2 min-rt 128
d
 158 (84) 159 (11)
l
 95 
 
H
N
NO2
Ph
R  
160 (R=Br)  
 
N
N
OMe
R  
134 
 
N
N
OMe
OMe
R
Ph
 
161 
 
N
N
OMe
OHR
Ph
 
162  
28 160 1 h-0 °C 134 (22) 161 (22) 162 (13) 57 
29 160 38 min-rt 134 (92)   92 
     a. 3.15 equivalents of NaH and MeI were used. The Time/Temp is the time elapsed before addition of      
MeI and the temperature of the reaction mixture for the addition. 
   b. Isolated yields of pure products after chromatography unless stated as ~%. The ~% are yields 
calculated from 
1
H NMR spectrum of an inseparable mixture. 
c. Total yield of benzimidazoles isolated 
d. Trace amount of the compound was observed in the 
1
H NMR of the crude reaction mixture. 
e. Trace amount of 138 was observed in the 
1
H NMR spectrum. 
     f. 4-Carbomethoxy-N-methyl-N-(2-methyl-1-propen-1-yl)-2-nitroaniline, the N-methylation product of 
142 was isolated in 62% yield. 
    g. 2,4-Dinitro-N-methyl-N-(2-methyl-1-propen-1-yl)aniline, the N-methylation product from 144, was 
isolated in 85% yield. 
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h. No product or unreacted 144 was observed. 
i. 5-Methoxy-2-nitro-N-methylaniline
128
 was isolated in 55% yield. 
j. 5.0 Equivalents of NaH and 3.9 equivalents of MeI were used. 
   k. 5-Chloro-N-methyl-N-(2-methyl-1-propen-1-yl)-2-nitroaniline, the N-methylation product of 147, was 
isolated in 52% yield. 
l. Trace amount of 128 was observed in the 
1
H NMR spectrum.   
Finally, feasibility of formation of mono-alkylated benzimidazoles was evaluated next using Conditions 
B. Under this condition as well all enamines but except 4-nitro-substituted enamine 144, gave the 
expected products. In general, reactions under this condition were not as selective as the reaction of the 4-
methoxy-substituted enamine 127 to give 130 (See Table 4.1, entry 4 and Table 4.3, entry 1). However, 
cyclization to produce benzimidazoles was observed in all cases. For all enamines except 4-
carbomethoxy- and the 5-methoxy-substituted compounds 142 and 145, the reaction went on smoothly to 
give monoalkylated benzimidazoles in 45-74% yields as the major product in addition to minor amounts 
of either 2H-N-methoxybenzimidazoles (2-21%) or dimethylated benzimidazoles (15-22%). Under 
conditions B, the position and the electronic properties of the substituents on the aromatic ring had little 
effect on the product distribution. Similar to Condition A, enamines 142 and 145 gave rise to 2H-N-
methoxybenzimidazoles. 
Table 4.3 Base-mediated synthesis of bezimidazoles under Condition B  
Entry
a
 
H
N
NO2R
1
2
4
5
 
Enamine 
Alkoxybenzimidazoles
b 
 
∑ (%)c 
N
N
OMe
R
 
 
% Yield 
N
N
OMe
R
OMe
 
% Yield 
N
N
OMe
R
OH
 
% Yield 
1 122 (R=H)   126 (55)
d
 55 
2 123 (R=4-OMe) 128 (2)  130 (74) 76 
3 131 (R=4-Cl)  132 (20) 163 (59) 79 
4 133 (R=4-Br)  135 (22) 164 (68) 90 
5 136 (R=4-F)  137 (15) 165 (56) 72 
6 138 (R=4-Me) 139 (11)  141 (45) 55 
7 142 (R=4-CO2Me)
e
    - 
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8 142
f
  143 (73)   73 
9 145 (R=5-OMe)
g
    - 
10 145
f
 146 (64)   64 
11 147 (R=5-Cl)  149 (15) 166 (55) 70 
12 140 (R=5-Br)  152 (16) 167 (63) 79 
13 153 (R=5-Me)   156 (61) 61 
 
 
 
14 
H
N
NO2R  
157 (R=4-OMe)  
N
N
OMe
OMe
R
 
158 (19) 
N
N
OMe
OHR
 
159 (51) 70 
 
 
15 
H
N
NO2
Ph
R  
160 (R=4-Br) 
 
 
134 (22)  
N
N
OMe
OHR
Ph
 
162 (52) 
 
 
74 
a. Condition B: 2.1 equivalents of NaH and 1.05 equivalents of MeI. The mixture was stirred for 1 h at 
ambient temperature then cooled to 0 °C prior to addition of MeI unless otherwise stated. 
b. Isolated yields of pure products after chromatography unless otherwise stated. The % yields are 
calculated from the 
1
H NMR spectrum of an inseparable mixture. 
c. Total yield of benzimidazoles. 
d. Trace amount of 124 was observed in the 1H NMR spectrum. 
e. A nearly 3:1 mixture of 4-carbomethoxy-N-methyl-N-(2-methyl-1-propen-1-yl)-2-nitroaniline and 
142 was observed in the 
1
H NMR spectrum of the crude reaction mixture. 
f. The base substrate mixture was stirred for 24 h before addition of MeI. 
g. Neither product nor starting material was observed. 
The formation of 2H-N-alkoxybenzimidazoles in the above reactions involves a carbon-carbon bond 
fission during the reaction and a loss of three carbon unit probably in the form of acetone (see mechanism 
below). However, neither acetone nor acetophenone or cyclohexanone, the anticipated by-products from 
enamines 157 and 160 were recovered from the reactions. This is probably due to evaporative loss upon 
removal of solvents. With a hope to isolate, characterize and quantify any potential by-product derived 
from carbon-carbon bond cleavage, enamine 168 was prepared. The enamine was subjected to reaction 
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under Conditions A and a small amount of benzophenone (170) was obtained along with the expected 
product 169. Gratifyingly, when the base and the solvent system described by Gardiner et al
123b
 (t-
BuOK/t-BuOH) was used, an almost quantitative yield of benzophenone was isolated in addition to the 
product 128 in 78% yield (Scheme 4.3). 
Scheme 4.3 Formation of N-methoxybenzimidazole 169 and benzophenone 170 
 
 
A small selection of other carbon-based electrophiles including benzyl bromide, allyl bromide, propargyl 
bromide, 3-bromo-1-butyne, diiodomethane, and acetyl chloride were also employed with enamine 127. 
Moderate yields of products were obtained. The result from acetyl chloride is presented in Scheme 4.4. 
Scheme 4.4 Reaction of 127 with Acetyl Chloride 
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Table 4.4 Base-mediated synthesis of N-oxygenated benzimidazoles from enamine 127 
Entry Time/Temp
a
 Electrophile (R-X) Alkoxybenzimidazoles
b
 ∑ (%)c 
NHO2N
MeO
 
1. NaH, DMSO
2. R-X  
N NRO
MeO
 
N NRO
RO
MeO
 
N NRO
HO
MeO
 
1 1 h-0 °C Bn-Br  171 (38%) 172 (29%) 67% 
2 2 min-rt Bn-Br  171 (19%) 172 (50%) 69% 
3 1 h-0 °C Allyl bromide 173 (5%) 174 (14%) 175 (31%) 50% 
4 1 min-rt Allyl bromide  174 (59%)  59% 
5 2 min-rt CH2I2  176 (40%)  40% 
6 1 min-rt Propargyl bromide 177 (6%)  178 (47%) 53% 
7 1 h-0 °C 3-Bromo-1-butyne 179 (9%)  180 (41%) 50% 
8 2 min-rt 3-Bromo-1-butyne   180 (66%) 66% 
a. Condition A: 3.15 equivalents of NaH and R-X. The Time/Temp is the time before addition of 
electrophile (R-X) and addition temperature. 
b. Isolated yields of pure products after chromatography unless otherwise stated. The yields are 
calculated from the 
1
H NMR spectrum of an inseparable mixture. 
c. Total yield of benzimidazole(s) isolated. 
A limitation of this methodology is the use of enamines derived from condensation of alpha-branched 
aldehydes and 4- or 5-substituted-2-nitroanilines. Attempts to prepare enamines from simple and 
unbranched aliphatic aldehydes, for example propanal and hexanal, were unsuccessful. In addition, 3- and 
6-substituted 2-nitrobenzenamines did not form any enamines using the conditions described. Only 
unreacted starting materials were obtained from the reactions. 
4.C Mechanistic Discussion 
The formation of N-oxygenated benzimidazoles in the above transformations can be mechanistically 
understood as follows. Deprotonation of 122 forms anions of type 183 and 184. 1,7-Electrocyclization of 
184 will give 185 which in turn may undergo ring opening to form nitroso-imine 186. 1,5-
Electrocyclization of 186 to 187 is plausible. Aromatization of intermediate 187 would furnish 
alkoxybenzimidazole 188 by the loss of acetone or dialkoxybenzimidazole 189 via deprotonation. It is 
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unclear when the alkylation is taking place; it is possible that alkylation can occur both prior to and after 
aromatization. The proposed mechanism hints that two equivalents of a base will be required for the 
transformation of 122 to 125 and 126; one for the initial deprotonation to give 183/184 and another for 
deprotonation-aromatization of 187 to give 189. Although 2.10 equivalents of base proved optimal for the 
formation of monoalkylated products, it remained unclear why an addition equivalent of the base was 
required to maximize the yield of dialkylated products. 
 
Scheme 4.5 Proposed mechanism for the N-oxygenated benzimidazoles 124-126 
 
 
The mechanism outlined here is supported by previous studies in the literature.
129
 In the preparation of 
indazole-N-oxide from azomethine ylides, Nyerges et al proposed 1,7-electrocyclization.
130,131
 The 
authors suggested a ring-contraction with loss of formaldehyde followed by a nitroso-imine 1,5-
electrocyclization. We have reported a related palladium catalyzed reductive cyclization of 2-
nitrostyrenes in the presence of base to give oxygenated indoles.
132
 
4.D Conclusion 
We have developed a mild base mediated cyclization of enamines derived from the condensation of 2-
nitroanilines with α-branched aldehydes to give N-alkoxy-substituted benzimidazoles with or without an 
oxygenated side chain in the second position. A large number of carbon-based electrophiles can be 
employed.   
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Chapter 5 A facile base-mediated synthesis of N-alkoxy-2H-benzimidazoles   
5.A Introduction 
The methodology presented here can be viewed as a modification of the synthesis of N-alkoxy -2-
substituted benzimidazoles discussed in chapter 4. Reaction of 2-nitrobenzenamines with an electrophile 
in the presence of sodium hydride in dimethylsulfoxide or acetonitrile is not specific giving rise to a 
mixture of 2-substituted N-alkoxybenzimidazoles. The product distribution was very much dependent on 
the amount of base used. For example, treatment of enamine 127 with MeI in dimethylsulfoxide (DMSO) 
in the presence of sodium hydride (NaH) with varying amount of base gave the following products 
(Scheme 5.1).136 
 
Scheme 5.1 Reaction of enamine 127 with methyl iodide 
 
127    2.10 equiv. NaH/1.05 equiv. MeI         130 (74%)                       129 (-)                                    128 (2%) 
127    3.50 equiv. NaH/3.50 equiv. MeI         130 (-)                              129 (71%)                             128 (trace) 
 
In the course of our investigation for suitable reaction conditions, we found that the reaction can be 
tailored to give N-alkoxy-2H-benzimidazole as the sole product when enamines are allowed to react with 
potassium t-butoxide (t-BuOK) for prolonged period of time followed by the trapping of the electrophile. 
Herein we report the scope and limitations of the cyclization to give N-oxygenated benzimidazoles from 
reactions of 2-nitrobenzenamines with an array of carbon-centered electrophiles.   
5.B Results and Discussion 
Very limited number of methods have been reported for the synthesis of N-alkoxybenzimidazoles. Direct 
alkylation of N-hydroxybenzimidazole or its tautomer 1H-benzimidazole-3-oxide has been used to 
prepare N-methoxy, N-ethoxy and N-allyloxybenzimidazoles.137 Gardiner et al has previously reported the 
synthesis of N-alkoxybenzimidazoles from 2-nitroanilines and an alkyl halide.123 However, mixtures of N-
alkylated anilines and N-alkoxybenzimidazoles were observed in many cases. In addition, only one case 
of a 2H- N-alkoxybenzimidazole was reported (Scheme 5.2). 
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Scheme 5.2 Gardiner’s synthesis of N-methoxybenzimidazole 
                          
 
The objective of this work was to develop short and efficient synthetic routes to 2H-N-
alkoxybenzimidazoles from easily accessible starting materials. A detailed study on the screening of 
reaction conditions and the suitable solvents can be found in chapter 4. Our group has disclosed the 
synthesis of a variety of N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamines.134 Following the same 
procedure, we synthesized 2-nitrobenzenamines and subjected them to the reaction with t-BuOK for 24 h 
and then trapped the intermediates with the desired carbon-based electrophiles to afford 2H-N-
alkoxybenzimidazoles in good to excellent yields (Table 5.1). Four equivalents of base and longer 
reaction time were required for the completion of the reaction. Reaction of 4-carbomethoxy-N-methyl-N-
(2-methyl-1-propen-1-yl)-2-nitrobenzenamine and 2,4-dinitro-N-(2-methyl-1-propen-1-yl)benzenamine, 
however, did give neither the starting materials back nor any identifiable products for the similar reason 
discussed in the preceding chapter (chapter 4).  
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Table 5.1 Formation of N-methoxybenzimidazoles from enamines 
a) A solution of the enamine in t-BuOH was treated with t-BuOK (4 equiv.) stirred for 24 h then treated 
with MeI (3 equiv.) b) Isolated yield of pure product after chromatography on silica gel.  
 
Results from a number of other electrophiles are presented in Table 5.2 below. Of the various 
electrophiles tested, propargyl bromide and 3-bromo-1-butyne gave allenes instead of the normal 
products, albeit in low yield. Similarly, less reactive electrophiles, such as, 1-bromoheptane, 1-iodobutane 
and 2-iodopropane gave low isolated yield of the products. It should be born in mind that the pathway 
presented here represents the easiest and the cheapest route to access a wide variety of 2H-N-
Entry Enaminea Methoxybenzimidazoleb 
 
 
H
N
NO2R
1
2  
  
R
N
N
OMe  
1 127 (R=4-OMe) 128 (76%) 
2 122 (R=H) 124 (100%) 
3 138 (R=4-Me) 139 (76%) 
4 131 (R=4-Cl) 191 (92%) 
5 133 (R=4-Br) 134 (85%) 
6 136 (R=4-F) 192 (67%) 
7 142 (R=4-CO2Me) not observed 
8 144 (R=4-NO2) not observed 
9 145 (R=5-OMe) 146 (85%) 
10 153 (R=5-Me) 154 (71%) 
11 147 (R=5-Cl) 148 (71%) 
12 150 (R=5-Br) 151 (73%) 
 
 
 
 
13 
14 
H
N
Ph
NO2R  
190 (R=OMe) 
160 (R=Br) 
N
N
OMe
R
 
128 (94%) 
134 (94%) 
 
 
 
 
15 
H
N
NO2MeO  
157 
 
 
 
 
128 (76%) 
 
 
 
 
16 
H
N
NO2MeO
Ph
Ph
 
168 
 
 
 
 
128 (78%) 
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alkoxybenzimidazoles to date. Clean reaction, easy work up and isolation of compounds will make this 
methodology useful. 
 
Table 5.2 Base-mediated synthesis of N-oxygenated benzimidazoles from enamine 127 
Entry Enaminea Electrophile Benzimidazoleb 
1  
 
 
 
 
 
 
Benzyl bromide 193 (82%) 
2 Allyl bromide 194 (100%) 
3 2-Methyl-3-bromopropene 195 (90%) 
4 Propargyl bromide 196 (15%) 
5 3-Bromo-1-butyne 197 (12%) 
6 Acetyl chloride 198 (54%) 
7 1-Bromoheptane 199 (16%) 
8 1-Iodobutane 200 (15%) 
9 2-Iodopropane 201 (8%) 
a) A solution of the enamine in t-BuOH was treated with t-BuOK (4 equiv.) stirred for 24 h then treated 
with MeI (3 equiv.) b) Isolated yield of pure product after chromatography on silica gel.   
 
The formation of product can be rationalized via 1,7-electrocyclization130,131 of the azomethine ylide 
followed by ring opening. The second ring closing step leads to a relatively unstable intermediate that 
loses the side chain possibly in the form of acetone opening the door for aromatization. The N-alkoxy 
anion then abstracts the electrophile giving rise to N-alkoxybenzimidazole. A detailed mechanistic 
viewpoint has been discussed in chapter 4. We have isolated benzophenone from the reaction of 168 with 
MeI in the presence of t-BuOK / t-BuOH.136   
5.C Conclusion 
In summary, short and efficient synthetic route to a variety of 2H-N-alkoxybenzimidazoles from easily 
accessible N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamines has been developed for the first time. This 
methodology presents a useful approach to the formation of NO-C bond. Mild reaction conditions, easy 
work up and isolation of compound are additional benefits.  
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Chapter 6 Chemoselectivity in the Kosugi-Migita-Stille coupling of bromonitrophenyl 
trifluoromethanesulfonates 
6.A Introduction 
Palladium catalyzed cross coupling reactions of aromatic halides and trifluoromethanesulfonates have 
long history of use in the modern organic synthesis. The reactions have undergone extensive 
modifications over the last four decades. In this chapter will be discussed the shortcomings and recent 
development related to Stille and Echavarren’s study on the relative chemoselectivity of carbon-bromine 
(C-Br) versus carbon-trifluoromethanesulfonate (C-OTf) in the palladium catalyzed cross couplings of 
bromophenyl- and bromonitrophenyl- trifluoromethanesulfonates with ethenyltributyltin. Stille and 
Echavarren disclosed that use of additives and varying reaction conditions can dramatically alter the 
product distribution.
138
 For example, treatment of 202 with vinyltin in the presence of Pd(PPh3)4 in 
dioxane at 98 ˚C gave product derived from highly selective oxidative addition to C-Br bond whereas 
product derived from highly selective oxidative addition to C-OTf bond was obtained when the reaction 
was carried out using PdCl2(PPh3)2 and LiCl in DMF at 24 ˚C.
139,140
 In the same seminal work was 
reported the formation of products from both 4-iodophenyl trifluoromethanesulfonate and 1-bromo-4-
iodobenzene via the completely selective oxidative addition to C-I bond. After a careful consideration, 
they proposed the following reactivity order:  
1. I>Br>OTf>Cl in the presence of LiCl 
2. I>OTf>Br>Cl in the absence of LiCl 
However, the proposed reactivity order should not be taken as an absolute scale. The presence of other 
functional groups in the substrate, catalyst design and reaction conditions may greatly change the 
reactivity order where product derived from much less selective coupling site predominates. For example, 
reaction of 4-chlorophenyl trifluoromethanesulfonate with PhBu3Sn in the presence of Pd2(dba)3-Pd(t-
Bu3)2
141
 and CsF in dioxane at ambient temperature gave exclusive C-Cl coupling products.
142,143
 The 
effect of added LiCl has been attributed to Ar-Pd-OTf to Ar-Pd-Cl metathesis followed by rapid 
transmetallation and reductive elimination. Thus, use of LiCl certainly affects chemoselectivity but 
literature reports
144-149 
suggest that the magnitude of effect is related to more than one factor. An increase 
in the rate of oxidative addition cannot be the sole reason behind the change in selectivity for C-Br to C-
OTf bond with the added LiCl. To the best of our knowledge, there are no Kosugi-Migita-Stille couplings 
reported to date wherein even a fraction of C-Br or C-OTf coupling occurred on benzene ring also 
containing a C-I bond.
150
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We have reported the synthesis of a wide variety of indoles, biindoles, and the total synthesis of a number 
of indole alkaloids via the palladium catalyzed carbon monoxide mediated en route reductive N-
heteroannulation of orthonitrostyrene derivatives.
45,113
 We envisioned that chemoselective sequential 
introduction of two different alkenes to dinitrobenzenes may lead to dialkenyldinitrobenzenes that are the 
potential precursors to pyrroloindoles. We thought that the chemoselectivity reported by Stille and 
Echavarren would enable us to prepare a variety of dialkenyldinitrobenzenes that can be used for 
palladium catalyzed double reductive cyclization.  
In order to test the hypothesis, 5-bromo-2,4-dinitrophenyl trifluoromethanesulfonate (204) was prepared 
in good yield by dinitration of 3-bromophenyl trifluoromethanesulfonate (203). Treatment of 204 with 
ethenyltributyltin in DMF under Stille-Echavarren conditions discussed above that should result in C-OTf 
coupling did not give any identifiable product. To simplify possible work up and the analysis of crude 
1
H 
NMR, the solvent was changed to toluene and the reaction was carried out at ambient temperature. 
However, no appreciable reaction was observed. The reaction temperature was then raised to 80 °C 
whereby all starting material was consumed within 17 h. The 
1
H NMR of the crude reaction mixture 
revealed the presence of one site coupling product. The crude reaction mixture was purified by 
chromatography on a silica gel to afford 205 in good isolated yield. The product was identified and 
characterized by 
1
H, 
19
F and 
13
C NMRs. A very indicative quartet (J=320 Hz) in the 
13
C NMR and a 
resonance at -72.9 Hz in the 
19
F NMR confirmed the product to be 205; the expected C-OTf coupling 
product was not observed.     
Scheme 6.1 Preparation and Kosugi-Migita-Stille coupling of 204 
Br OTf Br OTf
NO2O2N
OTf
NO2O2N
Br
NO2O2N
Fum. HNO3
Conc. H2SO4, 80 °C
PdCl2(PPh3)2
PPh3, LiCl, PhMe
SnBu3, 80 °C203 204
80%
205
78%
Not observed  
 
The absence of C-OTf coupling in the above reaction is in sharp contrast to what Stille and Echavarren 
reported. The structure of compound 204 suggests that both the coupling sites have to be activated by the 
adjacent nitro groups more or less to the same extent for the oxidative addition. In addition, the steric 
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environments for both the sites seem to be more or less equal as both are followed by an ortho nitro group 
and separated by a free carbon. The absence of the C-OTf coupling under the reaction conditions known 
to be selective for C-OTf coupling became a driving force for us to consider a detailed systematic study of 
chemoselectivity in the palladium catalyzed Kosugi-Migita-Stille cross couplings of halophenyl triflates 
and halonitrophenyl triflates with ethenyltributyltin. Thus, all possible permutations of bromophenyl 
trifluoromethanesulfonates and bromonitrophenyl trifluoromethanesulfonates were synthesized although 
few additional substrate types were also pursued in order to evaluate the selectivity more accurately. To 
the best of our knowledge, the study presented in this chapter represents the first of its kind. 
6.B Results and Discussion 
All the bromophenyl trifluoromethanesulfonates and bromonitrophenyl trifluoromethanesulfonates were 
tested under the following three different conditions: 
1. Conditions A: Pd(dba)2, PPh3, 1,4-dioxane, ethenyltributyltin, reflux 
2. Conditions B: PdCl2(PPh3)2, LiCl, ethenyltributyltin, DMF, 24 °C 
3. Conditions C: PdCl2(PPh3)2, ethenyltributyltin, 1,4-dioxane, reflux 
It is worth mentioning that Conditions A are the reported conditions for C-Br coupling, Conditions B are 
the reported conditions for C-OTf coupling. Under conditions A and B, efforts were focused on 
duplicating the results reported by Stille and Echavarren. Under C-Br selective conditions, compound 202 
is reported to give a 33:1 ratio of C-Br to C-OTf bond coupling based on 
1
H NMR of the crude reaction 
mixture (Table 6.1). When the reaction was repeated, in our hands only product 206 was detected in the 
1
H NMR of the crude reaction mixture (600 MHz, Table 6.1, entry 2). The palladium catalyst, 
(Pd(PPh3)4), used by Stille and Echavarren is not very air stable; handling and storage of this catalyst 
often results into diminished catalytic activity. In our hands, a combination of 2 mol% of Pd(dba)2 and 8 
mol% of PPh3 gave the same exclusive selectivity as Pd(PPh3)4 (entry 3). So, this catalyst system 
(Pd(dba)2 and PPh3) was used as a substitute for Pd(PPh3)4 in order to minimize possible catalytic 
degredation under Conditions A. Under Conditions B, Stille and Echavarren reported exclusive C-OTf 
coupling (entry 4). In our hands, use of the same reaction conditions gave a much lower selectivity (1:6.7, 
entry 5). This product distribution is same as the one reported by Stille and Echavarren at higher 
temperature (70 °C, entry 6).
151
 It should be noted that products (206-207) are susceptible to 
decomposition/polymerization while performing chromatography on silica gel. 
In order to examine the effect of relative position of bromide and trifluoromethanesulfonate on 
chemoselectivity, isomeric compounds 2-bromophenyl- and 3-bromophenyl- trifluoromethanesulfonates 
(208 and 203) were prepared according to literature procedures. Reactions of both the isomers displayed 
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the same high selectivity for C-Br coupling under Conditions A and a similar selectivity for C-OTf 
coupling under Conditions B as was observed with compound 202. Reaction of 203 under Conditions B 
using PdCl2(dppp) has been reported.
152
 Only C-OTf coupling was reported in 25% yield although it 
remains unclear if the reported selectivity is based on crude reaction mixture or after chromatographic 
purification. 
Table 6.1 Reactions of bromophenyl trifluoromethanesulfonates with ethenytributyltin 
Entry  Conditions
a
                 Product (s) & ratio
b
 Yield
c
 
 
OTf
Br
SnBu3
 
                            202 
OTf
 
206 
Br
207  
1
d
 Pd(PPh3)4, 1,4-dioxane, reflux 33 1 77% 
2 Pd(PPh3)4, 1,4-dioxane, reflux >30 1  
3 Pd(dba)2, 4 PPh3, 1,4-dioxane, reflux >30 1 30% 
4 PdCl2(PPh3)2, 1,4-dioxane, reflux >30 1 90% 
5
d
 PdCl2(PPh3)2, LiCl, DMF, 24 °C 0 100 77% 
6 PdCl2(PPh3)2, LiCl, DMF, 24 °C 1 6.7  
7
d
 PdCl2(PPh3)2, LiCl, DMF, 70 °C 1 5 45%
e
 
8
d
 PdCl2(PPh3)2, LiCl, 1,4-dioxane, reflux 1 6 75%
e
 
 
OTf
Br
SnBu3
 
                             208 
OTf
 
209 
Br  
210  
9 Pd(dba)2, 4 PPh3, 1,4-dioxane, reflux >30 1 5% 
10 PdCl2(PPh3)2, LiCl, DMF, 24 °C 1 5.9  
 OTfBr SnBu3
 
                              203 
OTf
 
211 
Br
212 
 
11 Pd(dba)2, 4 PPh3, 1,4-dioxane, reflux 30 1
f
 34%
g
 
12 PdCl2(PPh3)2, 1,4-dioxane, reflux
h,i
 30 1 47% 
13 PdCl2(PPh3)2, LiCl, DMF, 24 °C 1 6.3
j
 K 
14
l
 PdCl2(dppp), LiCl, DMF 25 °C
m
 0 100 25% 
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a) See experimental section for details. b) Ratio of products in crude reaction mixture. c) Isolated yield of 
pure product after chromatography. d) See reference
 138
. e) Less than nearly 10% of decoupling product 
was also observed. f) A 19:30:1:6 ratio of 203/211/212:ethenytributyltin was observed in the crude 
1
H 
NMR spectrum. g) Isolated as a mixture with 203. Yield calculated from 
1
H NMR spectrum. h) A 
significant amount of 203 remained unreacted even after 72 h. i). The reaction time was 39 h.  j) A 
5.6:1:6.3 ratio of 203/211/212 was observed in the crude 
1
H NMR spectrum. K) Product 212 was not 
isolated.  l) See reference 
152
. m) The reaction time was 39 h. 
 
Chemoselectivity of substrates containing both C-Br and C-OTf bonds can be significantly affected by 
electronic effects. For example, exclusive coupling at C-OTf bond was observed in the Suzuki-Miyaura 
coupling of 202 with triethylboron.
151
 On the other hand, reaction of 202 with 4-MeC6H4SnBu3 in the 
presence of PdCl2(PPh3)2, PPh3, and CuBr in refluxing dioxane afforded C-Br coupling product 
exclusively.
139
 For Suzuki-Miyaura couplings with aryl/alkenyboronic acids, the C-Br bond generally 
undergoes selective coupling regardless of electron density of the substrate and regardless of the 
palladium based catalyst used.
143a,152-156
 For substrates containing two trifluoromethanesulfonate groups in 
Suzuki-Miyaura reactions, the cross coupling may take place either at the more electron deficient site
157 
or 
at the least hindered but more electron rich site.
158 
 Oh-e, Miyaura and Suzuki established the order of 
reactivity as I>Br>OTf for Suzuki-Miyaura couplings with 9-BBN reagent.
159
 Fu and coworkers have 
shown that the chemoselectivity could be changed depending on the ligand system and the type of the 
reaction solvents.
143
 Similarly, Sonogashira coupling of 202 and 203 with phenylethyne gave exclusive 
coupling at C-Br bond in the presence of 10 mol% of ZnCl2 at ambient temperature
160
 whereas the same 
reaction gave only C-OTf coupling product when trimethylsilylethyne was used as a coupling partner in 
the presence of CuI.
161
 Kumada coupling of 202 and a variety of ortho bromo trifluoromethanesulfonates 
with phenylethynyl magnesium bromide or phenyl magnesium bromide afforded product derived from C-
OTf coupling.
152,162
 Negishi coupling of 207 with organozinc reagents gave C-OTf coupling product in 
the presence of PdCl2(dppp)
152
, [Pd2(dba)3]-dppb
163
. In contrast, coupling of 202 with Me2Zn gave C-Br 
coupling product using Pd(OAc)2-AsPPh3 and a 3:1 ratio of C-Br to C-OTf coupling products when 
PdCl2(dppe)2 was used.
164 
 
The effects of substituents on the coupling reactions were further examined with additional substrates. All 
the possible isomeric permutations of bromonitrophenyl trifluoromethanesulfonates (213-222) were 
prepared from the corresponding phenols using literature procedures. The phenols were treated with 
trifluoromethanesulfonic anhydride in the presence of either pyridine or triethylamine.  
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Figure 6.1 Isomeric bromonitrophenyl trifluoromethanesulfonates (213-222) 
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All the above isomeric compounds were tested under the previously mentioned three reaction conditions 
for the cross coupling results with ethenyltributytin. Under Conditions A, a combination of relatively air 
stable Pd(dba)2 and PPh3, a substitute for Pd(PPh3)4 was used. The reactions were carried out in refluxing 
1,4-dioxane. This condition is known to afford product derived from highly selective oxidative addition to 
C-Br bond. Conditions B comprise of a combination of 2 mol% of PdCl2(PPh3)2 and 3 equivalents of 
LiCl. The reactions were carried out in DMF at ambient temperature. This condition as reported by Stille 
and Echavarren is known to give product derived from highly selective oxidative addition to C-OTf bond. 
Under conditions C, the reactions were carried out in the presence of 2 mol% of PdCl2(PPh3)2 in refluxing 
1,4-dioxane. Under conditions A and B, all the reactions were carried out for 24 h regardless of whether 
the starting material was consumed or left over within 24 h. Starting materials were observed in the 
1
H 
NMR of the crude reaction mixture in many cases after the allocated reaction time. Under conditions C, a 
majority of reactions were run for approximately 24 h. For details, visit the experimental section. For all 
the reactions, the ratio of products was analyzed by 
1
H NMR of the crude reaction mixtures before 
chromatographic separation. Since the objective of this study was to examine the selectivity of the 
coupling reactions (C-Br vs C-OTf), no attempts were made to optimize the yield of a product for a 
particular substrate. High selectivity was observed under both conditions A and B for 216 and 219 
wherein the bromo and the trifluromethanesulfonate groups are both ortho or meta to the nitro group. 
Similarly, enhanced selectivity for C-OTf couplings was observed for 217-220 under Condtions B when 
the bromide was meta to the nitro group. Under Conditions C, a completely different selectivity pattern 
was observed for all the substrates tested regardless of positions of the groups on the aromatic rings. 
Under this condition, all substrates gave products derived from highly selective oxidative addition to C-Br 
or C-I bond. The results are summarized in the table below. 
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Table 6.2 Cross-couplings of 213-222 with ethenyltributyltin 
Entry Substrate C-Br coupling 
product 
C-OTf coupling 
product 
Additional product(s) 
 NO2
Br
OTf  
NO2
OTf  
NO2
Br
 
NO2
 
NO2
Br
OH  
1-A
a
    213   223 (36%)     (
b
) 
1-B
c
    213 (~27%)   223 (20%)   224 (38%)    (~12%) 
1-C    213   223 (77%)    
1-D
e
    213 (75%)     
1-E
f
    213   223 (19%)   224 (49%)   225 (10%)   (11%) 
1-F
g
    213   223 (91%)    
 NO2
Br
OTf  
NO2
OTf  
NO2
Br
 
NO2
 
 
2-A    214   226 (82%)    227 (9%)  
2-B    214   226 (~9%)
h
   228 (~37%)
h
   227 (15%)  
2-C    214   226 (68%)    
2-D
i
    213   226 (68%)    227 (4%)  
 NO2
Br
TfO  
NO2
TfO  
NO2
Br
 
NO2
 
 
3-A    215   229 (68%)    230 (2%)  
3-B    215 (17%)
i
   229 (~23%)
i
   231 (36%)   230 (3%)  
3-C    215   229 (81%)    230 (3%)  
3-D
i
    215   229 (74%)    230 (2%)  
 NO2
BrTfO
 
NO2
TfO
 
NO2
Br
 
NO2
 
 
4-A    216   232 (60%)   233 (3%)   234 (30%)  
4-B    216    233 (61%)   234 (trace)  
4-C    216   232 (68%)   233 (1%)   234 (23%)  
 NO2
OTf
Br  
NO2
OTf
 
NO2
Br  
NO2
 
NO2
OH
Br  
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5-A
j
    217 (9%)   235 (24%)   236 (~5%)
k
   225 (~5%)
k
   (7%) 
5-B
l
    217 (5%)    236 (43%)    (12%) 
5-C    217   235 (66%)   236 (~4%)
k
   225 (~8%)
k
  
 NO2
Br
OTf  
NO2
OTf  
NO2
Br
 
 NO2
Br
OH  
6-A
m
    218 (7%)   237 (22%)     (7%) 
6-B
n
    218 (8%)    238 (57%)    (16%) 
6-C
o
    218   237 (94%)    
 NO2
BrTfO  
NO2
TfO  
NO2
Br  
  
7-A    219 (4%)   239 (78%)    
7-B    219    240 (66%)   
7-C    219   239 (89%)    
 NO2
Br
TfO
 
NO2
TfO
 
NO2
Br  
NO2
 
 
8-A
p
    220   241 (~41%)
q
    
8-B    220    242 (78%)   
8-C    220 (9%)   241 (67%)   242 (~3%)   230 (~8%)  
 NO2
TfO
Br  
NO2
TfO
 
NO2
Br  
NO2
 
 
9-A    221    243 (41%)    
9-B    221 (22%)    243 (23%)   244 (17%)   
9-C    221    243 (74%)   244 (~1%)   227 (~5%)  
 NO2
Br
OTf
 
NO2
OTf
 
NO2
Br  
  
10-A    222 (20%)   245 (48%)    
10-B    222 (31%)   245 (31%)   246 (7%)   
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10-C    222   245 (89%)    
 
Details of the reaction Conditions A-C 
A) Pd(dba)2 (2 mol%), PPh3 (8 mol%), 14,-dioxane, reflux 
B) PdCl2(PPh3)2 (2 mol%), LiCl (300 mol%), DMF, ambient temperature 
C) PdCl2(PPh3)2 (2 mol%), 1,4-dioxane, reflux 
a) A ratio of 1:2 was observed for 213/223 in the 
1
H NMR of the crude reaction mixture. b) Isolated as a 
mixture with unknown impurities. c) A ratio of 1.14:1:1.93 was observed for 213/223/224 in the 
1
H NMR 
of the crude reaction mixture. d) A mixture of 213 and 2-bromo-3-nitrophenol was obtained from the 
1
H 
NMR of the mixture. e) PdCl2(dppp)2 (2 mol%), LiCl (300 mol%), DMF, ambient temperature used for 
the reaction. f) PdCl2(dppp)2 (2 mol%), DMF, ambient temperature was used for the reaction. g) 
Pd(PPh3)4 (2 mol%), toluene, reflux condition used for the reaction. h) An inseparable mixture of 226 and 
228 was obtained; yield calculated from 
1
H NMR of the crude reaction mixture. i) An inseparable mixture 
of 215 and 229 was obtained; yield calculated from the 
1
H NMR of the crude reaction mixture. j) A ratio 
of 3.22:3.55:1.10:1 was observed for 217/235/236/225 in the crude reaction mixture. k) An inseparable 
mixture of 225 and 236 was obtained; yield calculated from 
1
H NMR of the crude reaction mixture. l) A 
ratio of 1:6.67 for compounds 217/236 was observed by 
1
H NMR of the crude reaction mixture. m) A 
ratio of 1:2.58 for compounds 218/237 was observed by 
1
H NMR of the crude reaction mixture. n) A ratio 
of 1:5 for compounds 218/239 was observed by 
1
H NMR of the crude reaction mixture. o) Reaction time 
36 h. p) A ratio of 1:2.2 was observed for mopounds 220/241 by the 
1
H NMR of the crude reaction 
mixture. q) Calculated from a mixture of 241 and dibenzylideneacetone. 
 
Hayashi and Kamikawa have demonstrated that chemoselectivity of oxidative addition to C-Br vs C-OTf 
bond can be modulated by proper choice of ligands.
165
 Jutand and Mosleh have shown that a faster 
oxidative addition to C-OTf bond generally predominates when the OTf group sits para to an electron 
withdrawing group such as, a nitro group.
166
 4-Cyanobromobenzene has been reported to be 326 times 
more reactive than the bromobenzene.
167
 Stille couplings of usually unreactive aryl fluorides have also 
been reported.
168,169
 
 
The chemoselectivity of C-I vs C-OTf bond was evaluated under all the three different conditions (A, B 
and C). The trifluoromethanesulfonate group was placed at an activated site. The results are outlined in 
the scheme below. In general, iodides are known to undergo coupling much faster than the OTf group 
even in the presence of LiCl. Reaction of 3-bromo-4-iodo-1-methoxybenzene with an alkenyltin reagent 
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to give C-I coupling product had been reported although C-I is positioned at an electronically unfavorable 
site.
170 
 
Scheme 6.2 Kosugi-Migita-Stille coupling of 247 with ethenyltributyltin 
OTf
I
NO2
SnBu3
 
 
OTf
NO2
 
 
OH
NO2
 
 
NO2
 
 
I
NO2
 
 
OH
I
NO2
 
 
  247 Conditions A    241 (38%)    248 (14%)    230 (5%)   
  247 Conditions B    241 (50%)      249 (4%)     (11%) 
  247 Conditions C    241 (87%)     230 (8%)   
 
 
Reaction of 5-bromo-2-trifloxybenzaldehyde has been shown to give C-OTf coupling product when the 
reaction is carried out with Pd2(dba)3 and chiral ferrocenyldiphosphine in DMF at 80 °C without added 
LiCl. Only a very limited number of palladium catalyzed coupling reactions of bromophenyl 
trifluoromethanesulfonates containing an electron donating group has been reported.
139,171
   
Compound 250 was selected to minimize the possible steric interactions between the Br/OTf and the 
methoxy groups. Based on electronic considerations, the trifluoromethanesulfonate group may be 
expected to show less selectivity while the bromide in the less electron rich position should be more 
selective. This compound was also tested under all the three reaction conditions. The results are 
summarized in the scheme below. The reaction of 250 did not reach completion under Conditions C even 
with an excess of ethenyltributytin. 
 
Scheme 6.3 Kosugi-Migita-Stille coupling of 250 
OTf
MeO
Br
SnBu3
 
OTf
MeO
 
MeO
Br
 
        250 Conditions A           251 (33%)  
        250 Conditions B         251 (4%)          252 (39%) 
 
 
As a final test substrate, compound 253 was chosen. The purpose here was to examine if the 
generalization of chemoselectivity may be extended to other electron withdrawing groups. Under all the 
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three reaction conditions, only one cross coupling product was observed in the 
1
H NMR spectrum of the 
crude reaction mixtures.  
 
 
 
Scheme 6.4 Kosugi-Migita-Stille coupling of 253 
OTf
Br
SnBu3
O
 
OTf
O
 
Br
O
 
253 Conditions A 254 (14%)  
253 Conditions B  255 (58%) 
252 Conditions C 254 (57%)  
 
 
6.C Conclusion  
The chemoselectivity of Kosugi-Migita-Stille couplings of all isomeric permuatations of bromphenyl 
trifluoromethanesulfonates and bromonitrophenyl trifluoromethanesulfonates was examined in order to 
compare and contrast the reactivity of C-Br and C-OTf bonds under three different reaction conditions. 
Under all conditions, discrepancies were observed from the literature reported results. High selectivity 
was observed only for few of the compounds under both the reaction conditions (A and B). Enhanced 
selectivity for carbon-triflate bond was observed under conditions B only for some of the compounds. All 
substrates tested under conditions C showed very high selectivity for carbon-bromine bond coupling 
regardless of the type of functional groups and their positions on the aromatic rings. Although some 
generalizations can be made for some of the isomeric and potentially useful compounds, it is worth not to 
extend them to compounds having additional functional groups and/or more sterically demanding 
functionalities. 
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Chapter 7 Synthesis of pyrroloindoles via a double reductive N-heterocyclization 
 
7.A Introduction 
There are five isomeric pyrroloindoles. For simplicity, they have been grouped into five types (types A-E, 
Figure 7.1). The structures of these compounds remind of the notion that chemistry is indeed a creative 
science. Another interesting fact about these compounds is that they form a good basis for separate NMR 
studies. For example, the 
1
H and 
13
C NMRs of pyrroloindoles (of types A, C and D) look similar. Unless 
one knows the identity of the starting material, it is hard to tell what pyrroloindoles have been 
synthesized. In addition to their wide range of possible applications, the pyrroloindole skeleton can be 
found in natural products. Pyrroloindoles have been shown to possess bactericidal, antimicrobial, and 
antitumor activities.
193
 Among other representative examples of pyrroloindole containing natural products 
include terreusinone A,
194,195
 and indolo[3,2-b]carbazole.
196-198
 Terreusinone A possesses significant UV-
A protecting properties.
195
 
 
Figure 7.1 Isomeric pyrroloindoles 
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There are several methods reported to access these isomeric compounds. They can be broadly classified 
into two categories. One route consists of fusing a pyrrole ring onto a preformed indole
 
or indoline ring,
 
and the other route is the direct double ring closure of the precursors without a preformed indole or 
indoline. Examples of the first methodology includes a Fischer indole synthesis
199
 intramolecular 
cyclization of a bis-(β-aminoethyl)-hydroquinone derivative in presence of water.200 The second general 
methodology includes a double Reissert indole synthesis
201,202
 and a double Batcho-Leimgruber
203
  
Shannon et al. prepared pyrrolo[3,2-f]- and –[2,3-f]-indoles through the Montmorillonite K-10 clay 
catalyzed Vilsmeier formylation of pyrrole.
204 
 
Scheme 7.1 Vilsmeier formylation route to pyrroloindoles 
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Samsoniya et al. reported numerous methods to prepare pyrroloindoles.
205,206
 The first method utilized a 
Fischer-type bicyclization of bishydrazone to form the two pyrrole rings (Scheme 7.2). An inherent 
drawback of this methodology was the formation of four isomers.  
 
Scheme 7.2 Samsoniya et al synthesis of pyrroloindoles 
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Although the second methodology by Samsoniya et al attempted to circumvent the previously reported 
issue of isomer formation by using a pre-formed aminoindoline, two non-substituted pyrroloindoles were 
obtained only at the expense of additional steps.  
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Scheme 7.3 Preparation of pyrroloindoles from Aminoindoline 
N
Ac
N
H
N
CO2Et
N
Ac
N
H
CO2Et
N
Ac NH
CO2Et
N
H
N
H
N
H NH
EEPPA
 
  
While the palladium-catalyzed aerobic oxidative bicyclization route to the preparation of pyrroloindoles 
from N-aryl imines reported by Yoshikai et al
207
 seemed to have broader substrate scope, the authors did 
not attempt to prepare non-symmetrical compounds. The yields of products were modest at best and the 
regioselectivities observed in the cyclizations were also not explained. 
 
Scheme 7.4 Preparation of pyrroloindoles from Diimines  
N Ph
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Fujii and Ohno reported a copper-catalyzed bis-cyclization of di-alkynyl-dimesylamide (Scheme 7.5).
208 
This approach was limited to terminal alkynes, affording only non-substituted pyrroloindoles.  
A related rhodium catalyzed hydroamination of di-alkynyl-diamines and di-alkynyl-acetylamide have 
been used to prepare type B-and C benzoindoles.
209
 2-Substituted pyrroloindoles cannot be made by this 
methodology.  
 
Scheme 7.5 Intramolecular Hydroamination route to pyrroloindoles   
NHMsMsHN NMs
N
Ms
CuI, Et3N
Dioxane, 110 °C
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One serious limitation of the previously reported synthetic routes is that they allow only for the 
preparation of symmetrical pyrroloindoles. This is in part due to limitations associated with the methods 
used to prepare the required starting materials, most of which also involve symmetrical compounds. 
Therefore, methods to prepare non-symmetrical substrates that can be converted to non-symmetrical 
pyrroloindoles are highly desirable. 
Over the last twenty years, our group has extensively studied applications of palladium catalyzed carbon 
monoxide mediated reductive cyclizations. This versatile methodology has been used to prepare a wide 
variety of indoles, bi-1H-indoles and indole alkaloids.
45,113 
We envisioned that this methodology could be 
applied in the synthesis of benzoindoles from dialkenyldinitrobenzenes. The relatively mild conditions 
used in such reactions could allow for broad functional group compatibility and offer significant 
improvements over the previously disclosed methods. With the goal of preparing non-symmetrical 
pyrroloindoles using the reductive cyclization methodology, efforts were made to establish routes to 
prepare the requisite dialkenyldinitrobenzenes. Specifically, efforts were focused on synthesizing non-
symmetrical cyclization precursors in a controlled, sequential manner. For organizational clarity, each 
isomeric substrate is presented separately, although numerous commonalities were encountered in the 
preparation of each substrate. The synthetic strategy is presented below. 
 
Scheme 7.6 Possible routes to pyrroloindoles 
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Accordingly, we hypothesized that pyrroloindole of type A could be obtained by reductive cyclization of 
1,4-dialkenyl-2,3-dinitrobenzenes which, in turn, could be derived by Kosugi-Migita-Stille coupling with 
the appropriate tin reagents. A similar strategy was envisioned for the synthesis of the other pyrroloindole 
types. 
7.B Results and Discussion  
Compound 285 was chosen as a test substrate. Compound 285 was synthesized by a double Kosugi-
Migita-Stille coupling of 1,4-dibromo-2,3-dinitrobenzene with vinyltin 282. Treatment of 285 under our 
standard conditions for reductive cyclization (Pd(dba)2, dppp, 1,10-phen, CO (6 atm), DMF, 120 °C) 
afforded the expected product 336 in 23% isolated yield. The monocyclized product 337 was not 
observed. The problem, however, was the low yield of product. We hypothesized that the low yield 
(Table 7.1, entry 1) might be a result of the catalyst inactivity after prolonged period of reaction and is 
probably a call for the reevaluation of the catalytic systems. This catalyst was replaced with a robust 
catalyst system (Pd(OAc)2, dppp, 1,10-phen) which improved the yield, but this was again not very 
satisfactory (Table 7.1, entry 2). Although a combination of Pd(dba)2 and PPh3 did improve the yield 
tremendously (64%, entry 3), the best result (70%, entry 6), was obtained with the combination of the 
very simple catalyst (Pd(OAc)2, 1,10-phen). Notice that entries 4 and 5 are conditions leading to 
monocyclized product 337 although a minor amount of pyrroloindole was also isolated (9%, entry 5).  
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Table 7.1 Condition screening 
 
            285 
 
  
  
Entry 
             Conditions  
Time 
(h) 
        336 
  % Yield 
       337 
  % Yield 
 ∑ (%) 
1. Pd(dba)2, dppp, 1,10-phen 89 23 - 23 
2. Pd(OAc)2, dppp, 1,10-phen 100 35 - 35 
3. Pd(dba)2, PPh3 126 64 - 64 
4. Pd(OAc)2, PPh3 126 - 54 54 
5. Pd(OAc)2, dppp 36 9 49 58 
6. Pd(OAc)2, 1,10-phen 48 41 - 48 
7. Pd(OAc)2, 1,10-phen 90 70 - 70 
 
In order to validate the result presented in Table 7.1, we commenced to synthesize symmetrical as well as 
unsymmetrical cyclization precursors. Most of the cross-coupling precursors were novel and they were 
prepared as described below. All other starting materials were commercially available or prepared 
according to literature procedures. For the 1H,8H-pyrrolo[3,2-g]indole (Type A) precursors, 4-bromo-2,3-
dinitrophenol (257) and 4-bromo-2,3-dinitrophenyltriflate (258) were prepared from 1,4-dibromo-2,3-
dinitrobenzene (256)
210
 by a sequential nucleophilic aromatic substitution using an excess of sodium 
hydroxide in a water-THF mixture and triflation (Scheme 7.7).  
 
Scheme 7.7 Preparation of 258 
BrBr
O2N NO2
OHBr
O2N NO2
OTfBr
O2N NO2
NaOH, 80 °C
H2O, THF
TF2O, Pyridine
CH2Cl2
256 257
94%
258
82%  
  
4-Bromo-2,3-dinitrophenol (257) can alternatively be obtained from nitration of 4-bromo-3-nitrophenol 
(259). In addition to 257, the isomeric nitration product 4-bromo-2,5-dinitrophenol (262) was also 
obtained. The latter is a plausible precursor to Type C pyrroloindoles. The isomers were readily separated 
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and transformed into the corresponding triflates 258, and 265, respectively (Scheme 7.8).  In a similar 
fashion, nitration of 4-iodo-3-nitrophenol (260)
211
 gave rise to two readily separable products, 4-iodo-2,5-
dinitrophenol (263) and 4-iodo-2,3-dinitrophenol (261), and after triflation the corresponding triflates 266 
and 264 respectively. 
 
Scheme 7.8 Synthesis of bromo- and iodo-phenyl trifluoromethanesulfonates 
HO XHO
O2N NO2
TF2O, Pyridine
CH2Cl2
X
NO2
XHO
NO2
O2N
+ XTfO
O2N NO2
XTfO
NO2
O2N
HNO3
 
       259 (X=Br)            257 (51%)       262 (37%) 258 (82%) 265 (80%) 
       260 (X=I)           261 (50%)       263 (30%) 264 (92%) 266 (80%) 
A selective oxidative iodination of 2,5-dinitrophenol (267)
212
 using potassium iodide and 
benzyltriphenylphosphonium peroxymonosulfate to give 263 has been reported. However, we were 
unable to repeat the reported result using this procedure. Iodination of deactivated aromatic compounds 
using N-iodosuccinimide (NIS) in trifluoromethanesulfonic acid has been reported by Olah et al.
213
 In a 
slight modification of this procedure, treatment of 267 with NIS in sulfuric acid afforded the desired 4-
iodo-2,5-dinitrophenol (263) in moderate yield (Scheme 7.9). 
 
Scheme 7.9 Iodination of 2,5-dinitrophenol (267).  
O2N OH
NO2
O2N OH
NO2I
NIS, H2SO4
0-60 °C
267 263 (57%)  
 
Nitration of 5-iodo-2-nitrophenol (269)
214
 with sodium nitrate in sulfuric acid afforded 5-iodo-2,4-
dinitrophenol (274)
215
 as the major product along with the novel nitration product 3-iodo-2,4-
dinitrophenol (275) as an inseparable mixture by chromatography (Scheme 7.10).  Since the products 
were inseparable, they were treated with triflic anhydride to give the readily separated triflates 276 and 
277. The same results were obtained using 5-bromo-2-nitrophenol (268) affording an inseparable mixture 
of dinitrobromophenols 270 and 271 and the readily separable corresponding triflates 204 and 273 
(Scheme 7.10). 
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Scheme 7.10 Synthesis of bromo- and iodo-phenyl trifluoromethanesulfonates 
HO X HO X
NO2O2NO2N
HO X
O2N
NO2
+
TfO X
NO2O2N
TfO X
O2N
NO2
NaNO3, H2SO4
0 °C
Tf2O, Et3N
CH2Cl2
 
       268 (X=Br)                          270 + 271 (99%) 204 (57%) 273 (16%) 
       269 (X=I)                          274 + 275 (99%) 276 (62%) 277 (28%) 
Finally, the elusive Kosugi-Migita-Stille coupling precursor, 2-bromo-3,6-dintrophenyl 
trifluoromethanesulfonate (281) was prepared in the same fashion as discussed above for compounds 204 
and 273. A minor amount of the undesired product 280 was also obtained from the nitration reaction 
(Scheme 7.11). 
 
Scheme 7.11 Synthesis of 281 
NO2
BrHO
NO2
BrHO
O2N NO2
BrTfO
O2NNO2
BrHO
NaNO3
H2SO4
0 °C-rt
+
279, Tf2O, Et3N
CH2Cl2, 0 °C-rt
278 279 (61%) 280 (10%) 281 (91%)
NO2
 
 
7.C Synthesis of pyrroloindole (Type A-E) precursors 
The Kosugi-Migita-Stille cross coupling was used to introduce the required alkenes onto the benzene 
ring. Some of the advantages of this type of coupling reaction include the vast array of alkenyltins already 
reported in the literature, their ease of preparation either from Grignard reagents or hydrostannation of 
alkynes and their stability relative to alternative reagents. Variation of the alkenyl tin used in either 
coupling step would allow for preparation of a number of structurally diverse pyrroloindoles. A double 
Kosugi-Migita-Stille cross-coupling was used for the synthesis of symmetrical cyclization precursors 
using 1,4-dibromo-2,3-dinitrobenzene (256), 1,5-dibromo-2,4-dinitrobenzene (288),
209
 4-iodo-2,5-
dinitrophenyl triflate (266) or 4-bromo-2,5-dinitrophenyl triflate (265), 5-bromo-2,4-dinitrophenyl triflate 
(204), 5-iodo-2,4-dinitrophenyl triflate (276), 3-bromo-2,6-dinitrophenyl triflate (273), and 2-bromo-3,6-
dinitrophenyl triflate (281).  
Thus, ethenyl (282), 1-propen-1-yl (283), and 1-propen-2-yl (284) tributyltin were treated with the 
appropriate substrate in the presence of PdCl2(PPh3)2 and/or PPh3 in 1,4-dioxane at 90-100 
o
C and the 
results are summarized in Table 7.2.  
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Table 7.2 Synthesis of cyclization precursor by double Kosugi-Migita-Stille coupling 
Entry Aryl-Br/OTf Tin reagent Product 
 
Br Br
NO2O2N  
R
SnBu3
R'  NO2O2N
RR
R'R'
 
1 256 282 (R=R’=H) 285 (R=R’=H, 67%) 
2 256 283 (R=H, R’=Me) 286 (R=H, R’=Me, 85%) 
3 256 284 (R=Me, R’=H) 287 (R=Me, R’=H, 70%) 
 
O2N NO2
BrBr
 
 RR
R'R'
NO2O2N  
4 288 282 289 (R=R’=H, 73%) 
5 288 283 290 (R=H, R’=Me, 93%) 
6 288 284 291 (R=Me, R’=H, 87%) 
 
NO2
IO2N
TfO  
 R
R'
NO2
R
R'
O2N
 
7 266 282 292 (R=R’=H, 60%) 
8 266 283 293 (R=H, R’=Me, 52%) 
9 266 284 294 (R=Me, R’=H, 54%) 
 
TfO Br
NO2O2N
 
 
NO2O2N
RR' R R'  
10 288 282 295 (R=R’=H, 34%) 
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11 288 283 296 (R=H, R’=Me, 48%) 
12 288 284 297 (R=Me, R’=H, 47%) 
 
TfO NO2
BrO2N
 
 
NO2
O2N
 
13 273 282 298 (R=R’=H, 32%) 
 
It was anticipated that the chemoselectivity between bromides and triflates (discussed in chapter 6) could 
be used to our advantage for the introduction of two different alkenes onto an aromatic ring. However, 
cross coupling of 258 proved to be relatively unselective under the two conditions established by 
Echavarren and Stille and under some additional conditions examined (Scheme 7.12). Inseparable 
mixtures of di- and C-OTf coupled products and C-Br coupled product and starting material in addition to 
unknown impurities were obtained in each case. Compound 258 was not further examined as a possible 
starting material to unsymmetrically substituted precursors for pyrroloindole type A. 
 
Scheme 7.12 Attempted selective Kosugi-Migita-Stille coupling of 258 
SnBu3
O2N NO2
OTfBr
PdCl2(PPh3)2
PPh3, BHT
Dioxane, 100 °C
O2N NO2 O2N NO2
Br
O2N NO2
TfO +
O2N NO2
OTfBr+
258 285 299 300 258282
A selective introduction of one alkene was, however, feasible using iodo- and bromo-triflates and limited 
amounts of alkenyl tin reagent (Table 7.3). Attempted coupling at the triflate using an excess of lithium 
chloride resulted in an OTf–chloride exchange (Scheme 7.13, 7.14). Thus, all reactions were performed in 
the absence of LiCl.  
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Table 7.3 Selective cross coupling of bromo- and iodo-phenyl triflates. 
Entry Aryl-Br/I/Cl/OTf Tin reagent Products 
     
1 264 282 300 (65%) 285 (2%) 
     
2 264 283 301 (64%)  
     
3 264 284 302 (64%) 287 (2%) 
     
4 264  303 (50%)  
 
I OTf
NO2O2N   
OTf
NO2O2N   
5 276 282 205 (35%)  
 
Br OTf
NO2O2N   
OTf
NO2O2N  NO2O2N  
6 204 283 305 (75%) 290 (12%) 
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I OTf
NO2O2N   
OTf
NO2O2N  NO2O2N  
7 276 284 306 (51%) 291 (6%) 
     
8 266 282 307 (76%) 292 (4%) 
     
9 266 283 308 (70%) 293 (7%) 
     
10 281 282 309 (35%) 295 (10%) 
     
11 281 283 310 (45%) 296 (6%) 
     
12 281 284 311 (51%) 297 (3%) 
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13 273 282 312 (42%)  
   
NO2
OTfO2N   
 273 284 313 (45%)  
 
The second alkene was thought to be readily introduced by an aryl triflate – organotin cross coupling 
using the conditions described by Echavarren and Stille (PdCl2(PPh3)2, LiCl, DMF, RT). However 
attempted coupling of 300 and 307 resulted only in a replacement of the triflate with a chlorine to give 
314 and 315, respectively (Schemes 7.13-7.14). Cross coupling of the chlorine was not feasible at 
ambient temperature but 317 underwent coupling at elevated temperature to give 316 in excellent isolated 
yield after chromatography. The triflate to chloride transformation could readily be avoided by either 
excluding lithium chloride at ambient temperatures or perform the reaction at elevated temperatures in the 
presence of lithium chloride. The results from the second Kosugi-Migita-Stille coupling of phenyl triflates 
are summarized in the following table (Table 7.13). 
 
 
Scheme 7.13 Problem in Kosugi-Migita-Stille coupling 
OTf
O2N NO2
PdCl2(PPh3)2, LiCl
BHT, DMF, rt
SnBu3
284
Cl
O2N NO2
300 314 (63%)
 
 
Scheme 7.14 Synthesis and attempted Kosugi-Migita-Stille coupling of 315 
OTf
O2N PdCl2(PPh3)2, LiCl
BHT, DMF, rt
SnBu3
284
Cl
O2N
307 315 (53%)
NO2 NO2
PdCl2(PPh3)2, PPh3
BHT, Dioxane, 100 °C
SnBu3
284
O2N
316 (79%)
NO2
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Table 7.4 Synthesis of unsymmetrical cyclization precursors 
Entry Aryl-Br/I/Cl/OTf Tin reagent Product 
 
1 
 
300 
 
283 
 
317 (66%) 
 
2 
 
300 
 
284 
 
318 (64%) 
 
3 
 
302 
 
283 
 
319 (45%) 
 
 
 
4 
 
300 
 
 
 
320 (51%) 
 
 
5 
 
301  
 
321 (51%) 
 
6 
 
303 
 
283 
 
321 (43%) 
70 
 
 
 
7 
 
302  
 
322 (55%) 
 
 
8 
OTf
O2N NO2  
205 284 
O2N NO2  
323 (64%) 
 
 
9 
OTf
O2N NO2  
305 284 
O2N NO2  
324 (73%) 
10 
O2N
NO2
OTf  
307 283 
NO2
O2N  
325 (64%) 
11 
O2N
NO2
OTf  
308 284 
NO2
O2N
 
326 (65%) 
12 
NO2O2N
OTf  
309 283 
NO2O2N
 
327 (63%) 
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13 
NO2O2N
OTf  
309 284 
NO2O2N
 
328 (64%) 
14 
NO2O2N
OTf
 
311 283 
NO2O2N
 
329 (50%) 
15 
O2N
TfO NO2  
313 282 
O2N
NO2  
330 (45%) 
16 
O2N
TfO NO2  
312 284 
O2N
NO2
 
331 (27%) 
 
The route to Type E pyrroloindoles involved the separation of isomeric nitration product affording the 
precursor in moderate to low yield. Thus, a second route to the precursors was pursued. Aniline 332
216 
was converted to aryl iodide 333 via reaction of the corresponding diazonium salt with potassium iodide 
(Scheme 7.15). Employing Mundla’s methodology217 condensation of 333 with para-formaldehyde in the 
presence of a catalytic amount of potassium hydroxide afforded alcohol 334. Conversion of alcohol 334 
to the corresponding mesylate, which was not isolated, followed by subsequent elimination afforded 
dinitrostyrene 330. Kosugi-Migita-Stille coupling between iodide 335 and 284 gave the expected 
substrate 330. Unfortunately, all attempts to broaden the scope of Mundla’s methodology substituting 
para-formaldehyde with other aldehydes, for example hexanal, were unsuccessful. 
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Scheme 7.15 Alternative route to 330 
 
 332 333 (86%)  334 (72%)  
 
 
  335 (77%)  330 (64%)  
 
7.D Synthesis of 1H, 8H-pyrrolo[3,2-g]indoles (Type A) 
After successful synthesis of symmetrically as well as unsymmetrically substituted cyclization precursors, 
they were subjected to the reductive cyclization conditions as discussed in table 7.1. To our delight, all 
diakenyl-dinitrobenzenes smoothly participated in the reactions to give rise to symmetrical as well as 
unsymmetrical pyrroloindoles of type A (Table 7.5). The symmetrical substrates 286 and 287 also 
behaved as 285 to give rise to monocyclized indoles 339 and 341 along with pyrroloindoles 338 and 340 
respectively. In order to compare the reactivity of substituted and the unsubstituted double bonds, 
compound 317 was subjected to the monocyclization conditions (Pd(OAc)2, PPh3) as revealed in Table 
7.1. Only double cyclization product 342 (53%) was obtained; the expected monocyclization product was 
not detected. The formation of unsymmetrically substituted pyrroloindoles here represents the first 
synthesis of these compounds. All the results are summarized the table below (Table 7.5). 
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Table 7.5 Synthesis of 1H,8H-pyrrolo[3,2-g]indoles (Type A) 
Entry Substrate 
Reaction 
conditions Pyrroloindole Indole 
 NO2O2N   
N
H
N
H  
NO2NH  
1 286 Pd(OAc)2-phen 338 (67%)  
2 286 Pd(OAc)2-dppp 338 (9%) 339 (69%) 
3 286 
Pd(OAc)2-
dppp-phen 338 (36%)  
 NO2O2N   
N
H
N
H  
NO2NH  
4 287 Pd(OAc)2-phen 340 (54%)  
5 287 
Pd(dba)2-dppp-
phen 340 (67%)  
6 287 Pd(dba)2-PPh3 340 (62%)  
7 287 Pd(dba)2-dppp 340 (16%) 341 (78%) 
 NO2O2N   
N
H
N
H   
8 317 Pd(OAc)2-phen 342 (63%)  
9 317 Pd(OAc)2-PPh3 342 (25%)  
 NO2O2N   
N
H
N
H   
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10 318 Pd(OAc)2-phen 343 (64%)  
 NO2O2N   
N
H
N
H   
11 319 Pd(OAc)2-phen 344 (67%)  
 NO2O2N
EtO2C
  
N
H
N
H
EtO2C
  
12 320 Pd(OAc)2-phen 345 (68%)  
 NO2O2N
EtO2C
  
N
H
N
H
EtO2C
  
13 321 Pd(OAc)2-phen 346 (73%)  
 NO2O2N
EtO2C
  
N
H
N
H
EtO2C
  
14 322 Pd(OAc)2-phen 347 (74%)  
 
The results summarized in Table 7.5 are exciting in the sense that they open the door for the synthesis of 
unsymmetrically substituted pyrroloindoles of type A. Encouraged with these results, we were very sure 
that a combination of Pd(OAc)2-1,10-phen would be a good catalyst for the synthesis of rest of the 
pyrroloindole types. Problems then started arising. Although compound 291 gave pyrroloindole in 
moderate yield (53%), the case of formation of pyrroloindole 350 was realized only with Pd(dba)2-dppp-
1,10-phen; all other conditions gave monocyclized indole (Table 7.6, entries 4). Compound 290 gave 
monocyclized indole even after prolonged reaction time (Table 7.6, entries 2, 3). On the other hand, the 
non-substituted 1,5-diethenyl-2,4-dinitrobenzene (289) did not afford any identifiable monocyclized or 
double cyclized product although all the starting material was consumed under any of the several 
conditions tested. A possible route is the polymerization but this possibility was also ruled out when 
similar result was obtained with Pd(dba)2-dppp-1,10-phen, BHT. The unsymmetrically substituted 1,5-
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dialkenyl-2,4-dinitrobenzenes of this series (compounds 323 and 324) afforded monocyclized products in 
very diminished yields along with an inseparable mixture of unknown impurities under all reaction 
conditions tried. We were unable to find a good condition for the cyclization of compounds 323 and 324.  
 Similar results were obtained when we attempted to synthesize pyrroloindoles of type C. The non-
substituted 1,4-dialkenyl-2,5-dinitrobenzene 292 participated in double cyclization to afford pyrroloindole 
351 (60%) uneventfully. The related cyclization precursor 294 gave pyrroloindole 387 only with 
Pd(dba)2-PPh3 albeit in low yield (26%). Under all other conditions tried, compounds 293 and 294 gave 
monocyclized normal indoles 352 and 353 respectively. Here also the unsymmetrically substituted 
cyclization partners gave monocyclized indoles in diminished yield along with an inseparable mixture of 
unknow impurities. These compounds were not further explored for the unsymmetrically substituted 
pyrroloindoles of type C. 
The results from the attempted cyclizations of 298, 330 and 331 that are possible precursors to 
pyrroloindoles of type E are outlined in Table 7.6. As can been, compound 298 gave monocyclized and 
dicyclized products 364 (20%) and 363 (50%) respectively whereas the unsymmetrical partners 330 and 
331 gave indoles. Compound 366 was obtained along with minor amount of pyrroloindole 367 as an 
inseparable mixture by chromography. 
The cyclization precursors to type D were also tested for any possibility of formation of pyrroloindoles. 
Unsurprisingly, however, all the symmetrical dialkeynyldinitrobenzenes went on smoothly to give rise to 
indoles in high isolated yields after chromatography. Completely different observations were noticed 
when the unsymmetrically substituted dialkenyldinitrobenzenes were subjected to double cyclization; 
these compounds gave rise to two indoles resulting from each of the double bond cyclization as an 
iseparable mixture in nearly 1:1 ratio. The results are included in Table 7.6. 
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Table 7.6 Attempted synthesis of pyrroloindoles (Type B-E)  
Entr
y 
Substrate Conditions Pyrroloindole Indole 
 
NO2O2N  
   
1 289 Pd(OAc)2, 
phen 
  
 
NO2O2N
 
  
N
H
NO2
 
2 290 Pd(OAc)2, 
phen 
 348 (37%) 
3 290 Pd(dba)2, PPh3  348 (64%) 
 
NO2O2N  
 
N
H
N
H  
N
H
NO2
 
4 291 Pd(dba)2, dppp, 
phen 
349 (56%)  
5 291 Pd(dba)2, dppp 349 (16%) 350 (78%) 
6 291 Pd(dba)2, phen  350 (20%) 
7 291 Pd(dba)2, PPh3  350 (85%) 
 
NO2
O2N
 
 H
N
N
H  
 
8 292 Pd(OAc)2, 
phen 
351 (60%)  
77 
 
 
NO2
O2N
 
  H
N
NO2  
9 293 Pd(OAc)2, 
phen 
 352 (31%) 
10 293 Pd(dba)2, PPh3  352 (100%) 
 
NO2
O2N
 
  
N
H
NO2
 
11 294 Pd(dba)2, PPh3  353 (73%) 
 
O2N NO2
 
  
NO2HN
 
12 295 Pd(OAc)2, 
phen 
 354 (44%) 
13 295 Pd(dba)2, PPh3  354 (68%) 
 
O2N NO2
 
  
NO2HN
 
14 296 Pd(OAc)2, 
phen 
 355 (74%) 
15 296 Pd(dba)2, PPh3  355 (70%) 
 
O2N NO2
 
  
NO2HN
 
16 297 Pd(OAc)2,  356 (86%) 
78 
 
phen 
17 297 Pd(OAc)2, 
dppp, phen 
 356 (51%) 
18 297 Pd(OAc)2, 
PPh3 
 356 (84%) 
 
O2N NO2
 
  
NO2HN O2N NH
 
19 327 Pd(OAc)2, 
dppp, phen 
 357 +358 (46%, 1:1) 
 
O2N NO2
 
  
NO2HN O2N NH
 
20 328 Pd(OAc)2, 
phen 
 359 +  360 (70%, 1:1) 
 
O2N NO2
 
  
NO2HN O2N NH
 
21 329 Pd(OAc)2, 
phen 
 361 + 362 (77%, 1:1) 
 
O2N
NO2  
 
HN
N
H  
O2N
N
H  
22 298 Pd(OAc)2, 
phen 
363 (50%) 364 (20%) 
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23 298 Pd(OAc)2, 
PPh3 
 364 (49%) 
 
O2N
NO2
 
  
HN
NO2
 
24 331 Pd(OAc)2, 
phen 
 365 (73%) 
 
O2N
NO2  
 
HN
N
H
 
HN
NO2  
25 330 Pd(OAc)2, 
phen 
 366 (61%) 
26 330 Pd(dba)2, dppp, 
phen 
367 (minor 
product) 
366 (major product) 
 
A second cyclization of the indoles 348 and 352 was also attempted. Submitting the mono-cyclized 
product from 290 to the reaction conditions Pd(OAc)2-PPh3 -30h gave only 38% of recovered starting 
material whereas quantitative amount of starting material was recovered from the attempted second 
cyclization of 352 under the reaction conditions Pd(OAc)2-PPh3 -30h. A possible hindrance to the second 
cyclization may be the electronic factor associated with the indoles resulting from the first cyclization. 
Once the indole is formed, the ring becomes electron rich and this may be acting as an obstacle to the 
second cyclization. We then considered introducing electron withdrawing group to the NH group of the 
indole and subjecting the resulting indole to the second cyclization. The first electron withdrawing that 
came into our consideration was the acetyl group. Accordingly, we synthesized the acetylated indoles 368 
and 369 and submitted them to our standard conditions of reductive cyclization. 
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Scheme 7.16 Attempted reductive cyclization of 368 and 369 
Pd(dba)2, dppp, 1,10-phen
CO (6 atm), DMF, 120 °C
36 h
O2N
H
N
352
O2N
Ac
N
368 (100%)
352 (39% Recovery)
(CH3CO)2O, Et3N
DMAP, DCE, 75 °C
18 h
O2N
356
NH O2N
369 (94%)
NAc(CH3CO)2O, Et3N
DMAP, DCE, 75 °C
18 h
Pd(dba)2, dppp, 1,10-phen
CO (6 atm), DMF, 120 °C
46 h
356 + Negligible pyrroloindole
 
Although the result from the attempted cyclization of 368 was frustrating, the presence of a minor amount 
of pyrroloindole in the isolated starting material from the reductive cyclization of 369 was an indication 
that an electron withdrawing group may play a crucial role in the second cyclization. With this in mind, 
we synthesized the tosylated indole 370 by reacting 356 with TsCl in the presence of a base in DMF and 
subjected to reductive cyclization. To our delight, the tosylated pyrroloindole 371 was obtained in 
excellent yield (88%) after chromatographic separation.  
 
Scheme 7.17 Reductive cyclization of 370 
O2N
356
NH O2N
370 (78%)
NTs
371 (88%)
NTsHNPd(dba)2, dppp, 1,10-phen
CO (6 atm), DMF
120 °C, 24 h
NaH, TsCl
DMF, 0 °C-rt
6 h-overnight
 
Encouraged with this result, the tosylated indoles 372-379 were prepared in a similar fashion and 
subjected to reductive cyclization. The results are summarized in the table below. 
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Table 7.7 Synthesis of N-tosylated indoles 
Entry Indole Reaction conditions N-Tosyl indole 
1 
N
H
O2N
 
350 
NaH, TsCl, DMF, 0 °C-rt 
N
Ts
O2N
 
372 (77%) 
2 
N
H
O2N
 
348 
N
Ts
O2N
 
373 (69%) 
3 
N
H
O2N
 
353 
N
Ts
O2N
 
374 (72%) 
4 
N
H
O2N
 
352 
N
Ts
O2N
 
375 (71%) 
5 
NO2HN
 
354 
NO2TsN
 
376 (77%) 
6 
NO2HN
 
355 
NO2TsN
 
377 (79%) 
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7 
NO2
HN
 
366 
NO2
TsN
 
378 (77%) 
8 
NO2NH  
337 
NO2NTs  
379 (80%) 
 
As is clear, all the problematic substrates but 379 smoothly participated in cyclization giving rise to 
pyrroloindoles in high to excellent isolated yields. Compound 379 was tested for cyclization under two 
different catalytic conditions (Table 7.8, entries 8, 9). The use of tosyl group as an electron withdrawing 
group has several advantages, for example, it improves the yields and leads to enhanced stability of the 
pyrroloindoles and diminishes the overall reaction time. The non-tosylated indoles are relatively unstable 
in air. The results are summarized in Table 7.8. 
 
Table 7.8 Synthesis of N-tosylated pyrroloindoles (Types B-E)  
Entry N-Tosyl indole   Reaction conditions Pyrroloindole 
1 
N
Ts
O2N
 
372 
Pd(dba)2, dppp, 1,10-phen 
CO (6 atm), DMF, 120 °C 
N
Ts
N
H  
380 (79%) 
2 
N
Ts
O2N
 
373 
N
Ts
N
H  
381 (70%) 
83 
 
3 
N
Ts
O2N
 
374 
N
Ts
H
N
 
382 (88%) 
4 
N
Ts
O2N
 
375 
N
Ts
H
N
 
383 (76%) 
5 
NO2TsN
 
376 
TsN NH
 
384 (89%) 
6 
NO2TsN
 
377 
TsN NH
 
385 (77%) 
7 
NO2
TsN
 
378 
TsN
N
H  
386 (87%) 
8 
NO2NTs  
379 
NO2NTs  
379 (70%) 
84 
 
9 
NO2NTs  
379 
Pd(OAc)2, 1,10-phen 
CO (6 atm), DMF, 120 °C 
NO2NTs  
379 (82%) 
 
7.E Conclusion Palladium catalyzed, carbon monoxide mediated, double reductive N-heterocyclization 
of dialkenyldinitrobenzenes to the functionalized and novel non-symmetrical pyrroloindoles has been 
developed for the first time. This methodology represents the first common synthetic routes to all the 
isomeric pyrroloindoles which are of interest in a number of applications in addition to their presence as a 
core moiety in a wide range of bioactive natural products. The functionalized isomeric cyclization 
precursors were prepared through use of Kosugi-Migita-Stille coupling reaction. The generally mild 
catalyst conditions offer significant improvements over previously reported methods that utilize harsh 
conditions. This pathway opens the door for the synthesis of all the otherwise synthetically challenging 
unsymmetrically substituted pyrroloindoles in general. 
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Experimental Section 
General Procedures. All NMR spectra were recorded in CDCl3 at 600 MHz (
1H NMR), 150 MHz (13C 
NMR, 1H broadband decoupled) and 376 MHz 19F NMR at ambient temperature unless otherwise stated. 
The chemical shifts are expressed in δ values relative to SiMe4 (0.0 ppm, 
1H and 13C) or CDCl3 (77.0 
ppm, 13C) internal standards. HRMS data were obtained via electrospray ionization (ESI) with an ion trap 
mass analyzer. THF, dichloromethane and toluene were purified and dried via a two consecutive columns 
composed of activated alumina and Q5 catalyst on a Glass Contours solvent purification system. 
Anhydrous N,N-dimethylformamide was used as received. Hexanes, ethyl acetate, and 1,4-dioxane were 
distilled from calcium hydride. Chemicals prepared according to literature procedures have been 
footnoted the first time used; all other reagents were obtained from commercial sources and used as 
received. All reactions were performed under a nitrogen atmosphere in oven-dried glassware. Solvents 
were removed from reaction mixtures and products on a rotary evaporator at water aspirator pressure 
unless otherwise stated. Melting points (uncorrected) were recorded from the pure products obtained by 
chromatography.  
 
2-(5-Benzyloxy-2-nitrophenyl)-1-trimethylsilylethyne (2). 5-Benzyloxy-2-nitro-1-bromobenzene41 (1) 
(3.91 g, 12.7 mmol) was dissolved in toluene (10 mL) and triethylamine (NEt3, 40 mL) whereby 
bis(triphenylphosphinepalladium dichloride (PdCl2(PPh3)2, 0.62 g, 0.88 mmol) and copper iodide (CuI, 
0.17 g, 0.89 mmol) were added successively. The reaction mixture was stirred under a nitrogen 
atmosphere for five minutes. Trimethylsilylethyne (2.17 mL, 15.2 mmol) was added drop wise and the 
resulting mixture was stirred at 48 oC for 24 h. After cooling to ambient temperature, the mixture was 
filtered through celite, and the celite was washed with EtOAc. The solvents were removed from the 
filtrate under reduced pressure. The resulting residue was purified by chromatography (EtOAc/hexane, 
1:9) affording 2 (3.71 g, 11.4 mmol, 90%) as a faint yellow solid. mp=96 oC; 1H NMR (400 MHz, CDCl3) 
δ 8.07 (d, J=9.2 Hz, 1H), 7.43-7.36 (m, 5H), 7.18 (d, J=2.8 Hz, 1H), 6.97 (dd, J=9.2, 2.8 Hz, 1H), 5.14 (s, 
2H), 0.29 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 161.8, 143.2, 135.3, 128.8, 128.5, 127.5, 127.0, 120.7, 
120.1, 115.4, 103.7, 99.9, 70.7, 0.4; IR (APT) 1572, 1515, 1333. 1248, 836 cm-1; HRMS (ESI) calcd for 
C18H20NO3Si (M+H
+) 326.1212, found 326.1195. 
1-(5-Benzyloxy-2-nitrophenyl)ethyne (3). A solution of tetrabutylammonium fluoride (1M in THF) was 
added drop wise to a 0 oC cold solution of 2 (2.32 g, 7.13 mmol) in THF (30 mL). The resulting mixture 
was stirred at 0 oC for 30 min. The solvent was removed under reduced pressure and the resulting residue 
was purified by chromatography (EtOAc/hexane, 2:8) to give 3 (1.63 g, 6.44 mmol, 90%) as a white 
solid. mp=122 oC; 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J=9.2 Hz, 1H), 7.45-7.35 (m, 5H), 7.22 (d, 
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J=2.8 Hz, 1H), 7.02 (dd, J=9.2, 2.8 Hz, 1H), 5.15 (s, 2H), 3.52 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
161.9, 143.2, 135.1, 128.8, 128.7, 127.5, 127.1, 120.8, 119.7, 115.7, 85.0, 79.0, 70.8; IR (APT) 3284, 
1579, 1507, 1327, 1249, 1073 cm-1; HRMS (ESI) calcd for C15H12NO3 (M+H
+) 254.0817, found 
254.0805. 
1-(5-Benzyloxy-2-nitrophenyl)-1-tributylstannylethene (4). To a solution of 3 (1.60 g, 6.32 mmol) in 
THF (30 mL) under N2 was added PdCl2(PPh3)2 (0.44 g, 0.63 mmol) and  tributyltin hydride (2.76 g, 9.48 
mmol). The resulting dark brown mixture was stirred at ambient temperature under N2 for 24 h. The 
mixture was diluted with EtOAc (30 mL) and washed with H2O (3x30 mL) and brine (30 mL), The 
organic layer was dried (MgSO4), filtered, at the solvent was removed under reduced pressure. The 
residue was purified by chromatography (EtOAc/hexane, 1:19) affording 4 (2.99 g, 5.49 mmol, 87%) as a 
brown viscous liquid. 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J=9.2 Hz, 1H), 7.45-7.33 (m, 5H), 6.86 (dd, 
J=9.2, 2.4 Hz, 1H), 6.63 (d, J=2.0 Hz, 1H), 5.72 (d, J=2.4 Hz, 1H), 5.41 (d, J=2.0 Hz, 1H), 5.14 (s, 2H), 
1.56-1.37 (m, 6H), 1.27 (sext, J=7.2 Hz, 6H), 0.95 – 0.84 (m, 15H); 13C NMR (100 MHz, CDCl3) δ 162.3, 
155.7, 147.6, 139.1, 135.6, 128.7, 128.4, 127.5, 127.1, 124.8, 114.6, 112.7,70.5, 28.8, 27.3, 13.6, 11.0; IR 
(ATR) 2954, 2922, 1567, 1329, 1283, 1243, 1228, 694 cm-1; HRMS (ESI) calcd for C27H40NO3Sn 
(M+H+) 546.2030, found 546.2025. 
2,5-Di(1-(5-benzyloxy-2-nitrophenyl)-1-ethenyl)pyrazine (6) and 2,3-di(5-benzyloxy-2-nitrophenyl)-
1,3-butadiene (7). To a solution of 2,5-dibromopyrazine (5) (100 mg, 0.420 mmol) and 4 (458 mg, 0.841 
mmol) in dry DMF (2 mL) was added bis(dibenzylideneacetone)palladium (Pd(dba)2, 19.4 mg, 0.034 
mmol), CuI (160 mg, 0.841 mmol), and PPh3 (35.3 mg, 0.135 mmol) respectively. The resulting brown 
mixture was stirred under an atmosphere of N2 at 90 
oC for 41 h.  EtOAc (25 mL) was added and the 
mixture was washed with H2O (3x25 mL) and brine (3x25 mL).  The organic layer was dried (MgSO4), 
filtered, and the solvents were removed under reduced pressure. The residue was purified by 
chromatography on SiO2/K2CO3 (10% K2CO3, EtOAc/hexane, 1:9, then 2:8) to give, in order of elution, 7 
(85.5 mg, 0.168 mmol, 40%) followed by 6 (96 mg, 0.16 mmol, 39%) both as white solids. Analytical 
data for 6: mp=186-187 oC;  1H NMR (400 MHz, CDCl3) δ 8.51 (s, 1H), 8.15 (d, J=9.0 Hz, 1H), 7.45-7.33 
(m, 5H), 7.04 (dd, J=8.8, 2.4 Hz, 1H), 7.01 (d, J=2.4 Hz, 1H), 6.29 (s, 1H), 5.57 (s, 1H), 5.17 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 162.7, 149.9, 144.7, 141.2, 140.5, 137.8, 135.4, 128.8, 128.5, 127.6, 127.3, 
118.8, 118.4, 114.6, 70.8; IR (APT) 1578, 1508, 1326, 1242, 1001, 919, 750 cm-1; HRMS (ESI) calcd for 
C34H27N4O6 (M+H
+) 587.1931, found 587.1925. Analytical data for 7: mp=158-160 oC; 1H NMR (400 
MHz, CDCl3)  δ 8.08 (d, J=9.2 Hz, 1H), 7.48-7.36 (m, 5H), 7.17 (d, J=2.8 Hz, 1H), 7.03 (dd, J=9.2, 2.8 
Hz, 1H), 5.20 (s, 2H), 5.08 (s, 1H), 4.88 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 162.2, 145.6, 141.7, 
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138.3, 135.5, 128.7, 128.4, 127.8, 126.8, 117.5, 117.1, 114.9, 70.7; IR (ATR) 1573, 1513, 1343, 1230, 
1007 cm-1; HRMS (ESI) calcd for C30H25N2O6 (M+H
+) 509.1713, found 509.1715. 
5,5’-Dibenzyloxy-3,3’-(2,5-pyrazindiyl)bis-1(H)-indole (8). To a solution of 5 (114 mg, 0.194 mmol) in 
dry DMF (2 mL), in a treaded ACE-Glass pressure tube, was added 1,3-bis(diphenylphosphino)propane 
(dppp, 6 mg, 0.014 mmol), 1,10-phenanthroline (phen, 5 mg, 0.027 mmol) and Pd(dba)2 (8 mg, 0.014 
mmol). The tube was fitted with a pressure head, and the solution was saturated with 3 cycles of CO (6 
atm) and stirred at 120 oC (6 atm CO, 72 h). The reaction mixture was cooled to ambient temperature, 
diluted with EtOAc (30 mL), and washed with H2O (3x30 mL) and brine (3x30 mL). The organic layer 
was dried (MgSO4), filtered, and the solvents were removed under reduced pressure. The residue was 
purified by chromatography (EtOAc/hexane, 3:7, then 6:4) to afford 8 (90 mg, 0.172 mmol, 89%) as 
yellow powder. mp=264-265 oC; 1H NMR (400 MHz, acetone-d6) δ 10.63 (s, 1H), 9.09 (s, 1H), 8.22 (d, 
J=2.5 Hz, 1H), 8.14 (d, J=2.8 Hz, 1H), 7.58 (d, J=7.6 Hz, 2H), 7.46–7.29 (m, 5H), 6.98 (dd, J=8.8, 2.5 
Hz, 1H), 5.22 (s, 2H); 13C NMR (100 MHz, acetone-d6) δ 155.0, 148.0, 141.0, 139.2, 133.6, 129.2, 128.6, 
128.5, 127.2, 126.3, 114.5, 113.8, 113.2, 106.3, 71.3; IR (APT) 3228, 2927, 1546, 1478, 1154 cm-1; 
HRMS (ESI) calcd for C34H26N4O2 (M+H
+) 523.2134, found 523.2116. 
Alocasin A. To a solution of 8 (41 mg, 0.078 mmol) in EtOH (2 mL), in a treaded pressure tube, was 
added Pd/C (10%-Pd, 18 mg, 0.017 mmol). The tube was fitted with a pressure head and the mixture was 
pressurized with H2 (4 atm) and stirred at 60 
oC (12 h). After cooling to ambient temperature, the mixture 
was filtered through a pad of celite and the celite was washed with warm ethanol (5 mL). The solvent was 
removed under reduced pressure and residue was purified by chromatography (EtOAc/hexane, 7:3) to 
afford alocasin A (23 mg, 0.067 mmol, 86%) as faint yellow solid. mp=244-245 oC (lit. mp=243-244 
oC);9 1H NMR (400 MHz, CD3OD) δ 8.94 (s, 2H), 7.90 (s, 2H), 7.72 (d, J=2.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 
2H), 6.79 (dd, J=8.8, 2.4 Hz, 2H); 13C NMR (100 MHz, CD3OD) δ 152.8, 148.4, 141.4, 133.6, 127.3, 
126.6, 113.8, 113.3, 113.2, 106.1; IR (ATR) 3298, 2927, 1551, 1466, 1154 cm-1; HRMS (ESI) calcd for 
C20H15N4O2 (M+H
+) 343.1195, found 343.1188. 
2,3-Di(5-benzyloxy-2-nitrophenyl)-1,3-butadiene (7). To a solution of 3,5-dibromopyridine (9) (217 
mg, 0.919 mmol) and 4 (1.00 g, 1.84 mmol) in dry DMF (6 mL) was added Pd(dba)2 (52.8 mg, 0.092 
mmol), CuI (350 mg, 1.84 mmol), and PPh3 (96.4 mg, 0.367 mmol) respectively. The resulting brown 
mixture was stirred under an atmosphere of N2 at 80 
oC for 24 h.  EtOAc (25 mL) was added and the 
mixture was washed with brine (6x50 mL).  The organic layer was dried (MgSO4), filtered, and the 
solvents were removed under reduced pressure. The residue was purified by chromatography on 
SiO2/K2CO3 (10% K2CO3, EtOAc/hexane, 1:9, then 2:8) to give 7 (139 mg, 0.273 mmol, 30%). 
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3,5-(1-Tributylstannyl-1-ethenyl)pyridine (11). Treatment of 3,5-diethynylpyridine (10)42 (150 mg, 
1.18 mmol) with Bu3SnH (1.03 mg, 3.59 mmol) in the presence of PdCl2(PPh3)2 (100 mg, 0.142 mmol) in 
THF (4 mL), as described for 4 (36 h), gave after work up and chromatography (EtOAc/hexanes, 2:98) 11 
(510 mg, 0.719 mmol, 61%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, J=2.4 Hz, 1H), 7.23 (t, 
J=2.0 Hz, 1H), 6.05 (d, J=2.4 Hz, 1H), 5.51 (d, J=2.4 Hz, 1H), 1.57-1.24 (m, 6H), 1.29 (sext, J=7.2 Hz, 
6H), 1.07-0.79 (m, 15H); 13C NMR (100 MHz, CDCl3) δ 151.3, 145.4, 141.5, 130.4, 128.7, 29.0, 27.2, 
13.6, 10.3; IR (ATR) 2956, 2925, 1463, 920 cm-1; HRMS (ESI) calcd for C33H62NSn2 (M+H
+) 712.2926, 
found 712.2929. 
2-Iodo-4-benzyloxy-1-nitrobenzene (12). A mixture of 3-iodo-4-nitrophenol (5.83 g, 22.0 mmol), 
benzyl bromide (4.86 g, 35.2 mmol) and K2CO3 (5.64 g, 40.8 mmol) in absolute EtOH (50 mL) was 
heated ate reflux for 18 h. The resulting mixture was concentrated under reduced pressure and EtOAc (50 
mL) was added to the resulting residue. The mixture was washed with water (3x40 mL), dried (MgSO4), 
and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified 
by chromatography (EtOAc/hexanes, 2:8) to afford 12 (7.32 g, 20.6 mmol, 94%) as an orange-yellow 
solid. mp=73-75 oC; 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J=9.2 Hz, 1H), 7.63 (d, J=2.8 Hz, 1H), 7.45-
7.36 (m, 5H), 7.00 (dd, J=8.8, 2.8 Hz, 1H), 5.12 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 161.6, 145.4, 
135.0, 128.8, 128.6, 128.0, 127.5, 127.5, 114.7, 88.1, 70.8; IR (ATR) 1575, 1507, 1332, 1241, 982 cm-1; 
HRMS (ESI) calcd for C13H11INO3 (M+H
+) 355.9784 , found 355.9785. 
3,5-Di(5-benzyloxy-2-nitrophenyl)pyridine (13). Reaction of 11 (750 mg, 1.06 mmol) with 12 (1.13 g, 
3.17 mmol) in the presence of Pd(dba)2 (61 mg, 0.11 mmol, PPh3 (111 mg, 0.423 mmol) and CuI (403 
mg, 2.11 mmol) in DMF (6 mL), as described for 5 (120 oC, 48 h) gave after work up and 
chromatography (EtOAc/hexanes, 2:8 then 3:7) 13 (216 mg, 0.369 mmol, 35%) as viscous yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 8.33 (d, J=2.0 Hz, 2H), 8.07 (d, J=8.8 Hz, 2H), 7.51 (t, J=2.0 Hz, 1H), 7.46-
7.37 (m, 10H), 7.04 (dd, J=9.2, 2.8 Hz, 2H), 6.98 (d, J=2.8 Hz, 2H), 5.73 (s, 2H), 5.36 (s, 2H), 5.17 (s, 
4H); 13C NMR (100 MHz, CDCl3) δ 162.4, 146.8, 144.1, 141.2, 138.4, 135.3, 134.4, 130.8, 128.8, 128.5, 
127.6, 127.4, 118.2, 116.8, 114.7, 70.8; IR (ATR) 1572, 1509, 1332, 1224 cm-1; HRMS (ESI) calcd for 
C35H28N3O6 (M+H
+) 586.1978,  found 586.1979. 
3,5-Bis(5-benzyloxy-3-indolyl)pyridine (14). Treatment of a solution of 13 (176 mg, 0.300 mmol) in the 
presence of Pd2(dba)3 (28 mg, 0.030 mmol), dppp (12 mg, 0.030 mmol), and phen (11 mg, 0.060 mmol) 
in DMF (1.5 mL) with CO (6 atm), as described for 8 (120 oC, 68 h), gave after work up and 
chromatography (EtOAc/hexanes, in order 7:3, 3:7) 14 (105 mg, 0.201 mmol, 67%) as a viscous yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 8.91 (br, s, 2H), 8.84 (d, J=2.0 Hz, 2H), 8.12 (t, J=2.0 Hz, 1H), 7.50 
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(d, J=2.4 Hz, 2H), 7.44-7.42 (m, 4H), 7.35-7.24 (m, 10H), 7.02 (dd, J=8.8, 2.4 Hz, 2H), 5.07 (s, 4H); 13C 
NMR (100 MHz, CDCl3) δ 154.0, 145,2, 137.4, 132.6, 132.1, 131.9, 128.4, 127.7, 127.5, 125.9, 123.4, 
114.1, 113.5, 112.4, 102.9, 70.9; IR (ATR) 3427, 3287, 1594, 1477, 1196 cm-1; HRMS (ESI) calcd for 
C35H28N3O2 (M+H
+) 522.2181, found 522.2182. 
Scalaridine A. Treatment of a solution of 14 (87 mg, 0.168 mmol) with Pd/C (10%, 21 mg, 0.020 mmol) 
in EtOH (1.5 mL), as decribed for alocasin A (4 atm, 60 oC, 12 h) gave after work up and chromatography 
(EtOAc), scalaradine A (45 mg, 0.13 mmol, 79%) as yellow solid. mp=321 oC dec. (lit. mp = 319-329 oC 
dec.);13 1H NMR (400 MHz, DMSO-d6) δ 11.26 (br, s, 2H), 8.80 (s, 2H), 8.69 (br, s, 2H), 8.18 (s, 1H), 
7.78 (d, J=2.4 Hz, 2H), 7.29 (d, J=8.8 Hz, 2H), 7.23 (d, J=2.4 Hz, 2H), 6.70 (dd, J=8.4, 2.0 Hz, 2H); 13C 
NMR (100 MHz,DMSO-d6) δ 151.6, 143.7, 132.0, 131.3, 130.0, 125.6, 124.5, 112.6, 112.0, 111.5, 102.6 ; 
IR (ATR) 3427, 3286, 1594, 1475, 1195 cm-1; HRMS (ESI) calcd for C21H16N3O2 (M+H
+) 342.1243, 
found 342.1240. 
(5-Benzyloxy-2-nitrophenyl)ethene (16), 2,3-di(5-benzyloxy-2-nitrophenyl)-1,3-butadiene (7), 1-(5-
benzyloxy-2-nitrophenyl)-1-(2-pyrimidyl)ethene (17). Reaction of 2,5-dibromopyrimidine (15) (300 
mg, 1.26 mmol) and 4 (2.06 g, 3.78 mmol) in the presence of  Pd(dba)2 (73 mg, 0.13 mmol), CuI (720 
mg, 3.78 mmol), and PPh3 (132 mg, 0.504 mmol) in dry DMF (5 mL) under argon as described for 5 (100 
oC, 48 h), gave after work up and chromatography on SiO2/K2CO3 (10% K2CO3, EtOAc/hexane, 1:9, then 
2:8), in order of elution, 16 (101 mg, 0.396 mmol, 10%) as a white solid, an inseparable mixture of 7 and 
an unknown impurity (90 mg, <8%) as a white solid, and 17 (114 mg, 0.342 mmol, 27%) as a viscous 
greenish-brown oil.  Analytical data for 16 mp=58-59 oC; 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J=9.2 
Hz, 1H), 7.44-7.32 (m, 5H), 7.30 (dd, J=17.2, 10.8 Hz, 1H), 7.11 (d, J=2.8 Hz, 1H), 6.94 (dd, J=9.2, 2.8 
Hz, 1H), 5.65 (dd, J=17.2, 0.8 Hz, 1H), 5.46 (dd, J=11.2, 0.8 Hz, 1H), 5.17 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 162.3, 140.9, 136.7, 135.5, 133.7, 128.8, 128.5, 127.5, 127.3, 118.6, 114.4, 114.0, 70.6; IR 
(ATR) 1581, 1501, 1238, 1078, 987, 930 cm-1. 
Analytical data for 17: 1H NMR (400 MHz, CDCl3) δ  8.65 (d, J=5.2 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 
7.46-7.35 (m, 5H), 7.10 (t, J=5.2 Hz, 1H), 7.07 (d, J=2.8 Hz, 1H), 7.04 (dd, J=8.8, 2.8 Hz, 1H), 6.86 (d, 
J=1.2 Hz, 1H), 5.78 (d, J=1.2 Hz, 1H), 5.17 (s, 2H); 13C NMR (100 MHz, CDCl3) δ  163.9, 162.6, 156.9, 
146.9, 141.6, 138.2, 135.5, 128.7, 128.5, 127.6, 127.0, 122.4, 119.2, 118.4, 113.9, 70.6; IR (ATR) 1583, 
1567, 1554, 1506, 1336, 1249, 758, 698 cm-1; HRMS (ESI) calcd for C19H16N3O3 (M+H
+) 334.1192, 
found 334.1190. 
2,5-Di(2-trimethylsilyl-1-ethynyl)pyrimidine (18). A solution of 15 (2.25 g, 9.49 mmol), PdCl2(PPh3)2 
(666 mg, 0.949 mmol), and CuI (362 mg, 1.90 mmol) in toluene (9 mL) was stirred at ambient 
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temperature under an atmosphere of N2 for 5 min. Triethylamine (25 mL) and a solution of 
trimethylsilylethyne (2.52 g, 25.6 mmol) in NEt3 (4 mL) was added. The resulting dark brown reaction 
mixture was stirred at 50 oC for 24 h. After cooling to ambient temperature, the mixture was filtered 
through Celite and the bed was washed with Et2O (25 mL). The filtrate was concentrated under reduced 
pressure and the resulting residue was purified by chromatography (EtOAc/hexanes, 5:95) to afford 18 
(2.59 g, 0.949 mmol, 100%) as pale green solid. mp=99-100 oC; 1H NMR (400 MHz, CDCl3) δ 8.72 (s, 
2H), 0.29 (s, 9H), 0.27 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 159.2, 149.9, 118.2, 104.6, 102.1, 97.6, 
96.8, -0.4, -0.6; IR (ATR) 2963, 2163,1413, 1245, 838 cm-1; HRMS (ESI) calcd for C14H21N2Si2 (M+H
+) 
273.1243, found 273.1240. 
2,5-Diethynylpyrimidine (19). A heterogeneous mixture of 18 (744 mg, 2.94 mmol), K2CO3 (2.43 g, 
17.6 mmol) in MeOH/Et2O (1:2, 15 mL) was stirred at ambient temperature under an N2 atmosphere for 1 
h. Water (20 mL) was added and the mixture was extracted in EtOAc (3x10 mL). The combined organic 
layer was concentrated under reduced pressure and the resulting crude product was purified by 
chromatography (EtOAc/hexanes, 1:1) to afford 19 (326 mg, 2.54 mmol, 93%) as a white solid. mp=97-
98 oC; 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 2H), 3.49 (s, 1H), 3.26 (s, 1H); 
13C NMR (100 MHz, 
CDCl3) δ 159.6, 150.2, 117.8, 86.1, 81.5, 78.0, 76.7; IR (ATR) 3291, 3180, 2129, 2100, 1415 cm
-1; 
HRMS (ESI) calcd for C8H5N2 (M+H
+) 129.0452, found 129.0448. 
2,5-Di(1-tributylstannyl-1-ethenyl)pyrimidine (20). THF (4 mL) was added to a flask containing 19 
(257 mg, 2.01 mmol) and PdCl2(PPh3)2 (169 mg, 0.241 mmol) under an atmosphere of N2. The mixture 
was stirred at ambient temperature for 5 min followed by slow addition of Bu3SnH (1.75 g, 6.03 mmol) 
dissolved in THF (1 mL). The resulting brown mixture was stirred at the ambient temperature for 34 h. 
The mixture was then concentrated under reduced pressure and the residue was purified by 
chromatography (EtOAc/hexanes, 2:98) to give 20 (566 mg, 0.797 mmol, 40%) as pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 8.47 (s, 2H), 7.10 (d, J=2.8 Hz, 1H), 6.12 (d, J=2.0 Hz, 1H), 5.86 (d, J=2.8 
Hz, 1H), 5.56 (d, J=2.4 Hz, 1H), 1.58-1.43 (m, 12H), 1.30 (dhex, J=7.2, 3.2 Hz, 12H), 1.04-0.84 (m, 
30H); 13C NMR (100 MHz, CDCl3) δ 166.7, 154.4, 153.9, 147.8, 136.3, 132.4, 129.7, 29.1, 28.9, 27.3, 
27.2, 13.7, 13.6, 10.4, 10.3; IR (ATR) 2955, 2922, 2852, 1427 cm-1; HRMS (ESI) calcd for C32H61N2Sn2 
(M+H+) 713.2879, found 713.2883. 
2,5-Di[1-(5-benzyloxy-2-nitrophenyl)-1-ethenyl]pyrimidine (21). Treatment of 20 (436 mg, 0.615 
mmol) with 12 (655 mg, 1.84 mmol) in the presence of Pd2(dba)3 (56 mg, 0.061 mmol), PPh3 (65 mg, 
0.25 mmol) and CuI (234 mg, 1.23 mmol) in DMF (5 mL), as described for 5 (120 oC, 48 h), gave after 
work up and chromatography (EtOAc/hexanes, 1:9 then 8:2) 21 (189 mg, 0.323 mmol, 53%) as viscous 
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yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.52 (s, 2H), 8.16 (dd, J=8.0, 0.8 Hz, 1H), 8.12 (d, J=8.8 Hz, 
1H), 7.44-7.35 (m, 10H), 7.06-7.01 (m, 3H), 6.96 (d, J=2.4 Hz, 1H), 6.86 (d, J=1.2 Hz, 1H), 5.81 (s, 1H), 
5.76 (d, J=1.2 Hz, 1H), 5.37 (s, 1H), 5.17 (s, 2H), 5.16 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 162.7, 
162.5, 162.5, 154.0, 146.4, 141.5, 141.5, 140.7, 138.1, 137.5, 135.5, 135.1, 130.1, 128.8, 128.7, 128.5, 
128.4, 127.6, 127.6, 127.5, 126.9, 122.4, 118.2, 118.2, 116.9, 114.8, 114.0, 70.8, 70.6; IR (ATR) 1574, 
1509, 1334, 1228, 1003 cm-1; HRMS (ESI) calcd for C34H27N4O6 (M+H
+) 587.1931, found 587.1934. 
3-[2-(5-benzyloxy-1H-indol-3-yl)-5-pyrimidinyl]-5-benzyloxy-1H-indole (22). Treatment of a solution 
of 21 (141 mg, 0.240 mmol) in the presence of tris(dibenzylideneacetone)dipalladium (Pd2(dba)3, 22 mg, 
0.024 mmol), dppp (10 mg, 0.024 mmol), and phen (9 mg, 0.048 mmol) in DMF (1.5 mL) with CO (6 
atm), as described for 8 (120 oC, 60 h), gave after work up and chromatography (hexanes/EtOAc, 3:7) 22 
(85 mg, 0.163 mmol, 68%) as a yellow solid. mp=199-200 oC; 1H NMR (400 MHz, DMSO-d6) δ 11.54 
(br, s, 1H), 11.46 (br, s, 1H), 9.09 (s, 2H), 8.26 (s, 1H), 8.19 (s, 1H), 7.88 (s, 1H), 7.55-7.32 (m, 13H), 
6.94 (d, J=8.4 Hz, 2H), 5.20 (s, 2H), 5.17 (s, 2H); 13C NMR (100 MHz, DMSO-d6) δ 160.6, 153.7, 154.4, 
153.2, 137.8, 137.7, 132.3, 132.0, 129.0, 128.3, 128.3, 127.8, 127.7, 127.6, 127.6, 126.1, 125.0, 124.9, 
124.6, 114.6, 112.8, 112.7, 112.5, 112.2, 109.3, 105.7, 102.3, 69.9, 69.9; IR (ATR) 3409, 2884, 1543, 
1447, 1199 cm-1;  HRMS (ESI) calcd for C34H27N4O2 (M+H
+) 523.2135, found 523.2135. 
Hyrtinandine A. Treatment of a solution of 22 (56 mg, 0.107 mmol) with Pd/C (10%-Pd, 14 mg, 0.013 
mmol) in MeOH (2 mL), as described for alocasine A (4 atm H2, 60
 oC, 14 h) gave after work up and 
chromatography (EtOAc/hexanes, 9:1) hyrtinadine A (32 mg, 0.093 mmol, 87%) as a white solid. 
mp=290-291 oC (lit. mp = 296 oC);14 1H NMR (400 MHz, DMSO-d6) δ 11.38 (br s, 1H), 11.29 (br s, 1H), 
8.99 (s, 2H), 8.84 (s, 2H), 8.11 (d, J=3.2 Hz, 1H), 7.97 (d, J=2.4 Hz, 1H), 7.80 (d, J=2.8 Hz, 1H), 7.30-
7.25 (m, 2H), 7.20 (d, J=1.6 Hz, 1H), 6.73-6.68 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 160.7, 153.5, 
151.8, 151.6, 131.4, 131.3, 128.7, 126.4, 125.4, 125.0, 124.2, 114.1, 112.6, 112.2, 112.1, 112.0, 108.6, 
106.2, 102.7. IR (ATR) 3295, 1542, 1448, 1364, 1229 cm-1; HRMS (ESI) calcd for C20H15N4O2 (M+H
+) 
343.1195, found 343.1194. 
1-(5-Pyrimidyl)-1-tributylstannylethene (24). Treatment of 5-ethynylpyrimidine 23 (388 mg, 3.73 
mmol) with tributyltin hydride (1.63 g, 5.59 mmol) in the presence of PdCl2(PPh3)2 (262 mg, 0.373 
mmol) in THF (9 mL), as described for 4 (ambient temperature, 36 h), gave after work up and 
chromatography (EtOAc/hexanes, 5:95) 24 (1.02 g, 2.57 mmol, 69%) as pale yellow oil.  1H NMR (600 
MHz, CDCl3) δ 9.04 (s, 1H), 8.52 (s, 2H), 6.10 (d, J=1.8 Hz, 1H), 5.62 (d, J=2.4 Hz, 1H), 1.52-1.42 (m, 
6H), 1.29 (sext, J=7.8 Hz, 6H), 1.06-0.84 (m, 15H); 13C NMR (100 MHz, CDCl3) δ 156.4, 153.9, 147.5, 
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139.7, 130.9, 28.8, 27.1, 13.5, 10.2; IR (APT) 2956, 2925, 1544, 1407 cm-1; HRMS (ESI) calcd for 
C18H33N2Sn (M+H
+) 397.1666, found 397.1666. 
 
1-(5-Benzyloxy-2-nitrophenyl)-1-(4-pyrimidyl)ethene (25). To mixture of 12 (584 mg, 1.64 mmol), 
PPh3 (66 mg, 0.25 mmol), CuI (241 mg, 1.26 mmol) and Pd2dba3 (58 mg, 0.063 mmol) in DMF (5 mL) at 
ambient under an atmosphere of N2, was added a solution of 24 (500 mg, 1.26 mmol) in DMF (1 mL). 
The resulting brown reaction mixture was heated at 120 oC for 36 h. After cooling to ambient temperature, 
the mixture was diluted with EtOAc (30 mL) and the organic layer was washed with water (4x20 mL) and 
brine (20 mL). The organic phase was dried over MgSO4, filtered, and the solvent was removed under 
reduced pressure. The crude product was purified by column (EtOAc/hexanes, 3:7, then 1:1) to afford 25 
(223 mg, 0.669 mmol, 53%) as viscous pale brown oil that slowly solidified. mp=113 oC; 1H NMR (400 
MHz, CDCl3) δ 9.11 (s, 1H), 8.62 (s, 2H), 8.17 (d, J=8.8, 1H), 7.45-7.37 (m, 5H), 7.09 (dd, J=8.8, 2.4 Hz, 
1H), 6.99 (d, J=2.8 Hz, 1H), 5.82 (s, 1H), 5.44 (s, 1H), 5.19 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 
162.5, 157.7, 153.9, 141.5, 137.3, 135.0, 132.6, 128.7, 128.5, 127.7, 127.4, 118.4, 117.7, 114.6, 70.7; IR 
(APT) 1575, 1510, 1340, 1223 cm-1; HRMS calcd for C19H16N3O3 (M+H
+) 334.1192, found 334.1190. 
5-Benzyloxy-3-(4-pyrimidyl)indole (26). Treatment of a solution of 25 (200 mg, 0.600 mmol) in the 
presence of Pd2(dba)3 (33 mg, 0.036 mmol), dppp (15 mg, 0.036 mmol), and phen (13 mg, 0.072 mmol) 
in DMF (2 mL) with CO (6 atm), as described for 8 (120 oC, 28 h), gave after work up and 
chromatography (EtOAc/hexanes, 7:3) 26 (163 mg, 0.540 mmol, 90%) as a white solid. mp=189 oC; 1H 
NMR (400 MHz, CDCl3) δ  9.14 (s, 1H), 9.00 (s, 2H), 8.52 (br, s, 1H), 7.48 (d, J=7.2 Hz, 2H), 7.45 (d, 
J=2.8 Hz, 1H), 7.42-7.31 (m, 5H), 7.05 (dd, J=8.4, 2.0 Hz, 1H), 5.12 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 156.0, 154.5, 154.4, 137.2, 131.9, 129.9, 128.6, 127.9, 127.6, 125.5, 123.3, 114.2, 112.6, 110.7, 
102.3, 70.9; IR (ATR) 3017,1533, 1486, 1157 cm-1; HRMS (ESI) calcd for C19H16N3O (M+H
+) 302.1293 
, found 302.1291. 
Hyrtinadine B. Treatment of a solution of 21 (90 mg, 0.30 mmol) with Pd/C (10%, 28 mg, 0.026 mmol) 
in MeOH (1.5 mL), as described for alocasin A (4 atm H2, 60
 oC, 6 h) gave after work up and 
chromatography (EtOAc) hyrtinadine B (53 mg, 0.251 mmol, 84%) as a white solid. mp=289-290 oC;  1H 
NMR (400 MHz, CD3OD) δ 9.05 (s, 2H), 8.89 (s, 1H), 7.62 (s, 1H), 7.24 (d, J=8.4 Hz, 1H), 7.16 (d, 
J=2.4 Hz, 1H), 6.72 (dd, J=8.8, 2.0 Hz, 1H); 13C NMR (100 MHz, CD3OD) δ 155.5, 155.0, 153.3, 133.7, 
133.1, 127.0, 126.1, 113.8, 113.8, 109.5, 103.8; IR (ATR) 3327, 2727, 1557, 1420, 1386 cm-1; HRMS 
(ESI) calcd for C12H10N3O (M+H
+) 212.0824, found 212.0821. 
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[(6-Chloro-2-nitrophenyl)methyl]triphenylphosphonium bromide (28). To a solution of 2-chloro-6-
nitrobenzylbromide (3.03 g, 12.1 mmol) in toluene (36 mL) was added, in portions, triphenylphosphine 
(PPh3, 3.49 g, 13.3 mmol). The resulting solution was stirred under a nitrogen atmosphere, at 100 
o
C, for 
12 h. A precipitate started to form after 15 min.  The mixture was cooled to ambient temperature, the 
precipitate was removed by filtration, the solid was washed with Et2O and the solvents were removed to 
afford 28 (6.21 g, 12.1 mmol, 100%) as a white solid.
 
mp=235-243 
o
C; 
1
H NMR (600 MHz, DMSO-d6) δ 
7.96 (d, J=8.4 Hz, 1H), 7.89-7.85 (m, 4H), 7.73-7.66 (m, 12H), 7.63 (td, J=7.8, 1.8 Hz, 1H), 5.34 (d, 
J=14.4 Hz, 2H); 
13
C NMR (150 MHz, DMSO-d6) δ 149.7 (d, J
CP
=4.5 Hz), 136.4 (d, J
CP
=6.0 Hz), 135.4 
(d, J
CP
=3.0 Hz), 135.1 (d, J
CP
=3.0 Hz), 133.8 (d, J
CP
=10.5 Hz), 131.3 (d, J
CP
=3.0 Hz), 130.0 (d, J
CP
=13.5 
Hz), 124.9 (d, J
CP
=3.0 Hz), 123.5 (d, J
CP
=9.0 Hz), 117.9 (d, J
CP
=85.5 Hz), 25.9 (d, J
CP
=51.0 Hz); IR 
(ATR) 1533, 1434, 1355, 1107, 748 cm
-1
; HRMS (ESI, negative ion mode) calcd for C25H20BrClNO2P 
(M
-
) 511.0104, found 511.0133. 
[(3-Methoxy-2-nitrophenyl)methyl] triphenylphosphonium bromide (29). Treatment of 3-methoxy-2-
nitrobenzylbromide (1.48 g, 6.05 mmol) with PPh3 (1.74 g, 6.64 mmol) in toluene (15 mL) as described 
for 28 (100 
o
C, 12 h), gave after work up 29 (2.67 g, 5.26 mmol, 87%) as a white solid. mp=213-215 
o
C; 
1
H NMR (600 MHz, DMSO-d6) δ 7.92 (t, J=7.8 Hz, 3H), 7.74 (dt, J=7.8, 3.6 Hz, 6H), 7.63 (dd, J=8.4, 
7.2 Hz, 6H), 7.42 (t, J=8.4 Hz, 1H), 7.35 (d, J=9.0 Hz, 1H), 6.66 (dd, J=8.4, 2.4 Hz, 1H), 5.10 (d, J=15.0 
Hz, 2H), 3.84 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ 151.4 (d, J
CP
=2.2 Hz), 140.9(d, J
CP
=6.9 Hz), 
135.3 (d, J
CP
=3.4 Hz), 133.9 (d, J
CP
=10.2 Hz), 132.1 (d, J
CP
=3.4 Hz), 130.2 (d, J
CP
=12.6 Hz), 123.1 (d, 
J
CP
=4.6 Hz), 121.8 (d, J
CP
=7.9 Hz), 117.1 (d, J
CP
=84.6 Hz), 114.3 (d, J
CP
=2.2 Hz), 57.0, 25.3 (d, J
CP
=49.2 
Hz); IR (ATR) 1536, 1433, 1281, 1108, 685 cm
-1
; HRMS (ESI, negative ion mode) calcd for 
C26H23BrNO3P (M
-
) 507.0599, found 507.0628. 
[(4-Bromo-2-nitrophenyl)methyl] triphenylphosphonium bromide (30). Treatment of 4-bromo-2-
nitrobenzylbromide (208 mg, 0.705 mmol) with PPh3 (203 mg, 0.774 mmol) in toluene (8 mL) as 
described for 28 (100 
o
C, 8 h), gave after work up 30 (393 mg, 0.705 mmol, 100%) as a white solid. 
mp=242-244
 o
C; 
1
H NMR (400 MHz, DMSO-d6) δ 8.24 (d, J=2.0 Hz, 1H), 7.97-7.90 (m, 3H), 7.92(d, 
J=1.6 Hz, 1H), 7.77-7.72 (m, 6H), 7.66-7.61 (m, 6H), 7.31 (dd, J=8.0, 2.4 Hz, 1H), 5.42 (d, J=15.2 Hz, 
2H); 
13
C NMR (150 MHz, DMSO-d6) δ 148.8 (d, J
CP
=6.1 Hz), 137.3 (d, J
CP
=3.0 Hz), 135.3 (d, J
CP
=3.0 
Hz), 133.9 (d, J
CP
=10.6 Hz), 130.3 (d, J
CP
=12.1 Hz), 128.4 (d, J
CP
=2.3 Hz), 123.1 (d, J
CP
=8.4 Hz), 122.6 
(d, J
CP
=4.5 Hz), 117.4, 116.6, 26.4 (d, J
CP
=49.3 Hz); IR (ATR) 1521, 1367, 1346, 1284, 1066, 852 cm
-1
; 
HRMS (ESI) calcd for C25H20Br2NO2P (M-Br) 476.0415, found 476.0416. 
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3-(5-Bromo-2-nitrophenyl)-2-propenal (32) and 5-(5-Bromo-2-nitrophenyl)-2,4-pentadienal (43). A 
mixture of 5-bromo-2-nitrobenzaldehyde (600 mg, 2.61 mmol), (formylmethyl)triphenylphosphonium 
chloride (1.78 mg, 5.22 mmol) and DMAP (956 mg, 7.82 mmol) in CHCl3 (36 mL) was stirred at ambient 
temperature for 4 h followed by heating at reflux for 3 h. After cooling to ambient temperature, the 
solvent was removed under reduced pressure and the resulting crude product was purified by 
chromatography (hexane/EtOAc, 95:5) to afford, in order of elution, 32 (337 mg, 1.32 mmol, 51%) and 
43 (153 mg, 0.542 mmol, 21%) both as pale yellow solids.  Analytical data for 32: mp=125-130 °C; 
1
H 
NMR (600 MHz, CDCl3) δ 9.78 (d, J=7.2 Hz, 1H), 8.01 (d, J=3.0 Hz, 1H), 7.99 (d, J=9.6 Hz, 1H), 7.80 
(d, J=1.8 Hz, 1H), 7.73 (dd, J=9.0, 1.8 Hz, 1H), 6.61 (dd, J=15.5, 7.8 Hz, 1H); 
13
C NMR(150 MHz, 
CDCl3) δ 192.5, 146.5, 145.7, 133.9, 133.4, 132.0, 131.9, 128.8, 126.7; IR (ATR) 1675, 1521, 1345, 
1098, 834 cm
-1
; HRMS (ESI, negative ion mode) calcd for C9H6BrNO3 (M
-
) 254.9531, found 254.9530. 
Analytical data for 43: mp=110-119 °C; 
1
H NMR (600 MHz, CDCl3) δ 9.68 (d, J=7.8 Hz, 1H), 7.92 (d, 
J=8.4 Hz, 1H), 7.84 (d, J=2.4 Hz, 1H), 7.62 (dd, J=9.0, 1.8 Hz, 1H), 7.50 (d, J=15.6 Hz, 1H), 7.30 (dd, 
J=15.6, 10.8 Hz, 1H), 6.96 (dd, J=15.6, 11.4 Hz, 1H), 6.36 (dd, J=15.0, 7.8 Hz, 1H);
 13
C NMR (150 MHz, 
CDCl3) δ 193.2, 149.8, 146.6, 135.0, 134.1, 133.1, 132.5, 131.8, 131.4, 128.4, 126.6;IR (ATR) 3417, 
1676, 1512, 1345, 1334, 1117, 983 cm
-1
; HRMS (ESI, negative ion mode) calcd for C11H8BrNO3 (M
-
) 
280.9688, found 280.9709. 
E,E-1-(2-Chloro-6-nitrophenyl)-4-(2-nitrophenyl)-1,3-butadiene (34). A solution of freshly prepared 
sodium ethoxide (NaOEt, 1.5 M in EtOH, 6 mL, 9.0 mmol) was added drop wise to a solution of 31 (389 
mg, 2.20 mmol) and 28 (1.13 g, 2.20 mmol) in absolute EtOH (9 mL) at ambient temperature.  The 
reaction mixture turned dark purple slowly changing to red.  After 36 h at ambient temperature, water (30 
mL) was added, and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic phases 
were dried (MgSO4), filtered, and the solvents were removed under reduced pressure. The residue was 
purified by chromatography (hexane/EtOAc, 9:1, then 8:2) to give 34 (399 mg, 1.21 mmol, 55%) as an 
orange solid. mp=153-155 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.92 (dd, J=8.0, 0.8 Hz, 1H), 7.90 (dd, 
J=8.4, 1.2 Hz, 1H), 7.82 (dd, J=8.4, 1.2 Hz, 1H), 7.73-7.63 (m, 3H), 7.60 (td, J=7.2, 0.4 Hz, 1H), 7.51 (td, 
J=8.0, 0.8 Hz, 1H), 7.46-7.32 (m, 6H), 7.19 (d, J=15.2 Hz, 1H), 7.17 (d, J=15.2 Hz, 1H), 6.93 (dd, 
J=13.4, 10.0 Hz, 1H), 6.83 (d, J=15.6 Hz, 1H), 6.73-6.59 (m, 3H), 6.40 (dd, J=15.2, 10.0 Hz, 1H); 
13
C 
NMR (100 MHz, DMSO-d6) δ 150.7, 150.3, 147.9, 147.8, 136.6, 135.7, 135.1, 133.7, 133.6, 133.2, 133.0, 
133.0, 132.9, 132.2, 132.0, 130.8, 130.2, 130.2, 129.7, 128.9, 128.4, 128.4, 128.3, 128.3, 127.9, 127.7, 
125.8, 124.7, 124.6, 124.3, 122.5, 122.4; IR (ATR) 1515, 1343, 986, 751, 725 cm
-1
; HRMS (ESI) calcd 
for C16H12ClN2O2 (M+H
+
) 331.0485, found 331.0480. 
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EE/ZE-1-(3-Methoxy-2-nitrophenyl)-4-(2-nitrophenyl)-1,3-butadiene (35). Treatment of a solution of 
31 (300 mg, 1.69 mmol) and 29 (861 mg, 1.69 mmol) in EtOH (18 mL) in the presence of NaOEt (1.7 M, 
11 mL, 18.7 mmol), as described for 34 (24 h), gave after work up and chromatography (hexane/EtOAc, 
8:2, then 7:3) 35 (354 mg, 1.08 mmol, 64%, EE/ZE=1:1) as an orange solid. mp=130-135 
o
C; 
1
H NMR 
(600 MHz, DMSO-d6) δ 7.97-7.95 (m, 3H), 7.76 (dd, J=7.9, 1.4 Hz, 1H), 7.71 (dd, J=7.8, 1.3 Hz, 1H), 
7.68 (dd, J=7.9, 1.3 Hz, 1H), 7.59 (t, J=8.3 Hz, 1H), 7.56-7.51 (m, 4H), 7.41-7.30 (m, 3H), 7.25 (dd, 
J=8.3, 0.8 Hz, 1H), 7.17 (d, J=15.2 Hz, 1H), 7.16 (d, J=7.9 Hz, 1H), 7.13 (d, J=15.2 Hz, 1H), 7.03 (dd, 
J=15.2, 11.5 Hz, 1H), 6.73 (t, J=11.4 Hz, 1H), 6.59 (d, J=15.5 Hz, 1H), 6.45 (d, J=11.3 Hz, 1H), 3.92 (s, 
3H), 3.90 (s, 3H); 
13
C NMR (150 MHz, CDCl3, major and minor) δ 150.3, 150.2, 147.9, 147.8, 139.9, 
139.7, 134.4, 133.9, 133.6, 133.5, 133.2, 131.6, 131.3, 130.9, 130.9, 130.8, 129.3, 129.1, 129.1, 128.9, 
128.7, 128.3, 128.2, 127.7, 125.5, 124.4, 124.4, 124.1, 121.9, 117.4, 112.8, 112.5, 56.7, 56.7; IR (ATR) 
1519, 1369, 1343, 1285, 1063 cm
-1
; HRMS (ESI) calcd for C17H15N2O5 (M+H
+
) 327.0981, found 
327.0976. 
EE/EZ-1-(4-Bromo-2-nitrophenyl)-4-(2-nitrophenyl)-1,3-butadiene (36). Treatment of a solution of 
31 (51 mg, 0.29 mmol) and 30 (155 mg, 0.278 mmol) in EtOH (7 mL) in the presence of NaOEt (1.7 M, 7 
mL, 11.9 mmol), as described for 34 (36 h), gave after work up and chromatography (hexane/EtOAc, 9:1) 
36 (78.4 mg, 0.209 mmol, 73%, EE/EZ=1:2) as an orange solid. NMR data from the EE/EZ=1:2 mixture 
of 36: mp=141-142 
o
C;
 1
H NMR (600 MHz, DMSO-d6) δ 8.32 (d, J=2.1 Hz, 1H), 8.19 (d, J=2.1 Hz, 
0.5H), 7.99-7.94 (m, 3H), 7.91 (dd, J=8.6, 2.0 Hz, 0.5H), 7.78 (dd, J=8.0, 1.3 Hz, 1H), 7.72 (t, J=6.7 Hz, 
0.5H), 7.65 (dd, J=7.4, 0.7 Hz, 1H), 7.54-7.50 (m, 3H), 7.38 (dd, J=15.1, 10.5 Hz, 0.5H), 7.31 (dd, 
J=14.9, 10.6 Hz, 0.5H), 7.17-7.14 (m, 1.5H), 7.05-6.98 (m, 1.5H), 6.79 (d, J=11.4 Hz, 1H), 7.73 (t, 
J=11.2 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ 148.3, 148.2, 147.9, 147.8, 136.3, 135.8, 134.6, 
134.0, 133.7, 133.3, 133.2, 131.8, 130.9, 130.7, 130.4, 130.2, 129.3, 129.0, 128.9, 128.9, 128.5, 128.2, 
128.2, 127.7, 127.2, 127.1, 126.9, 122.4, 124.3, 120.7, 120.6;
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cm
-1
; HRMS (ESI) calcd for C16H12BrN2O4 (M+H
+
) 374.9980, found 374.9975. 
EZ/EE-1-(4-Bromo-2-nitro-nitrophenyl)-4-(5-bromo-2-nitrophenyl)-1,3-butadiene (37). Treatment of 
a solution of 32 (320 mg, 1.25 mmol) with 30 (696 mg, 1.25 mmol) in the presence of NaOEt (2.0 M in 
EtOH, 2.81 mL, 5.62 mmol) in EtOH (16 mL), as described for 34 (24 h) gave after work up and 
chromatography (hexane/EtOAc, 9:1) 37 (424 mg, 0.934 mmol, 75%, EZ/EE=7:1) as an orange solid. 
mp=159-162 °C; 
1
H
 
NMR data from the EZ/EE=7:1 mixture of 37, major isomer: 
1
H NMR (600 MHz, 
CDCl3) δ 8.29 (d, J=1.8 Hz, 1H), 7.83 (d, J=8.6 Hz, 1H), 7.78 (dd, J=8.3, 1.8 Hz, 1H), 7.60 (d, J=2.0 Hz, 
1H), 7.51 (dd, J=8.8, 1.9 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.22 (d, J=15.3 Hz, 1H), 6.90 (d, J=11.2 Hz, 
1H), 6.78 (dd, J=15.2, 11.2 Hz, 1H), 6.64 (t, J=11.4 Hz, 1H); partial 
1
H
 
NMR data for minor isomer: 
1
H 
96 
 
NMR (600 MHz, CDCl3) δ 8.11 (d, J=1.6 Hz, 1H), 7.87 (d, J=2.5 Hz, 1H), 7.73 (dd, J=9.1, 1.8 Hz, 1H), 
7.62 (d, J=8.3 Hz. 1H), 7.54 (dd, J=8.6, 1.7 Hz, 1H), 7.02-6.96 (m, 2H); 
13
C NMR (150 MHz, DMSO-d6) 
δ 148.1, 148.0, 146.4, 146.3, 136.3, 136.2, 134.4, 134.2, 134.0, 133.7, 133.6, 131.5, 131.4, 131.0, 130.9, 
130.8, 130.0, 129.5, 129.3, 129.2, 128.8, 128.6, 128.1, 128.1, 128.0, 127.8, 126.5, 126.4, 126.4, 126.3, 
121.9, 121.7; IR (ATR) 3381, 1589, 1517, 1335, 748 cm
-1
; HRMS (ESI, negative ion mode) calcd for 
C16H10Br2N2O4 (M
-
) 451.9007, found 451.9018. 
2,2’-Bi-1H-indole (38). 1,4-Di(2-nitrophenyl)-1,3-butadiene (33)94 (51 mg, 0.17 mmol), Pd(dba)2 (6 mg, 
0.01 mmol), dppp (4 mg, 0.01 mmol) and phen (5 mg, 0.02 mmol) were dissolved in anhydrous DMF (1 
mL) in a threaded ACE glass pressure tube. The tube was fitted with a pressure head, and the solution was 
saturated with carbon monoxide (four cycles of 6 atm of CO). The reaction mixture was heated at 120 
o
C 
under CO (6 atm) until all starting material was consumed (60 h), as judged by TLC (hexanes/EtOAc, 
9:1). Brine (10 mL) was added and the red-brown solution was extracted with EtOAc (3x20 mL). The 
combined organic phases were dried (MgSO4), filtered, and the solvent was removed under reduced 
pressure. The resulting crude product was purified by chromatography (hexane/EtOAc, 19:1) to afford 38 
(29 mg, 0.13 mmol, 73%) as a white solid. mp 310-313 
o
C (lit.
95
 mp 310-312 
o
C). 
4-Chloro-2,2’-bi-1H-indole (39). Treatment of a solution of 34 (297 mg, 0.898 mmol) in DMF (2 mL) 
with Pd(dba)2 (36 mg, 0.063 mmol), dppp (26 mg, 0.063 mmol) and phen (23 mg, 0.126 mmol), as 
described for 38 (6 atm CO, 120 
o
C, 40 h), gave after work up and chromatography (hexane/EtOAc, 9:1) 
39 (226 mg, 0.846 mmol, 94%) as a white solid. mp=186-187 
o
C; 
1
H NMR (400 MHz, Acetone-d6) δ 
11.03 (br, s, 1H), 10.81 (br, s, 1H), 7.60 (dd, J=7.6, 0.8 Hz, 1H), 7.46 (dd, J=8.0, 0.8 Hz, 1H), 7.39 (ddd, 
J=7.2, 2.4, 0.8 Hz, 1H), 7.18 (td, J=7.6, 0.4 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H), 7.14-7.05 (m, 4H), 7.01 (dd, 
J=2.4, 0.8 Hz, 1H); 
13
C NMR (100 MHz, Acetone-d6) δ 138.9, 138.3, 133.3, 131.5, 129.8, 128.6, 125.7, 
123.5, 123.2, 121.2, 120.7, 120.1, 111.9, 110.8, 100.2, 97.6; IR (ATR) 3409, 3063, 1334, 1185, 747 cm
-1
; 
HRMS (ESI) calcd for C16H12ClN2 (M+H
+
) 267.0689, found 267.0686. 
7-Methoxy-2,2’-bi-1H-indole (40). Treatment of a solution of 35 (86 mg, 0.26 mmol) in DMF (2 mL) 
with Pd(dba)2 (11 mg, 0.018 mmol), dppp, (8 mg, 0.018 mmol) and phen (23 mg, 0.126 mmol), as 
described for 38 (CO 6 atm, 120 
o
C, 72 h), gave after work up and chromatography (hexane/EtOAc, 9:1) 
40 (64 mg, 0.24 mmol, 93%) as a white solid. mp=228-229 
o
C; 
1
H NMR (400 MHz, Acetone-d6) δ 10.68, 
(br, s, 1H), 10.58 (br, s, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.42 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.17 (d, J=8.0 Hz, 
1H), 7.13 (td, J=6.8, 1.2 Hz, 1H), 7.11 (d, J=1.2 Hz, 1H), 7.04 (td, J=6.8, 1.2 Hz, 1H), 6.98 (d, J=8.0 Hz, 
1H), 6.94 (d, J=2.4 Hz, 1H), 6.68 (d, J=7.6 Hz, 1H), 3.94 (s, 3H); 
13
C NMR (100 MHz, Acetone-d6) δ 
147.2, 138.1, 132.3, 132.1, 131.3, 130.0, 128.3, 122.7, 121.2, 121.0, 120.5, 113.8, 111.8, 103.7, 100.2, 
97 
 
100.0, 55.6; IR (ATR) 3346, 1580, 1344, 1252, 1094, 729 cm
-1
; HRMS (ESI) calcd for C17H15N2O 
(M+H
+
) 263.1184, found 263.1184. 
6-Bromo-2,2’-bi-1H-indole (41). Treatment of a solution of 36 (72 mg, 0.19 mmol) in DMF (1.5 mL) 
with Pd(dba)2 (8 mg, 0.013 mmol), dppp, (6 mg, 0.013 mmol) and phen (5 mg, 0.027 mmol), as described 
for 38 (CO 6 atm, 120 
o
C, 49 h), gave after work up and chromatography (hexane/EtOAc, 1:9) 41 (44 mg, 
0.142 mmol, 74%) as a white solid. mp=251-252 
o
C; 
1
H NMR (400 MHz, Acetone-d6) δ 10.93 (s, 1H), 
10.79 (s, 1H), 7.58 (s, 1H), 7.57 (d, J=8.8 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.41 (dd, J=7.6, 0.8 Hz, 1H), 
7.17 (dd, J=8.8, 2.0 Hz, 1H), 7.14 (dd, J=8.4, 1.2 Hz, 1H), 7.04 (t with further fine splittings, J=7.2 Hz, 
1H), 6.96 (br s, 2H); 
13
C NMR (100 MHz, Acetone-d6) δ 138.9, 138.2, 133.4, 131.7, 129.8, 129.0, 123.6, 
123.1, 122.5, 121.1, 120.6, 115.6, 114.5, 111.9, 100.0, 99.5; IR (ATR) 3425, 1386, 1338, 1218, 741 cm
-1
; 
HRMS (ESI) calcd for C16H12BrN2 (M+H
+
) 311.0183, found 311.0176. 
5,6’-Dibromo-2,2’-bi-1H-indole (42). Treatment of a solution of 37 (100 mg, 0.220 mmol) in the 
presence of Pd(dba)2 (8.9 mg, 0.015 mmol), dppp (6.4 mg, 0.015 mmol) and phen (5.6 mg, 0.031 mmol) 
in DMF (1.5 mL) with CO (6 atm), as described for 38 (120 
o
C , 58 h), gave after work up and 
chromatography (hexane/EtOAc, 9:1) 42 (61.3 mg,  0.157 mmol, 71%) as a white solid. mp=275-276 °C; 
1
H NMR (600 MHz, CDCl3/DMSO-d6) δ 11.73 (br, s, 1H), 11.69 (br, s, 1H), 7.74 (s, 1H), 7.53 (s, 1H), 
7.50 (d, J=8.4 Hz, 1H), 7.34 (d, J=9.0 Hz, 1H), 7.19 (dd, J=8.4, 1.8 Hz, 1H), 7.12 (dd, J=8.4, 1.8 Hz, 1H), 
6.94 (s, 1H), 6.90 (s, 1H); 
13
C NMR (150 MHz, CDCl3/DMSO-d6) δ 137.8, 135.6, 132.2, 131.6, 130.2, 
127.3, 124.1, 122.3, 122.1, 121.6, 114.4, 113.5, 112.8, 111.9, 99.0, 98.3; IR (ATR) 3416, 1599, 1437, 
1332, 802 cm
-1
; HRMS (ESI) calcd for C16H11Br2N2 (M+H
+
) 388.9289, found 388.9286. 
Tributyl(1-(2-nitrophenyl)ethenyl)tin (48). Tributyltin hydride (742 mg, 2.55 mmol) was added drop 
wise, at ambient temperature, to a solution of PdCl2(PPh3)2 (119 mg, 0.170 mmol) and 1-ethynyl-2-
nitrobenzene (44)
96
 (250 mg, 1.70 mmol) in THF (5 mL). The dark brown reaction mixture was stirred for 
34 h followed by removal of the solvent under reduced pressure. Purification by chromatography 
(hexane/EtOAc, 95:5) gave 48 (707 mg, 1.61 mmol, 95%) as a pale green oil. 
1
H NMR (600 MHz, 
CDCl3) δ 7.99 (dd, J = 8.4, 1.2 Hz, 1H), 7.52 (dt, J = 7.8, 1.2 Hz, 1H), 7.31 (dt, J = 7.2, 1.2 Hz, 1H), 7.11 
(dd, J = 7.8, 1.2 Hz, 1H), 5.74 (d, J = 3.0 Hz, 1H), 5.45 (d, J = 2.4 Hz, 1H), 1.43-1.48 (m, 6H), 1.26 (sext, 
J = 7.8 Hz, 6H), 0.91-0.94 (m, 6H), 0.86 (t, J = 7.2 Hz, 9H); 
13
C NMR (150 MHz, CDCl3) δ 154.6, 146.0, 
144.3, 133.2, 129.7, 126.3, 126.0, 124.3, 28.8, 27.3, 13.6, 10.9; IR (ATR) 2922, 1518, 1339, 1038 cm
-1
; 
HRMS (ESI) calcd for C20H34NO2
120
Sn (M+H
+
) 440.1606, found 440.1607. 
Tributyl(1-(5-benzyloxy-2-nitrophenyl)ethenyl)tin (4). Treatment of 3
58
 (1.30 g, 5.15 mmol) in dry 
THF (15 mL) with tributyltin hydride (2.30 g, 7.90 mmol) in the presence of PdCl2(PPh3)2 (362 mg, 0.515 
98 
 
mmol), as described for 48 (24 h), gave after solvent removal and chromatography (hexane/EtOAc, 9:1) 4 
(2.70 g, 4.96 mmol, 96%) as a brown viscous oil. 
1
H NMR (400 MHz, CDCl3) δ 8.10 (d, J=9.2 Hz, 1H), 
7.45-7.33 (m, 5H), 6.86 (dd, J=9.2, 2.4 Hz, 1H), 6.63 (d, J=2.0 Hz, 1H), 5.72 (d, J=2.4 Hz, 1H), 5.41 (d, 
J=2.0 Hz, 1H), 5.14 (s, 2H), 1.56-1.37 (m, 6H), 1.27 (sext, J=7.2 Hz, 6H), 0.95 – 0.84 (m, 15H); 13C 
NMR (100 MHz, CDCl3) δ 162.3, 155.7, 147.6, 139.1, 135.6, 128.7, 128.4, 127.5, 127.1, 124.8, 114.6, 
112.7,70.5, 28.8, 27.3, 13.6, 11.0; IR
 
(ATR) 2954, 2922, 1567, 1329, 1283, 1243, 1228, 694 cm
-1
; HRMS 
calcd for C27H40NO3Sn (M+H
+
) 546.2030, found 546.2030. 
Tributyl(1-(4-chloro-2-nitrophenyl)ethenyl)tin (49). Treatment of a solution of 45
97
 (215 mg, 1.18 
mmol) in THF (3 mL) with tributyltin hydride (577 mg, 1.78 mmol) in the presence of PdCl2(PPh3)2 (83.1 
mg, 0.118 mmol), as described for 48 (24 h), gave after solvent removal and chromatography 
(hexane/EtOAc, 19:1) 49 (537 mg, 1.13 mmol, 96%) as a brown viscous oil. 
1
H NMR (400 MHz, CDCl3) 
δ 7.99 (d, J=2.0 Hz, 1H), 7.48 (dd, J=8.4, 2.4 Hz, 1H), 7.05 (d, J=8.0, Hz, 1H), 5.73 (d, J=2.4 Hz, 1H), 
5.46 (d, J=2.4 Hz, 1H), 1.51-1.43 (m, 6H), 1.30 (sext, J=8.0 Hz, 6H),  0.99-0.82 (m, 15H); 
13
C NMR (100 
MHz, CDCl3) δ 153.6, 146.1, 142.8, 133.2, 131.8, 130.8, 126.8, 124.2, 28.8, 27.2, 13.6, 10.9; IR (ATR) 
2954, 2922, 1567, 1329, 1283, 1243, 1228, 694 cm
-1
; HRMS (ESI, negative ion mode) calcd for 
C20H32ClNO2Sn (M
-
) 473.1144, found 473.1188. 
Tributyl(1-(4-carbomethoxy-2-nitrophenyl)ethenyl)tin (50). Treatment of a solution of 46
90
 (100 mg, 
0.487 mmol) in THF (2 mL) with tributyltin hydride (213 mg, 0.731 mmol) in the presence of 
PdCl2(PPh3)2 (34 mg,  0.049 mmol), as described for 48 (35 h) gave after solvent removal  and 
chromatography (hexane/EtOAc, 19:1) 50 (189 mg, 0.380 mmol, 78%) as a brown viscous oil.  
1
H NMR 
(400 MHz, CDCl3) δ 8.63 (d, J=1.6 Hz, 1H), 8.15 (dd, J=7.6, 1.6 Hz, 1H), 7.17 (d, J=8.0 Hz, 1H), 5.75 
(d, J=2.8 Hz, 1H), 5.48 (d, J=2.8 Hz, 1H), 3.96 (s, 3H), 1.51-1.43 (m, 6H), 1.25 (sext, J=7.2 Hz, 6H), 
0.94-0.90 (m, 6H), 0.85 (t, J=6.8 Hz, 9H); 
13
C NMR (100 MHz, CDCl3) δ 165.0, 154.1, 148.7, 145.8, 
133.5, 129.9, 128.6, 126.4, 125.6, 52.4, 28.7, 27.2, 13.6, 11.0; IR (ATR) 2954, 2922, 1567, 1329, 1283, 
1243, 1228, 694 cm
-1
; HRMS (ESI, negative ion mode) calcd for C22H35N2O4Sn (M
-
) 497.1588, found 
497.1645. 
Tributyl(1-(4-methoxy-2-nitrophenyl)ethenyl)tin (51). Treatment of a solution of 47
99
 (1.10 g, 6.21 
mmol) in THF (130 mL) with tributyltin hydride (2.71 g, 9.31 mmol) in the presence of PdCl2(PPh3)2 
(436 mg, 0.621 mmol), as described for 48 (32 h), gave after solvent removal and chromatography 
(hexane/EtOAc, 9:1) 51 (2.62 g, 5.58 mmol, 90%) as a brown viscous oil. 
1
H NMR (400 MHz, CDCl3) δ 
7.52 (d, J=2.8 Hz, 1H), 7.10 (dd, J=8.4, 2.8 Hz, 1H), 7.01 (d, J=8.0,Hz, 1H), 5.72 (d, J=2.4 Hz, 1H), 5.42 
(d, J=2.8 Hz, 1H), 3.86 (s, 3H),  1.51-1.32 (m, 6H), 1.26 (sext, J=7.6 Hz, ,6H), 0.98-0.82 (m, 15H); 
13
C 
99 
 
NMR (100 MHz, CDCl3) δ 157.9, 154.3, 146.1, 136.8, 130.7, 126.1, 120.6, 108.2, 55.8, 28.8, 27.3, 13.6, 
10.8; IR (ATR) 2924, 1521, 1341, 1303, 1034 cm
-1
; HRMS (ESI) calcd for C21H36NO3
120
Sn (M+H
+
-C4H8) 
412.0935, found 412.0931. 
2,3-Di(2-nitrophenyl)-1,3-butadiene (52).
58
 To a solution of 48 (348 mg, 0.794 mmol) in DMF (10 mL) 
was added PdCl2(PPh3)2 (28 mg, 0.040 mmol), PPh3 (21 mg, 0.080 mmol) and CuI (113 mg, 0.595 
mmol). The reaction was stirred at ambient temperature for 36 h. Et2O (30 mL) was added and the organic 
phase was washed with NH4OH (10%, aqueous, 3 X 30 mL), H2O (30 mL), and brine (30 mL). The 
organic phase was dried (MgSO4), filtered, and the solvents were removed under reduced pressure. The 
resulting solid was purified by chromatography (hexane/EtOAc, 95:5) to afford 52 (78 mg, 0.263 mmol, 
67%) as a dark yellow solid. mp=122-124 
o
C; 
1
H NMR (600 MHz, CDCl3) δ 7.98 (dd, J=8.4, 1.2 Hz, 2H), 
7.66 (dt, J=7.8, 1.2 Hz, 2H), 7.61 (dd, J=7.8, 1.2 Hz, 2H), 7.52 (dt, J=7.2, 1.2 Hz, 2H), 5.15 (s, 2H), 4.92 
(s, 2H); 
13
C NMR (150 MHz, CDCl3) δ 149.0, 145.2, 135.3, 132.9, 132.4, 128.7, 124.0, 118.3; IR (ATR) 
1514, 1332, 911, 790, 749, 697 cm
-1
; HRMS (ESI) calcd for C16H12N2NaO4 (M+Na
+
) 319.0695, found 
319.0690. 
2,3-Di(5-benzyloxy-2-nitrophenyl)-1,3-butadiene (7). Treatment of 4 (103 mg, 0.189 mmol) in DMF 
(1.5 mL) with Pd(dba)2 (7.2 mg, 0.013 mmol), PPh3 (14 mg, 0.053 mmol), and CuI (36 mg, 0.189 mmol), 
as described for 52 (28 h), gave after work up and chromatography
100
 (hexane/EtOAc, 9:1) 7 (37.6 mg, 
0.074 mmol, 78%) as a white solid. mp=158-160 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 8.08 (d, J=9.2, Hz, 
1H), 7.48-7.36 (m, 5H), 7.17 (d, J=2.8 Hz, 1H), 7.02 (dd, J=9.6, 3.2 Hz, 1H), 5.19 (s, 2H), 5.08 (s, 1H), 
4.88 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 162.2, 145.6, 141.7, 138.3, 135.5, 128.7, 128.4, 127.8, 126.8, 
117.5, 117.1, 114.9, 70.7; IR (ATR) 1573, 1513, 1343, 1230, 1007 cm
-1
; HRMS (ESI) calcd for 
C30H25N2O6 (M+H
+
) 509.1713, found 509.1715. 
2,3-Di(4-chloro-2-nitrophenyl)-1,3-butadiene (53). To a slurry of copper chloride (210 mg, 2.12 mmol) 
in DMF (2 mL) in a round bottomed flask covered with aluminum foil to exclude light was added a 
solution of 49 (400 mg, 0.846 mmol) in DMF (2 mL). The resulting mixture was stirred at ambient 
temperature for 1 h. A saturated solution of NH4Cl (aqueous, 4 mL) was added and the mixture was 
allowed to stir for an additional hour. The mixture was diluted with EtOAc (30 mL), was washed with 
H2O (3 x 30 mL) and brine (20 mL). The organic phase was dried (MgSO4), filtered, and the solvent was 
removed under reduced pressure. The residue was purified by chromatography
100
 (hexane/EtOAc, 9:1) 
affording 53 (124 mg, 0.340 mmol, 80%) as a white solid. mp=182 
o
C;
 1
H NMR (400 MHz, CDCl3) δ 
7.98 (d, J = 2.0, Hz, 1H), 7.64 (dd, J=8.0, 1.6 Hz 1H), 7.54 (d, J = 8.4 Hz, 1H), 5.15 (s, 1H), 4.92 (s, 1H); 
13 
C NMR (100 MHz, DMSO-d6) δ 149.2, 143.4, 133.5, 133.3, 133.2, 132.6, 124.1, 119.4; IR (ATR) 
100 
 
3086, 1523, 1344, 914, 700 cm
-1
; HRMS (ESI, negative ion mode) calcd for C16H10Cl2N2O4 (M
-
) 
364.0018, found 364.0048. 
2,3-Di(4-carbomethoxy-2-nitrophenyl)-1,3-butadiene (54). Treatment of 50 (400 mg, 0.806 mmol) 
with CuCl (207 mg, 2.10 mmol) in DMF (2 mL), as described for 53 (3 h), gave after work up and 
chromatography
100
 (hexan/EtOAc, 9:1), 54 (306 mg, 0.742 mmol, 92%) as a white solid. mp=187-188 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 8.60 (d, J=1.2, Hz, 1H), 8.29 (dd, J=7.6, 1.2 Hz 1H), 7.68 (d, J=8.0 Hz, 
1H), 5.18 (s, 1H), 5.20 (s, 2H), 4.92 (s, 1H), 3.98 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 164.7, 148.9, 
144.2, 139.0, 133.5, 132.6, 131.2, 125.3, 118.9, 52.8; IR (ATR) 1721, 1532, 1358, 1288, 1219 cm
-1
; 
HRMS (ESI, negative ion mode) calcd for C20H16N2O8 (M
-
) 412.0907, found 412.0937. 
2,3-Di(4-methoxy-2-nitrophenyl)-1,3-butadiene (55). Treatment of 51 (100 mg, 0.214 mmol) in the 
presence of CuCl (55 mg, 0.56 mmol), in DMF (1.5 mL), as described for 53 (2 h), gave after work up 
and chromatography
100
 (hexane/EtOAc, 9:1) 55 (37.1 mg, 0.104 mmol, 98%) as a white solid. mp=163.5-
164 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.48 (d, J=9.2, Hz, 1H), 7.47 (d, J=2.4, Hz 1H), 7.17 (dd, J=8.8 
2.8 Hz, 1H), 5.09 (s, 1H), 4.90 (s, 1H), 3.90 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.3, 149.5, 145.3, 
133.2, 127.6, 119.3, 118.0, 108.8, 55.9; IR (ATR) 1521, 1340, 1308, 1278, 1028 cm
-1
; HRMS (ESI) calcd 
for C18H17N2O6 (M+H
+
) 357.1087, found 357.1081. 
3,3’-Bi-1H-indole (56).101 Treatment of a solution of 52 (68 mg, 0.229 mmol) in the presence of 
Pd(OAc)2 (3 mg, 0.014 mmol), dppp (6 mg, 0.014 mmol), and phen (6 mg, 0.028 mmol), and in DMF (3 
mL) with CO (6 atm), as described for 38 (120 
o
C, 39 h) gave, after chromatography (hexane/EtOAc, 
8:2), 56 (36 mg, 0.155 mmol, 68%) as a white solid. All data in accordance with previously reported 
values. 
5,5’-Dibenzyloxy-3,3’-Bi-1H-indole (57). Treatment of a solution of 7 (100 mg, 0.197 mmol) in the 
presence of Pd(dba)2 (9 mg, 0.016 mmol), dppp (6 mg, 0.016 mmol) phen (6 mg, 0.031 mmol) in DMF (2 
mL) with CO (6 atm), as described for 38 (72 h), gave after work up and chromatography 
(hexane/EtOAc; 7:3) 57 (76.3 mg, 0.172 mmol, 87%) as a white solid. mp=125-126 
o
C; 
1
H NMR (400 
MHz, CDCl3) δ 8.10 (br, s, 1H), 7.46 (d, J=6.8, Hz, 2H), 7.39-7.31 (m, 6H), 7.02 (dd, J=8.8, 2.4 Hz, 1H), 
5.07 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ 153.5, 137.6, 131.6, 128.4, 127.7, 127.6, 127.3, 122.4, 113.2, 
111.9, 110.7, 103.6, 71.0; IR (ATR) 3406, 1452, 1186, 1151, 794 cm
-1
; HRMS (ESI) calcd for 
C30H24N2O2 (M
-
) 444.1838, found 444.1834. 
6,6’-Dichloro-3,3’-Bi-1H-indole (58). Treatment of a solution of 53 (23 mg, 0.064 mmol) in the presence 
of Pd(dba)2 (4 mg, 0.006 mmol), dppp (4 mg, 0.006 mmol), and phen (2 mg, 0.013 mmol) in DMF (1.5 
101 
 
mL) with CO (6 atm), as described for 38 (72 h), gave after work up and chromatography (hexane/EtOAc, 
7:3) 58 (190 mg, 0.063 mmol, 100%) as a white solid. mp=225-226 
o
C; 
1
H NMR (400 MHz, Acetone-d6) 
δ 10.52 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.69 (d, J=2.4 Hz, 1H), 7.53 (d, J=2.0 Hz, 1H), 7.09 (dd, J=8.4, 
2.0 Hz, 1H); 
13
C NMR (100 MHz, Acetone-d6) δ 138.1, 127.9, 126.3, 123.9, 121.7, 120.4, 112.2, 111.1; 
IR (ATR) 3411, 1448, 1376, 1227, 914, 802 cm
-1
; HRMS (ESI) calcd for C16H11Cl2N2 (M+H
+
) 301.0299, 
found 301.0292. 
6,6’-Carbomethoxy-3,3’-Bi-1H-indole (59). Treatment of a solution of 54 (100 mg, 0.243 mmol) in the 
presence of Pd(dba)2 (10 mg, 0.017 mmol), dppp (7 mg, 0.017 mmol) and phen (6 mg, 0.034 mmol) in 
DMF (2 mL) with CO (6 atm), as described for 38 (44 h), gave after work up and chromatography 
(hexane/EtOAc, 1:1) 59 (84.3 mg, 0.242 mmol, 100%) as a white solid. mp = 300-301
 o
C; 
1
H NMR (400 
MHz, CDCl3/DMSO-d6) δ 11.67 (br, s, 1H), 8.13 (s with further fine splittings, 1H), 7.96 (d, J=2.4 Hz, 
1H), 7.86 (d, J=8.4 Hz, 1H), 7.69 (dd, J=8.4, 1.6 Hz, 1H), 3.87 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3/DMSO-d6 ) δ 167.1, 135.5, 129.2, 125.7, 122.3, 119.5, 118.9, 113.6, 109.5, 51.4; IR (ATR) 3305, 
1689, 1436, 1319, 1227 cm
-1
; HRMS (ESI) calcd for C20H17N2O4 (M+H
+
) 349.1188, found 349.1182. 
6,6’-Dimethoxy-3,3’-Bi-1H-indole (60). Treatment of a solution of 55 (421 mg, 1.18 mmol) in the 
presence of Pd(dba)2 (47 mg, 0.083 mmol), dppp (34 mg, 0.083 mmol), and phen (30 mg, 0.17 mmol) in 
DMF (2.5 mL) with CO (6 atm), as described for 38 (30 h), gave after work up and chromatography 
(hexane/EtOAc, 1:1) 60 (221 mg, 0.757 mmol, 64%) as a white solid. mp=282-284 
o
C; 
1
H NMR (400 
MHz, DMSO-d6) δ 10.90 (s, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.46 (d, J=2.0 Hz, 1H), 6.92 (d, J=2.4 Hz, 1H), 
6.70 (dd, J=8.4, 1.6 Hz, 1H), 3.79 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 155.5, 137.1, 120.3, 120.2, 
120.1, 109.8, 108.9, 94.5, 55.1; IR (ATR) 3379, 1626, 1298, 1155, 1026 cm
-1
; HRMS (ESI) calcd for 
C18H17N2O2 (M+H
+
) 293.1290, found 293.1284. 
Tributyl(1-(3-nitro-2-pyridyl)ethenyl)tin (62). Treatment of a solution of 61
102
 (100 mg, 0.675 mmol) 
in THF (2 mL) with tributyltin hydride (295 mg, 1.01 mmol) in the presence of PdCl2(PPh3)2 (47 mg, 
0.068 mmol), as described for 48 (36 h), gave after solvent removal  and chromatography (hexane/EtOAc, 
9:1), 62 (181 mg, 0.412 mmol, 61%) as a brown viscous oil. 
1
H NMR (400 MHz, CDCl3) δ 8.70 (dd, 
J=4.8, 1.6 Hz, 1H), 8.10 (dd, J=8.4, 1.6 Hz, 1H), 7.24 (dd, J=8.0, 4.4 Hz, 1H), 5.95 (d, J=2.8 Hz, 1H), 
5.64 (d, J=2.4 Hz, 1H),  1.49-1.43 (m, 6H), 1.30-125 (m, 6H), 1.00-0.83 (m, 15H); 
13
C NMR (100 MHz, 
CDCl3) δ 159.6, 153.4, 152.0, 143.8, 131.8, 129.1, 120.7, 28.7, 27.2, 13.6, 10.9; (ATR) 2956, 2924, 1526, 
1352, 808 cm
-1
; HRMS (ESI) calcd for C19H33N2O2
120
Sn (M+H
+
) 441.1564, found 441.1558. 
2,3-Di(3-nitro-2-pyridyl)-1,3-butadiene (63). Treatment of 62 (500 mg, 1.14 mmol) with CuCl (282 mg, 
2.85 mmol) in DMF (3 mL), as described for 53 (5 h), gave after work up and chromatography
100
 
102 
 
(hexane/EtOAc, 1:1) 63 (91.4 mg, 0.306 mmol, 54%)  as a white solid. mp=198-199 
o
C; 
1
H NMR (400 
MHz, CDCl3) δ 8.88 (dd, J=4.8, 1.6 Hz, 1H), 8.22 (dd, J=8.4, 1.6 Hz 1H), 7.48 (dd, J=8.4, 4.8 Hz, 1H), 
5.40 (s, 1H), 5.24 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 152.6, 152.4, 146.4, 143.6, 132.0, 123.2, 120.0; 
IR (ATR) 3019, 1522, 1361, 1217, 932 cm
-1
; HRMS (ESI) calcd for C14H11N4O4 (M+H
+
) 299.0780, found 
299.0774. 
3,3’-Bi-1H-pyrrolo[3,2-b]pyridine (64). Treatment of a solution of 63 (90 mg, 0.302 mmol) in the 
presence of Pd(dba)2 (12 mg, 0.021 mmol), dppp (9 mg, 0.021 mmol), and phen (8 mg, 0.042 mmol) in 
DMF (2 mL) with CO (6 atm), as described for 38 (36 h), gave after work up and chromatography 
(EtOAc) 64 (52.3 mg, 0.223 mmol, 74%) as a white solid. mp=309-310 
o
C; 
1
H NMR (400 MHz, DMSO-
d6) δ 11.26 (s, 1H), 8.63 (d, J=2.4 Hz, 1H), 8.44 (dd, J=4.8, 1.6 Hz, 1H), 7.81 (dd, J=8.0, 1.2 Hz, 1H), 
7.16 (dd, J=8.4, 4.8 Hz, 1H); 
13
C NMR (100 MHz, DMSO-d6) δ 143.7, 142.1, 128.6, 125.6, 118.5, 116.3, 
108 .9; IR (ATR) 3088, 3019, 1522, 1361, 1217 cm
-1
; HRMS (ESI) calcd for C14H11N4 (M+H
+
) 235.0984, 
found 235.0978. 
2-(1-Bromo-1-ethenyl)-5-methoxy-1-nitrobenzene (66). A mixture of 2-(2-trimethylsilyl-1-ethynyl)-5-
methoxy-1-nitrobenzene (65)
103
 (756 mg, 3.03 mmol) and HBr (aq.-48%, 1.10 mL) in 3-pentanone (7 
mL) was stirred at 100
 o
C for 2 h. After cooling to ambient temperature, the dark brown solution was 
diluted with EtOAc (15 mL) and the organic phase was washed with water (3x15 mL), dried (MgSO4), 
filtered, and the filtrate was concentrated under reduced pressure. The resulting brown oil was purified by 
chromatography (hexane/EtOAc, 95:5) to give 66 (446 mg, 1.73 mmol, 57%) as a brown oil. 
1
H NMR 
(400 MHz, CDCl3) δ 7.42 (d, J=2.0 Hz, 1H), 7.37 (d, J=8.4 Hz, 1H), 7.10 (dd, J=8.4, 2.8 Hz, 1H), 5.84 
(d, J=2.4 Hz, 1H), 5.82 (d, J=2.4 Hz, 1H), 3.89 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 160.2, 148.2, 
132.2, 127.5, 124.3, 121.2, 118.8, 109.4, 56.0; IR (ATR) 1611, 1526, 1352, 1245, 1029 cm
-1
; HRMS 
(ESI) calcd for C9H9BrNO3 (M+H
+
) 257.9765, found 257.9763. 
2-(4-Methoxy-2-nitrophenyl)-3--(2-nitrophenyl)-1,3-butadiene (67). To a mixture of 66 (320 mg, 1.24 
mmol), CuI (307 mg, 1.61 mmol), CsF (382 mg, 2.52 mmol) and Pd(PPh3)4 (143 mg, 0.124 mmol) in 
DMF (3 mL) was added, under a N2 atmosphere, a solution of 48 (706 mg, 1.61 mmol) in DMF (3 mL). 
The resulting mixture was stirred at 70
 o
C
 
for 12 h. The mixture was cooled to ambient temperature and 
EtOAc (30 mL) was added. The mixture was washed with water (5x20 mL) and brine (20 mL), and the 
organic phase was dried (MgSO4), filtered, and the filtrate was concentrated under reduced pressure. The 
resulting brown oil was purified by chromatography
100
 (hexane/EtOAc, 95:5) to give, in order of elution, 
52 (66 mg, 0.22 mmol, 28%) as a white solid and 67 (247 mg, 0.756 mmol, 61%) as a yellow solid. 
mp=91-95
 o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.96 (dd, J=8.4, 1.2 Hz, 1H), 7.65 (dt, J=8.4, 1.2 Hz, 1H), 
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7.59 (dd, J=8.0, 1.6 Hz, 1H), 7.52-7.47 (m, 3H), 7.19 (dd, J=8.4, 2.8 Hz, 1H), 5.12 (d, J=2.8 Hz, 2H), 
4.93 (s, 1H), 4.88 (s, 1H), 3.91 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 159.3, 149.4,148.9, 145.4, 145.0, 
135.4, 133.1, 132.9, 132.3, 128.6, 127.3, 123.9, 119.2, 118.1, 117.9, 108.8, 55.8; IR (ATR) 1520, 1351, 
1233, 1027, 910 cm
-1
; HRMS (ESI) calcd for C17H15N2O5 (M+H
+
) 327.0981, found 327.0979. 
6-Methoxy-3,3’-Bi-1H-indole (68). Treatment of a solution of 67 (200 mg, 0.613 mmol) in the presence 
of Pd2(dba)3 (56 mg, 0.061 mmol), dppp (26 mg, 0.063 mmol), and phen (22 mg, 0.123 mmol) in DMF 
(1.5 mL) with CO (6 atm), as described for 38 (30 h), gave after work up and chromatography 
(hexane/EtOAc, 7:3 then 1:1) 68 (161 mg, 0.613 mmol, 100%) as a white solid. mp=252
 o
C (dec.); 
1
H 
NMR (400 MHz, DMSO-d6) δ 11.11 (br s, 1H), 10.93 (br s, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.64 (d, J=8.4 
Hz, 1H), 7.61 (d, J=2.4 Hz, 1H), 7.49 (d, J=2.4 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 7.13 (t, J=7.2 Hz, 1H), 
7.05 (t, J=7.2 Hz, 1H), 6.94 (d, J=2.4 Hz, 1H), 6.72 (dd, J=8.4, 2.4 Hz, 1H), 3.80 (s, 3H); 
13
C NMR (100 
MHz, DMSO-d6) δ 155.6, 137.1, 136.4, 126.0, 121.6, 121.2, 120.4, 120.3, 120.2, 119.6, 118.8, 111.5, 
109.9, 109.7, 108.9, 94.5, 55.2; IR (ATR) 3395, 1629, 1454, 1239, 1105 cm
-1
; HRMS (ESI) calcd for 
C17H15N2O (M+H
+
) 263.1184, found 263.1180. 
[(5-Bromo-2-nitrophenyl)methyl] triphenylphosphonium bromide (69).
104
 Treatment of 5-bromo-2-
nitrobenzyl bromide (486 mg, 1.65 mmol) with PPh3 (519 mg, 1.977 mmol) in toluene (6 mL) as 
described for 28 (100 
o
C, 10 h), gave after work up 69 (918 mg, 1.647 mmol, 100%) as a white solid. 
mp=249-250 °C, 
1
H NMR (600 MHz, DMSO-d6) δ 7.97 (d, J=9.0 Hz, 1H), 7.93 (td, J=8.4, 1.8 Hz, 3H), 
7.87 (dt, J=7.2, 2.4 Hz, 1H), 7.75 (sext, J=3.6 Hz, 6H), 7.67-7.64 (m, 6H), 7.56 (d, J=2.4 Hz, 1H), 5.47 
(d, J=15.0 Hz, 2H); 
13
C NMR (150 MHz, DMSO-d6) δ 147.3 (d, J
CP
=5.7 Hz), 136.3 (d, J
CP
=10.3 Hz), 
136.3, 135.4, 134.0 (d, J
CP
=10.3 Hz), 133.3, 127.9 (d, J
CP
=4.5 Hz), 127.8, 125.9 (d, J
CP
=9.1 Hz), 116.9 (d, 
J
CP
=85.8 Hz), 26.6 (d, J
CP
=49.2 Hz); IR 1519, 1330, 1109, 884, 754 cm
-1
; HRMS (ESI) calcd for 
C25H20Br2NO2P (M-Br) 476.0415, found 476.0416. 
EZ/EE-1,3-Di(2-nitrophenyl)-1,3-butadiene (71). Treatment of a solution of 2-(2-nitrophenyl)propenal 
70
105
 (250 mg, 1.41 mmol) and 27 (810 mg, 1.69 mmol) in EtOH (10 mL) in the presence of NaOEt (1.8 
M in EtOH, 5.5 mL, 9.90 mmol), as described for 34 (24 h), gave after work up and chromatography 
(hexane/EtOAc, 17:3) 71 (171 mg, 0.579 mmol, 41%, EZ/EE=10:1) as a faint yellow solid. mp =132-138 
o
C; Data from the mixture of isomers of 71, major isomer: 
1
H NMR (600 MHz, CDCl3) δ 7.77 (dd, J=7.9, 
1.3 Hz, 1H), 7.53 (dd, J=8.0, 1.3 Hz, 1H), 7.22-7.06 (m, 6H), 6.83 (d, J=12.1 Hz, 1H), 6.58 (d, J=12.3 
Hz, 1H), 5.51 (d, J=0.8 Hz, 1H), 5.20 (d, J=0.4 Hz 1H); partial data of minor isomer: 
1
H NMR (600 MHz, 
CDCl3) δ 8.01 (dd, J=8.2, 1.1 Hz, 1H), 7.90 (dd, J=8.2, 1.3 Hz, 1H), 7.68-7.65 (m, 2H), 7.57 (t with 
further fine splittings, J=7.2 Hz, 1H), 7.43 (dd, J=7.6, 1.3 Hz, 1H), 7.37 (dt, J=7.8, 1.4 Hz, 1H), 6.99 (d, 
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J=16.0 Hz, 1H), 5.59 (s, 1H), 5.30 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 148.6, 147.8, 147.6, 146.9, 
144.6, 142.0, 135.4, 134.4, 134.2, 133.2, 133.1, 132.5, 132.4, 132.3, 132.1, 132.1, 132.0, 131.0, 131.0, 
128.9, 128.4, 128.2, 128.0, 127.9, 127.5, 126.8, 127.7, 124.3, 123.8, 123.7, 122.4, 120.2; IR (ATR) 1568, 
1514, 1339, 912, 786 cm
-1
; HRMS (ESI) calcd for C16H13N2O4 (M+H
+
) 297.0875, found 297.0870. 
E-1-(3-methoxy-2-nitrophenyl)-3-(2-nitrophenyl)-1,3-butadiene (72). Treatment of a solution of 70 
(69.7 mg, 0.393 mmol) and 29 (200 mg, 0.393 mmol) in absolute EtOH (2 mL) in the presence of NaOEt 
(2 M, 1.1 mL, 2.2 mmol), as described for 34 (30 h), gave after work up and chromatography 
(hexane/EtOAc, 85:15) 72 (49.1 mg, 0.150 mmol, 38%) as a yellow-orange oil. 
1
H NMR (400 MHz, 
CDCl3) δ 7.65 (dd, J=8.4, 1.6 Hz, 1H), 7.27-7.23 (m, 1H), 7.21-7.15 (m, 2H), 6.92 (t, J=8.0 HZ, 1H), 6.74 
(dt, J=7.6, 1.2 Hz, 1H), 6.67 (d, J=8.4 Hz, 1H), 6.55 (d, J=12.4 Hz, 1H), 6.44 (d, J=12.0 Hz 1H), 6.52 (d, 
J=0.8 Hz, 1H), 5.23 (s, 1H), 3.80 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 150.2, 150.2, 148.2, 141.6, 
139.8, 135.0, 133.8, 131.9, 131.4, 130.5, 129.9, 128.0, 123.7, 123.6, 123.0, 121.9, 56.4; IR (ATR) 1522, 
1337, 1107, 8333, 756, 721, 690 cm
-1
; HRMS (ESI) calcd for C17H15N2O5 (M+H
+
) 327.0981, found 
327.0977. 
E-1-(4-bromo-2-nitrophenyl)-3-(2-nitrophenyl)-1,3-butadiene (73). Treatment of a solution of 70 (320 
mg, 1.80 mmol) with 30 (1.20 g, 2.23 mmol) in the presence of NaOEt (2.0 M, 4.2 mL, 8.41 mmol) in 
EtOH (15 mL), as described for 34 (26 h), gave after work up and chromatography (hexane/EtOAc, 9:1) 
73 (139 mg, 0.370 mmol, 21%) as a faint yellow solid. mp=119-121 °C; 
1
H NMR (400 MHz, CDCl3) δ 
7.92 (d, J=2.0 Hz, 1H), 7.58 (dd, J=7.2, 1.2 Hz, 1H), 7.27-7.19 (m, 3H), 7.10-7.05 (m, 2H), 6.74 (d, 
J=12.0 Hz, 1H), 6.60 (d, J=12.4 Hz, 1H), 5.54 (s, 1H), 5.25 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 147.9, 
147.2, 141.7, 135.2, 135.1, 133.3, 132.2, 131.8, 131.3, 131.1, 128.1, 126.8, 126.3, 123.9, 123.0, 121.0; IR 
(ATR) 1517, 1338, 1147, 859, 784 cm
-1
; HRMS (ESI) calcd for C16H11BrN2O4 (M
-
) 373.9902, found 
373.9898. 
E-1-(5-bromo-2-nitrophenyl)-3-(2-nitrophenyl)-1,3-butadiene (74). Treatment of a solution of 70 (246 
mg, 1.39 mmol) and 69 (850 mg, 1.53 mmol) in EtOH (8 mL) in the presence of NaOEt (2.0 M, 3.1 mL, 
6.24 mmol), as described for 34 (26 h) gave after work up and chromatography (hexane/EtOAc, 9:1) 74 
(113 mg, 0.301 mmol, 22%) as a yellow solid. mp=129-134 °C; 
1
H NMR (600 MHz, CDCl3) δ 7.66 (d, 
J=8.4 Hz, 1H), 7.60 (dd, J=8.4, 1.2 Hz, 1H), 7.29 (d, J=2.4 Hz, 1H), 7.24 (dd, J=7.2, 1.2 Hz, 1H), 7.20 
(dd, J=9.0, 2.4 Hz, 1H), 7.13 (td, J=8.4, 1.8 Hz, 1H), 7.08 (dd, J=7.8, 1.8 Hz, 1H), 6.78 (d, J=12.0 Hz, 
1H), 6.63 (d, J=12.6 Hz, 1H), 5.58 (s, 1H), 5.28 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 147.7, 145.6, 
141.8, 135.1, 135.1, 133.8, 132.3, 132.0, 130.9, 130.8, 128.2, 127.3, 125.8, 125.3, 124.0, 123.4; IR (ATR) 
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1598, 1518, 1340, 855, 754 cm
-1
; HRMS (ESI, negative ion mode) calcd for C16H11BrN2O4 (M
-
) 
373.9902, found 373.9898.
 
2,3’-Bi-1H-indole (75).  Treatment of a solution of 71 (200 mg, 0.675 mmol) in the presence of Pd(dba)2 
(19 mg, 0.034 mmol), dppp (14 mg, 0.034 mmol), and phen (12 mg, 0.067mmol) in DMF (2 mL) with 
CO (6 atm), as described for 38 (41 h), gave after work up and chromatography (hexane/EtOAc, 7:3) 75 
(96 mg, 0.41 mmol, 61%) as a white solid. mp=206-207  
o
C; 
1
H NMR (600 MHz, CDCl3) δ 11.32 (s, 1H), 
11.14 (s, 1H), 8.00 (d, J=7.8 Hz, 1H), 7.85 (d, J=1.8 Hz, 1H), 7.50 (d, J=7.8 Hz, 1H), 7.47 (d, J=7.8 Hz, 
1H), 7.36 (d, J=8.4 Hz, 1H), 7.18 (t, J=6.0 Hz, 1H), 7.16 (t, J=6.0 Hz, 1H), 7.03 (t, J=7.2 Hz, 1H), 6.96 (t, 
J=7.2 Hz, 1H), 6.74 (d, J=1.2 Hz, 1H); 
13
C NMR (150 MHz, CDCl3) δ 136.6, 135.9, 134.1, 129.1, 124.6, 
123.0, 121.5, 120.1, 119.6, 119.6, 118.9, 118.7, 111.8, 110.3, 108.4, 96.7; IR (ATR) 3405, 3054, 1596, 
1456, 1308, 743 cm
-1
; HRMS (ESI) calcd for C16H13N2 (M+H
+
) 233.1078, found 233.1073. 
7-Methoxy-2,3’-Bi-1H-indole (76). Reaction of a solution of 72 (46 mg, 0.14 mmol) in the presence of 
Pd(dba)2 (8.1 mg, 0.014 mmol), dppp (6.0 mg, 0.015 mmol) and phen (5.1 mg, 0.028 mmol) in DMF (0.8 
mL) with CO (6 atm), as described for 38 (120 
o
C, 48 h), gave after work up and chromatography 
(hexane/EtOAc, 7:3) 76 (26.7 mg,  0.102 mmol, 72%) as a yellowish-brown oil. 
1
H NMR (600 MHz, 
CDCl3) δ 8.45 (br s, 1H), 8.29 (br s, 1H), 7.48 (d, J=2.6 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.29 (dt, J=7.0, 
1.2 Hz, 1H), (7.25-7.23 (m, 3H), 7.05 (t, J=7.9 Hz, 1H), 6.77 (d, J=2.2 Hz, 1H), 6.66 (d, J=7.6 Hz, 1H), 
3.99 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 145.7, 136.4, 132.8, 130.7, 126.3, 125.4, 122.9, 121.3, 120.7, 
120.3, 120.0, 112.9, 111.5, 110.4, 101.6, 99.7, 55.4; IR (ATR) 3395, 1703, 1598, 1576, 1254, 1094, 789, 
742 cm
-1
; HRMS (ESI) calcd for C17H15N2O (M+H
+
)  263.1184, found 263.1182. 
6-Bromo-2,3’-Bi-1H-indole (77). Reaction of a solution of 73 (50 mg, 0.133 mmol) in the presence of 
Pd(dba)2 (4.6 mg, 0.008 mmol), dppp (3.3 mg, 0.008 mmol) and phen (3 mg, 0.016 mmol) in DMF (1.5 
mL) with CO (6 atm), as described for 38 (120 
o
C , 43 h), gave after work up and chromatography 
(hexane/EtOAc, 7:3) 77 (27.4 mg,  0.088 mmol, 66%) as a white solid. mp=205-206 °C; 
1
H NMR (400 
MHz, CDCl3/DMSO-d6) δ 11.41 (br, s, 1H), 11.34 (br, s, 1H), 7.99 (d, J=7.8  Hz, 1H), 7.90 (d, J=2.4 Hz, 
1H), 7.67 (d, J=1.8 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 7.22-7.13 (m , 3H), 6.77 (d, 
J=1.8 Hz, 1H); 
13
C NMR (100 MHz, CDCl3/DMSO-d6) δ 136.9, 136.6, 135.2, 128.2, 124.5, 123.4, 121.7, 
121.5, 120.5, 119.8, 119.4, 112.8, 112.6, 111.9, 107.9, 96.8; IR (ATR) 3410, 3381, 1588, 1317, 747 cm
-1
; 
HRMS (ESI) calcd for C16H12BrN2 (M+H
+
) 311.0184, found 311.0183. 
5-Bromo-2,3’-Bi-1H-indole (78). Reaction of a solution of 74 (121 mg, 0.323 mmol) in the presence of 
Pd(dba)2 (13 mg, 0.023 mmol), dppp (9.4 mg, 0.023 mmol) and phen (8.2 mg, 0.045 mmol) in DMF (1.5 
mL) with CO (6 atm), as described for 38 (120 
o
C , 44 h), gave after work up and chromatography 
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(hexane/EtOAc, 7:3) 78 (67.3 mg,  0.216 mmol, 67%) as a white solid. mp=205-206 °C 
1
H NMR (600 
MHz, DMSO-d6) δ 11.46 (br, s, 1H), 11.42 (br, s, 1H), 7.99 (d, J=7.8 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 
7.67 (d, J=1.8 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H),  7.22-7.15 (m, 3H), 7.14 (dd, 
J=7.8, 1.8 Hz, 1H), 7.27 (d, J=1.8 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ 136.6, 135.8, 134.7, 131.2, 
124.5, 123.7, 122.6, 121.9, 121.1, 119.9, 119.5, 112.3, 112.0, 111.3, 107.9, 96.4; IR (ATR) 3412, 3356, 
1589, 1234, 748 cm
-1
; HRMS (ESI) calcd for C16H12BrN2 (M+H
+
) 311.0184, found 311.0182. 
Indolo[1,2-c]quinazolin-6(5H)-one (81)
87
 and 5,11-Dihydro-6H-Indolo[3,2-c] quinolin-6-one (82).
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Treatment of a solution of trans-2,2’-di(2-nitrophenyl)ethene (79)107 (200 mg, 0.740 mmol) in the 
presence of Pd(dba)2 (25.6 mg, 0.044 mmol), dppp (18.3 mg, 0.044 mmol) and phen (16 mg, 0.089 mmol) 
in DMF (2 mL) with CO (6 atm), as described for 38 (120 
o
C , 56 h), gave after work up and 
chromatography (hexane/EtOAc, 9:1, 8:2, and 1:1), in order of elution, 81 (132 mg,  0.565 mmol, 76%) 
and 82 (21 mg, 0.090 mmol, 12%) both as white solids. Analytical data for 81: mp = 320-321 
o
C; 
1
H 
NMR (600 MHz, CDCl3/DMSO-d6) δ 11.23 (br, s, 1H), 8.56-8.55 (m, 1H), 7.96 (d, J=9.6 Hz, 1H), 7.68-
7.66 (m, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.31-7.27 (m, 2H), 7.24 (d, J=8.4 Hz, 1H), 7.19-7.15 (m, 2H); 
13
C 
NMR (150 MHz, CDCl3/DMSO-d6) δ 147.0, 134.1, 133.9, 133.3, 129.4, 128.9, 123.1, 123.0, 122.5, 
122.5, 119.8, 115.4, 115.2, 113.5, 97.7; IR (ATR) 2920, 1697, 1596, 1339, 739 cm
-1
; HRMS (ESI) calcd 
for C15H11N2O (M+H
+
) 235.0871, found 235.0868. 
Analytical data for 82: mp=396-397
 o
C (dec.); 
1
H NMR (600 MHz, DMSO-d6) δ 12.55 (br, s, 1H), 11.42 
(br, s, 1H), 8.20 (dd, J=7.8, 1.2 Hz, 2H), 7.62 (d, J=7.8 Hz, 1H), 7.51 (td, J=8.4, 1.2 Hz, 1H), 7.47(dd, 
J=8.4, 0.6 Hz, 1H), 7.38-7.35 (m, 1H), 7.30-7.25 (m, 2H); 
13
C NMR (150 MHz, DMSO-d6) δ 159.8, 
140.7, 137.9, 137.7, 129.1, 124.4, 124.0, 122.1, 121.5, 121.0, 120.7, 116.0, 111.9, 111.7, 106.4; IR (ATR) 
3050, 2925, 1698, 1596, 1395 cm
-1
; HRMS (ESI) calcd for C15H11N2O (M+H
+
) 235.0871, found 
235.0869. 
1-(5-Chloro-2-nitrophenyl)-2-(2-nitrophenyl)ethane (88). Treatment of a solution of 2-
nitrobenzaldehyde (531 mg, 3.51 mmol) with 28 (2.20 mg, 4.29 mmol) in EtOH (18 mL) in the presence 
of NaOEt (1.8 M, 10.5 mL, 18.9 mmol), as described for 34 (24 h) gave after work up and 
chromatography (hexane/EtOAc, 1:1) 88 (300 mg, 0.985 mmol, 28%) as a faint yellow solid. mp=139-
140 
o
C; 
1
H NMR (600 MHz, CDCl3) δ 8.05 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.79 (d, J=9.6 Hz, 
1H), 7.70 (d, J=8.4 Hz, 1H), 7.68 (t, J=7.8 Hz, 1H), 7.50 (t, J=7.2 Hz, 1H), 7.41 (t, J=8.4 Hz, 1H), 7.30 
(d, J=16.8 Hz, 1H), 7.09 (d, J=16.8 Hz, 1H); 
13
C NMR (150 MHz, CDCl3) δ 150.4, 147.7, 135.5, 133.9, 
133.6, 132.3, 132.1, 130.8, 129.2, 129.1, 128.8, 125.5, 124.8, 122.6;  IR (ATR) 1525, 1347, 1217, 738 
cm
-1
; HRMS (ESI, negative ion mode) calcd for C14H9ClNO2 (M
-
) 304.0251, found 304.0272. 
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2-(2-Nitro-6-chlorophenyl)indole (89) and 4-Chloro-5,10-dihydroindolo[3,2-b]indole (90).  Reaction 
of 88 (250 mg, 0.822 mmol) in the presence of Pd(dba)2 (23.6 mg, 0.041 mmol), dppp (16.9 mg, 0.041 
mmol) and phen (14.8 mg, 0.082 mmol) in DMF (2 mL), as described for 38 (120 
o
C, 76 h), gave, after 
work up and chromatography (hexane/EtOAc, 9:1, 8:2, 1:1), in order of elution, 90 (26 mg, 0.107 mmol, 
13%) and 89 (153 mg, 0.570 mmol, 69%) both as white solids. Analytic data for 89: mp=269-270 
o
C; 
1
H 
NMR (400 MHz, DMSO-d6) δ 11.52 (br, s, 1H), 8.52 (dd, J=8.2, 0.8 Hz, 1H), 8.24 (dd, J=7.6, 1.2 Hz, 
1H), 7.48-7.44 (m, 3H), 7.35 (t, J=8.2 Hz, 1H), 7.28 (d, J=8.2 Hz, 1H), 7.26 (t, J=7.8 Hz, 1H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 146.8, 135.2, 134.4, 134.0, 130.0, 128.2, 124.1, 124.0, 123.8, 123.1, 123.0, 
115.4, 114.4, 113.2, 96.0; IR (ATR) 3053, 1712, 1419, 1398, 748 cm
-1
; HRMS (ESI) calcd for 
C15H10ClN2O (M+H
+
) 269.0482, found 269.0475. 
Analytic data for 90: mp=182-183 
o
C; 
1
H NMR (400 MHz, DMSO-d6) δ 11.33 (br, s, 1H), 11.05 (br, s, 
1H), 7.75 (d, J=8.0 Hz, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.18 (t, J=7.6 Hz, 1H), 7.11-
7.04 (m, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 141.0, 140.7, 125.9, 123.3, 122.6, 122.0, 122.0, 118.2, 
117.7, 117.4, 113.9, 113.5, 112.5, 110.9; IR (ATR) 3424, 1455, 1391, 1322, 730 cm
-1
; HRMS (ESI) calcd 
for C14H9ClN2 (M
+
) 240.0454, found 240.0447. 
Z/E-1-(3-Methoxy-2-nitrophenyl)-2-(2-nitrophenyl)ethene (91). Treatment of a solution of 2-
nitrobenzaldehyde (500 mg, 3.31 mmol) with 29 (1.68 mg, 3.31 mmol) in EtOH (16 mL) in the presence 
of NaOEt (1.8 M, 12 mL, 21.6 mmol), as described for 34 (ambient temperature, 24 h) gave after work up 
and chromatography (hexane/EtOAc, 7:3 then 1:1) 91 (891 mg, 2.97 mmol, 90%, Z/E=1.8:1) as an orange 
solid. NMR data from the E/Z=1.8:1 mixture of 91, major isomer: 
1
H NMR (600 MHz, CDCl3) δ 8.10-
8.08 (m, 1H), 7.17 (d, J=7.5 Hz, 1H), 7.48 (t, J=8.3 Hz, 1H), 7.40-7.36 (m, 2H), 7.09 (t, J=8.5 Hz, 1H), 
6.87 (d, J=8.3 Hz, 1H), 6.68 (d, J=11.7 Hz, 1H), 6.48 (d, J=7.7 Hz, 1H), 3.89 (s, 3H); minor isomer: 
 1
H 
NMR (600 MHz, CDCl3) δ 8.02 (d, J=8.2 Hz, 1H), 7.69 (d, J=15.7 Hz, 1H), 7.63 (t, J=8.2 Hz, 1H), 7.45 
(d, J=8.2 Hz, 1H), 7.19-7.16 (m, 2H), 7.11 (d, J=12.1 Hz, 1H), 7.01 (d, J=8.2 Hz, 1H), 6.88 (d, J=15.8 
Hz, 1H), 3.92 (s, 3H); Analytical data for both isomers from the mixture: mp=135-140 
o
C; 
13
C NMR (150 
MHz, CDCl3) δ 151.0, 150.8, 148.0, 147.9, 141.1, 140.7, 133.5, 133.3, 132.4, 132.4, 132.1, 132.0, 131.1, 
130.6, 130.3, 130.0, 129.4, 129.0, 128.8, 128.7, 125.4, 124.9, 124.7, 124.6, 122.1, 118.1, 112.1, 111.5, 
56.5, 56.4; IR (ATR) 1518, 1342, 1285, 1063, 852 cm
-1
; HRMS (ESI) calcd for C15H13N2O5 (M+H
+
) 
301.0824, found 301.0817. 
7-Methoxy-2-(2-nitrophenyl)indole (92), 2-(3-Methoxy-2-nitrophenyl)indole (93), and 5,11-Dihydro-
4-methoxy-6H-indolo[3,2-c]quinolin-6-one (94). Reaction of 91 (439 mg, 1.46 mmol) in the presence of 
Pd(dba)2 (50.4 mg, 0.088 mmol), dppp (36.2 mg, 0.088 mmol) and phen (31.6 mg, 0.175 mmol) in DMF 
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(3 mL) with CO (6 atm) as described for 38 (120 
o
C, 56 h), gave, after work up and chromatography 
(hexane/EtOAc, 9:1, 8:2, 1:1, 3:7), in order of elution 92 (38 mg, 0.14 mmol, 10%) as a viscous oil, 93 
(290 mg, 1.08 mmol, 74%) as a yellow solid and 94 (23.2 mg, 0.088 mmol, 6%) as a white solid. 
Analytic data for 92: 
1
H NMR (400 MHz, CDCl3) δ 8.69 (d, J=7.2 Hz, 1H), 8.11 (br s, 1H), 7.71 (dd, 
J=6.8, 2.4 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.42-7.36 (m, 2H), 7.17 (t, J=8.0 Hz, 1H), 7.09 (s, 1H), 6.91 
(d, J=8.0 Hz, 1H), 3.99 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 146.3, 134.0, 133.4, 129.6, 123.8, 
123.5, 123.2, 123.0, 120.2, 115.6, 115.3, 114.1, 110.7, 98.4, 56.0; IR (ATR) 3424, 2230, 1611, 1535, 
1052 cm
-1
; HRMS (ESI) calcd for C15H13N2O3 (M+H
+
) 269.0926, found 269.0919. 
Analytic data for 93: mp=158-160 
o
C; 
1
H NMR (600 MHz, CDCl3/DMSO-d6) δ 11.57 (br s, 1H), 7.59 (t, 
J=8.4 Hz, 1H), 7.56 (d, J=7.6 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.23 (d, J=8.0 Hz, 
1H), 7.17 (t, J=7.6 Hz, 1H), 7.04 (t, J=8.0 Hz, 1H), 6.54 (d, J=1.6 Hz, 1H), 3.92 (s, 3H); 
13
C NMR (150 
MHz, CDCl3/DMSO-d6) δ 150.4, 139.1, 137.0, 131.0, 130.6, 128.2, 125.2, 122.4, 120.4, 120.3, 119.6, 
112.0, 111.5, 101.1, 56.5; IR (ATR) 3402, 1609, 1527, 1275, 1112 cm
-1
; HRMS (ESI) calcd for 
C15H13N2O3 (M+H
+
) 269.0926, found 269.0919. 
Analytic data for 94: mp=355-360
 o
C; 
1
H NMR (600 MHz, DMSO-d6) δ 12.57 (br, s, 1H), 10.16 (br, s, 
1H), 8.20 (d, J=7.8 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.62 (d, J=8.4 Hz, 1H), 7.37 (td, J=8.4, 1.2 Hz, 1H), 
7.28-7.25 (m, 2H), 7.17 (d, J=7.8 Hz, 1H), 3.96 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 159.1, 146.3, 
140.7, 137.7, 127.6, 124.4, 124.1, 121.7, 121.1, 120.8, 113.9, 112.4, 111.7, 110.0, 106.7, 56.1; IR (ATR) 
3407, 1523, 1377, 1275, 1110 cm
-1
; HRMS (ESI) calcd for C16H13N2O2 (M+H
+
) 265.0977, found 
265.0971. 
1,1-Bis(2-nitrophenyl)ethene (95) and 2,3-di(2-nitrophenyl)-1,3-butadiene (52). To a solution of 2-
iodonitrobenzene (473 mg, 1.90 mmol) in DMF (10 mL) was added 48 (1.00 g, 2.28 mmol), PdCl2(PPh3)2 
(67 mg, 0.095 mmol), PPh3 (50 mg, 0.190 mmol) and CuI (271 mg, 1.43 mmol). The reaction was stirred 
at ambient temperature for 24 h. Et2O (30 mL) was added and the organic phase was washed with NH4OH 
(10%-aqueous, 3x30 mL), H2O (30 mL), and brine (30 mL). The organic phase was dried (MgSO4), 
filtered, and the solvents were removed under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 9:1) to afford, in order of elution 52 (30 mg, 0.10 mmol, 11%) and 95 
(320 mg, 1.18 mmol, 62%) both as a white solid. mp=132-134 
o
C; 
1
H NMR (600 MHz, CDCl3) δ 5.62 (s, 
2H), 7.43-7.46 (m, 2H), 7.58-7.59 (m, 4H), 7.71 (dt, J=7.8, 0.6 Hz, 2H); 
13
C NMR (150 MHz, CDCl3) δ 
121.3, 123.9, 129.1, 132.4, 133.1, 133.9, 142.4, 148.7; IR (ATR) 716, 774, 1351, 1516 cm
-1
; HRMS (ESI) 
calcd for C14H10N2NaO4 (M+Na
+
) 293.0538, found 293.0534. 
109 
 
Indolo[2,3-b]indole (96) and 6H-Indolo[2,3-c]quinolin-6-one (97).
108
 Reaction of 95 (210 mg, 0.777 
mmol) in the presence of Pd(OAc)2 (17.5 mg, 0.078 mmol), dppp (32 mg, 0.078 mmol), phen (28 mg, 
0.155 mmol), and CO (6 atm) in DMF (3 mL), as described for 38 (41 h), gave, after chromatography 
(hexane/EtOAc, 4:6), in order of elution, 96 (22.6 mg, 0.110 mmol, 14%) and 97 (106 mg, 0.451 mmol, 
58%) both as white solids. Analytical data for 96: mp 340-343 
o
C; 
1
H NMR (600 MHz, DMSO-d6) δ 
11.35 (br, s, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.10 (dt, J = 7.2, 0.6 Hz, 1H),; 7.05 
(dt, J = 8.4, 1.8 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6)) δ 144.5, 138.6, 121.9, 119.2, 119.0, 117.4, 
111.5, 99.7; IR (ATR) 3413, 3363, 1450, 736, 696 cm
-1
; HRMS (ESI) calcd for C14H11N2 (M+H
+
) 
207.0922, found 207.0917. 
Analytical data for 97: mp 312-314 
o
C; 
1
H NMR (600 MHz, DMSO-d6) δ 12.34 (br s, 1H), 11.85 (br s, 
1H), 8.47 (d, J = 7.8 Hz, 1H), 8.44 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 
7.47 (t, J = 7.8 Hz, 1H), 7.41 (t, J = 7.2 Hz, 1H), 7.34 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H) ; 
13
C 
NMR (150 MHz, DMSO-d6) δ 155.7, 138.8, 134.9, 127.6, 125.9, 125.7, 123.0, 122.3, 122.3, 122.2, 120.7, 
118.2, 118.0, 116.1, 113.0, ; IR (ATR) 3316, 3158, 1648, 1620, 1328, 729 cm
-1
; HRMS (ESI) calcd for 
C15H11N2O (M+H
+
) 235.0871, found 235.0867. 
1-(5-Benzyloxy-2-nitrophenyl)-2-(4-methoxy-2-nitrophenyl)ethene (99). To a solution of 98 (500 mg, 
1.79 mmol) in DMF (4 mL) was added CuI (34 mg, 0.18 mmol), CsF (546 mg, 3.62 mmol), Pd(PPh3)4 
(124 mg, 0.108 mmol) and 4 (1.10 g, 2.01 mmol). The mixture was stirred at 50 
o
C under N2 for 8 h. 
After cooling to ambient temperature, the crude mixture was diluted with EtOAc (35 mL), washed with 
H2O (3x35 mL) and brine (2x35 mL). The organic layer was dried (MgSO4), filtered, and the solvents 
were removed under reduced pressure. The residue was purified by chromatography on SiO2/K2CO3 (9:1) 
using (hexane/EtOAc, 9:1 then 85:15) to give, in order of elution, 7 (69.2 mg, 0.136 mmol, 15%) and 99 
(503 mg, 1.24 mmol, 69%) both as white solids. Analytical data for 99: mp =127-128 
o
C; 
1
H NMR (400 
MHz, CDCl3) δ 7.81 (d, J=9.2 Hz, 1H), 7.50 (d, J=8.8 Hz, 1H), 7.45-7.34 (m, 5H), 7.17 (d, J=2.8 Hz, 
1H), 7.11 (d, J=2.8 Hz, 1H), 7.09 (dd, J=8.8, 2.8 Hz, 1H), 6.95 (dd, J=8.8, 2.4 Hz, 1H), 5.55 (s, 1H), 5.52 
(s, 1H), 5.16 (s, 2H), 3.85 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 161.6, 159.5, 149.1, 142.8, 141.6, 
137.2, 135.5, 134.2, 128.7, 128.4, 127.7, 126.7, 126.0, 120.3, 119.1, 118.5, 114.7, 108.7, 70.7, 55.8; IR 
(ATR) 1515, 1348, 1228, 1004, 826 cm
-1
; HRMS (ESI) calcd for C22H19N2O6 (M+H
+
) 407.1243, found 
407.1236. 
6-Methoxy-indolo[2,3-b]-5-benzyloxyindole (100), 2-benzyloxy-5,7-dihydro-9-methoxy-6H-
indolo[2,3-c]quinolin-6-one (101), and 10-benzyloxy-5,7-dihydro-3-methoxy-6H-indolo[2,3-
c]quinolin-6-one (102). Reaction of 99 (300 mg, 0.738 mmol) in the presence of Pd(dba)2, dppp (29.7 
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mg, 0.0527 mmol), phen (21.3 mg, 0.052 mmol) in DMF (2.5 mL), as described for 38 (pCO=6 atm, 41 
h), gave, after chromatography (hexane/EtOAc, in order 7:3, 1:1, 3:7, 2:8), in order of elution, 100 (75.8 
mg, 0.221 mmol, 30%), 101 (84.7 mg, 0.229 mmol, 31%) and 102 (104 mg, 0.281 mmol, 38%) all as 
white solids. 
Analytical data for 100: mp=206-207
 o
C;
 1
H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 10.50 (s, 1H), 
8.16 (d, J=8.4 Hz, 1H), 8.01-797 (m, 2H), 7.95 (d, J=2.8 Hz, 1H), 7.87-7.81 (m, 2H), 7.79-7.75 (m, 1H), 
7.74 (d, J=8.8 Hz, 1H), 7.47 (d, J=2.4 Hz, 1H), 7.25 (dd, J=8.8 Hz, 2.4 Hz, 1H), 7.22 (dd, J=9.2, 2.4 Hz, 
1H), 5.65 (s, 2H), 4.26 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 153.9, 152.6, 144.9, 139.6, 138.0, 
133.3, 128.3, 127.6, 127.6, 122.2, 117.8, 116.2, 111.7, 107.4, 107.0, 102.8, 99.6, 96.9, 69.9, 55.3; IR 
(ATR) 3373, 1577, 1452, 1148, 1022 cm
-1
; HRMS (ESI) calcd for C22H18N2O2 (M
+
) 342.1368, found 
342.1361. 
Analytical data for 101 mp=285-286
 o
C; 
1
H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 11.66 (s, 1H), 
8.34 (d, J=8.4 Hz, 1H), 7.92 (d, J=2.4 Hz, 1H), 7.56 (d, J=6.8 Hz, 2H), 7.53 (d, J=9.2 Hz, 1H), 7.42 (t, 
J=7.2 Hz, 2H), 7.34 (tt, J=6.8, 1.2 Hz, 1H), 7.19 (dd, J=9.2, 2.4 Hz, 1H), 7.05 (d, J=2.8 Hz, 1H), 6.95 
(dd, J=8.4, 2.4 Hz, 1H), 5.27 (s, 2H), 3.83 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 157.5, 155.9, 153.2, 
137.5, 136.3, 134.2, 128.4, 127.8, 127.7, 126.6, 124.2, 122.0, 118.3, 117.0, 113.8, 111.9, 110.2, 104.8, 
99.8, 70.1, 55.2; IR (ATR) 3437, 3026, 1621, 1288, 811 cm
-1
; HRMS (ESI) calcd for C23H19N2O3 (M+H
+
) 
371.1396, found 371.1389. 
Analytical data for 102: mp=276-277
 o
C; 
1
H NMR (400 MHz, DMSO-d6) δ 12.16 (s, 1H), 11.65 (s, 1H), 
8.27 (d, J=8.8 Hz, 1H), 7.80 (d, J=2.8 Hz, 1H), 7.56 (d, J=7.2 Hz, 2H), 7.44-7.40 (m, 3H), 7.34 (t, J=7.6 
Hz, 1H), 7.12 (dd, J=8.8, 2.4 Hz, 1H), 7.05 (d, J=2.4 Hz, 1H), 6.94 (dd, J=8.8, 2.4 Hz, 1H), 5.29 (s, 2H), 
3.86 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 158.3, 154.9, 153.7, 140.2, 137.4, 129.4, 128.4, 127.8, 
127.7, 127.2, 123.1, 118.4, 118.4, 117.2, 116.2, 115.0, 111.5, 106.7, 94.8, 69.8, 55.2; IR (ATR) 3448, 
1652, 1458, 1264, 1228 cm
-1
; HRMS (ESI) calcd for C23H19N2O3 (M+H
+
) 371.1396, found 371.1389. 
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2-(5-Bromo-2-nitrophenyl)-1-trimethylsilylethyne (113). To a mixture of 5-bromo-2-nitro-1-
iodobenzene (112) (3.50 g, 10.7 mmol), CuI (203 mg, 1.07 mmol) and bis(triphenylphosphine)palladium 
dichloride (PdCl2(PPh3)2, 374 mg, 0.533 mmol) at ambient temperature under a N2 atmosphere was added 
tetrahydrofuran (THF, 10 mL) followed by the addition of triethylamine (Et3N, 16 mL). After stirring the 
mixture for 5 minutes, the solution of trimethylsilylethyne (1.40 g, 13.4 mmol) in Et3N (4 mL) was added 
via syringe. The resulting dark brown mixture was stirred at this temperature for 36 h. The reaction 
mixture was then filtered through Celite, and the Celite was washed with EtOAc (30 mL). The solvents 
were removed from the filtrate under reduced pressure. The resulting residue was purified by 
chromatography (hexane/EtOAc, 95:5) to give 113 (2.93 mg, 9.82 mmol, 92%) as a yellow oil.  
1
H NMR 
(600 MHz, CDCl3) δ 7.89 (d, J=8.4 Hz, 1H), 7.79 (d, J=1.8 Hz, 1H), 7.56 (dd, J=8.4, 1.8 Hz, 1H), 0.27 (s, 
9H); 
13
C NMR (150 MHz, CDCl3) δ 148.7, 137.6, 131.9, 127.4, 125.8, 120.1, 105.7, 98.0, 0.5; IR (ATR) 
2958, 1596, 1523, 1341, 1248, 833 cm
-1
; HRMS (ESI) calcd for C11H13BrNO2Si (M+H
+
) 297.9899, found 
297.9883. 
1-(5-Bromo-2-nitrophenyl)ethyne (114). A heterogeneous mixture of 113 (2.56 g, 8.58 mmol) and 
K2CO3 (2.37 g, 17.2 mmol) in MeOH/Et2O (1:1, 40 mL) was stirred at ambient temperature under a N2 
atmosphere for 2 h. The mixture was diluted with EtOAc (30 mL) and the organic layer was washed with 
water (3x20 mL). The resulting organic layer was dried (MgSO4), filtered and the solvents were removed 
under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 9:1) to give 
114 (1.76 g, 7.81 mmol, 91%) as a white solid. mp=89-90 °C; 
1
H NMR (600 MHz, CDCl3) δ 7.93 (d, 
J=8.4 Hz, 1H), 7.83 (d, J=2.4 Hz, 1H), 7.63 (dd, J=9.0, 2.4 Hz, 1H), 3.58 (s, 1H);
 13
C NMR (150 MHz, 
CDCl3) δ 148.9, 138.0, 132.5, 127.6, 125.9, 119.2, 86.6, 77.3; IR (ATR) 3276, 2111, 1598, 1513, 1324, 
836 cm
-1
; HRMS (ESI) calcd for C8H5BrNO2 (M+H
+
) 225.9504, found 225.9502. 
Tributyl(1-(5-bromo-2-nitrophenyl)ethenyl)tin (115). Tributyltin hydride (1.98 g, 6.79 mmol) was 
added drop wise, at ambient temperature, to a solution of PdCl2(PPh3)2 (318 mg, 0.453 mmol) and 114 
(1.02 g, 4.53 mmol) in THF (10 mL). The dark brown reaction mixture was stirred for 36 h followed by 
removal of the solvent under reduced pressure. Purification by chromatography (hexane/EtOAc, 98:2) 
gave 115 (2.16 g, 4.185 mmol, 92%) as a brown viscous oil. 
1
H NMR (600 MHz, CDCl3) δ 7.89 (d, J=9.0 
Hz, 1H), 7.44 (dd, J=8.4, 1.8 Hz, 1H), 7.27 (d, J=1.8 Hz, 1H), 5.75 (d, J=2.4 Hz, 1H), 5.46 (d, J=2.4 Hz, 
1H), 1.48-1.42 (m, 6H), 1.26 (sext, J=7.8 Hz, 6H), 0.94-0.91 (m, 6H), 0.86 (t, J=7.2 Hz, 9H);
  13
C NMR 
(150 MHz, CDCl3) δ 153.8, 146.2, 144.6, 132.4, 129.4, 128.0, 126.7, 125.8, 28.8, 27.3, 13.6, 11.0; IR 
(ATR)  2955, 2923, 1522, 1339, 878 cm
-1
; HRMS (ESI) calcd for C20H33BrNO2Sn (M+H
+
) 518.0717, 
found 518.0730. 
112 
 
2,3-Di(5-bromo-2-nitrophenyl)-1,3-butadiene (116). To a slurry of copper chloride (437 mg, 4.42 
mmol) in DMF (5 mL) in a round bottomed flask covered with aluminum foil to exclude light was added 
a solution of 115 (914 mg, 1.77 mmol) in DMF (3 mL). The resulting mixture was stirred at ambient 
temperature for 3 h. A saturated solution of NH4Cl (aqueous, 6 mL) was added and the mixture was 
allowed to stir for an additional hour. The mixture was diluted with EtOAc (50 mL), was washed with 
H2O (3 x 40 mL) and brine (40 mL). The organic phase was dried (MgSO4), filtered, and the solvent was 
removed under reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 9:1) 
affording 116 (223 mg, 0.491 mmol, 56%) as a white solid. mp=235 °C (decomposed);
 1
H NMR (600 
MHz, CDCl3) δ 7.90 (d, J=9.0 Hz, 1H), 7.75 (d, J=1.8 Hz, 1H), 7.67 (dd, J=8.4, 1.8 Hz, 1H), 5.18 (s, 1H), 
4.94 (s, 1H);
 1
H NMR (100 MHz, CDCl3) δ 147.6, 143.8, 136.7, 135.0, 132.1, 128.0, 125.7, 119.0; IR 
(ATR) 1558, 1516, 1333, 1084, 868 cm
-1
; HRMS (ESI) calcd for C16H11Br2N2O4 (M+H
+
) 452.9085, 
found 452.9068. 
5,5’-Dibromo-3,3’-bi-1H-indole (111). 2,3-Di(5-bromo-2-nitrophenyl)-1,3-butadiene (116) (207 mg, 
0.456 mmol), Pd(dba)2 (26.2 mg, 0.046 mmol), dppp (22.6 mg, 0.055 mmol) and phen (20.0 mg, 0.111 
mmol) were dissolved in anhydrous DMF (3 mL) in a threaded ACE glass pressure tube. The tube was 
fitted with a pressure head, and the solution was saturated with carbon monoxide (four cycles of 6 atm of 
CO). The reaction mixture was heated at 120 
o
C under CO (6 atm) for 60 h.  After cooling to ambient 
temperature, the crude was diluted with EtOAc (30 mL) and was washed with water (20 mLx4) and brine 
(20 mLx1) respectively. The organic layer was dried (MgSO4), filtered and the solvent was removed from 
the filtrate under reduced pressure. The resulting residue was purified by chromatograpy (hexane/EtOAc, 
7:3) to give 111 (80 mg, 0.205 mmol, 45%) as a white solid. 
1
H NMR (600 MHz, DMSO-d6) δ 11.42 (br 
s, 1H), d, J=1.8 Hz, 1H), 7.74 (d, J=2.4 Hz, 1H), 7.42 (d, J=8.4 Hz,1H), 7.25 (dd, J=9.0, 1.8 Hz, 1H);
  1
H 
NMR (100 MHz, DMSO-d6) δ 135.0, 127.7, 123.9, 123.8, 121.4, 113.6, 111.6, 108.6; IR (ATR) 3423, 
1658, 1455, 1098, 794 cm
-1
. 
2,2’,5,5’-Tetrabromo-3,3’-bi-1H-indole (103). A mixture of 111 (51.3 mg, 0.132 mmol)  and N-
bromosuccinimide (NBS, 46.8 mg, 0.263 mmol) in carbon tetrachloride (2 mL) was stirred at reflux (78 
o
C ) for 2 h. After cooling to ambient temperature, the dark brown mixture was filtered through silica gel 
and the silica gel was washed with EtOAc (3 mL). The combined filtrate was concentrated under reduced 
pressure and purified by chromatography (hexane/EtOAc, 9:1) to give 103 (42.8 mg, 0.078 mmol, 59%) 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.43 (br s, 1H), 7.45 (d, J=1.2 Hz, 1H), 7.31 (dd, J=8.8, 
2.0 Hz, 1H), 7.24 (d, J=2.8 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 134.7, 129.6, 125.6, 122.0, 114.0, 
112.0, 111.1, 108.2; IR (ATR) 3404, 1452, 1432, 1397, 1327, 794 cm
-1
; HRMS (ESI) calcd for 
C16H8Br4N2 (M
+
) 547.7380, found 547.7359.   
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2,2’,5,5’,6,6’-Hexabromo-3,3’-bi-1H-indole (105). Reaction of 111 (70.1 mg, 0.180 mmol) and NBS 
(192 mg, 1.08 mmol) in THF/CH2Cl2 (1:1, 4 mL), as described for 103 (70 °C, 13 h), gave after work up 
and chromatography (hexane/EtOAc, 9:1) 105 (58.0 mg, 0.082 mmol, 46%) as a colorless oil. 
1
H NMR 
(400 MHz, CDCl3) δ 8.43 (br s, 1H), 7.67 (s, 1H), 7.55 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 135.5, 
128.4, 123.5, 118.1, 116.3, 115.3, 112.0, 107.8; IR (ATR) 3410, 1431, 1364, 1308, 936, 731 cm
-1
; HRMS 
(ESI) calcd for C16H6Br6N2 (M
+
) 705.5570, found 705.5597. 
Tributyl(1-(4-bromo-2-nitrophenyl)ethenyl)tin (118). Tributyltin hydride (2.56 g, 8.81 mmol) was 
added drop wise, at ambient temperature, to a solution of PdCl2(PPh3)2 (412 mg, 0.587 mmol) and 1-(4-
bromo-2-nitrophenyl)ethyne (117) (1.28 g, 5.88 mmol) in THF (13 mL). The dark brown reaction mixture 
was stirred for 24 h followed by removal of the solvent under reduced pressure. Purification by 
chromatography (hexane) gave 118 (2.95 g, 5.70 mmol, 97%) as a brown oil. 
1
H NMR (600 MHz, 
CDCl3) δ 8.13 (d, J=1.8 Hz, 1H), 7.63 (dd, J=8.4, 1.8 Hz, 1H), 6.98 (d, J=7.8 Hz, 1H), 5.73 (d, J=2.4 Hz, 
1H), 5.46 (d, J=2.4 Hz, 1H), 1.47-1.42 (m, 6H), 1.26 (sext, J=7.2 Hz, 6H), 0.93-0.90 (m, 6H), 0.86 (t, 
J=7.2 Hz, 9H); 
13
C NMR (150 MHz, CDCl3) δ 153.7, 146.3, 143.3, 136.1, 131.1, 127.1, 126.7, 119.0, 
28.8, 27.3, 13.6, 10.9; IR (ATR) 2921, 1522, 1464, 1339, 878 cm
-1
; HRMS (ESI, negative ion mode) 
calcd for C20H32BrNO2Sn (M
-
) 517.0638, found 517.0638. 
2,3-Di(4-bromo-2-nitrophenyl)-1,3-butadiene (119). To a slurry of copper chloride (CuCl, 579 mg, 
5.85 mmol) in DMF (3 mL) in a round bottomed flask covered with aluminum foil to exclude light was 
added a solution of 118 (1.21 g, 2.34 mmol) in DMF (3 mL). The resulting mixture was stirred at ambient 
temperature for 2 h. A saturated solution of NH4Cl (aqueous, 6 mL) was added and the mixture was 
allowed to stir for an additional hour. The mixture was diluted with EtOAc (50 mL), was washed with 
H2O (3 x 40 mL) and brine (40 mL). The organic phase was dried (MgSO4), filtered, and the solvent was 
removed under reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 9:1) to 
give 119 (438 mg, 0.965 mmol, 82%) as a white solid. mp=185-187 °C; 
1
H NMR (400 MHz, CDCl3) δ 
8.13 (d, J=2.0 Hz, 1H), 7.79 (dd, J=8.0, 2.0 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 5.15 (s, 1H), 4.92 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 149.2, 144.1, 136.1, 133.8, 133.6, 127.2, 122.1, 118.9; IR (ATR) 1555, 
1522, 1336, 913, 840 cm
-1
; HRMS (ESI, negative ion mode) calcd for C16H10Br2N2O4 (M
-
) 453.8987, 
found 453.9017. 
6,6’-Dibromo-3,3’-Bi-1H-indole (120). 2,3-Di(4-bromo-2-nitrophenyl)-1,3-butadiene (119) (320 mg, 
0.705 mmol), Pd(dba)2 (28.4 mg, 0.049 mmol), dppp (20.4 mg, 0.049 mmol) and phen (17.8 mg, 0.099 
mmol) were dissolved in anhydrous DMF (3 mL) in a threaded ACE glass pressure tube. The tube was 
fitted with a pressure head, and the solution was saturated with carbon monoxide (four cycles of 6 atm of 
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CO). The reaction mixture was heated at 120 
o
C under CO (6 atm) for 42 h. The combined organic phases 
were dried (MgSO4), filtered, and the solvent was removed under reduced pressure. The resulting crude 
product was purified by chromatography (hexane/EtOAc, 19:1) to afford 120 (176 mg, 0.451 mmol, 64%) 
as a white solid. mp=239-240 °C; 
1
H NMR (400 MHz, DMSO-d6) δ 11.34 (br s, 1H), 7.70 (d, J=8.8 Hz, 
1H), 7.68 (d, J=2.4 Hz, 1H), 7.61 (d, J=1.6 Hz, 1H), 7.18 (dd, J=8.4, 2.0 Hz, 1H); 
13
C NMR (150 MHz, 
DMSO-d6) δ 137.2, 124.9, 123.0, 121.7, 121.2, 114.1, 114.0, 109.3; IR (ATR) 3382, 1589, 1519, 1335, 
801 cm
-1
; HRMS (ESI) calcd for C16H11Br2N2 (M+H
+
) 388.9289, found 388.9287. 
2,2’,6,6’-Tetrabromo-3,3’-bi-1H-indole (104). A mixture of 120 (41.2 mg, 0.106 mmol) and N-
bromosuccinimide (NBS, 28.6 mg, 0.161 mmol) in carbon tetrachloride (1 mL) was stirred at reflux (78 
o
C ) for 2 h. After cooling to ambient temperature, the dark brown mixture was filtered through silica gel 
and the silica gel was washed with EtOAc (3 mL). The combined filtrate was concentrated under reduced 
pressure and purified by chromatography (hexane/EtOAc, 9:1) to give 104 (32.9 mg, 0.060 mmol, 57%) 
as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.37 (br s, 1H), 7.55 (d, J=1.2 Hz, 1H), 7.22 (dd, J=8.4, 
1.6 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 136.7, 126.9, 123.9, 120.9, 116.3, 
113.5, 110.1, 108.9; IR (ATR) 3425, 1432, 1371, 1308, 910, 815 cm
-1
; HRMS (ESI) calcd for C16H8Br4N2 
(M
+
) 547.7380, found 547.7364.  
 2,2’,5,5’,6,6’-Hexabromo-3,3’-bi-1H-indole (105) and 2,2’,5,6,6’-pentabromo-3,3’-bi-1H-indole 
(121). Treatment of 120 (76.1 mg, 0.195 mmol) with NBS (174 mg, 0.978 mmol) in THF/CH2Cl2 (1:1, 4 
mL), as described for 103 (70 °C, 6 h), gave after work up and chromatography (hexane/EtOAc, 9:1), in 
order of elution, 121 (40.3 mg, 0.064 mmol, 33%) and 105 (64.9 mg, 0.098 mmol, 47%) both as a 
colorless oil. Analytical data for 121: 
1
H NMR (400 MHz, CDCl3) δ 8.41 (br s, 1H), 8.40 (s, 1H), 7.68 (s, 
1H), 7.59 (s, 1H), 7.55 (d, J=1.2 Hz, 1H), 7.24 (dd, J=8.4, 1.6 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H); 
13
C NMR 
(400 MHz, CDCl3) δ 136.6, 135.5, 128.6, 126.7, 124.1, 123.8, 120.7, 118.0, 116.4, 116.2, 115.3, 113.5, 
111.7, 110.3, 108.4, 108.3; IR (ATR) 3411, 1433, 1372, 1303, 805 cm
-1
; HRMS (ESI) calcd for 
C16H8Br5N2 (M+H
+
) 622.6604, found 622.6589.  
2,2’,6,6’-Tetrabromo-3,3’-bi-1H-indole (104) and 2,2’,5,6,6’-Pentabromo-3,3’-bi-1H-indole (121). 
Compound 56 (40.1 mg, 0.173 mmol) was treated with NBS (123 mg, 0.690 mmol) in THF/CH2Cl2 (1:1, 
3 mL), as described for 103 (70 °C, 15 h). Work up and chromatography (hexane/EtOAc, 95:5) gave, in 
order of elution, 104 (7.8 mg, 0.014 mmol, 8%) and 121 (8.5 mg, 0.014 mmol, 8%) both as a colorless 
oil. 
2,2’,5,6,6’-Pentabromo-3,3’-bi-1H-indole (121) and 2,2’,5,5’,6,6’-Hexabromo-3,3’-bi-1H-indole 
(105). Compound 56 (32.2 mg, 0.139 mmol) was treated with NBS (126 mg, 0.708 mmol) in 
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THF/CH2Cl2 (1:1, 3 mL), as described for 103 (70 °C, 16 h). Work up and chromatography 
(hexane/EtOAc, 95:5) gave, in order of elution, 121 (10.8 mg, 0.017 mmol, 12%) and 105 (10.1 mg, 
0.014 mmol, 10%) both as a colorless oil. 
2,2’,5,5’,6,6’-Hexabromo-3,3’-bi-1H-indole (105). Compound 56 (40.8 mg, 0.176 mmol) was treated 
with NBS (250 mg, 1.40 mmol) in THF/CH2Cl2 (1:1, 3 mL), as described for 103 (70 °C, 22 h). Work up 
and chromatography (hexane/EtOAc, 95:5) gave 105 (19.3 mg, 0.027 mmol, 16%) as a colorless oil. 
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5-Methoxy-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (145). To a solution of 5-methoxy-2-
nitrobenzenamine (1.00 g, 5.95 mmol) and 2-methylpropanal (515 mg, 7.14 mmol) in dichloromethane 
(DCM, 12 mL) at ambient temperature under a nitrogen atmosphere was added 4 Å molecular sieves (3 g, 
activated by heating at 120 °C under vacuum overnight, then stored under nitrogen). The reaction mixture 
was allowed to sit without agitation or stirring for 48 h. The mixture was then filtered and the sieves were 
washed with DCM (20 mL). The filtrate was concentrated under reduced pressure and the resulting 
residue was purified by chromatography (hexane/EtOAc, 9:1) to give 145 (484 mg, 2.18 mmol, 37%) as a 
red solid. mp=83-84 °C; 
1
H NMR (600 MHz, CDCl3) δ 9.86 (d, J=7.2 Hz, 1H), 8.14 (d, J=9.6 Hz, 1H), 
6.32 (d, J=3.0 Hz, 1H), 6.29 (dd, J=9.6, 2.4 Hz, 1H), 6.20 (dpent, J=9.6, 1.2 Hz, 1H), 3.88 (s, 3H), 1.83 
(s, 3H), 1.80 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 165.7, 143.5, 129.0, 126.0, 119.0, 118.0, 106.1, 95.0, 
55.7, 22.5, 16.8;  IR (ATR) 2923, 1616, 1585, 1497, 1239 cm
-1
; HRMS (ESI) calcd for C11H14N2O3Na 
(M+Na
+
) 245.0902, found 245.0896.  
 
4-Bromo-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (133). Treatment of a solution of 4-bromo-
2-nitrobenzenamine (1.04 g, 4.78 mmol) and 2-methylpropanal (414 mg, 5.74 mmol) in dichloromethane 
(DCM, 12 mL) at ambient temperature under a nitrogen atmosphere in the presence of 4 Å molecular 
sieves (3 g), as described for 145 (24 h), gave after work up and chromatography, (hexane/EtOAc, 95:5), 
133 (726 mg, 2.68 mmol, 56%) as a violet solid. mp=119-120 °C; 
1
H NMR (400 MHz, CDCl3) δ 9.55 (d, 
J=8.0 Hz, 1H), 8.29 (d, J=2.4 Hz, 1H), 7.47 (dd, J=9.2, 2.4 Hz, 1H), 6.93 (d, J=9.6 Hz, 1H), 6.20 (d, 
J=9.6 Hz, 1H), 1.81 (s, 3H), 1.78 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 140.3, 138.8, 128.8, 119.9, 
117.9, 116.0, 107.6, 22.5, 16.8; IR (ATR) 2912, 1564, 1340, 1165 cm
-1
; HRMS (ESI) calcd for 
C10H12BrN2O2 (M+H
+
) 271.0082, found 271.0078.  
 
5-Bromo-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (150). Treatment of a solution of 5-bromo-
2-nitrobenzenamine (455 mg, 2.10 mmol) with 2-methylpropanal (182 mg, 2.52 mmol) in benzene (6 
mL), in the presence of 4 Å molecular sieves (4 g), at ambient temperature under a nitrogen atmosphere, 
as described for 145 (24 h), gave after work up and chromatography (hexane/EtOAc, 95:5), 150 (416 mg, 
1.534 mmol, 73%) as a red solid. mp=94-95 °C; 
1
H NMR (600 MHz, CDCl3) δ 9.56 (d, J=7.2 Hz, 1H), 
8.03 (d, J=9.0 Hz, 1H), 7.20 (d, J=1.2 Hz, 1H), 6.81 (dd, J=9.0, 1.8 Hz, 1H), 6.18 (d with further fine 
splitting, J=9.6 Hz, 1H), 1.83 (s, 3H), 1.79 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 141.8, 131.6, 130.7, 
128.1, 120.7, 119.8, 117.8, 117.0, 22.5, 16.9; IR (ATR) 3495, 3381, 1616, 1560, 1489, 1218 cm
-1
; HRMS 
(ESI) calcd for C10H12BrN2O2 (M+H
+
) 271.0082, found 271.0078.  
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4-Fluoro-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (136). Treatment of a solution of 4-fluoro-
2-nitrobenzenamine (845 mg, 5.41 mmol) with 2-methylpropanal (390 mg, 5.41 mmol) in DCM (12 mL), 
in the presence of 5 Å molecular (12 g), at ambient temperature under a nitrogen atmosphere, as described 
for 145, (24 h), gave after work up and chromatography (hexane/EtOAc, 97:3), 136 (788 mg, 3.75 mmol, 
69%) as a reddish-brown solid. mp=79-80 °C; 
1
H NMR (400 MHz, CDCl3) δ 9.48 (d, J=7.6 Hz, 1H), 7.87 
(dd, J=8.8, 2.8 Hz, 1H), 7.27-7.22 (ddd, J=9.6, 6.4, 2.4 Hz, 1H), 7.02 (dd, J=9.6, 4.8 Hz, 1H), 6.21 (d, 
with further fine splitting J=9.6 Hz, 1H), 1.81 (s, 3H), 1.78 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  δ 153.0 
(d, J
C-F
=239.0 Hz), 138.6 (d, J
C-F
=1.0 Hz), 130.5 (d, J
C-F
=8.0 Hz), 124.9 (d, J
C-F
=24 Hz), 119.2, 118.2, 
115.7 (d, J
C-F
=8.0 Hz), 111.8 (d, J
C-F
=26.0 Hz), 22.3, 16.7; IR (ATR) 1580, 1519, 1404, 1185, 1158, 1112 
cm
-1
; HRMS (ESI) C10H12FN2O2 (M+H
+
) 211.0883, found 211.0897. 
 
5-Methyl-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (153). Treatment of a solution of 5-methyl-
2-nitrobenzenamine (200 mg, 1.31 mmol) and 2-methylpropanal (114 mg, 1.58 mmol) in benzene (3 mL), 
in the presence of 4 Å molecular sieves (1 g) at ambient temperature under a nitrogen atmosphere, as 
described for 145 (24 h), gave after work up and chromatography (hexane/EtOAc, 95:5), 153 (106 mg, 
0.514 mmol, 39%) as a red solid. mp=75-76 °C; 
1
H NMR (600 MHz, CDCl3) δ 9.63 (d, J=7.8 Hz, 1H), 
8.06 (d, J=9.0 Hz, 1H), 6.81 (s, 1H), 6.51 (dd, J=9.0, 1.2 Hz, 1H), 6.27 (d with further fine splitting, 
J=9.0 Hz, 1H), 2.35 (s, 3H), 1.82 (s, 3H), 1.79 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 147.7, 141.4, 
129.9, 126.8, 118.5, 118.4, 118.2, 113.8, 22.5, 22.1, 16.8; IR (ATR) 1618, 1578, 1332, 1210, 1183 cm
-1
; 
HRMS (ESI) calcd for C11H15N2O2 (M+H
+
) 207.1133, found 207.1128.  
 
4-Bromo-2-nitro-N-(2-phenyl-1-propen-1-yl)benzenamine (160). Treatment of a solution of 4-bromo-
2-nitrobenzenamine (430 mg, 1.98 mmol) with 2-phenylpropanal (239 mg, 1.78 mmol) in DCM (7 mL), 
in the presence of 5 Å molecular sieves (3.5 g), at ambient temperature under a nitrogen atmosphere, as 
described for 145 (24 h), gave after work up and chromatography (hexane/EtOAc, 95:5), 160 (446 mg, 
1.34 mmol, 67%) as a violet solid. mp=106-107 °C;
 1
H NMR (400 MHz, CDCl3) δ 9.93 (d, J=10.4 Hz, 
1H), 8.37 (d, J=2.4 Hz, 1H), 7.56 (dd, J=9.2, 2.4 Hz, 1H), 7.42-7.34 (m, 4H), 7.29-7.25 (m, 1H), 7.09 (d, 
J=9.2 Hz, 1H), 6.87 (dq, J=10.4, 1.2 Hz, 1H), 2.21 (d, J=1.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
140.9, 139.4, 138.9, 132.7, 129.0, 128.5, 126.8, 125.3, 120.6, 120.5, 116.0, 108.8, 14.7; IR (ATR) 1618, 
1564, 1175, 1126, 749 cm
-1
; HRMS (ESI) calcd for C15H14BrN2O2 (M+H
+
) 333.0238, found 333.0234.  
A detailed experimental procedure for the experiment shown in Entry 1 in Table 1 is shown below. All 
other entries in Tables 1-3 are slight variations of this procedure. Detailed experimental procedures for all 
entries discussed can be found below the analytical data section.  
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Table 4.2, Entry 11 
1-Methoxybenzimidazole (124),
133
 1-Methoxy-2-(2-methoxy-2-propyl)benzimidazole (125), and 2-(2-
Hydroxy-2-propyl)-1-methoxybenzimidazole (126). A mixture of 2-nitro-N-(2-methyl-1-propen-1-
yl)benzenamine (122)
134
 (160 mg, 0.833 mmol) and sodium hydride
135
 (NaH, 74.4 mg, 3.10 mmol) in 
dimethylsulfoxide (DMSO, 10 mL) was stirred at ambient temperature under a nitrogen atmosphere.  
After stirring for 1 h, the mixture was cooled to 0 °C and methyl iodide (379 mg, 2.67 mmol) was added 
via a syringe. The reaction vessel was removed from the cold bath and stirred for 1 h. The resulting 
mixture was diluted with EtOAc (20 mL), washed with water (5x15 mL), dried (MgSO4), and filtered. 
The solvents were removed from the filtrate under reduced pressure and the resulting residue was purified 
by chromatography (hexane/EtOAc, 7:3 then 3:7) to give, in order of elution 125 (105 mg, 0.477 mmol, 
57%) as a colorless oil, 126 (25.3 mg, 0.123 mmol, 15%) as a white solid, and 124 (6.3 mg, 0.043 mmol, 
5%) as a colorless oil. 
 
Analytical data for all compounds: 
1-Methoxybenzimidazole (124). Colorless oil; 
1
H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.78 (d, 
J=8.0 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 7.34 (td, J=7.2, 1.2 Hz, 1H), 7.29 (td, J=8.0, 1.2 Hz, 1H), 4.17 (s, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 139.4, 137.4, 129.2, 123.6, 122.5, 120.9, 108.3, 67.2; IR (ATR) 
1476, 1449, 1318, 1074, 962 cm
-1
; HRMS (ESI) calcd for C8H9N2O (M+H
+
) 149.0715, found 149.0710. 
 
1-Methoxy-2-(2-methoxy-2-propyl)benzimidazole (125). Colorless oil; 
1
H NMR (400 MHz, CDCl3) δ 
7.75 (d, J=8.0 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.32 (td, J=7.2, 1.2 Hz, 1H), 7.26 (td, J=7.2, 1.2 Hz, 1H), 
4.20 (s, 3H), 3.19 (s, 3H), 1.80 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 151.3, 136.9, 131.4, 123.4, 122.2, 
120.4, 108.3, 74.5, 65.2, 51.3, 24.8; IR (ATR) 1244, 1176, 1151, 1066, 969 cm
-1
; HRMS (ESI) calcd for 
C12H17N2O2 (M+H
+
) 221.1290, found 221.1285. 
 
1-Methoxy-2-(2-hydroxy-2-propyl)benzimidazole (126).
 
White solid; mp=121-122 
o
C;
 1
H NMR (400 
MHz, CDCl3) δ 7.71 (d, J=7.6 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.31 (td, J=7.2, 1.2 Hz, 1H), 7.26 (td, 
J=8.0, 1.6 Hz, 1H), 4.22 (s, 3H), 3.51 (br s, 1H), 1.77 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 154.2, 
136.9, 131.2, 123.3, 122.5, 120.4, 108.5, 69.8, 65.7, 28.8; IR (ATR) 3240, 1438, 1359, 1234, 1176, 1147 
cm
-1
; HRMS (ESI) calcd for C11H15N2O2 (M+H
+
) 207.1133, found 207.1118. 
 
1,6-Dimethoxybenzimidazole (128). Colorless oil; 
1
H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.64 (d, 
J=9.6 Hz, 1H), 6.93-6.90 (m, 2H), 4.17 (s, 3H), 3.89 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.3, 136.6, 
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133.9, 129.9, 121.6, 112.4, 91.3, 67.0, 55.8; IR (ATR) 1493, 1236, 1020, 815 cm
-1
; HRMS (ESI) calcd for 
C9H11N2O2 (M+H
+
) 179.0820, found 179.0814. 
 
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). Pale yellow oil; 
1
H NMR (400 MHz, 
CDCl3) δ 7.61 (d, J=9.6 Hz, 1H), 6.88 (dd, J=7.2, 2.4 Hz, 1H), 6.87 (s, 1H), 4.17 (s, 3H), 3.88 (s, 3H), 
3.16 (s, 3H), 1.77 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 150.5, 132.1, 131.3, 121.1, 111.8, 91.4, 
74.5, 65.0, 55.8, 51.3, 24.9; IR (ATR) 2929, 1738, 1215, 1063, 817 cm
-1
; HRMS (ESI) calcd for 
C13H19N2O3 (M+H
+
) 251.1395, found 251.1389.  
 
2-(2-Hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130).  Data from a 37:1 mixture of 130 and 128: 
White solid; mp=119-120 
o
C, 
1
H NMR δ 7.59 (d, J=8.6 Hz, 1H), 6.90 (dd, J=8.8, 2.5 Hz, 1H), 6.87 (d, 
J=2.2 Hz, 1H), 4.21 (s, 3H), 3.89 (s, 3H), 3.26 (br s, 1H), 1.76 (s, 6H); 
13
C NMR δ 157.1, 153.4, 131.8, 
131.4, 121.0, 111.8, 92.0, 69.8, 65.5, 55.9, 28.8; IR (neat) 3234, 1625, 1497, 1242, 1217, 1178, 1147, 
1018, 956, 823 cm
-1
; HRMS (ESI) calcd for C12H17N2O3 (M+H
+
) 237.1239, found 237.1229. 
 
6-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (132). Orange solid; mp=66-67 
o
C; 
1
H 
NMR (400 MHz, CDCl3) δ 7.62 (d, J=8.4 Hz, 1H), 7.41 (d, J=1.6 Hz, 1H), 7.19 (dd, J=8.4, 1.6 Hz, 1H), 
4.16 (s, 3H), 3.16 (s, 3H), 1.76 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 152.4, 135.5, 132.1, 129.4, 123.1, 
121.4, 108.4, 74.5, 65.5, 51.3, 24.8; IR (ATR) 2944, 1677, 1496, 1340, 1268, 1228 cm
-1
; HRMS (ESI) 
calcd for C12H16ClN2O2 (M+H
+
) 255.0900, found 255.0893. 
 
6-Bromo-1-methoxybenzimidazole (134). White solid; mp=46-47 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 
8.05 (s, 1H), 7.66 (d, J=2.0 Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 7.38 (dd, J=8.4, 1.6 Hz, 1H), 4.17 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 138.3, 138.1, 130.3, 126.0, 122.3, 117.1, 111.5, 67.4; IR (ATR) 1462, 
1347, 1220, 1086, 952 cm
-1
; HRMS (ESI) calcd for C8H8BrN2O (M+H
+
) 226.9820, found 226.9814. 
 
6-Bromo-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (135). Orange oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.57 (s, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.32 (dd, J=8.4, 1.8 Hz, 1H), 4.15 (s, 3H), 3.15 (s, 3H), 
1.74 (s, 6H); 
13
C NMR (150 MHz, CDCl3) δ 152.3, 136.0, 132.6, 125.8, 121.8, 116.9, 111.5, 74.6, 65.6, 
51.4, 24.8; IR (ATR) 2941, 1461, 1355, 1240, 1177 cm
-1
; HRMS (ESI) calcd for C12H16BrN2O2 (M+H
+
) 
299.0395, found 299.0390. 
6-Fluoro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (137). Pale yellow oil; 
1
H NMR (400 
MHz, CDCl3) δ 7.62 (dd, J=8.8, 4.8 Hz, 1H), 7.07 (dd, J=8.0, 2.4 Hz, 1H), 6.95 (td, J=9.6, 2.4 Hz, 1H), 
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4.13 (s, 3H), 3.14 (s, 3H), 1.73 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 159.9 (d, J
C-F
=241.0 Hz), 152.2 (d, 
J
C-F
=3.0 Hz), 133.2, 131.5 (d, J
C-F
=13.0 Hz), 121.4 (d, J
C-F
=10.0 Hz), 110.8 (d, 
JC-F
=25.0 Hz), 95.0 (d, J
C-
F
=28.0 Hz), 74.4, 65.2, 51.3, 24.7; IR (ATR) 1486, 1448, 1172, 1067, 965, 811 cm
-1
; HRMS (ESI) calcd 
for C12H16FN2O2 (M+H
+
) 239.1196, found 239.1191. 
 
1-Methoxy-6-methylbenzimidazole (139). Colorless oil; 
1
H NMR (400 MHz, CDCl3) δ 8.02 (br s, 1H), 
7.65 (d, J=8.4 Hz, 1H), 7.29 (s, 1H), 7.11 (dd, J=8.0, 1.2 Hz, 1H), 4.17 (s, 3H), 2.51 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ 137.5, 137.0, 133.8, 129.4, 124.2, 120.4, 108.1, 67.1, 21.7; IR (ATR) 2922, 1457, 
1060, 965, 806 cm
-1
; HRMS (ESI) calcd for C9H11N2O (M+H
+
) 163.0871, found 163.0867. 
 
1-Methoxy-2-(2-methoxy-2-propyl)-6-methylbenzimidazole (140). Colorless oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.60 (d, J=8.4 Hz, 1H), 7.21 (d, J=1.2 Hz, 1H), 7.06 (dd, J=8.4, 1.2 Hz, 1H), 4.15 (s, 3H), 3.15 
(s, 3H), 2.48 (s, 3H), 1.76 (s, 6H); 
13
C NMR (150 MHz, CDCl3) δ 150.8, 135.1, 133.6, 131.6, 123.9, 
119.9, 108.1, 74.5, 65.1, 51.3, 24.9, 21.7; IR (ATR) 2947, 1242, 1176, 810 cm
-1
; HRMS (ESI) calcd for 
C13H19N2O2 (M+H
+
) 235.1446, found 235.1441.  
 
2-(2-Hydroxy-2-propyl)-1-methoxy-6-methylbenzimidazole (141). White solid; mp=99-100 
o
C; 
1
H 
NMR (600 MHz, CDCl3) δ 7.58 (d, J=8.4 Hz, 1H), 7.22 (s, 1H), 7.08 (dd, J=8.4, 1.2 Hz, 1H), 4.21 (s, 
3H), 3.44 (br s, 1H), 2.50 (s, 3H), 1.76 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 153.8, 135.0, 133.5, 131.4, 
124.1, 119.9, 108.3, 69.8, 65.6, 28.8, 21.8; IR (ATR) 3241, 1145, 951, 815 cm
-1
; HRMS (ESI) calcd for 
C12H17N2O2 (M+H
+
) 221.1290, found 221.1285. 
 
Methyl 1-methoxybenzimidazole-6-carboxylate (143). White solid; mp=126-127
 o
C; 
1
H NMR (600 
MHz, CDCl3) δ 8.23 (br s, 1H), 8.19 (s, 1H), 7.99 (dd, J=8.4, 1.2 Hz, 1H), 7.78 (d, J=8.4 Hz, 1H), 4.22 (s, 
3H), 3.95 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 167.0, 142.6, 140.0, 129.0, 125.6, 123.9, 120.7, 110.9, 
67.7, 52.2; IR (ATR) 1698, 1441, 1320, 1280, 1226 cm
-1
; HRMS (ESI) calcd for C10H11N2O3 (M+H
+
) 
207.0769, found 207.0763. 
 
1,5-Dimethoxybenzimidazole (146). Colorless oil;
 1
H NMR (600 MHz, CDCl3) δ 8.01 (s, 1H), 7.35 (d, 
J=8.4 Hz, 1H), 7.23 (d, J=2.4 Hz, 1H), 6.98 (dd, J=8.4, 2.4 Hz, 1H), 4.15 (s, 3H), 3.85 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3) δ 156.4, 140.3, 137.4, 123.9, 114.1, 108.8, 102.7, 67.2, 55.7; IR (ATR) 1213, 1125, 
969, 803 cm
-1
; HRMS (ESI) calcd for C9H11N2O2 (M+H
+
) 179.0820, found 179.0820. 
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5-Chloro-1-methoxybenzimidazole (148). Yellow oil; 
1
H NMR (600 MHz, CDCl3) δ 8.09 (s, 1H), 7.75 
(d, J=1.8 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.29 (dd, J=9.0, 1.8 Hz, 1H), 4.16 (s, 3H); 
13
C NMR (150 
MHz, CDCl3) δ 140.0, 138.5, 128.1, 127.8, 124.1, 120.5, 109.1, 67.3; IR (ATR) 1457, 1309, 1054, 965, 
898 cm
-1
; HRMS (ESI) calcd for C8H7ClN2O (M+Na
+
) 205.0144, found 205.0139. 
 
5-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (149). Yellow oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.71 (d, J=1.2 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.28 (dd, J=8.4, 1.8 Hz, 1H), 4.18 (s, 3H), 3.18 
(s, 3H), 1.77 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 152.7, 137.8, 130.2, 128.0, 124.0, 120.3, 109.2, 74.6, 
65.5, 51.4, 24.8; IR (ATR) 2938, 1700, 1608, 1575, 1493, 1245 cm
-1
; HRMS (ESI) calcd for 
C12H16ClN2O2 (M+H
+
) 255.0900, found 255.0901. 
 
5-Bromo-1-methoxybenzimidazole (151). Faint yellow oil; 
1
H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 
7.91 (d, J=1.6 Hz, 1H), 7.43 (dd, J=8.8, 2.0 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 4.16 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 140.6, 138.4, 128.2, 126.8, 123.7, 115.6, 109.7, 67.4; IR (ATR) 1454, 1308, 1175, 1066, 
729 cm
-1
; HRMS (ESI) calcd for C8H8BrN2O (M+H
+
) 226.9820, found 226.9815. 
 
5-Bromo-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (152). Red oil; 
1
H NMR (400 MHz, 
CDCl3) δ 7.87 (d, J=1.6 Hz, 1H), 7.41 (dd, J=8.4, 1.6 Hz, 1H), 7.31 (d, J=8.8 Hz, 1H), 4.17 (s, 3H), 3.17 
(s, 3H), 1.77 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 152.6, 138.3, 130.5, 126.6, 123.4, 115.2, 109.6, 74.6, 
65.5, 51.4, 24.8; IR (ATR) 1454, 1308, 1246, 1176, 1066 cm
-1
; HRMS (ESI) calcd for C12H16BrN2O2 
(M+H
+
) 299.0395, found 299.0376. 
 
1-Methoxy-5-methylbenzimidazole (154). Orange oil; 
1
H NMR (600 MHz, CDCl3) δ 8.04 (s, 1H), 7.56 
(s, 1H), 7.37 (d, J=8.4 Hz, 1H), 7.17 (d, J=7.8 Hz, 1H), 4.17 (s, 3H), 2.48 (s, 3H); 
13
C NMR (150 MHz, 
CDCl3) δ 139.9, 137.4, 132.3, 127.4, 125.2, 120.6, 107.9, 21.5; IR (ATR) 2931, 1686, 1607, 1523, 1341, 
1077 cm
-1
; HRMS (ESI) calcd for C9H11N2O (M+H
+
) 163.0871, found 163.0866.  
 
1-Methoxy-5-methyl-(2-methoxy-2-propyl)benzimidazole (155). Orange oil; 
1
H NMR (400 MHz, 
CDCl3) δ 7.53 (br s, 1H), 7.32 (d, J=8.0 Hz, 1H), 7.14 (dd, J=8.0, 0.8 Hz, 1H), 4.17 (s, 3H), 3.17 (s, 3H), 
2.47 (s, 3H), 1.78 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 151.2, 137.4, 132.0, 129.6, 124.9, 120.2, 107.9, 
74.6, 65.2, 51.4, 25.0, 21.5; IR (ATR) 2939, 1455, 1314, 1248, 1067 cm
-1
; HRMS (ESI) calcd for 
C13H19N2O2 (M+H
+
) 235.1446, found 235.1439. 
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1-Methoxy-(2-hydroxy-2-propyl)-5-methylbenzimidazole (156). White solid; mp=99-100 
o
C; 
 1
H NMR 
(400 MHz, CDCl3) δ 7.50 (br s, 1H), 7.31 (d, J=8.0 Hz, 1H), 7.14 (dd, J=8.4, 1.2 Hz, 1H), 4.20 (s, 3H), 
3.45 (br s, 1H), 2.47 (s, 3H), 1.76 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 154.2, 137.3, 132.3, 129.3, 
124.7, 120.1, 108.0, 69.7, 65.6, 28.7, 21.5; IR (ATR) 3242, 1372, 1309, 1236, 1145 cm
-1
; HRMS (ESI) 
calcd for C12H17N2O2 (M+H
+
) 221.1290, found 221.1285. 
 
6-Bromo-1-methoxy-(1-methoxy-1-phenylethyl)benzimidazole (161). Orange oil; 
1
H NMR (400 MHz, 
CDCl3) δ 7.67 (dd, J=8.8, 0.4 Hz, 1H), 7.51 (d, J=1.6 Hz, 1H), 7.38 (dd, J=8.8, 1.6 Hz, 1H), 7.42-7.40 
(m, 2H), 7.35-7.24 (m, 3H), 3.53 (s, 3H), 3.29 (s, 3H), 2.04 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 152.1, 
144.0, 136.1, 128.2, 127.4, 125.9, 125.2, 122.0, 117.0, 111.6, 110.0, 78.3, 64.8, 51.4, 25.0; IR (ATR) 
1437, 1373, 1245, 1185, 981, 792 cm
-1
; HRMS (ESI) calcd for C17H18N2O2 (M+H
+
) 361.0551, found 
361.0549. 
 
6-Bromo-(1-hydroxy-1-phenylethyl)-1-methoxybenzimidazole (162). Colorless oil; 
1
H NMR (400 
MHz, CDCl3) δ 7.65 (d, J=8.4 Hz, 1H), 7.50 (d, J=1.6 Hz, 1H), 7.48-7.46 (m, 2H), 7.39 (dd, J=8.4, 1.6 
Hz, 1H), 7.38-7.27 (m, 3H), 3.90 (br s, 1H), 3.39 (s, 3H), 2.08 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
154.2, 144.4, 136.0, 132.0, 128.6, 127.9, 126.1, 125.2, 122.0, 116.9, 111.5, 73.4, 65.0, 28.6; IR (ATR) 
3233, 1449, 1364, 1251, 1089 cm
-1
; HRMS (ESI) calcd for C16H16N2O2 (M+H
+
) 347.0395, found 
347.0395. 
 
1,6-Dimethoxy-2-(1-methoxycyclohexyl)benzimidazole (158). Colorless oil; 
1
H NMR (400 MHz, 
CDCl3) δ 7.62 (d, J=9.6 Hz, 1H), 6.88 (dd, J=9.6, 2.4 Hz, 1H), 6.87 (s, 1H), 4.16 (s, 3H), 3.89 (s, 3H), 
3.10 (s, 3H), 2.34-2.31 (m, 2H), 2.16-2.10 (m, 2H), 1.76-1.64 (m, 2H), 1.62-1.56 (m, 3H), 1.42-1.35 (m, 
1H); 
13
C NMR (150 MHz, CDCl3) δ 157.0, 149.9, 131.8, 131.4, 120.9, 111.7, 91.3, 75.8, 64.9, 55.7, 50.4, 
32.5, 25.5, 21.7; IR (ATR) 2944, 1739, 1450, 1365, 1207 cm
-1
; HRMS (ESI) calcd for C16H23N2O3 
(M+H
+
) 291.1708, found 291.1701. 
 
1,6-Dimethoxy-2-(1-hydroxycyclohexyl)benzimidazole (159). White solid; mp=132-133 
o
C; 
1
H NMR 
(400 MHz, CDCl3) δ 7.58 (dd, J=8.4, 1.2 Hz, 1H), 6.87 (dd, J=8.4, 2.4 Hz, 1H, 6.86 (s, 1H), 4.19 (s, 3H), 
3.88 (s, 3H), 2.87 (br s, 1H), 2.17 (td, J=12.8, 4.0 Hz, 2H), 2.02-1.99 (m, 2H), 1.85-1.77 (m, 2H), 1.72-
1.62 (m, 3H), 1.42-1.33 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 157.0, 153.2, 131.7, 131.5, 121.0, 111.7, 
91.8, 71.3, 65.5, 55.9, 36.1, 25.3, 21.6; IR (ATR) 3281, 2940, 1504, 1451, 1435, 1237 cm
-1
; HRMS (ESI) 
calcd for C15H21N2O3 (M+H
+
) 277.1552; found: 277.1547. 
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6-Chloro-2-(2-hydroxy-2-propyl)-1-methoxybenzimidazole (163). White solid; mp=94-95 
o
C; 
1
H 
NMR (400 MHz, CDCl3) δ 7.61 (d, J=8.8 Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.23 (dd, J=8.8, 2.0 Hz, 1H), 
4.22 (s, 3H), 3.19 (br s, 1H), 1.77 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 155.1, 135.6, 131.8, 129.2, 
123.3, 121.3, 108.6, 69.9, 66.0, 28.7; IR (ATR) 3286, 1457, 1309, 1054, 965 cm
-1
; HRMS (ESI) calcd for 
C11H14ClN2O2 (M+H
+
) 241.0743, found 241.0739. 
 
6-Bromo-2-(2-hydroxy-2-propyl)-1-methoxybenzimidazole (164). White solid; mp=118-119 
o
C; 
1
H 
NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.36 (dd, J=8.4, 0.8 Hz, 1H), 4.21 (s, 
3H), 3.36 (br s, 1H), 1.76 (s, 6H);
 13
C NMR (100 MHz, CDCl3) δ 155.0, 135.9, 132.2, 126.0, 121.7, 
116.6, 111.5, 69.8, 66.0, 28.7; IR (ATR) 3332, 1458, 1269, 1104, 729 cm
-1
; HRMS (ESI) calcd for 
C11H14BrN2O2 (M+H
+
) 285.0238, found 285.0233. 
 
6-Fluoro-2-(2-hydroxy-2-propyl)-1-methoxybenzimidazole (165). White solid; mp=123-124 °C; 
1
H 
NMR (400 MHz, CDCl3) δ 7.61 (dd, J=9.2, 4.8 Hz, 1H), 7.10 (dd, J=8.0, 2.4 Hz, 1H), 6.99 (ddd, J=9.6, 
8.8, 2.4 Hz, 1H), 4.19 (s, 3H), 3.46 (br s, 1H), 1.75 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 159.8 (d, J
C-
F
=241.0 Hz), 155.0 (d, J
C-F
=3.0 Hz), 133.2, 131.2 (d, J
C-F
=14.0 Hz), 121.3 (d, J
C-F
=10.0 Hz), 111.0 (d, J
C-
F
=25.0 Hz), 95.3 (d, J
C-F
=28.0 Hz), 69.8, 65.7, 28.7; IR (ATR) 3232, 1488, 1438, 1363, 1172, 960, 833 
cm
-1
; HRMS (ESI) calcd for C11H14FN2O2 (M+H
+
) 225.1039, found 225.1035. 
 
5-Chloro-2-(2-hydroxy-2-propyl)-1-methoxybenzimidazole (166).
 
Yellow oil;
 1
H NMR (400 MHz, 
CDCl3) δ 7.67 (d, J=2.0 Hz, 1H), 7.34 (d, J=8.8 Hz, 1H), 7.26 (dd, J=8.8, 2.0 Hz, 1H), 4.21 (s, 3H), 3.71 
(br s, 1H), 1.76 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 155.4, 1376, 129.8, 128.1, 123.7, 120.1, 109.2, 
69.8, 65.9, 28.6; IR (ATR) cm
-1
; HRMS (ESI) calcd for C11H14ClN2O2 (M+H
+
) 241.0744, found 
241.0727. 
 
5-Bromo-2-(2-hydroxy-2-propyl)-1-methoxybenzimidazole (167).
 
 White solid; mp=109-110 
o
C;
 1
H 
NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.40 (dd, J=8.8, 1.6 Hz, 1H), 7.29 (d, J=8.8 Hz, 1H), 4.20 (s, 
3H), 3.49 (br s, 1H), 1.75 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 155.3, 138.1, 130.1, 126.4, 123.2, 
115.4, 109.7, 69.8, 66.0, 28.7; IR (ATR) 3257, 1455, 1309, 1175, 918, 731cm
-1
; HRMS (ESI) calcd for 
C11H14BrN2O2 (M+H
+
) 285.0239, found 285.0233. 
 
1,6-Dimethoxy-2-(1-hydroxy-1,1-diphenylmethyl)benzimidazole (169). Red viscous oil; 
1
H NMR (600 
MHz, CDCl3) δ 7.24-7.21 (m, 2H), 7.19-7.16 (m, 1H), 7.15 (d, J=1.8 Hz, 1H), 7.14-7.13 (m, 1H), 7.09-
124 
 
7.02 (m, 6H), 7.01 (d, J=9.0 Hz, 1H), 6.81 (dd, J=9.0, 3.0 Hz, 1H), 6.33 (br s, 1H), 3.72 (s, 3H), 3.12 (s, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 154.8, 142.9, 142.6, 138.7, 135.9, 134.1, 130.4, 128.0, 127.6, 127.3, 
127.0, 126.3, 126.0, 122.6, 120.5, 108.9, 55.9, 42.7; IR (ATR) 2835, 1529, 1493, 1228, 1040 cm
-1
; 
HRMS (ESI) calcd for C22H21N2O3 (M+H
+
) 361.1552, found 361.1548. 
 
1-Benzyloxy-2-(2-benzyloxy-2-propyl)-6-methoxybenzimidazole (171). Orange oil; 
1
H NMR (400 
MHz, CDCl3) δ 7.64 (d, J=8.8 Hz, 1H), 7.38-7.20 (m, 10H), 6.87 (dd, J=8.8, 2.4 Hz, 1H), 6.66 (d, J=2.8 
Hz, 1H), 5.18 (s, 2H), 4.48 (s, 2H), 3.78 (s, 3H), 1.93 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 157.1, 
150.9, 138.4, 134.2, 132.9, 131.2, 129.3, 129.1, 128.6, 128.2, 127.3, 126.9, 121.0, 1119, 92.0, 79.8, 74.7, 
65.6, 55.7, 25.5; IR (ATR) 2938, 1625, 1490, 1454, 1381, 1306 cm
-1
; HRMS (ESI) calcd for C25H27N2O3 
(M+H
+
) 403.2022, found 403.2014. 
 
1-Benzyloxy-2-(2-hydroxyl-2-propyl)-6-methoxybenzimidazole (172). White solid; mp=118-119 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.57 (d, J=8.8 Hz, 1H), 7.53-7.50 (m, 2H), 7.45-7.42 (m, 3H), 6.85 (dd, 
J=8.8, 2.4 Hz, 1H), 6.69 (d, J=2.4 Hz, 1H), 5.36 (s, 2H), 3.79 (s, 3H), 3.46 (br s, 1H), 1.80 (s, 6H); 
13
C 
NMR (100 MHz, CDCl3) δ 156.9, 153.5, 133.9, 132.4, 131.2, 129.5, 129.4, 128.9, 120.8, 111.7, 92.2, 
80.3, 69.9, 55.7, 28.9; IR (ATR) 3240, 1627, 1491, 1452, 1250, 1213 cm
-1
; HRMS (ESI) calcd for 
C18H21N2O3 (M+H
+
) 313.1552, found 313.1547. 
 
1-(2-Propen-1-yloxy)-6-methoxybenzimidazole (173). Pale yellow oil; 
1
H NMR (400 MHz, CDCl3) δ 
7.88 (s, 1H), 7.61 (dd, J=9.6, 1.2 Hz, 1H), 6.90-6.87 (m, 2H), 6.07 (ddt, J=17.2, 10.4, 6.8 Hz, 1H), 5.33 
(dq, J=17.2, 1.2 Hz, 1H), 4.71 (dt, J=6.4, 1.2 Hz, 1H), 3.85 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 
137.6, 133.7, 130.5, 130.3, 123.1, 121.3, 112.1, 91.6, 79.7, 55.7; IR (ATR) 1624, 1495, 1224, 1061, 932, 
815cm
-1
; HRMS (ESI) calcd for C11H13N2O2 (M+H
+
) 205.0977, found 205.0961. 
 
1-(2-Propen-1-yloxy)-2-(2-(2-propen-1-yloxy)-2-propyl)-6-methoxybenzimidazole (174). Yellow oil; 
1
H NMR (400 MHz, CDCl3) δ 7.60 (dd, J=8.8, 0.8 Hz, 1H), 6.87 (dd, J=8.4, 2.4 Hz, 1H), 6.85 (d, J=2.0 
Hz, 1H), 6.15 (ddt, J=16.8, 10.4, 6.4, 1H), 5.87 (ddt, J=17.2, 10.4, 5.2 Hz, 1H), 5.50 (dq, J=17.2, 1.2 Hz, 
1H), 5.41 (dd, J=17.2, 1.2 Hz, 1H), 5.23 (dq, J=17.2, 1.6 Hz, 1H), 5.10 (dq, J=10.4, 1.6 Hz, 1H), 4.84 (dt, 
J=6.4, 1.2 Hz, 2H), 3.87 (s, 3H), 3.85 (dt, J=5.2, 1.6 Hz, 2H), 1.82 (s, 6H); 
13
C NMR (100 MHz, CDCl3) 
δ 157.1, 150.7, 134.8, 132.7, 131.1, 130.9, 121.0, 120.9, 116.1, 111.7, 91.9, 78.7, 74.2, 64.5, 55.7, 25.3; 
IR (ATR) 2939, 1626, 1490, 1212, 1158, 1026 cm
-1
; HRMS (ESI) calcd for C17H23N2O3 (M+H
+
) 
303.1708, found 303.1702. 
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2-(2-Hydroxy-2-propyl)-6-methoxy-1-(2-propen-1-yloxy)benzimidazole (175). White solid; mp=110-
111 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.56 (dd, J=8.4, 0.8 Hz, 1H), 6.87 (dd, J=8.8, 2.4 Hz, 1H), 6.84 (d, 
J=2.0 Hz, 1H), 6.13 (ddt, J=16.8, 10.4, 6.4 Hz, 1H), 5.52 (dq, J=17.2, 1.2 Hz, 1H), 5.44 (dq, J=10.8, 1.2 
Hz, 1H), 4.86 (d, J=6.4 Hz, 2H), 3.86 (s, 3H), 3.48 (br s, 1H), 1.75 (s, 6H); 
13
C NMR (100 MHz, CDCl3) 
δ 156.9, 153.6, 132.3, 131.2, 130.4, 121.5, 120.9, 111.7, 92.3, 79.0, 69.7, 55.8, 28.8; IR (ATR) 3208, 
2991, 1490, 1252, 1252, 1176 cm
-1
; HRMS (ESI) calcd for C14H19N2O3 (M+H
+
) 263.1396, found 
263.1390. 
 
8-Methoxy-4,4-dimethyl-4H-benzo[4,5]imidazo[1,2-b]dioxazine (176). White solid; mp=121-122 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.55 (dd, J=8.8, 1.2 Hz, 1H), 6.88 (dd, J=8.4, 2.4 Hz, 1H), 6.86 (d, J=2.4 
Hz, 1H), 5.44 (s, 2H), 3.83 (s, 3H), 1.76 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 156.6, 146.3, 131.6, 
129.0, 120.4, 112.6, 91.3, 91.2, 75.8, 55.8, 27.4; IR (ATR) 1523, 1451, 1234, 1209, 1148 cm
-1
; HRMS 
(ESI) calcd for C12H15N2O3 (M+H
+
) 235.1082, found 235.1077. 
 
6-Methoxy-1-(2-propyn-1-yloxy)benzimidazole (177). Pale yellow oil; 
1
H NMR (400 MHz, CDCl3) δ 
8.03 (s, 1H), 7.62 (d, J=8.8 Hz, 1H), 6.92 (d, J=2.0 Hz, 1H), 6.90 (dd, J=8.8, 2.4 Hz, 1H), 4.86 (d, J=2.4 
Hz, 2H), 3.85 (s, 3H), 2.68 (t, J=2.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 157.3, 137.8, 133.6, 130.1, 
121.5, 112.4, 91.6, 79.1, 76.4, 66.0, 55.8; IR (ATR) 3286, 1626, 1496, 1238, 1021; HRMS (ESI) calcd for 
C11H11N2O2 (M+H
+
) 203.0820, found 203.0811. 
 
2-(2-Hydroxy-2-propyl)-6-methoxy-1-(2-propyn-1-yloxy)benzimidazole (178). White solid; mp=150-
151 
o
C (dec.); 
1
H NMR (600 MHz, CDCl3) δ 7.57 (d, J=8.4 Hz, 1H), 6.89 (d, J=1.8 Hz, 1H), 6.87 (dd, 
J=8.4, 2.4 Hz, 1H), 5.26 (d, J=2.4 Hz, 2H), 3.87 (s, 3H), 2.89 (br s, 1H), 2.33 (t, J=3.0 Hz, 1H), 1.77 (s, 
6H); 
13
C NMR (150 MHz, CDCl3) δ 156.8, 156.2, 136.4, 135.7, 120.2, 111.4, 93.6, 77.8, 73.2, 71.2, 55.9, 
34.5, 29.3; IR (ATR) 3282, 1627, 1490, 1214, 1146 cm-1; HRMS (ESI) calcd for C14H16N2O3 (M+Na
+
) 
283.1058, found 283.1042. 
 
1-(3-Butyn-2-yloxy)-6-methoxybenzimidazole (179). Colorless oil; 
1
H NMR (400 MHz, CDCl3) δ 8.04 
(s, 1H), 7.62 (d, J=9.6 Hz, 1H), 6.89 (d, J=2.8 Hz, 1H), 6.88 (dd, J=9.6, 2.8 Hz, 1H), 5.02 (dq, J=6.4, 2.0 
Hz, 1H), 3.85 (s, 3H), 2.63 (d, J=2.0 Hz, 1H), 1.70 (d, J=6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
157.2, 138.3, 133.6, 130.7, 121.3, 112.1, 92.0, 80.6, 76.7, 74.1, 55.8, 20.3; IR (ATR) 1624, 1495, 1234, 
1061, 816; HRMS (ESI) calcd for C12H13N2O3 (M+H
+
) 217.0977, found 217.0968. 
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1-(3-Butyn-2-yloxy)-2-(2-hydroxy-2-propyl)-6-methoxybenzimidazole (180). White solid; mp=131-
132 
o
C; 
1
H NMR (400 MHz, CDCl3) δ 7.54 (d, J=8.8 Hz, 1H), 7.13 (d, J=2.4 Hz, 1H), 6.86 (dd, J=8.8, 
2.4 Hz, 1H), 5.52 (dq, J=6.8, 2.0 Hz, 1H), 3.86 (s, 3H), 2.78 (br s, 1H), 2.56 (d, J=2.0 Hz, 1H), 1.83 (s, 
3H), 2.74 (d, J=1.2 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 156.8, 153.7, 133.9, 131.0, 120.5, 112.0, 
93.9, 81.9, 74.3, 70.2, 55.8, 29.7, 28.4, 20.7; IR (ATR) 3168, 1489, 1251, 1217, 1179 cm
-1
; HRMS (ESI) 
calcd for C15H19N2O3 (M+H
+
) 275.1396, found 275.1391. 
 
1-Acetoxy-2-(2-acetoxy-2-propyl)-6-methoxybenzimidazole (181). Yellow oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.60 (d, J=8.4 Hz, 1H), 6.87 (dd, J=8.4, 2.4 Hz, 1H), 6.57 (d, J=2.4 Hz, 1H), 3.84 (s, 3H), 2.46 
(s, 3H), 1.82 (s, 6H), 1.76 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 167.1, 157.5, 150.4, 133.4, 130.8, 
120.9, 112.0, 91.6, 55.8, 43.0, 31.5, 27.1, 18.9, 12.4; IR (ATR) 1809, 1630, 1491, 1213, 1158 cm
-1
; 
HRMS (ESI) calcd for C15H19N2O5 (M+H
+
) 307.1294, found 307.1275. 
 
1-Acetoxy-2-(1-propen-2-yl)-6-methoxybenzimidazole (182). Pale yellow oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.63 (d, J=9.0  Hz, 1H), 6.89 (dd, J=9.0, 2.4 Hz, 1H), 6.63 (d, J=2.4 Hz, 1H), 5.69 (pent, J=1.2 
Hz, 1H), 5.50 (pent, J=1.2 Hz, 1H), 3.84 (s, 3H), 2.40 (s, 3H), 2.27 (dd, J=1.8, 1.2 Hz, 3H); 
13
C NMR 
(150 MHz, CDCl3) δ 167.2, 157.7, 148.3, 133.3, 133.0, 132.3, 121.2, 118.3, 112.4, 91.6, 55.8, 21.2, 18.3; 
IR (ATR) 1805, 1623, 1491, 1221, 1157, 813; HRMS (ESI) calcd for C13H15N2O3 (M+H
+
) 247.1083, 
found 247.1066. 
 
2,4-Dinitro-N-methyl-N-(2-methyl-1-propen-1-yl)benzenamine. Red oil; 
1
H NMR (400 MHz, CDCl3) 
δ 8.54 (d, J=2.8 Hz, 1H), 8.20 (dd, J=9.6, 2.8 Hz, 1H), 7.04 (d, J=9.6 Hz, 1H), 5.71 (sept, J=1.2 Hz, 1H), 
3.09 (s, 3H), 1.71 (d, J=1.2 Hz, 3H), 1.42 (d, J=1.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 147.3, 141.3, 
136.8, 132.3, 127.7, 127.0, 123.2, 117.3, 40.7, 21.4, 17.5; ; IR (ATR)  1601, 1580, 1501, 1311, 1137 cm
-1
; 
HRMS (ESI) calcd for C11H14N3O4 (M+H
+
) 252.0984 , found 252.0980. 
 
Methyl 4-N-methyl-N-(2-methyl-1-propen-1-yl)amino-3-nitrobenzoate. Red oil;
 1
H NMR (600 MHz, 
CDCl3) δ 8.27 (d, J=1.8 Hz, 1H), 7.96 (dd, J=9.0, 2.4 Hz, 1H), 6.99 (d, J=9.0 Hz, 1H), 5.64 (sept, J=1.2 
Hz, 1H), 3.87 (s, 3H), 3.02 (s, 3H), 1.67 (s, 3H), 1.38 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 165.5, 
146.3, 138.1, 133.5, 130.3, 128.2, 127.6, 118.7, 117.5, 52.0, 40.3, 21.4, 17.4; IR (ATR) 1704, 1607, 1525, 
1290, 1259, 1126 cm
-1
; HRMS (ESI) calcd for C13H17N2O4 (M+H
+
) 265.1188, found 265.1171. 
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5-Chloro-2-nitro-N-methyl-N-(2-methyl-1-propen-1-yl)benzenamine. Yellow oil; 
1
H NMR (600 MHz, 
CDCl3) δ 7.58 (d, J=8.4 Hz, 1H), 7.01 (d, J=1.8 Hz, 1H), 6.74 (dd, J=8.4, 1.8 Hz, 1H), 5.60 (sept, J=1.8 
Hz, 1H), 2.97 (s, 3H), 1.68 (d, J=1.2 Hz, 3H), 1.43 (d, J=1.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) δ 
144.4, 138.8, 137.7, 129.1, 127.7, 127.2, 118.5, 117.7, 40.5, 21.5, 17.5; IR (ATR) 1596, 1514, 1487, 
1340, 1288 cm
-1
; HRMS (ESI) calcd for C11H14ClN2O2 (M+H
+
) 241.0743, found 241.0733. 
 
Table 4.1, Entry 1 
4-Methoxy-N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamine (127) 
 A mixture of 127 (120 mg, 0.540 mmol) and NaH (80%, 17.0 mg, 0.567 mmol) in DMSO (10 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and 
MeI (35 µL, 0.57 mmol) was added via a syringe. The reaction vessel was removed from the cold bath 
and stirred for an additional 1 h. EtOAc (15 mL) was added and the mixture was washed with water (6x10 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 95:5) to give 127 (57.9 
mg, 0.261 mmol, 48%) as a deep red solid. 
 
Table 4.1, Entry 2  
4-Methoxy-N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamine (127), 1,6-dimethoxybenzimidazole 
(128), and 2-(2-hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130) 
A mixture of 127 (70 mg, 0.32 mmol) and NaH (80%, 9.9 mg, 0.33 mmol) in DMSO (9 mL) was stirred 
at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and MeI 
(41 µL, 0.66 mmol) was added via a syringe. The reaction vessel was removed from the cold bath and 
stirred for an additional 1 h. EtOAc (12 mL) was added and the mixture was washed with water (8x7 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 7:3) to give, in order of 
elution, 127 (28 mg, 0.126 mmol, 40%) as a deep red solid and an inseparable mixture of 128 and 130 
(26.1 mg, 128 (1%) and 130 (34%) as calculated from 
1
H NMR spectrum) as a white solid. 
 
Table 4.1, Entry 3  
4-Methoxy-N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamine (127), 1,6-dimethoxybenzimidazole 
(128), and 2-(2-hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130) 
A mixture of 127 (80 mg, 0.36 mmol) and NaH (80%, 11.4 mg, 0.379 mmol) in DMSO (6 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and 
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MeI (71 µL, 1.1 mmol) was added via a syringe. The reaction vessel was removed from the cold bath and 
stirred for an additional 1 h. EtOAc (13 mL) was added and the mixture was washed with water (7x8 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 7:3) to give, in order of 
elution, 127 (28.4 mg, 0.128 mmol, 35%) as a deep red solid and an inseparable mixture of 128 and 130 
(27.8 mg, 128 (3%) and 130 (30%) as calculated from 
1
H NMR spectrum) as a white solid. 
 
Table 4.1, Entry 4 See Table 4.3, Entry 1 
Table 4.1, Entry 5  
1,6-dimethoxybenzimidazole (128), 1,6-dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129), and 
2-(2-hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130) 
A mixture of 127 (120 mg, 0.540 mmol) and NaH (80%, 34.0 mg, 1.13 mmol) in DMSO (10 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and 
MeI (71 µL, 1.1 mmol) was added via a syringe. The reaction vessel was removed from the cold bath and 
stirred for an additional 1 h. EtOAc (15 mL) was added and the mixture was washed with water (6x10 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 7:3, then 1:1) to give, in 
order of elution, 129 (23.4 mg, 0.093 mmol, 17%) as a pale yellow oil and an inseparable mixture of 128 
and 130 (75.5 mg, 128 (5%) and 130 (56%) as calculated from 
1
H NMR spectrum) as a white solid.  
 
Table 4.1, Entry 6  
1,6-dimethoxybenzimidazole (128), 1,6-dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129), and 
2-(2-hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130) 
A mixture of 127 (70 mg, 0.32 mmol) and NaH (80%, 19.9 mg, 0.663 mmol) in DMSO (9 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and 
MeI (62 µL, 0.10 mmol) was added via a syringe. The reaction vessel was removed from the cold bath 
and stirred for an additional 1 h. EtOAc (14 mL) was added and the mixture was washed with water (8x8 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 7:3) to give, in order of 
elution, 129 (14.2 mg, 0.056 mmol, 18%) as a pale yellow oil and an inseparable mixture of 128 and 130 
(38.6 mg, 128 (7%) and 130 (46%) as calculated from 
1
H NMR spectrum) as a white solid. 
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Table 4.1, Entry 7  
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). A mixture of 127 (115 mg, 0.518 mmol) 
and NaH (80%, 58.1 mg, 1.94 mmol) in DMSO (10 mL) was stirred at ambient temperature under a 
nitrogen atmosphere for 9 h. MeI (171 µL, 2.75 mmol) was added and the mixture was stirred for 1 h. 
EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
product was purified by chromatography (hexane/EtOAc, 7:3) to give 129 (89.1 mg, 0.356 mmol, 69%) 
as a pale yellow oil. 
 
Table 4.1, Entry 8  
1,6-dimethoxybenzimidazole (128), 1,6-dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129), and 
2-(2-hydroxy-2-propyl)-1,6-dimethoxybenzimidazole (130) 
A mixture of 127 (62.3 mg, 0.280 mmol) and NaH (80%, 31.5 mg, 1.05 mmol) in DMSO (2 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After stirring for 1 h, MeI (58 µL, 0.93 
mmol) was added via a syringe. The resulting reaction mixture was stirred for an additional 1 h. EtOAc 
(10 mL) was added and the mixture was washed with water (7x6 mL). The organic phase was dried 
(MgSO4), filtered and the solvent was removed from the filtrate under reduced pressure. The residue was 
purified by chromatography (hexane/EtOAc, 7:3) to give, in order of elution, 129 (45.0 mg, 0.180 mmol, 
64%) as a pale yellow oil and an inseparable mixture of 128 and 130 (4.0 mg, 128 (5%) and 130 (2%) as 
calculated from 
1
H NMR spectrum) as a white solid. 
 
Table 4.1, Entry 9 
1,6-dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129) 
 To a mixture of 127 (165 mg, 0.741 mmol) and NaH (80%, 111 mg, 3.70 mmol) placed in ice bath at 0 
o
C under a nitrogen atmosphere was added DMSO (10 mL) followed by the immediate addition of MeI 
(231 µL, 3.71 mmol) via syringes. The reaction vessel was removed from the cold bath and the yellow 
solution was stirred at ambient temperature for 2 h. EtOAc (20 mL) was added and the mixture was 
washed with water (15x5 mL) and brine (15 mL). The organic phase was dried (MgSO4), filtered and the 
solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 7:3) to give 129 (120 mg, 0.479 mmol, 65%) as a pale yellow oil. 
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Table 4.1, Entry 10 
1,6-Dimethoxybenzimidazole (128) and 1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). 
A mixture of 127 (85.0 mg, 0.382 mmol) and NaH (80%, 42.9 mg, 1.43 mmol) in DMF (8 mL) was 
stirred at ambient temperature under a nitrogen atmosphere for 1-2 min. MeI (72 µL, 1.16 mmol) was 
added and the mixture was stirred for 2 h. EtOAc (10 mL) was added and the mixture was washed with 
water (4x8 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the 
filtrate under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 
then 1:1) to give, in order of elution, 129 (8.0 mg, 0.032 mmol, 8%) as a pale yellow oil followed by 128 
(14.1 mg, 0.079 mmol, 21%) as a colorless oil. 
 
Table 4.1, Entry 11 
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). A mixture of 127 (75.4 mg, 0.339 mmol) 
and NaH (80%, 38.1 mg, 1.27 mmol) in NMP (7 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 2 min. MeI (70 µL, 1.12 mmol) was added and the mixture was stirred for 2 h. EtOAc (10 
mL) was added and the mixture was washed with water (5x8 mL) and brine (8 mL). The organic phase 
was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The 
crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to give 129 (25.0 mg, 0.100 
mmol, 29%) as a pale yellow oil. 
 
Table 4.1, Entry 12 
1,6-Dimethoxybenzimidazole (128) and 1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). 
A mixture of 127 (150 mg, 0.675 mmol) and NaH (80%, 75.7 mg, 2.52 mmol) in acetonitrile (MeCN, 10 
mL) was stirred at ambient temperature under a nitrogen atmosphere for approximately 2 min. To the 
brown mixture was added MeI (134 µL, 2.15 mmol) and it was stirred for 2 h. An orange solution was 
obtained after 18-20 min. EtOAc (15 mL) was added and the mixture was washed with water (3x15 mL). 
The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to 
give, in order of elution 129 (21.5 mg, 0.086 mmol, 13%) as a pale yellow oil and 128 (78.1 mg, 0.438 
mmol, 65%) as a colorless oil. 
 
Table 4.2, Entry 1  
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). A mixture of 4-methoxy-2-nitro-N-(2-
methyl-1-propen-1-yl)benzenamine 127 (191 mg, 0.859 mmol) and NaH (80%, 96.4 mg, 3.21 mmol) in 
131 
 
DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The orange 
solution was cooled to 0 °C and MeI (171 µL, 2.75 mmol) was added via a syringe. The reaction vessel 
was removed from the cold bath and the orange solution was stirred for 1 h. EtOAc (20 mL) was added 
and the mixture was washed with water (5x15 mL). The organic phase was dried (MgSO4), filtered, and 
the solvent was removed from the filtrate under reduced pressure. The crude product was purified by 
chromatography (hexane/EtOAc, 7:3) to give 129 (153 mg, 0.609 mmol, 71%) as a pale yellow oil. 
 
Table 4.2, Entry 2 
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). A mixture of 127 (146 mg, 0.659 mmol) 
and NaH (80%, 98.7 mg, 3.29 mmol) in DMSO (10 mL) was stirred at ambient temperature under a 
nitrogen atmosphere for 2 min. MeI (205 µL, 3.29 mmol) was added and the mixture was stirred for 2 h. 
EtOAc (15 mL) was added and the mixture was washed with water (4x10 mL) and brine 10 mL). The 
organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced 
pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3) to give 129 (118 mg, 
0.471 mmol, 71%) as a pale yellow oil. 
 
Table 4.2, Entry 3 
1,6-Dimethoxy-2-(2-methoxy-2-propyl)benzimidazole (129). A mixture of 127 (115 mg, 0.518 mmol) 
and NaH (80%, 58.1 mg, 1.94 mmol) in DMSO (10 mL) was stirred at ambient temperature under a 
nitrogen atmosphere for 9 h. MeI (171 µL, 2.75 mmol) was added and the mixture was stirred for 1 h. 
EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
product was purified by chromatography (hexane/EtOAc, 7:3) to give 129 (89.1 mg, 0.356 mmol, 69%) 
as a pale yellow oil. 
 
Table 4.2, Entry 4 
6-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (132). A mixture of 4-chloro-2-nitro-N-(2-
methyl-1-propen-1-yl)benzenamine (131) (164 mg, 0.724 mmol) and NaH (80%, 110 mg, 3.66 mmol) in 
DMSO (13 mL) was stirred at ambient temperature under a nitrogen atmosphere 1 h. The mixture was 
cooled to 0 °C and MeI (144 µL, 2.31 mmol) was added. The reaction vessel was removed from the cold 
bath and the resulting orange solution was stirred for 1 h. EtOAc (20 mL) was added and the mixture was 
washed with water (5x15 mL). The organic phase was dried (MgSO4), filtered, and the solvent was 
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removed from the filtrate under reduced pressure. The crude product was purified by chromatography 
(hexane/EtOAc, 1:1) to give 132 (159 mg, 0.624 mmol, 86%) as an orange solid. 
 
Table 4.2, Entry 5 
6-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (132). A mixture of 131 (133 mg, 0.587 
mmol) and NaH (80%, 65.9 mg, 2.20 mmol) in DMSO (10 mL) was stirred at ambient temperature for 1 
h. MeI (121 µL, 1.94 mmol) was added and the resulting orange solution was stirred for an additional 1 h. 
EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL) and brine (10 mL). The 
organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced 
pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3) to give 132 (141 mg, 
0.555 mmol, 94%) as an orange solid. 
 
Table 4.2, Entry 6 
6-Bromo-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (135). A mixture of 4-bromo-2-nitro-N-(2-
methyl-1-propen-1-yl)benzenamine (133) (56 mg, 0.207 mmol) and NaH (80%, 23.0 mg, 0.767 mmol) in 
DMSO (4 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The brown 
reaction mixture was cooled to 0 °C and MeI (41 µL, 0.66 mmol) was added. The reaction vessel was 
removed from the cold bath and the resulting orange solution was stirred for 1 h. EtOAc (10 mL) was 
added and the mixture was washed with water (5x10 mL) and brine (10 mL). The organic phase was 
concentrated under reduced pressure and the residue was purified by chromatography (hexane/EtOAc, 
7:3) to give 135 (48.2 mg, 0.161 mmol, 78%) as an orange oil. 
 
Table 4.2, Entry 7  
6-Bromo-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (135). A mixture of 133 (96.2 mg, 0.355 
mmol) and NaH (80%, 39.8 mg, 1.33 mmol) in DMSO (10 mL) was stirred at ambient temperature under 
a nitrogen atmosphere for approximately 6 min. An immediate color change from purple to brown was 
observed. MeI (73 µL, 1.17 mmol) was added and the resulting orange solution was stirred for 4 h. 
EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL) and brine (10 mL). The 
organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced 
pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3) to give 135 (104 mg, 
0.329 mmol, 93%) as an orange oil. 
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Table 4.2, Entry 8 
6-Fluoro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (137). A mixture of 136 (134 mg, 0.636 
mmol) and NaH (80%, 71.8 mg, 2.39 mmol) in DMSO (10 mL) was stirred at ambient temperature under 
a nitrogen atmosphere. After stirring for 1 h, MeI (132 µL, 2.12 mmol) was added via a syringe and the 
resulting yellow-orange solution was stirred for an additional 1 h. EtOAc (15 mL) was added and the 
mixture was washed with water (7x10 mL). The organic phase was dried (MgSO4), filtered and the 
solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 7:3) to give 137 (113 mg, 0.474 mmol, 75%) as a pale yellow oil.  
 
Table 4.2, Entry 9 
1-Methoxy-6-methylbenzimidazole (139), 1-Methoxy-2-(2-methoxy-2-propyl)-6-
methylbenzimidazole (140), and 2-(2-Hydroxy-2-propyl)-1-methoxy-6-methylbenzimidazole (141). 
A mixture of 4-methyl-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (138) (145 mg, 0.705 mmol) and 
NaH (80%, 78.9 mg, 2.63 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 1 h. The resulting orange mixture was cooled to 0 
o
C and MeI (140 µL, 2.25 mmol) was 
added. The reaction was removed from the cold bath and the resulting solution was stirred for an 
additional 1 h. EtOAc (20 mL) was added and the mixture was washed with water (5x15 mL) and brine 
(10 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate 
under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, in order 7:3, 
1:1, 3:7) to give, in order of elution, 140 (86.3 mg, 0.368 mmol, 52%) as a colorless oil, 141 (0.008 mg, 
0.036 mmol, 5%) as a white solid and 139 (32.5 mg, 0.200 mmol, 28%) as a colorless oil. 
 
Table 4.2, Entry 10 
1-Methoxy-6-methylbenzimidazole (139) and 1-Methoxy-2-(2-methoxy-2-propyl)-6-
methylbenzimidazole (140) A mixture of 138 (114 mg, 0.555 mmol) and NaH (80%, 62.3 mg, 2.08 
mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. MeI 
(111 µL, 1.78 mmol) was added and the resulting orange solution was stirred for 1 h. EtOAc (15 mL) was 
added and the mixture was washed with water (6X10 mL). The organic phase was dried (MgSO4) filtered, 
and the solvent was removed from the filtrate under reduced pressure. The crude was purified by 
chromatography (hexane/EtOAc, 1:1) to give, in order of elution, 140 (88.6 mg, 0.378 mmol, 68%) and 
139 (24.6 mg, 0.152 mmol, 27%) both as a colorless oil. 
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Table 4.2, Entry 11 
1-Methoxybenzimidazole (124) and 1-Methoxy-2-(2-methoxy-2-propyl)benzimidazole (125) and 2-
(2-Hydroxy-2-propyl)-1-methoxybenzimidazole (126). A mixture of 122 (160.2 mg, 0.833 mmol) and 
NaH (80%, 93 mg, 3.10 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere. After stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (166 µL, 2.67 mmol) was 
added via a syringe. The reaction vessel was removed from the cold bath and stirred for an additional 1 h. 
EtOAc (30 mL) was added and the mixture was washed with water (20x5 mL) and brine (20 mL). The 
organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under reduced 
pressure. The residue was purified by chromatography (hexane/EtOAc, 7:3, then 3:7) to give, in order of 
elution, 124 (6.3 mg, 0.043 mmol, 5%) and, 125 (105.1 mg, 0.477 mmol, 57%) both as a colorless oil and 
126 (25.3 mg, 0.123 mmol, 15%) as a white solid.  
 
Table 4.2, Entry 12 
1-Methoxybenzimidazole (124) and 1-Methoxy-2-(2-methoxy-2-propyl)benzimidazole (125).  
A mixture of 122 (160 mg, 0.832 mmol) and NaH (80%, 93.4 mg, 3.11 mmol) in DMSO (10 mL) was 
stirred at ambient temperature under a nitrogen atmosphere for 1 h. Methyl iodide (MeI, 166 µL, 2.67 
mmol) was added via a syringe and the resulting orange solution was stirred for 1 h. EtOAc (20 mL) was 
added and the mixture was washed with water (6x15 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 7:3 then 1:1) to give, in order of elution, 125 (62.6 mg, 0.284 mmol, 
34%) and 124 (37.8 mg, 0.255 mmol, 31%) both as a colorless oil.  
 
Table 4.2, Entry 13  
Methyl 4-N-methyl-N-(2-methyl-1-propen-1-yl)amino-3-nitrobenzoate. A mixture of methyl 4-(N-2-
methyl-1-propen-1-yl)amino-3-nitrobenzoate (142) (195 mg, 0.779 mmol) and NaH (80%, 87.4 mg, 2.91 
mmol) in DMSO (10 mL)  was stirred at ambient temperature under a nitrogen atmosphere for 10 min. 
MeI (104 µL, 1.67 mmol) was added and the mixture was stirred for an additional 1 h 50 min. EtOAc (20 
mL) was added to the yellow-orange solution and the mixture was washed with water (5x15 mL) and 
brine (15 mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the 
filtrate under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 19:1) 
to give methyl 4-N-methyl-N-(2-methyl-1-propen-1-yl)amino-3-nitrobenzoate (128 mg, 0.484 mmol, 
62%) as a red viscous oil. 
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Table 4.2, Entry 14  
Methyl 1-methoxybenzimidazole-6-carboxylate (143). A mixture of 142 (83.5 mg, 0.334 mmol) and 
NaH (80%, 50.1 mg, 1.67 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 24 h. To the resulting colorless solution was added MeI (104 µL, 1.67 mmol) and it was 
stirred for 1 h. EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL) and brine 
(10 mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate 
under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 1:1) to give 
143 (51.0 mg, 0.247 mmol, 74%) as a white solid. 
 
Table 4.2, Entry 15 
N-Methyl-N-(2-methyl-1-propen-1-yl)-2,4-dinitrobenzenamine. A mixture of N-(2-methyl-1-propen-
1-yl)-2,4-dinitrobenzenamine (144) (45.1 mg, 0.190 mmol) and NaH (80%, 21.3 mg, 0.708 mmol) in 
DMSO (4 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The red solution 
was cooled to 0 
o
C and MeI (38 µL, 0.61 mmol) was added via a syringe. The reaction vessel was 
removed from the cold bath and the resulting solution was stirred for 1 h. EtOAc (15 mL) was added and 
the mixture was washed with water (5x10 mL) and brine (2x10 mL). The organic phase was dried 
(MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
product was purified by chromatography (hexane/EtOAc, 8:2) to give N-methyl-N-(2-methyl-1-propen-1-
yl)-2,4-dinitrobenzenamine (40.6 mg, 0.162 mmol, 85%) as a red oil. 
 
Table 4.2, Entry 16 
A mixture of 144 (36 mg, 0.15 mmol) and NaH (80%, 22.7 mg, 0.758 mmol) in DMSO (5 mL) was 
stirred at ambient temperature under a nitrogen atmosphere for 24 h. MeI (47 µL, 0.76 mmol) was added 
via a syringe and the resulting solution was stirred for an additional 2 h. EtOAc (10 mL) was added and 
the mixture was washed with water (5x7 mL) and brine (2x7 mL). The organic phase was dried (MgSO4), 
filtered, and the solvent was removed from the filtrate under reduced pressure. No product or unreacted 
starting material was observed in the 
1
H NMR of the crude reaction mixture. 
 
Table 4.2, Entry 17 
5-Methoxy-N-methyl-2-nitrobenzenamine. A mixture of 5-methoxy-2-nitro-N-(2-methyl-1-propen-1-
yl)benzenamine (145) (156 mg, 0.703 mmol) and NaH (80%, 84.4 mg, 2.81 mmol) in DMSO (10 mL) 
was stirred at ambient temperature under a nitrogen atmosphere for 1 h. To the resulting orange mixture 
was added MeI (145 µL, 2.33 mmol) and the solution was stirred for 1 h. EtOAc (20 mL) was added and 
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the mixture was washed with water (5x15 mL). The organic phase was dried (MgSO4), filtered, and the 
solvent was removed from the filtrate under reduced pressure. The crude was purified by chromatography 
(hexane/EtOAc, 9:1) to give the 5-methoxy-N-methyl-2-nitrobenzenamine (71.0 mg, 0.390 mmol, 55%) 
as an orange solid.  
 
Table 4.2, Entry 18  
1,5-Dimethoxybenzimidazole (146). A mixture of 145 (53 mg, 0.24 mmol) and NaH (80%, 35.7 mg, 
1.19 mmol) in DMSO (5 mL) was stirred at ambient temperature under a nitrogen atmosphere for 24 h. 
To the resulting almost clear solution was added MeI (58 µL, 0.93 mmol) and the solution was stirred for 
1 h. EtOAc (10 mL) was added and the mixture was washed with water (7x8 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
was purified by chromatography (hexane/EtOAc, 1:1) to give 146 (21.6 mg, 0.121 mmol, 51%) as a 
colorless oil.  
 
Table 4.2, Entry 19  
5-Chloro-2-nitro-N-methyl-N-(2-methyl-1-propen-1-yl)benzenamine and 5-chloro-1-methoxy-2-(2-
methoxy-2-propyl)benzimidazole (149). A mixture of 147 (175 mg, 0.775 mmol) and NaH (80%, 87.0 
mg, 2.90 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere for 6 
min. MeI (160 µL, 2.57 mmol) was added and the resulting solution was stirred for 2 h. EtOAc (20 mL) 
was added and the mixture was washed with water (5x15 mL) and brine (15 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
product was purified by chromatography (hexane/EtOAc, 8:2 then 1:1) to give, in order of elution, 5-
chloro-2-nitro-N-methyl-N-(2-methyl-1-propen-1-yl)benzenamine (109 mg, 0.452 mmol, 52%) and 149 
(17.8 mg, 0.070 mmol, 9%) both as a yellow oil.  
 
Table 4.2, Entry 20 
5-Chloro-1-methoxybenzimidazole (148) and 5-chloro-1-methoxy-2-(2-methoxy-2-
propyl)benzimidazole (149). A mixture of 5-chloro-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine 
(147) (225 mg, 0.991 mmol) and NaH (80%, 111 mg, 3.70 mmol) in DMSO (15 mL) was stirred at 
ambient temperature under a nitrogen atmosphere for 1 h. The orange solution was cooled to 0 °C and 
MeI (205 µL, 3.29 mmol) was added. The reaction vessel was removed from the cold bath and stirred for 
1 h. EtOAc (20 mL) was added and the mixture was washed with water (5x15 mL) and brine (15 mL). 
The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
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reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to 
give, in order of elution, 149 (68.2 mg, 0.268 mmol, 27%) and 148 (101 mg, 0.555 mmol, 56%) both as a 
yellow oil. 
 
Table 4.2, Entry 21 
5-Chloro-1-methoxybenzimidazole (148) and 5-chloro-1-methoxy-2-(2-methoxy-2-
propyl)benzimidazole (149). A mixture of 147 (53.3 mg, 0.235 mmol) and NaH (80%, 26.4 mg, 0.879 
mmol) in DMSO (2 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. MeI (49 
µL, 0.783 mmol) was added. The reaction mixture was stirred for an additional 1 h. EtOAc (10 mL) was 
added and the mixture was washed with water (5x7 mL). The organic phase was dried (MgSO4), filtered, 
and the solvent was removed from the filtrate under reduced pressure. The crude product was purified by 
chromatography (hexane/EtOAc, 7:3) to give, in order of elution, 149 (18.8 mg, 0.074 mmol, 31%) and 
148 (22.5 mg, 0.123 mmol, 52%) both as a yellow oil. 
 
Table 4.2, Entry 22 
5-Bromo-1-methoxybenzimidazole (151) and 5-Bromo-1-methoxy-2-(2-methoxy-2-
propyl)benzimidazole (152). A mixture of 5-bromo-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine 
(150) (141 mg, 0.519 mmol) and NaH (80%, 58.4 mg, 1.95 mmol) in DMSO (10 mL) was stirred at 
ambient temperature under a nitrogen atmosphere for approximately 10 min. An immediate color change 
from purple to brown was observed. MeI (107 µL, 1.72 mmol) was added and the resulting orange 
solution was stirred for 2 h. EtOAc (15 mL) was added and the mixture was washed with water (5x10 
mL) and brine (10 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed 
from the filtrate under reduced pressure. The crude product was purified by chromatography 
(hexane/EtOAc, 7:3 then 1:1) to give, in order of elution, 152 (43.4 mg, 0.145 mmol, 28%) as a red oil 
and 151 (79.3 mg, 0.349 mmol, 67%) as a pale yellow oil. 
 
Table 4.2, Entry 23  
5-Bromo-1-methoxybenzimidazole (151) and 5-bromo-1-methoxy-2-(2-methoxy-2-
propyl)benzimidazole (152). A mixture of 150 (76.8 mg, 0.283 mmol) and NaH (80%, 32 mg, 1.07 
mmol) in DMSO (9 mL) was stirred at ambient temperature under a nitrogen atmosphere for 
approximately 1 h. To the resulting orange solution was added MeI (59 µL, 0.943 mmol) was added and 
stirred for an additional 1 h. EtOAc (12 mL) was added and the mixture was washed with water (7x8 
mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
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reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to 
give, in order of elution, 152 (24.8 mg, 0.083 mmol, 29%) as a red oil and 151 (35.4 mg, 0.156 mmol, 
55%) as a pale yellow oil. 
 
Table 4.2, Entry 24 
1-Methoxy-5-methylbenzimidazole (154), 1-Methoxy-2-(2-methoxy-2-propyl)-5-
methylbenzimidazole (155), and 2-(2-Hydroxy-2-propyl)-1-methoxy-5-methylbenzimidazole (156). 
A mixture of 5-methyl-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine (153) (136 mg, 0.657 mmol) and 
NaH (80%, 73.4 mg, 2.45 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 1 h. The yellowish-brown solution was cooled to 0 °C and MeI (136 µL, 2.18 mmol) was 
added. The reaction vessel was removed from the cold bath and the resulting orange solution was stirred 
for 1 h. EtOAc (20 mL) was added and the mixture was washed with water (5X15 mL) and brine (15 mL). 
The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 3:7) to 
give, in order of elution, 155 (33.6 mg, 0.143 mmol, 22%) as an orange oil, 156 (29.2 mg, 0.133 mmol, 
20%) as a white solid and 154 (22.7 mg, 0.140 mmol, 21%) as an orange oil. 
 
Table 4.2, Entry 25 
1-Methoxy-5-methylbenzimidazole (154) and 1-Methoxy-2-(2-methoxy-2-propyl)-5-
methylbenzimidazole (155). A mixture of 5-methyl-2-nitro-N-(2-methyl-1-propen-1-yl)benzenamine 
(153) (47.1 mg, 0.228 mmol) and NaH (80%, 25.6 mg, 0.854 mmol) in DMSO (5 mL) was stirred at 
ambient temperature under a nitrogen atmosphere for approximately 10 min. To the yellowish brown 
solution was added MeI (47 µL, 0.76 mmol) and the resulting orange solution was stirred for 2 h. EtOAc 
(8 mL) was added and the mixture was washed with water (5x5 mL) and brine (5 mL). The organic phase 
was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The 
crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to give, in order of elution, 
155 (13.8 mg, 0.059 mmol, 26%) and 154 (11.5 mg, 0.071 mmol, 31%) both as an orange oil.  
 
Table 4.2, Entry 26  
1,6-Dimethoxy-2-(1-methoxycyclohexyl)benzimidazole (158). A mixture of 4-methoxy-2-nitro-N-
(cyclohexylmethylene)benzenamine (157) (149 mg, 0.569 mmol) and NaH (80%, 63.5 mg, 2.12 mmol) in 
DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The orange-
yellow solution was cooled to 0 
o
C and MeI (113 µL, 1.82 mmol) was added. The reaction vessel was 
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removed from the cold bath and the resulting orange solution was stirred for 1 h. EtOAc (20 mL) was 
added and the mixture was washed with water (5x20 mL) and brine (20 mL). The organic phase was 
concentrated under reduced pressure and the residue was purified by chromatography (hexane/EtOAc, 
7:3) to give 158 (129 mg, 0.446 mmol, 78%) as a colorless oil. 
 
Table 4.2, Entry 27 
 1,6-Dimethoxy-2-(1-methoxycyclohexyl)benzimidazole (158), 1,6-Dimethoxy-2-(1-
hydroxycyclohexyl)benzimidazole (159). A mixture of 157 (104 mg, 0.396 mmol) and NaH (80%, 44.5 
mg, 1.48 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere for 2 
min. An immediate color change from purple to brown was observed. MeI (82 µL, 1.32 mmol) was added 
and the resulting orange solution was stirred for 2 h. EtOAc (20 mL) was added and the mixture was 
washed with water (5x20 mL) and brine (15 mL). The organic phase was dried (MgSO4), filtered, and the 
solvent was removed from the filtrate under reduced pressure. The crude product was purified by 
chromatography (hexane/EtOAc, 7:3 then 4:6) to give, in order of elution, 158 (97 mg, 0.33 mmol, 84%) 
as a colorless oil and 159 (12.2 mg, 0.044 mmol, 11%) as a white solid.  
 
Table 4.2, Entry 28  
6-Bromo-1-methoxybenzimidazole (134), 6-Bromo-1-methoxy-(1-methoxy-1-
phenylethyl)benzimidazole (161), and 6-bromo-(1-hydroxy-1-phenylethyl)-1-methoxybenzimidazole 
(162). A mixture of 4-bromo-2-nitro-N-(2-phenyl-1-propen-1-yl)benzenamine (160) (157 mg, 0.471 
mmol) and NaH (80%, 52.6 mg, 1.75 mmol) in DMSO (10 mL) was stirred at ambient temperature under 
a nitrogen atmosphere for 1 h. The brown reaction mixture was cooled to 0 
o
C and MeI (94 µL, 1.51 
mmol) was added. The reaction vessel was removed from the cold bath and the resulting orange solution 
was stirred for 1 h. EtOAc (20 mL) was added and the mixture was washed with water (5x15 mL) and 
brine (15 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the 
filtrate under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 
then 3:7) to give, in order of elution, 161 (37.2 mg, 0.103 mmol, 22%) as an orange oil, 162 (20.5 mg, 
0.059 mmol, 13%) as a colorless oil and 134 (25.7 mg, 0.113 mmol, 22%) as a white solid. 
 
Table 4.2, Entry 29 
 6-Bromo-1-methoxybenzimidazole (134). A mixture of 160 (50.0 mg, 0.150 mmol) and NaH (80%, 
16.9 mg, 0.563 mmol) in DMSO (5 mL) was stirred at ambient temperature under a nitrogen atmosphere 
for approximately 38 min. Color change was not observed in the specified period of time. MeI (31 µL, 
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0.50 mmol) was added and the resulting faint yellow solution was stirred for an 1h 22 m. EtOAc (10 mL) 
was added and the mixture was washed with water (5x5 mL) and brine (5 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced pressure. The crude 
product was purified by chromatography (hexane/EtOAc, 7:3 then 3:7) to give 134 (34.1 mg, 0.150 
mmol, 92%) as a white solid. 
 
Scheme 4.3 
2-(2-Hydroxy-2,2-diphenylmethyl)-1,6-dimethoxybenzimidazole (169) and benzophenone (170). A 
mixture of 4-methoxy-2-nitro-N-(2,2-diphenylethenyl)benzenamine (168) (124 mg, 0.358 mmol) and 
NaH (80%, 40.1 mg, 1.34 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 35 min. MeI (74 µL, 1.19 mmol) was added and the resulting red solution was stirred for 
1 h 25 min. EtOAc (20 mL) was added and the mixture was washed with water (5x15 mL) and brine (15 
mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 3:7) to 
give, in order of elution, 170 (5.7 mg, 0.03 mmol, 9%) as a colorless oil and 169 (115 mg, 0.320 mmol, 
89%) as a red viscous oil. 
 
Scheme 4.3 
1,6-Dimethoxylbenzimidazole (128) and benzophenone (170). A mixture of 168 (124 mg, 0.385 mmol) 
and t-BuOK (201 mg, 1.79 mmol) in t-BuOH (5 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 24 h. MeI (89 µL, 1.43 mmol) was added and the mixture was stirred for 1 h. The 
resulting mixture was filtered through silica gel and silica gel was washed with EtOAc. The solvent was 
removed from the filtrate under reduced pressure and the resulting residue was purified by 
chromatography (hexane/EtOAc, 9:1 then 1:1) to give, in order of elution, 170 (63.6 mg, 0.349 mmol, 
97%) and 128 (49.8 mg, 0.279 mmol, 78%) both as a colorless oil. 
 
Table 4.3, Entry 1 
2-(2-Hydroxy-2-propyl)-1-methoxybenzimidazole (126). A mixture of 122 (83.1 mg, 0.432 mmol) and 
NaH (80%, 27.3 mg, 0.908 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen 
atmosphere. After stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (28 µL, 0.454 mmol) was 
added via a syringe. The reaction vessel was removed from the cold bath and stirred for an additional 1 h. 
EtOAc (13 mL) was added and the mixture was washed with water (7x8 mL). The organic phase was 
dried (MgSO4), filtered and the solvent was removed from the filtrate under reduced pressure. The residue 
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was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to give 126 (49.4 mg, 0.240 mmol, 55%) 
as a white solid.  
 
Table 4.3, Entry 2 
1,6-Dimethoxybenzimidazole (128) and 2-(2-Hydroxy-2-propyl)-1,6-dimethoxy-benzimidazole (130). 
A mixture of 127 (120 mg, 0.540 mmol) and NaH (80%, 34.0 mg, 1.13 mmol) in DMSO (10 mL) was 
stirred at ambient temperature under a nitrogen atmosphere. After 1 h, the mixture was cooled to 0 
o
C and 
MeI (35 µL, 0.57 mmol) was added via a syringe. The reaction vessel was removed from the cold bath 
and stirred for an additional 1 h. EtOAc (15 mL) was added and the mixture was washed with water (6x10 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
reduced pressure. The residue was purified by chromatography (hexane/EtOAc, 1:1) to give an 
inseparable mixture of 128 and 130 (96.1 mg, 128 (2%) and 130 (74%) as calculated from 
1
H NMR 
spectrum) as a white solid. 
 
Table 4.3, Entry 3 
6-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (132) and 6-Chloro-2-(2-hydroxy-2-
propyl)-1-methoxybenzimidazole (163). A mixture of 131 (121 mg, 0.534 mmol) and NaH (80%, 33.6 
mg, 1.12 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (35 µL, 0.56 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (20 mL) was 
added and the mixture was washed with water (8x15 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 7:3, then 6:4)) to give, in order of elution, 132 (27.5 mg, 0.108 mmol, 
20%) as a orange solid and 163 (76.0 mg, 0.316 mmol, 59%) as a white solid.  
 
Table 4.3, Entry 4 
6-Bromo-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (135) and 6-Bromo-2-(2-hydroxy-2-
propyl)-1-methoxybenzimidazole (164). A mixture of 133 (71.3 mg, 0.263 mmol) and NaH (80%, 16.6 
mg, 0.554 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (17 µL, 0.275 mmol) was added via a syringe. 
The reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (12 mL) was 
added and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
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chromatography (hexane/EtOAc, 6:4) to give, in order of elution, 135 (17.1 mg, 0.057 mmol, 22%) as an 
orange oil and 164 (51.0 mg, 0.178 mmol, 68%) as a white solid.  
 
Table 4.3, Entry 5 
6-Fluoro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (137) and 6-Fluoro-2-(2-hydroxy-2-
propyl)-1-methoxybenzimidazole (165). A mixture of 136 (80 mg, 0.381 mmol) and NaH (80%, 24 mg, 
0.80 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (25 µL, 0.40 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (10 mL) was 
added and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 6:4)) to give, in order of elution, 137 (14 mg, 0.06 mmol, 15%) as a pale 
yellow oil and 165 (48.1 mg, 0.215 mmol, 56%) as a white solid.  
 
Table 4.3, Entry 6 
1-Methoxy-6-methylbenzimidazole (139) and 2-(2-Hydroxy-2-propyl)-1-methoxy-6-
methylbenzimidazole (141). A mixture of 138 (83.0 mg, 0.402 mmol) and NaH (80%, 25.4 mg, 0.908 
mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After stirring 
for 1 h, the mixture was cooled to 0 
o
C and MeI (26 µL, 0.422 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (13 mL) was 
added and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 6:4) to give an inseparable mixture of 139 and 141 (57.5 mg, 139 (11%) 
and 141 (45%) as calculated from 
1
H NMR spectrum) as a white solid.  
 
Table 4.3, Entry 7  
Methyl 4-N-methyl-N-(2-methyl-1-propen-1-yl)amino-3-nitrobenzoate. A mixture of 142 (83 mg, 
0.33 mmol) and NaH (80%, 21 mg, 0.70 mmol) in DMSO (8 mL)  was stirred at ambient temperature 
under a nitrogen atmosphere for 1 h. The dirty brown mixture was cooled to 0 
o
C and MeI (22 µL, 0.35 
mmol) was added. The reaction vessel was removed from the cold bath and the resulting solution was 
stirred for an additional 1 h. EtOAc (12 mL) was added and the mixture was washed with water (8x8 
mL). The organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under 
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reduced pressure. An ~3:1 mixture of methyl 4-N-methyl-N-(2-methyl-1-propen-1-yl)amino-3-
nitrobenzoate and 159 was observed in the 
1
H NMR of the crude reaction mixture. 
 
Table 4.3, Entry 8 
Methyl 1-methoxybenzimidazole-6-carboxylate (143). A mixture of 142 (110.2 mg, 0.440 mmol) and 
NaH (80%, 27.7 mg, 0.925 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen 
atmosphere. After 24 h, the mixture was cooled to 0 
o
C and MeI (29 µL, 0.465 mmol) was added via a 
syringe. The reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (15 
mL) was added and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), 
filtered and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 1:1 then 3:7) to give 143 (66.2 mg, 0.321 mmol, 73%) as a white solid. 
 
Table 4.3, Entry 10 
1,5-Dimethoxybenzimidazole (146). A mixture of 145 (98.5 mg, 0.443 mmol) and NaH (80%, 27.9 mg, 
0.930 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 24 
h, the mixture was cooled to 0 
o
C and MeI (29 µL, 0.465 mmol) was added via a syringe. The reaction 
vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (15 mL) was added and 
the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered and the 
solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 1:1 then 3:7) to give 146 (50.8 mg, 0.285 mmol, 64%) as a colorless oil. 
 
Table 4.3, Entry 11 
5-Chloro-1-methoxy-2-(2-methoxy-2-propyl)benzimidazole (149) and 5-Chloro-2-(2-hydroxy-2-
propyl)-1-methoxybenzimidazole (166). A mixture of 147 (118 mg, 0.521 mmol) and NaH (80%, 32.7 
mg, 1.09 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (34 µL, 0.55 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (15 mL) was 
added and the mixture was washed with water (7x10 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 7:3, then 1:1)) to give, in order of elution, 149 (20.1 mg, 0.079 mmol, 
15%) and 166 (69.1 mg, 0.287 mmol, 55%) both as yellow oils.  
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Table 4.3, Entry 12  
5-Bromo-1-methoxy-2(2-methoxy-2-propyl)benzimidazole (152) and 5-Bromo-2(2-hydroxy-2-
propyl)-1-methoxybenzimidazole (167) A mixture of 150 (73 mg, 0.27 mmol) and NaH (80%, 17 mg, 
0.57 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. 
The reddish-brown solution was cooled to 0 °C and MeI (18 µL, 0.28 mmol) was added. The reaction 
vessel was removed from the cold bath and the mixture was stirred for 1 h. EtOAc (13 mL) was added 
and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered, and the 
solvent was removed from the filtrate under reduced pressure. The crude product was purified by 
chromatography (hexane/EtOAc, 6:4) to give, in order of elution, 152 (12.9 mg, 0.043 mmol, 16%) as a 
red oil and 167 (48 mg, 0.17 mmol, 63%) as a white solid. 
 
Table 4.3, Entry 13 
2-(2-Hydroy-2-propyl)-1-methoxy-5-methylbenzimidazole (156). A mixture of 153 (100 mg, 0.485 
mmol) and NaH (80%, 30.5 mg, 1.017 mmol) in DMSO (10 mL) was stirred at ambient temperature 
under a nitrogen atmosphere. After stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (32 µL, 0.51 
mmol) was added via a syringe. The reaction vessel was removed from the cold bath and stirred for an 
additional 1 h. EtOAc (15 mL) was added and the mixture was washed with water (7x10 mL). The 
organic phase was dried (MgSO4), filtered and the solvent was removed from the filtrate under reduced 
pressure. The residue was purified by chromatography (hexane/EtOAc, 6:4)) to give 156 (65.2 mg, 0.296 
mmol, 61%) as a white solid.  
 
Table 4.3, Entry 14  
1,6-Dimethoxy-2-(1-methoxycyclohexyl)benzimidazole (158), 1,6-Dimethoxy-2-(1-
hydroxycyclohexyl)benzimidazole (159). A mixture of 157 (73 mg, 0.28 mmol) and NaH (80%, 17.5 
mg, 0.583 mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
stirring for 1 h, the mixture was cooled to 0 
o
C and MeI (18 µL, 0.29 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (12 mL) was 
added and the mixture was washed with water (7x8 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 6:4) to give, in order of elution, 158 (15.4 mg, 0.053 mmol, 19%) as a 
colorless oil and 159 (39.4 mg, 0.143 mmol, 51%) as a white solid.  
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Table 4.3, Entry 15  
6-Bromo-1-methoxybenzimidazole (134) and 6-Bromo-2-(2-hydroxy-2-phenylethyl)-1-
methoxybenzimidazole (162). A mixture of 160 (73 mg, 0.22 mmol) and NaH (80%, 13.7 mg, 0.458 
mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere. After stirring 
for 1 h, the mixture was cooled to 0 
o
C and MeI (14 µL, 0.23 mmol) was added via a syringe. The 
reaction vessel was removed from the cold bath and stirred for an additional 1 h. EtOAc (13 mL) was 
added and the mixture was washed with water (7x9 mL). The organic phase was dried (MgSO4), filtered 
and the solvent was removed from the filtrate under reduced pressure. The residue was purified by 
chromatography (hexane/EtOAc, 6:4) to give, in order of elution, 162 (39.4 mg, 0.114 mmol, 52%) and 
134 (10.6 mg, 0.047 mmol, 22%) both as a white solid.  
 
Table 4.4, Entry 1 
1-Benzyloxy-2-(2-benzyloxy-2-propyl)-6-methoxybenzimidazole (171) and 1-benzyloxy-2-(2-
hydroxy-2-propyl)-6-methoxybenzimidazole (172) A mixture of 127 (108 mg, 0.484 mmol) and NaH 
(80%, 54.0 mg, 1.80 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for 1 h. The orange mixture was cooled to 0 
o
C and benzyl bromide (BnBr, 191 µL, 1.61 
mmol) was added via a syringe. The resulting almost colorless solution was stirred for an additional 1 h. 
EtOAc (20 mL) was added and the resulting mixture was washed with water (5x10 mL) and brine (10 
mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under 
reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) to 
give, in order of elution, 171 (56.3 mg, 0.140 mmol, 29%) as an orange oil and 172 (56.8 mg, 0.182 
mmol, 38%) as a white solid. 
 
Table 4.4, Entry 2 
1-Benzyloxy-2-(2-benzyloxy-2-propyl)-6-methoxybenzimidazole (171) and 1-Benzyloxy-2-(2-
hydroxyl-2-propyl)-6-methoxybenzimidazole (172). A mixture of 127 (104 mg, 0.469 mmol) and NaH 
(80%, 52.7 mg, 1.76 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen 
atmosphere for approximately 2 min. An immediate color change from purple to brown was observed. 
Benzyl bromide (185 µL, 1.56 mmol) was added via a syringe and the mixture was stirred for an 
additional 2 h. EtOAc (15 mL) was added and the resulting mixture was washed with water (5x10 mL) 
and brine (10 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the 
filtrate under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 
146 
 
then 1:1) to give, in order of elution, 171 (94.5 mg, 0.235 mmol, 50%) as an orange oil and 172 (27.9 mg, 
0.089 mmol, 19%) as a white solid. 
 
Table 4.4, Entry 3 
1-(2-Propen-1-yloxy)-2-(2-(2-propen-1-yloxy)-2-propyl)-6-methoxybenzimidazole (174) and 2-(2-
Hydroxyl-2-propyl)-1-(2-propen-1-yloxy)-6-methoxybenzimidazole (175) and 1-(2-propen-1-yloxy)-
7-methoxybenzimidazole (173). A mixture of 127 (80.3 mg, 0.389 mmol) and NaH (80%, 43.5 mg, 1.45 
mmol) in DMSO (8 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The 
orange mixture was cooled to 0 
o
C and allyl bromide (108 µL, 1.25 mmol) was added via syringe. The 
reaction vessel was removed from the cold bath and the resulting orange solution was stirred for an 
additional 1 h. EtOAc (15 mL) was added and the mixture was washed with water (5x10 mL) and brine 
(10 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate 
under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3 then 1:1) 
to give, in order of elution, 174 (16.7 mg, 0.055 mmol, 14%) as a pale yellow oil and a mixture of 173 
and 175 (36.3 mg, 173 (5%) and 175 (31%) as calculated from 
1
H NMR spectrum) as a white solid. 
 
Table 4.4, Entry 4 
 1-(2-Propen-1-yloxy)-2-(2-(2-propen-1-yloxy)-2-propyl)-6-methoxybenzimidazole (174). A mixture 
of 127 (178 mg, 0.803 mmol) and NaH (80%, 96.4 mg, 3.21 mmol) in DMSO (10 mL) was stirred at 
ambient temperature under a nitrogen atmosphere for approximately 1 min. An immediate color change 
from purple to brown was observed. Allyl bromide (236 µL, 2.73 mmol) was added via syringe and the 
resulting orange mixture was stirred for an addition 2 h. EtOAc (20 mL) was added and the mixture was 
washed with water (5x15 mL) and brine (15 mL). The organic phase was dried (MgSO4), filtered, and the 
solvent was removed from the filtrate under reduced pressure. The crude product was purified by 
chromatography (hexane/EtOAc) to give 174 (142.6 mg, 0.472 mmol, 59%) as a yellow oil. 
 
Table 4.4, Entry 5 
8-Methoxy-4,4-dimethyl-4H-benzo[4,5]imidazo[1,2-b]dioxazine (176). A mixture of 127 (143 mg, 
0.642 mmol) and NaH (80%, 72.0 mg, 2.40 mmol) in DMSO (10 mL) was stirred at ambient temperature 
under a nitrogen atmosphere for approximately 2 min. An immediate color change from purple to brown 
was observed. Diiodomethane (172 µL, 2.13 mmol) was added via a syringe and the resulting reddish-
brown solution was stirred for an additional 2 h. EtOAc (20 mL) was added and the mixture was washed 
with water (5x15 mL) and brine (15 mL). The organic phase was dried (MgSO4), filtered, and the solvent 
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was removed from the filtrate under reduced pressure. The crude product was purified by chromatography 
(hexane/EtOAc, 1:1) to give 176 (59.6 mg, 0.254 mmol, 40%) as a white solid. 
 
Table 4.4, Entry 6 
6-Methoxy-1-(2-propyn-1-yloxy)benzimidazole (177) and 2-(2-Hydroxy-2-propyl)-6-methoxy-1-(2-
propyn-1-yloxy)benzimidazole (178). A mixture of 127 (311 mg, 1.400 mmol) and NaH (80%, 157 mg, 
5.23 mmol) in DMSO (15 mL) was stirred at ambient temperature under a nitrogen atmosphere for 
approximately 1 min. An immediate color change from purple to brown was observed. Propargyl bromide 
(414 µL, 4.65 mmol) was added via a syringe and the resulting reddish-brown solution was stirred for an 
additional 2 h. EtOAc (20 mL) was added and the mixture was washed with water (7x10 mL). The 
organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced 
pressure. The crude product was purified by chromatography (hexane/EtOAc, 9:1, then 85:15) to give, in 
order of elution, 178 (171 mg, 0.656 mmol, 47%) as a white solid and 177 (17 mg, 0.084 mmol, 6%) as a 
pale yellow oil. 
 
Table 4.4, Entry 7 
1-(3-Butyn-2-yloxy)-6-methoxybenzimidazole (179) and 1-(3-Butyn-2-yloxy)-2-(2-hydroxy-2-
propyl)-6-methoxybenzimidazole (180). A mixture of 127 (100 mg, 0.450 mmol) and NaH (80%, 50.7 
mg, 1.69 mmol) in DMSO (10 mL) was stirred at ambient temperature under a nitrogen atmosphere. After 
1 h, the reaction mixture was cooled to 0 °C and 3-bromo-1-butyne (135 µL, 1.49 mmol) was added via 
syringe and the reaction vessel was removed from the cold bath and light brown solution was stirred for 
an additional 1 h. EtOAc (20 mL) was added and the mixture was washed with water (5x15 mL) and 
brine (15 mL). The organic phase was dried (MgSO4), filtered, and the solvent was removed from the 
filtrate under reduced pressure. The crude product was purified by chromatography (hexane/EtOAc, 1:1) 
to give, in order of elution, 180 (50.1 mg, 0.183 mmol, 41%) as a white solid and 179 (9 mg, 0.042 mmol, 
9%) as a colorless liquid.  
 
Table 4.4, Entry 8 
1-(3-Butyn-2-yloxy)-2-(2-hydroxy-2-propyl)-6-methoxybenzimidazole (180). A mixture of 127 (180 
mg, 0.871 mmol) and NaH (80%, 97.3 mg, 3.24 mmol) in DMSO (10 mL) was stirred at ambient 
temperature under a nitrogen atmosphere. After 1 h, the reaction mixture was cooled to 0 °C and 3-
bromo-1-butyne (261 µL, 2.79 mmol) was added via syringe and the reaction vessel was removed from 
the cold bath and light brown solution was stirred for an additional 1 h. EtOAc (20 mL) was added and 
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the mixture was washed with water (5x15 mL) and brine (15 mL). The organic phase was dried (MgSO4), 
filtered, and the solvent was removed from the filtrate under reduced pressure. The crude product was 
purified by chromatography (hexane/EtOAc, 7:3) to give 180 (157 mg, 0.572 mmol, 66%) as a white 
solid.  
 
Scheme 4.4 
1-Acetoxy-2-(2-acetoxy-2-propyl)-6-methoxybenzimidazole (181) and 1-Acetoxy-2-(2-propen-2-yl)-
6-methoxybenzimidazole (182). A mixture of 127 (334 mg, 1.50 mmol) and NaH (80%, 169 mg, 5.62 
mmol) in DMSO (15 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1 h. The 
reaction mixture was cooled to 0 °C and acetyl chloride (355 µL, 4.97 mmol) was added via a syringe. 
The reaction vessel was removed from the cold bath and the resulting mixture was stirred for an 
additional 1 h. EtOAc (20 mL) was added and the mixture was washed with water (7x15 mL). The 
organic phase was dried (MgSO4), filtered, and the solvent was removed from the filtrate under reduced 
pressure. The crude product was purified by chromatography (hexane/EtOAc, 7:3, then 1:1) to give, in 
order of elution, 182 (20.6 mg, 0.084 mmol, 6%) as a pale yellow oil and 181 (80.9 mg, 0.264 mmol, 
18%) as a yellow oil. 
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4-Methoxy-2-nitro-N-(2-phenyl-1-propen-1-yl)benzenamine (190). To a solution of 4-methoxy-2-
nitrobenzenamine (500 mg, 2.974 mmol) and 2-phenylpropanal (399.1 mg, 2.974 mmol) in 
dichloromethane (DCM, 12 mL) at ambient temperature under a nitrogen atmosphere was added 4 Å 
molecular sieves (3 g, activated by heating at 120 °C under vacuum overnight, then stored under 
nitrogen). The reaction mixture was allowed to sit without agitation or stirring for 48 h. The mixture was 
then filtered and the sieves were washed with DCM (20 mL). The filtrate was concentrated under reduced 
pressure and the resulting residue was purified by chromatography (hexane/EtOAc, 95:5) to give 190 
(501 mg, 1.762 mmol, 59%) as a red solid. mp=85-86 °C; 
1
H NMR (400 MHz, CDCl3) δ 9.92 (d, J=10.8 
Hz, 1H), 9.83 (d, J=10.8 Hz, 1H), 7.57 (d, J=2.8 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 7.38-7.32 (m, 5H), 
7.29-7.21 (m, 3H), 7.18-7.12 (m, 2H), 7.10-7.04 (m, 4H), 6.85 (dq, J=10.8, 0.8 Hz, 1H), 6.50 (dq, J=10.8, 
0.8 Hz, 1H), 3.74 (s, 3H), 3.71 (s, 3H), 2.12 (d, J=1.2 Hz, 3H), 2.06 (d, J=1.2 Hz, 1H); 
13
C NMR (100 
MHz, CDCl3) δ 151.1, 150.7, 141.4, 139.1, 136.1, 136.0, 131.8, 131.3, 129.0, 128.5, 127.3, 127.3, 127.0, 
126.9, 126.4, 125.2, 121.4, 119.9, 118.8, 118.4, 115.8, 115.6, 107.1, 107.0, 55.8, 55.8, 22.0, 14.6; IR 
(ATR) 3311, 1640, 1571, 1513, 1163, 1060 cm
-1
; HRMS (ESI) calcd for C16H17N2O3 (M+H
+
) 285.1239, 
found 285.1225 .  
 
1-Methoxybenzimidazole (124).
136
 A mixture of N-(2-methyl-1-propen-1-yl)-2-nitrobenzenamine 
(122)
134
 (63.8 mg, 0.332 mmol) and t-BuOK (149 mg, 1.33 mmol) in t-BuOH (5 mL) was stirred at 
ambient temperature under a nitrogen atmosphere for 24 h. MeI (62 µL, 0.996 mmol) was added via a 
syringe and the mixture was stirred for an additional 1 h. The resulting orange mixture containing floating 
white solids was filtered through silica gel and the filtrate was washed with EtOAc (10 mL). The solvent 
was removed from the filtrate under reduced pressure. The crude product was purified by chromatography 
(hexane/EtOAc, 1:1) to give 124 (0.049 mg, 0.332 mmol, 100%) as a colorless oil. 
 
1,6-Dimethoxybenzimidazole (128).
136
 Reaction of a solution of 4-methoxy-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (127)
134
 (216 mg, 0.973 mmol) with MeI (194 µL, 3.15 mmol) in t-BuOH (10 
mL) in the presence of t-BuOK (437 mg, 3.89 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124  (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
128 (131 mg, 0.735 mmol, 76%) as a colorless oil. 
 
1-Methoxy-6-methylbenzimidazole (139).
136
 Reaction of a solution of 4-methyl-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (138)
136
 (76 mg, 0.368 mmol) with MeI (69 µL, 1.105 mmol) in t-BuOH (5 
150 
 
mL) in the presence of t-BuOK (165.4 mg, 1.474 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124  (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
139 (45.5 mg, 0.281 mmol, 76%) as a colorless oil. 
 
6-Chloro-1-methoxybenzimidazole (191). Reaction of a solution of 4-chloro-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (131)
134
 (75 mg, 0.331 mmol) with MeI (62 µL, 0.993 mmol) in t-BuOH (5 
mL) in the presence of t-BuOK (148.5 mg, 1.323 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 1234 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
191 (55.6 mg, 0.304 mmol, 92%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.66 (d, 
J=8.8 Hz, 1H), 7.47 (d, J=2.0 Hz, 1H), 7.23 (dd, J=8.8, 2.0 Hz, 1H), 4.15 (s, 3H);  
13
C NMR (100 MHz, 
CDCl3) δ 138.2, 137.9, 129.8, 129.6, 123.4, 121.8, 108.5, 67.4; IR (neat) 3293, 1623, 1473, 1346, 1214 
cm
-1
HRMS (ESI) calcd for C8H7ClN2O (M+Na
+
) 205.0144, found 205.0139. 
 
6-Bromo-1-methoxybenzimidazole (134).
136
 Reaction of a solution of 4-bromo-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (133)
136
 (136.2 mg, 0.502 mmol) with MeI (94 µL, 1.506 mmol) in t-BuOH (8 
mL) in the presence of t-BuOK (225.5 mg, 2.010 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124  (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
134 (96.9 mg, 0.427 mmol, 85%) as a colorless oil. 
 
6-Fluoro-1-methoxybenzimidazole (192). Reaction of a solution of 4-fluoro-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (136)
136
 (118.1 mg, 0.562 mmol) with MeI (75 µL, 1.197 mmol) in t-BuOH (10 
mL) in the presence of t-BuOK (252.2 mg, 2.248 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124  (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
192 (62.6 mg, 0.377 mmol, 67%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.70 (dd, 
J=5.6, 2.8 Hz, 1H), 7.16 (dd, J=5.6, 1.6 Hz, 1H), 7.03 (td, J=6.4, 1.6 Hz, 1H), 4.17 (s, 3H);  
13
C NMR 
(100 MHz, CDCl3) δ 161.4, 158.9, 138.1, 135.8, 122.0 (d, J
C-F
=10 Hz, 1C), 111.3 (d, J
C-F
=25 Hz, 1C), 
95.1 (d, J
C-F
=28 Hz, 1C), 67.2; IR (neat) 3395, 1626, 1493, 1357, 1225 cm
-1
; HRMS (ESI) calcd for 
C8H8N2O2 (M+H
+
) 167.0621, found 167.0614. 
 
1,5-Dimethoxybenzimidazole (146).
136
 Reaction of a solution of 5-methoxy-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (12)
136
 (77.2 mg, 0.347 mmol) with MeI (65 µL, 1.041 mmol) in t-BuOH (5 
151 
 
mL) in the presence of t-BuOK (155.9 mg, 1.389 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124  (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
146 (45.4 mg, 0.255 mmol, 73%) as a colorless oil. 
 
1-Methoxy-5-methylbenzimidazole (154).
136
 Reaction of a solution of 5-methyl-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (153)
136
 (183 mg, 0.887 mmol) with MeI (166 µL, 2.662 mmol) in t-BuOH (10 
mL) in the presence of t-BuOK (398.3 mg, 3.550 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
154 (102.3 mg, 0.631 mmol, 71%) as an orange oil. 
 
5-Chloro-1-methoxybenzimidazole (148).
136
 Reaction of a solution of 5-chloro-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (147)
134
 (197.9 mg, 0.873 mmol) with MeI (163 µL, 2.619 mmol) in t-BuOH 
(10 mL) in the presence of t-BuOK (391.9 mg, 3.493 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
148 (113.5 mg, 0.622 mmol, 71%) as a yellow oil. 
 
5-Bromo-1-methoxybenzimidazole (151).
136
 Reaction of a solution of 5-bromo-2-nitro-N-(2-methyl-1-
propen-1-yl)benzenamine (150)
136
 (86.9 mg, 0.321 mmol) with MeI (60 µL, 0.962 mmol) in t-BuOH (5 
mL) in the presence of t-BuOK (143.9 mg, 1.282 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
151 (53.5 mg, 0.236 mmol, 73%) as a faint yellow oil. 
 
1,6-Dimethoxybenzimidazole (128).
136
 Reaction of a solution of 4-methoxy-2-nitro-N-
(cyclohexylmethylene)benzenamine (157)
134
 (339.5 mg, 1.295 mmol) with MeI (258 µL, 4.144 mmol) in 
t-BuOH (10 mL) in the presence of t-BuOK (580.9 mg, 5.177 mmol), at ambient temperature under a 
nitrogen atmosphere, as described for 124  (25 h), gave after work up and chromatography 
(hexane/EtOAc, 1:1), 128 (176.1 mg, 0.988 mmol, 76%) as a colorless oil. 
 
152 
 
1,6-Dimethoxybenzimidazole (128). Reaction of a solution of 4-methoxy-2-nitro-N-(2,2-
diphenylethylene)benzenamine (168)
134
 (123.9 mg, 0.358 mmol) with MeI (89 µL, 1.432 mmol) in t-
BuOH (5 mL) in the presence of t-BuOK (200.7 mg, 1.789 mmol), at ambient temperature under a 
nitrogen atmosphere, as described for 124 (25 h), gave after work up and chromatography 
(hexane/EtOAc, 9:1, then,1:1), in order of elution, benzophenone (170, 63.6 mg, 0.349 mmol, 98%) and 
128 (49.8 mg, 0.279 mmol, 78%) both as a colorless oil. 
 
6-Bromo-1-methoxybenzimidazole (134).
136
 Reaction of a solution of 4-bromo-2-nitro-N-(2-phenyl-1-
propen-1-yl)benzenamine (160)
136
 (50.8 mg, 0.153 mmol) with MeI (29 µL, 0.459 mmol) in t-BuOH (3 
mL) in the presence of t-BuOK (68.6 mg, 0.611 mmol), at ambient temperature under a nitrogen 
atmosphere, as described for 124 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1), 
134 (32.5 mg, 0.143 mmol, 94%) as a colorless oil that solidified upon standing. 
 
1-Benzyloxy-6-methoxybenzimidazole (193). Reaction of a solution of 127 (109.7 mg, 0.494 mmol) 
with benzyl bromide (BnBr, 152 µL, 1.283 mmol) in t-BuOH (8 mL) in the presence of t-BuOK (208.3 
mg, 1.856 mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave 
after work up and chromatography (hexane/EtOAc, 95:5, 6:4) 193 (103.4 mg, 0.407 mmol, 82%) as a 
colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.59 (d, J=8.8 Hz, 1H), 7.57 (s, 1H), 7.41-7.34 (m, 3H), 7.31-
7.28 (m, 2H), 6.87 (dd, J=8.8, 2.4 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 5.19 (s, 2H), 3.80 (s, 3H);  
13
C NMR 
(100 MHz, CDCl3) δ 157.1, 137.6, 133.8, 133.6, 130.3, 129.8, 129.6, 128.8, 121.3, 112.2, 91.5, 80.9, 
55.6;  IR (neat) 1624, 1494, 1234, 1061, 816 cm
-1
; HRMS (ESI) calcd for C15H15N2O2 (M+H
+
) 255.1133, 
found 255.1123. 
 
6-methoxy-1-(2-propen-1-yloxy)benzimidazole (194). Reaction of a solution of 127 (52.2 mg, 0.235 
mmol) with allyl bromide (41 µL, 0.470 mmol) in t-BuOH (5 mL) in the presence of t-BuOK (105.4 mg, 
0.939 mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave after 
work up and chromatography (hexane/EtOAc, 1:1) 194 (47.9 mg, 0.235 mmol, 100%) as a colorless oil. 
 
1-(2-Methyl-2-propen-1-yloxy)-6-methoxybenzimidazole (195). Reaction of a solution of 127 (106.4 
mg, 0.479 mmol) with 3-bromo-2-methyl-1-propene (102 µL, 1.016 mmol) in t-BuOH (10 mL) in the 
presence of t-BuOK (214.9 mg, 1.915 mmol), at ambient temperature under a nitrogen atmosphere, as 
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described for 124 (25 h), gave after work up and chromatography (hexane/EtOAc, 7:3) 195 (94.3 mg, 
0.432 mmol, 90%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.59 (d, J=9.2 Hz, 1H), 
6.88 (d, J=2.4 Hz, 1H), 6.86 (dd, J=9.6, 2.4 Hz, 1H), 5.05 (pentet, J=1.6 Hz, 1H), 4.93 (pentet, J=0.8 Hz, 
1H), 4.59 (s, with further fine splitting, 2H), 3.83 (s, 3H), 1.94 (t, J=1.2 Hz, 3H);  
13
C NMR (100 MHz, 
CDCl3) δ 157.1, 138.2, 137.4, 133.6, 130.0, 121.3, 118.4, 112.0, 91.5, 82.9, 55.6, 19.6; IR (neat) 1629, 
1499, 1449, 1230, 917, 822 cm
-1
; HRMS (ESI) calcd for C12H15N2O2 (M+H
+
) 219.1133, found 219.1123. 
 
6-Methoxy-1-(1,2-propadien-1-yloxy)benzimidazole (196). Reaction of a solution of 127 (131.3 mg, 
0.591 mmol) with propargyl bromide (112 µL, 1.259 mmol) in t-BuOH (8 mL) in the presence of t-BuOK 
(259.2 mg, 2.310 mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 
h), gave after work up and chromatography (hexane/EtOAc, 1:1) 196 (17.4 mg, 0.086 mmol, 15%) as a 
yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.54 (d, J=8.8 Hz, 1H), 7.28 (d, J=2.4 Hz, 1H), 
7.13 (t, J=6.4 Hz, 1H), 6.95 (dd, J=9.2, 2.4 Hz, 1H), 5.69 (d, J=6.4 Hz, 2H), 3.87 (s, 3H);  
13
C NMR (100 
MHz, CDCl3) δ 203.0, 156.5, 145.1, 141.8, 127.3, 113.5, 111.2, 102.6, 95.3, 88.2, 55.8; IR (neat) 3367, 
1488, 1239, 1144, 850 cm
-1
; HRMS (ESI) calcd for C11H11N2O2 (M+H
+
) 208.0820, found 208.0811. 
 
1-(1,2-Butadien-1-yloxy)-6-methoxybenzimidazole (197). Reaction of a solution of 127 (222.2 mg, 
1.000 mmol) with 3-bromo-1-butyne (181 µL, 2.000 mmol) in t-BuOH (12 mL) in the presence of t-
BuOK (449.6 mg, 4.007 mmol), at ambient temperature under a nitrogen atmosphere, as described for 
124 (25 h), gave after work up and chromatography (hexane/EtOAc, 1:1) 197 (26.1 mg, 0.121 mmol, 
12%) as a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.63 (d, J=8.8 Hz, 1H), 6.93 (d, J=2.4 
Hz, 1H), 6.90 (dd, J=8.8, 2.4 Hz, 1H), 4.82 (q, J=2.4 Hz, 2H), 3.86 (s, 3H), 1.85 (t, J=2.4 Hz, 3H);  
13
C 
NMR (100 MHz, CDCl3) δ 157.2, 138.4, 137.9, 133.7, 130.3, 121.4, 112.3, 91.7, 87.7, 72.3, 66.9, 55.8; 
IR (neat) 1624, 1495, 1234, 1061, 816 cm
-1
; HRMS (ESI) calcd for C12H13N2O2 (M+H
+
) 217.0977, found 
217.0968. 
 
1-Acetoxy-6-methoxybenzimidazole (198). Reaction of a solution of 127 (130.3 mg, 0.586 mmol) with 
acetyl chloride (88 µL, 1.236 mmol) in t-BuOH (10 mL) in the presence of t-BuOK (263.2 mg, 2.346 
mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave after work 
up and chromatography (hexane/EtOAc, 6:4) 198 (65.4 mg, 0.317 mmol, 54%) as a white solid. mp=231-
231.5 
o
C, 
1
H NMR (400 MHz, DMSO-d6) δ 11.28 (br, s, 1H), 7.84 (d, J=8.8 Hz, 1H), 6.61 (dd, J=8.8, 2.4 
Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 3.73 (s, 3H), 2.57 (s, 3H); 
13
C NMR (100 MHz, DSMO-d6) δ 169.9, 
156.6, 152.7, 129.5, 120.8, 115.6, 106.8, 95.4, 55.4, 25.0; IR (neat)  1709, 1634, 1377, 1332, 1158, 1014 
cm
-1
; HRMS (ESI) calcd for C10H10N2O3 (M+Na
+
) 229.0589, found 229.0596. 
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1-(Heptyloxy)-6-methoxybenzimidazole (199). Reaction of a solution of 127 (113.6 mg, 0.511 mmol) 
with 1-bromoheptane (169 µL, 1.073 mmol) in t-BuOH (10 mL) in the presence of t-BuOK (229.4 mg, 
2.044 mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave after 
work up and chromatography (hexane/EtOAc, 7:3) 199 (21.8 mg, 0.083 mmol, 16%) as a colorless oil.  
1
H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.63 (d, J=9.2 Hz, 1H), 6.91 (dd, J=8.4, 2.4 Hz, 1H), 6.88 (d, 
J=2.0 Hz, 1H), 4.28 (t, J=6.8 Hz, 2H), 3.88 (s, 3H), 1.84-1.76 (m, 3H), 1.52-1.48 (m, 1H), 1.39-1.29 (m, 
6H), 0.90 (t, with further splitting,  J=7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 137.3, 133.9, 
130.4, 121.4, 112.2, 91.5, 79.7, 55.8, 31.6, 28.9, 28.2, 25.6, 22.5, 14.0; IR (neat) 2928, 1625, 1496, 1236, 
1064 cm
-1
; HRMS (ESI) calcd for C15H23N2O2 (M+H
+
) 263.1759, found 263.1749. 
 
1-(1-butyloxy)-6-methoxybenzimidazole (200). Reaction of a solution of 127 (111.5 mg, 0.502 mmol) 
with 1-iodobutane (120 µL, 1.054 mmol) in t-BuOH (8 mL) in the presence of t-BuOK (224.1 mg, 1.997 
mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave after work 
up and chromatography (hexane/EtOAc, 6:4) 200 (16.8 mg, 0.076 mmol, 15%) as a colorless oil.  
1
H 
NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.63 (d, J=8.8 Hz, 1H), 6.91 (dd, J=8.4, 2.4 Hz, 1H), 6.88 (d, 
J=2.0 Hz, 1H), 4.29 (t, J=6.4 Hz, 2H), 3.88 (s, 3H), 1.84-1.75 (m, 2H), 1.58-1.52 (m, 1H), 1.01 (t, J=7.2 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 137.3, 133.9, 130.4, 121.4, 112.2, 91.5, 79.5, 55.8, 30.1, 
18.9, 13.7; IR (neat) 2959, 1625, 1496, 1236, 1063, 1022, 816 cm
-1
; HRMS (ESI) calcd for C12H17N2O2 
(M+H
+
) 221.1290, found 221.1280. 
 
6-methoxy-1-(2-methylethyloxy)benzimidazole (201). Reaction of a solution of 127 (143.6 mg, 0.646 
mmol) with 2-iodopropane (136 µL, 1.357 mmol) in t-BuOH (8 mL) in the presence of t-BuOK (290 mg, 
2.584 mmol), at ambient temperature under a nitrogen atmosphere, as described for 124 (25 h), gave after 
work up and chromatography (hexane/EtOAc, 6:4) 201 (10.9 mg, 0.053 mmol, 8%) as a colorless oil.  
1
H 
NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.63 (d, J=8.8 Hz, 1H), 6.90 (dd, J=8.8, 2.8 Hz, 1H), 6.87 (d, 
J=2.4 Hz, 1H), 4.57 (heptet, J=6.0 Hz, 1H), 3.88 (s, 3H), 1.39 (d, J=6.4 Hz, 6H); 
13
C NMR (100 MHz, 
CDCl3) δ 157.2, 138.2, 133.9, 131.2, 121.4, 112.0, 92.0, 81.3, 55.8, 21.0; IR (neat) 1625, 1497, 1105, 817 
cm
-1
; HRMS (ESI) calcd for C11H15N2O2 (M+H
+
) 207.1133, found 207.1124. 
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2,4-Dinitro-5-bromophenyl trifluoromethanesulfonate (204) To a solution of fuming HNO3 (2 mL) in 
H2SO4 (2 mL) was added 3-bromophenyl trifluoromethanesulfonate (203)
172 (297 mg, 0.974 mmol) and 
the mixture was heated at 60 oC for 7 h.  The resulting mixture was poured onto ice, the ice was allowed 
to melt, and the resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic phases 
were dried (MgSO4), filtered, and the solvents were removed under reduced pressure. The crude product 
was purified by chromatography (hexanes/EtOAc, 9:1) affording 204 (307 mg, 0.777 mmol, 80%) as a 
pale yellow oil that solidified upon standing. mp = 33-35 oC; 1H NMR (400 MHz, CDCl3) δ 8.73 (s, 1H), 
7.90 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 148.2, 142.6, 140.1, 131.2, 124.0, 122.2, 118.4 (q, J
C-F = 319 
Hz); IR (ATR) 1591, 1541, 1436, 1337, 1213, 1130 cm-1. 
 
5-Ethenyl-2,4-dinitro trifluoromethanesulfonate (205). A mixture of 204 (238 mg, 0.60 mmol), 
ethenyltributyltin (187 mg, 0.59 mmol), 2,6-di-t-butyl-4-methylphenol (22 mg, 0.10 mmol), LiCl (87 mg, 
2.05 mmol), PPh3 (25.2 mg, 0.098 mmol), and PdCl2(PPh3)2 (33.7 mg, 0.048 mmol) in toluene (4 mL) 
was heated at 80 oC for 17 h.  The solvent was removed at reduced pressure and the crude product was 
purified by chromatography (hexanes/EtOAc, 9:1) to give 205 (160 mg, 0.468 mmol, 78%) as a faint 
brown oil. 1H NMR (600 MHz, CDCl3) δ 8.82 (s, 1H), 7.69 (s, 1H), 7.26 (dd, J = 17.4, 10.8 Hz, 1H), 5.96 
(d, J = 17.4 Hz, 1H), 5.84 (d, J = 11.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 145.3, 143.6, 140.5, 129.8, 
127.4, 125.0, 124.4, 123.9, 118.5 (q, JC-F = 319 Hz); 19F NMR (376 MHz, CDCl3) δ -72.9; IR (ATR) 
1614, 1590, 1539, 1437, 1345, 1223, 1134 cm-1.173 
 
4-Bromo-3-nitrophenyl trifluoromethanesulfonate (215). To a solution of 4-bromo-3-nitrophenol174 
(269 mg, 1.23 mmol) in CH2Cl2 (5 mL) at 0 
oC was added pyridine (200 µL, 2.48 mmol) and 
trifluoromethanesulfonic anhydride (Tf2O, 250 µL, 1.48 mmol). The mixture was removed from the cold 
bath and allowed to stir at ambient temperature for 30 min. The resulting mixture was filtered through a 
small plug of silica gel and the solvent was removed under reduced pressure from the filtrate. Purification 
by chromatography (hexanes/EtOAc, 9:1) afforded 215 (391 mg, 1.12 mmol, 90%) as a yellow oil. 1H 
NMR (600 MHz, CDCl3) δ 7.88 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.41 (dd, J = 9.0, 3.0 Hz, 
1H); 13C NMR (150 MHz, CDCl3) δ 150.1, 147.9, 136.8, 126.2, 119.3, 118.6 (q, J
C-F = 319 Hz), 114.6; IR 
(ATR) 3103, 1541, 1428, 1208, 1132 cm-1; HRMS (ESI) calcd for C7H3BrNNaO5F3S (M+Na
+) 371.8765; 
found 371.8760. 
 
3-Bromo-2-nitrophenyl trifluoromethanesulfonate (216). Treatment of 3-bromo-2-nitrophenol175 (298 
mg, 1.37 mmol) in CH2Cl2 (5 mL) with pyridine (250 µL, 3.10 mmol) and Tf2O (300 µL, 1.77 mmol), as 
described for 213, gave after chromatography (hexanes/EtOAc, 8:2) 216 (394 mg, 1.13 mmol, 80%) as a 
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red solid. mp 52-53 oC; 1H NMR (400 MHz, CDCl3) δ 7.74-7.72 (m, 1H), 7.50-7.49 (m, 2H); 
13C NMR 
(150 MHz, CDCl3) δ 140.6, 133.4, 132.1, 121.6, 119.4, 117.3 (q, J
C-F = 319 Hz), 115.2; 19F NMR (376 
MHz, CDCl3) δ -73.2; IR (ATR) 3099, 1538, 1434, 1360, 1219, 1132 cm 
-1; HRMS (ESI) calcd for 
C7H3BrNNaO5F3S (M+Na
+) 371.8765; found 371.8767. 
 
2-Bromo-6-nitrophenyl trifluoromethanesulfonate (217). Treatment of 2-bromo-6-nitrophenol176 (189 
mg, 0.87 mmol) in CH2Cl2 (5 mL) with pyridine (150 µL, 1.85 mmol) and Tf2O (200 µL, 1.18 mmol), as 
described for 215, gave after chromatography (hexanes/EtOAc, 7:3) 217 (299 mg, 0.85 mmol 98%) as a 
colorless oil. 1H NMR (600 MHz, CDCl3) δ 8.03 (dd, J = 7.8, 1.2 Hz, 1H), 7.98 (dd, J = 8.4, 1.8 Hz, 1H), 
7.45 (dt, J = 8.4, 1.2 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 143.6, 139.4, 139.1, 129.3, 125.6, 119.0, 
118.4 (q, JC-F = 319 Hz); 19F NMR (376 MHz, CDCl3) δ -73.2; IR (ATR) 3093, 1588, 1540, 1431, 1347, 
1207 cm-1; HRMS (ESI) calcd for C7H3BrNNaO5F3S (M+Na
+) 371.8765; found 371.8761. 
 
3-Bromo-5-nitrophenyl trifluoromethanesulfonate (219) Treatment of 3-bromo-5-nitrophenol177 (329 
mg, 1.51 mmol) in CH2Cl2 (10 mL) with pyridine (250 µL, 3.10 mmol) and Tf2O (300 µL, 1.78 mmol), as 
described for 215, gave after chromatography (hexanes/EtOAc, 7:3) 219 (316 mg, 0.90 mmol, 60%) as a 
red oil. 1H NMR (600 MHz, CDCl3) δ 8.44 (t, J = 1.8 Hz, 1H), 8.11 (t, J = 2.4 Hz, 1H), 7.80 (t, J = 1.8 
Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 149.2, 130.8, 126.8, 123.8, 118.6 (q, J
C-F = 319 Hz), 116.1; IR 
(ATR) 3097, 1732, 1542, 1427, 1344, 1210, 1134 cm-1; HRMS (ESI) calcd for C7H3BrNNaO5F3S 
(M+Na+) 371.8765; found 371.8764. 
 
 4-Bromo-2-nitrophenyl trifluoromethanesulfonate (220).164  Treatment of 4-bromo-3-nitrophenol178 
(353 mg, 1.60 mmol) in CH2Cl2 (5 mL) with pyridine (260 µL, 3.22 mmol) and Tf2O (330 µL, 1.95 
mmol), as described for 215, gave after chromatography (hexanes/EtOAc, 7:3) 220 (540 mg, 1.54 mmol, 
97%) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.30 (d, J = 2.4 Hz, 1H), 7.88 (dd, J = 8.4, 2.4 Hz, 
1H), 7.36 (d, J = 9.0 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 141.9, 140.5, 138.2, 129.7, 125.6, 122.3, 
118.5 (q, JC-F = 319 Hz); IR (ATR) 3105, 1540, 1431, 1207, 1131 cm-1; HRMS (ESI) calcd for 
C7H3BrNNaO5F3S (M+Na
+) 371.8765; found 371.8764. 
 
2-Bromo-5-nitrophenyl trifluoromethanesulfonate (222). Treatment of 2-bromo-5-nitrophenol179 (119 
mg, 0.55 mmol) in CH2Cl2 (5 mL) with pyridine (90 µL, 1.12 mmol) and Tf2O (120 µL, 0.71 mmol), as 
described for 215, gave without further purification 222 (188 mg, 0.54 mmol, 98%) as a brown oil. 1H 
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 2.4 Hz, 1H), 8.16 (dd, J = 8.8, 2.4 Hz, 1H), 7.93 (d, J = 8.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 147.6, 146.9, 135.2, 124.0, 123.9, 118.5 (q, J
C-F = 320 Hz), 118.3; IR 
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(ATR) 3104, 1534, 1431, 1348, 1211, 1134 cm-1; HRMS (ESI) calcd for C7H3BrNNaO5F3S (M+Na
+) 
371.8765; found 371.8764. 
 
Conditions A 
4-Ethenylphenyl trifluoromethanesulfonate (206).138 To a solution of PPh3 (7.5 mg, 0.029 mmol) and 
Pd(dba)2 (4.3 mg, 0.007 mmol) in dioxane (1.5 mL), stirred for 5 min under an atmosphere of N2, was 
added 4-bromophenyl trifluoromethanesulphonate (202)138 (102 mg, 0.34 mmol) followed by 
ethenyltributyltin (128 mg, 0.40 mmol). The solution was heated at reflux for 24 h.  The solvent was 
removed under reduced pressure and the residue was dissolved in EtOAc (10 mL) and washed with 
NH4OH (10% aqueous, 3 x 20 mL), H2O (20 mL), and brine (20 mL). The organic phase was dried 
(MgSO4), filtered, and solvents were removed under reduced pressure. The crude product was purified by 
chromatography (hexanes/EtOAc, 97:3) to give 206 (25.2 mg, 0.10 mmol, 30%) as a colorless oil. Only 
206 was observed by 1H NMR (600 MHz, CDCl3) of the crude reaction mixture. 
 
Conditions B 
4-Ethenylphenyl trifluoromethanesulfonate (206) and 4-ethenyl-1-bromobenzene (207).138 To a 
solution of LiCl (45.5 mg, 1.07 mmol) and Pd(PPh3)2Cl2 (4.7 mg, 0.007 mmol) in DMF (1.5 mL), under 
an atmosphere of N2, was added 202 (108 mg, 0.35 mmol) followed by ethenyltributyltin (141 mg, 0.44 
mmol). After stirring at ambient temperature for 24 h, the solvent was removed by bulb-to-bulb 
distillation. The resulting residue was dissolved in EtOAc (15 mL) and washed with NH4OH (10% 
aqueous, 3 x 20 mL) and brine (20 mL). The organic phase was dried (MgSO4), filtered, and solvents 
were removed under reduced pressure. The terminal cis-alkene protons were clearly resolved in the 1H 
NMR spectrum at 600 MHz and these signals were used to determine the ratio of 206 (δ 5.35, d, J = 10.8 
Hz, 1H) to 207 (δ 5.27, d, J = 10.8 Hz, 1H). A 6.7:1 ratio of 207/206 was observed by NMR. The 
products decomposed upon attempted purification on silica gel.  
 
Conditions C 
4-Ethenylphenyl trifluoromethanesulfonate (206). To a solution of PdCl2(PPh3)2 (4.3 mg, 0.007 mmol) 
in dioxane (4 mL), stirred for 5 min under an atmosphere of N2, was added 202 (310 mg, 1.02 mmol) 
followed by ethenyltributyltin (340 mg, 1.07 mmol). The solution was heated at reflux for 24 h.  The 
solvent was removed under reduced pressure. The product was purified by chromatography on 
SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 98:2) to give 206 (231 mg, 0.917 mmol, 90%) as a colorless 
oil. Only 206 was observed by 1H NMR (600 MHz, CDCl3) of the crude reaction mixture. 
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2-Ethenylphenyl trifluoromethanesulfonate (209).180 Cross coupling of 2-bromophenyl 
trifluoromethanesulphonate (208)181 (95.6 mg, 0.31 mmol) with ethenyltributyltin (121 mg, 0.38 mmol) in 
the presence of PPh3 (6.9 mg, 0.026 mmol) and Pd(dba)2 (3.8 mg, 0.007 mmol) in dioxane (1.5 mL) was 
performed as described for 206 under Conditions A. Work up and chromatography chromatography 
(hexanes/EtOAc, 9:1) gave 209 (4.1 mg, 0.016 mmol, 5%) as a colorless oil. Only 209 was observed by 
1H NMR (600 MHz, CDCl3) of the crude reaction mixture after work up. 
 
2-Ethenylphenyl trifluoromethanesulfonate (209) and 2-ethenyl-1-bromobenzene (210).182 Cross 
coupling of 208 (88.3 mg, 0.25 mmol) with ethenyltributyltin (98.0 mg, 0.31 mmol) in the presence of 
LiCl (32.2 mg, 0.76 mmol) and Pd(PPh3)2Cl2 (3.8 mg, 0.005 mmol) in DMF (1.0 mL) was performed as 
described for 208 under Conditions B. A 5.9:1 ratio of 210/209 was observed by 1H NMR (600 MHz, 
CDCl3) of the crude reaction mixture after standard work up. The products decomposed upon attempted 
purification on silica gel. The terminal cis-alkene protons were clearly resolved in the 1H NMR spectrum 
at 600 MHz and these signals were used to determine the ratios of 209 (δ 5.49, d, J = 11.1 Hz, 1H) to 210 
(δ 5.37, dd, J = 10.9, 1.0 Hz, 1H). 
 
3-Ethenylphenyl trifluoromethanesulfonate (211) and 3-Ethenylphenyl-1-bromobenzene (212).182 
Cross coupling of 3-bromophenyl trifluoromethane sulphonate (203) (105 mg, 0.34 mmol) with 
ethenyltributyltin (127 mg, 0.40 mmol) in the presence of PPh3 (7.6 mg, 0.03 mmol) and Pd(dba)2 (4.0 
mg, 0.007 mmol) in dioxane (1.5 mL) was performed as described for 206 under Conditions A. Work up 
and chromatography chromatography (hexanes/EtOAc, 9:1) to give an inseparable mixture of 203 and 
211 (49.2 mg, calculated from 1H NMR spectrum: 20.2 mg 203 and 28.8 mg 211, 34%) as a colorless oil. 
A ~30:1 ratio of 211/212 was observed by 1H NMR (600 MHz, CDCl3) of the crude reaction mixture after 
standard work up. The terminal cis-alkene protons were clearly resolved in the 1H NMR spectrum at 600 
MHz and these signals were used to determine the ratios of 211 (δ 5.38, d, J = 11.4 Hz, 1H) to 212 (δ 
5.30, d, J = 10.8 Hz, 1H).  
 
3-Ethenylphenyl trifluoromethanesulfonate (211) and 3-Ethenylphenyl-1-bromobenzene (212). 
Cross coupling of 203 (108 mg, 0.36 mmol) with ethenyltributyltin (140 mg, 0.44 mmol) in the presence 
of LiCl (45.6 mg, 1.08 mmol) and Pd(PPh3)2Cl2 (5.4 mg, 0.008 mmol) in DMF (1.5 mL) was performed 
as described for 207 under Conditions B.  A 5.3:6.3:1 ratio of 203/212/211 was observed by 1H NMR 
(600 MHz, CDCl3) of the crude reaction mixture after standard work up. The products decomposed upon 
attempted purification on silica gel or basic alumina. 
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3-Ethenylphenyl trifluoromethanesulfonate (211) Cross coupling of 203 (310 mg, 1.02 mmol) with 
ethenyltributyltin (490 mg, 1.54 mmol) in the presence of Pd(PPh3)2Cl2 (13.3 mg, 0.019 mmol) in DMF 
(4 mL) was performed as described for 206 under Conditions C (100 oC, 50 h). Work up and 
chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 98:2) gave 211 (121 mg, 0.480 mmol, 
47%) as a colorless oil. Only 211 was observed by 1H NMR (600 MHz, CDCl3) of the crude reaction 
mixture Needs to be reintegrated some 212 can be seen. 1H NMR (600 MHz, CDCl3) δ 7.42-7.39 (m, 2H), 
7.29 (d, J=1.2 Hz, 1H), 7.17-7.15 (m, 1H), 6.70 (dd, J = 17.4, 10.8 Hz, 1H), 5.81 (d, J = 17.4 Hz, 1H), 
5.39 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 149.9, 140.3, 135.0, 130.2, 126.1, 120.2, 118.8, 
118.7 (q, JC-F = 319 Hz), 116.5; IR (ATR) 1574, 1420, 1205, 1136, 1117, 924, 825 cm-1; HRMS (ESI) 
calcd for C9H8F3O3S (M+H
+) 253.0146; found 253.0147. 
 
2-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (223).183 Cross coupling of 2-bromo-3-nitrophenyl 
trifluoromethanesulfonate (213)183 (105 mg, 0.30 mmol) with ethenyltributyltin (119 mg, 0.38 mmol) in 
the presence of in the presence of PPh3 (6.5 mg, 0.03 mmol) and Pd(dba)2 (3.7 mg, 0.006 mmol) in 
dioxane (1.5 mL) was performed as described for 206 under Conditions A. Work up and chromatography 
(hexanes/EtOAc, 97:3) gave , in order of elution, 223 (32.3 mg, 0.11 mmol, 36%) as a white solid and 
impure 2-bromo-3-nitrophenol182 (41 mg).  
 
2-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (223), 2-bromo-3-nitrophenol, and 2-bromo-3-
ethenyl-nitrobenzene (224). Cross coupling of 213 (110 mg, 0.32 mmol) with ethenyltributyltin (123 
mg, 0.39 mmol) in the presence of LiCl (40.9 mg, 0.96 mmol) and Pd(PPh3)2Cl2 (4.8 mg, 0.007 mmol) in 
DMF (1.5 mL) was performed as described for 207 under Conditions B. Work up and chromatography 
(hexanes/EtOAc, 97:3) gave , in order of elution, 223 (18.5 mg, 0.06 mmol, 20%), 224 (27.6 mg, 0.12 
mmol, 38%) as a colorless oil and an impure mixture of 213 and 2-bromo-3-nitrophenol (38.2 mg). 
Spectral data for 224: 1H NMR (600 MHz, CDCl3) δ 7.70 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 
7.41 (t, J = 7.8 Hz, 1H), 7.10 (dd, J = 17.4, 10.8 Hz, 1H), 5.76 (d, J = 17.4 Hz, 1H), 5.52 (d, J = 10.8 Hz, 
1H); 13C NMR (150 MHz, CDCl3) δ 147.2, 128.9, 128.3, 126.2, 125.7, 124.8, 123.8, 119.5; IR (ATR) 
3110, 1533, 1423, 1358, 1210, 1135 cm-1; HRMS (ESI) calcd for C8H6NNaO2Br (M+Na
+) 249.9474; 
found 249.9473.  
 
2-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (223). Cross coupling of 213 (127 mg, 0.362 
mmol) with ethenyltributyltin (149 mg, 0.471 mmol) in the presence of Pd(PPh3)2Cl2 (5.1 mg, 0.007 
mmol) in dioxane (1 mL) was performed as described for 206 under Conditions C (23 h). Work up and 
chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 98:2) gave 223 (83 mg, 0.28 mmol, 77%). 
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2-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (223) and 1-bromo-2-ethenyl-nitrobenzene 
(224) 2,3-Diethenyl-nitrobenzene (225), and 2-ethenyl-3-nitrophenol. Cross coupling of 213 (143 mg, 
0.41 mmol) with ethenyltributyltin (123 mg, 0.39 mmol) in the presence of LiCl (53.8 mg, 1.27 mmol) 
and 1,3-bis(diphenylphosphino)propanepalladium dichloride (5.3 mg, 0.009 mmol) in DMF (2 mL) was 
performed as described for 207 under Conditions B. Work up and chromatography (hexanes/EtOAc, 
97:3) gave in order of elution, 225 (7.0 mg, 0.04 mmol, 10%), 223 (22.9 mg, 0.077 mmol, 19%), 224 
(45.7 mg, 0.20 mmol, 49%) as a colorless oil, and 2-ethenyl-3-nitrophenol (7.7 mg, 0.046 mmol, 11%). 
Spectral data for 225:  1H NMR (400 MHZ, CDCl3) δ 7.75 (dd, J=8.0, 1.2 Hz, 1H), 7.71 (dd, J=8.0, 1.2 
HZ, 1H), 7.37 (t, J=8.0 Hz, 1H), 6.96 (dd, J=17.6, 10.8 Hz, 1H), 6.89 (dd, J=17.6, 11.6 Hz, 1H), 5.71 (dd, 
J=17.6, 0.8 Hz, 1H), 5.63 (dd, J=11.6, 1.2 Hz, 1H), 5.37 (dd, J=11.2, 1.2 Hz, 1H), 5.32 (d, J=18.0, 1.2 
Hz, 1H); 13C NMR (100 MHZ, CDCl3) δ 149.8, 138.7, 134.5, 131.4, 130.5, 130.0, 127.6, 122.8, 122.6, 
117.3; IR (ATR) 1521, 1348, 985, 921, 810, 774, 753, 735 cm-1; HRMS (ESI) calculated from C10H10NO2 
(M+H+) 176.0711, found 176.0709.  
 
2,3-Diethenyl-nitrobenzene (225). Cross coupling of 213 (70.2 mg, 0.201 mmol) with ethenyltributyltin 
(203 mg, 0.641 mmol) in the presence of Pd(PPh3)2Cl2 (6.0 mg, 0.008 mmol) and LiCl (6.0 mg, 0.008 
mmol) in dioxane (1 mL) was performed as described for 207 under Conditions B (100 oC, 24 h). Work 
up and chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 98:2) gave 223 (33.7 mg, 0.192 
mmol, 96%). 
 
3-Ethenyl-4-nitrophenyl trifluoromethanesulfonate (226) and 2,4-diethenyl-nitrobenzene (227). 
Cross coupling of 3-bromo-4-nitrophenyl trifluoromethanesulfonate (214)184 (67.6 mg, 0.19 mmol) with 
ethenyltributyltin (72.8 mg, 0.23 mmol) in the presence of in the presence of PPh3 (4.5 mg, 0.02 mmol) 
and Pd(dba)2 (2.2 mg, 0.004 mmol) in dioxane (1 mL) was performed as described for 206 under 
Conditions A. Work up and chromatography (hexanes/EtOAc, 97:3), gave in order of elution, 227 (3.0 
mg, 0.02 mmol, 9%) and 226 (47.3 mg, 0.16 mmol, 82%) as a colorless oil. Analytical data for 226: 1H 
NMR (600 MHZ, CDCl3) δ 8.06 (d, J = 9.0 Hz, 1H), 7.51 (d, J = 2.4 Hz, 1H), 7.33 (dd, J = 9.0, 3.0 Hz, 
1H), 7.18 (dd, J = 17.4, 11.4 Hz, 1H), 5.81 (d, J = 17.4 Hz, 1H), 5.66 (d, J = 11.4 Hz, 1H); 13C NMR(150 
MHZ, CDCl3) δ 151.7, 146.6, 136.4, 131.0, 127.0, 121.4, 121.3, 121.0, 118.6 (q, J
C-F = 319 Hz);IR (ATR) 
3118, 1530, 1424, 1350, 1207, 1131 cm-1; HRMS (ESI) calcd for C9H6NNaO5F3S (M+Na
+) 319.9811; 
found 319.9809.  
Analytical data for 227: 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 1.6 Hz), 7.44 
(dd, J = 8.4, 2.0 Hz, 1H), 7.23 (dd, J = 17.2, 10.8 Hz, 1H), 6.76 (dd, J = 17.6, 10.8 Hz, 1H), 5.92 (d, J = 
17.6 Hz, 1H), 5.75 (dd, J = 17.2, 0.8 Hz, 1H), 5.51 (dd, J = 11.2, 0.8 Hz, 1H), 5.49 (dd, J = 11.2, 0.8 Hz, 
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1H); 13C NMR (150 MHz, CDCl3) δ 146.6, 142.4, 134.9, 134.1, 132.9, 126.5, 125.5, 125.1, 118.9, 118.2; 
IR (ATR) 1600, 1575, 1509, 1337, 914, 835 cm-1; HRMS (ESI) calculated for C10H10NO2 (M+H
+) 
176.0711, found 176.0709.  
 
3-Ethenyl-4-nitrophenyl trifluoromethanesulfonate (226), 2,4-diethenyl-nitrobenzene (227), and 2-
bromo-4-ethenyl-nitrobenzene (228). Cross coupling of 214 (75.2 mg, 0.22 mmol) with 
ethenyltributyltin (85.5 mg, 0.27 mmol) in the presence of LiCl (28.1 mg, 0.66 mmol) and Pd(PPh3)2Cl2 
(3.6 mg, 0.005 mmol) in DMF (1 mL) was performed as described for 207 under Conditions B. Work up 
and chromatography (hexanes/EtOAc, 97:3) gave, in order of elution, 227 (5.5 mg, 0.03 mmol, 15%) 
followed by a mixture of 228 and 226 (23.8 mg, calculated from 1H NMR spectrum: 18.0 mg of 228, 37% 
, 5.8 mg of 226, 9%) as a yellow oil. Spectral data for 228 from the mixture: 1H NMR (600 MHz, CDCl3) 
δ 7.86 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 1.8 Hz, 1H), 7.45 (dd, J = 8.4, 1.2 Hz, 1H), 6.68 (dd, J = 17.4, 10.8 
Hz, 1H), 5.90, (d, J = 17.4 Hz, 1H), 5.52 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 142.9, 
136.4, 133.7, 132.6, 126.1, 125.5, 119.3, 115.1; IR (ATR) 3095, 1573, 1526, 1346, 1217, 1139 cm-1; 
HRMS (ESI) calcd for C8H6NNaO2Br (M+Na
+) 249.9474; found  
 
4-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (229) and 2,5-diethenyl-nitrobenzene (230).185  
Cross coupling of 215 (110 mg, 0.32 mmol) with ethenyltributyltin (134 mg, 0.42 mmol) in the presence 
of in the presence of PPh3 (6.9 mg, 0.03 mmol) and Pd(dba)2 (3.6 mg, 0.006 mmol) in dioxane (1.5 mL) 
was performed as described for 206 under Conditions A. Work up and chromatography (hexanes/EtOAc, 
97:3) gave, in order of elution, 230 (1.2 mg, 0.0068 mmol, 2%) and 229 (63.3 mg, 0.21 mmol, 68%) as 
colorless oils. Spectral data for 230 were in accordance with literature values. Analytical data for 229: 1H 
NMR (600 MHz, CDCl3) δ 7.90 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.53 (dd, J = 8.4, 2.4 Hz, 
1H), 7.18 (dd, J = 17.4, 11.4 Hz, 1H), 5.79 (d, J = 17.4 Hz, 1H), 5.60 (d, J = 11.4 Hz, 1H); 13C NMR (150 
MHz, CDCl3) δ 148.0, 147.7, 133.8, 131.1, 130.5, 126.2, 121.0, 118.6 (q, J
C-F = 319 Hz), 118.0; IR (ATR) 
3110, 1533, 1426, 1351, 1208, 1133 cm-1; HRMS (ESI) calcd for C9H6NNaO5F3S (M+Na
+) 319.9811; 
found 319.9810.  
 
4-Ethenyl-3-nitrophenyl trifluoromethanesulfonate (229), 2,5-diethenyl-nitrobenzene (230), and 2-
bromo-5-ethenyl-nitrobenzene (231).186 Cross coupling of 215 (120 mg, 0.34 mmol) with 
ethenyltributyltin (135 mg, 0.43 mmol) in the presence of LiCl (48.2 mg, 1.13 mmol) and Pd(PPh3)2Cl2 
(4.8 mg, 0.007 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 97:3) gave, in order of elution, 230 (1.7 mg, 0.0097 mmol, 3%), 
231 (27.8 mg, 0.12 mmol, 36%) as a colorless oil and a mixture of 229 and 215 (42 mg, calculated from 
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1H NMR spectrum: 229 22 mg, 23% and 215 20 mg, 17%). Spectral data for 231 were in accordance with 
literature values.  
 
3-Ethenyl-2-nitrophenyl trifluoromethanesulfonate (232), 2-bromo-6-ethenyl-nitrobenzene (233), 
and 2,6-diethenyl-nitrobenzene (234).  Cross coupling of 216 (104 mg, 0.30 mmol) with 
ethenyltributyltin (121 mg, 0.38 mmol) in the presence of in the presence of PPh3 (6.7 mg, 0.03 mmol) 
and Pd(dba)2 (3.7 mg, 0.006 mmol) in dioxane (1.5 mL) was performed as described for 206 under 
Conditions A. Work up and chromatography (hexanes/EtOAc, 97:3) gave, in order of elution, 234 (16.0 
mg, 0.09 mmol, 30%) a colorless oil, 233 (2.3 mg, 0.01 mmol, 3%) and 232 (52.9 mg, 0.18 mmol, 60%) 
as faint yellow solids.  
Analytical data for 232: mp = 38-39 oC; 1H NMR (400 MHZ, CDCl3) δ 7.67 (d, J = 8.0, 0.8 Hz, 1H), 7.57 
(t, J = 8.4 Hz, 1H), 7.40 (dd, J = 8.4, 1.2 Hz, 1H), 6.68 (dd, J = 17.6, 11.2 Hz, 1H), 5.91 (d, J = 17.2 Hz, 
1H), 5.61 (d, J = 11.2 Hz, 1H); 13C NMR (150 MHZ, CDCl3) δ 142.0, 140.2, 133.1, 131.6, 128.5, 126.4, 
121.9, 121.4, 118.4 (q, JC-F = 319 Hz);IR (ATR) 3090, 1533, 1427, 1361, 1211, 1138 cm-1; HRMS (ESI) 
calcd for C9H6NNaO5F3S (M+Na
+) 319.9811; found 319.9809.  
Analytical data for 233: mp = 42-44 oC; 1H NMR (600 MHz, CDCl3) δ 7.57 (t, J = 7.2 Hz, 2H), 7.32 (t, J 
= 8.4 Hz, 1H), 6.57 (dd, J = 17.4, 11.4 Hz, 1H), 5.85 (d, J = 17.4 Hz, 1H), 5.51 (d, J = 10.8 Hz, 1H); 13C 
NMR (150 MHz, CDCl3) δ 150.1, 132.6, 131.6, 130.9, 129.0, 125.5, 120.8, 112.9; IR (ATR) 3077, 1557, 
1521, 1460, 1365, 1187 cm1. HRMS (ESI) calcd for C8H6NNaO2Br (M+Na
+) 251.9454; found 251.9454. 
Analytical data for 234: 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.0 Hz, 2H), 7.43 (t, J = 7.2 Hz, 1H), 
6.59 (dd, J = 17.2, 10.8 Hz, 2H), 5.82 (d, J = 17.6 Hz, 2H), 5.47 (d, J = 11.2 Hz, 2H); 13C NMR (150 
MHz, CDCl3) δ 148.6, 130.2, 129.8, 129.6, 125.8, 119.6; IR (ATR) 1513, 1365, 926, 850, 809, 731 cm
-1; 
HRMS (ESI) calcd for C10H10NO2 (M+H
+) 176.0711; found 176.0709. 
 
2-Bromo-6-ethenyl-nitrobenzene (233). Cross coupling of 216 (119 mg, 0.34 mmol) with 
ethenyltributyltin (138 mg, 0.44 mmol) in the presence of LiCl (45.6 mg, 1.08 mmol) and Pd(PPh3)2Cl2 
(5.0 mg, 0.007 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 97:3) gave 233 (47.1 mg, 0.21 mmol, 61%) as an off-white 
solid.  
 
3-Ethenyl-2-nitrophenyl trifluoromethanesulfonate (232), 2-bromo-6-ethenyl-nitrobenzene (233), 
and 2,6-diethenyl-nitrobenzene (234). Cross coupling of 216 (105 mg, 0.300 mmol) with 
ethenyltributyltin (140 mg, 0.442 mmol) in the presence of Pd(PPh3)2Cl2 (4.2 mg, 0.006 mmol) in 1,4-
dioxane (1 mL) was performed as described in Conditions C (100 oC, 27 h).  Work up and purification 
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gave after chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 19:1), in order of elution, 234 
(11.9 mg, 0.068 mmol, 23%) a colorless oil, 233 (0.9 mg, 0.004 mmol, 1%) and 232 (60.6 mg, 0.204 
mmol, 68%). 
 
6-Ethenyl-2-nitrophenyl trifluoromethanesulfonate (235). Cross coupling of 217 (135 mg, 0.39 mmol) 
with ethenyltributyltin (129 mg, 0.41 mmol) in the presence of in the presence of PPh3 (8.2 mg, 0.03 
mmol) and Pd(dba)2 (4.5 mg, 0.008 mmol) in dioxane (2 mL) was performed as described for 206 under 
Conditions A. Work up and chromatography (hexanes/EtOAc, 97:3) to afford in order of elution, 236 and 
225 (8.5 mg, 1:1 mixture), 2-bromo-6-nitrophenol183 (22.7 mg mixed with dba), and a mixture of 217 and 
235 (95.1 mg). The latter fraction was repurified by chromatograhy (hexanes/EtOAc, 97:3) to give in 
order of elution, 235 as a colorless oil (27.8 mg, 0.09 mmol, 24%) and 217 (12.3 mg, 0.04 mmol, 9%). 
Analytical data for 235: 1H NMR (600 MHz, CDCl3) δ 7.98 (dd, J = 8.4, 1.8 Hz, 1H), 7.90 (dd, J = 7.8, 
1.8 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 6.99 (dd, J = 18.0, 11.4 Hz, 1H), 5.95 (d, J = 18.0 Hz, 1H), 5.67 (d, 
J = 11.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 143.1, 137.9, 134.4, 132.0, 128.5, 128.0, 125.5, 121.4, 
118.3 (q, JC-F = 319 Hz); IR (ATR) 3103, 1539, 1429, 1351, 1210, 1131 cm-1; HRMS (ESI) calcd for 
C9H6NNaO5F3S (M+Na
+) 319.9811; found 319.9808.  
 
3-Bromo-2-ethenyl-nitrobenzene (236).187 Cross coupling of 217 (99.8 mg, 0.29 mmol) with 
ethenyltributyltin (97.5 mg, 0.31 mmol) in the presence of LiCl (36.6 mg, 0.86 mmol) and Pd(PPh3)2Cl2 
(4.1 mg, 0.006 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 9:1) gave, in order of elution, 236 as a yellow oil (28.3 mg, 0.12 
mmol, 43%), 2-bromo-6-nitrophenol (7.4 mg, 0.03 mmol, 12%), and 217 (5.0 mg, 0.01 mmol, 5%). 
Spectral data for 236 were in accordance with literature values.  
 
 3-Ethenyl-6-nitrophenyl trifluoromethanesulfonate (235), 3-bromo-6-ethenylnitrobenzene (236), 
and 2,3-diethenyl-nitrobenzene (225).  Cross coupling of 217 (117 mg, 0.334 mmol) with 
ethenyltributyltin (159 mg, 0.501 mmol) in the presence of Pd(PPh3)2Cl2 (5.1 mg, 0.007 mmol) in 1,4-
dioxane (1 mL) was performed as described in Conditions C (100 oC, 24 h).  Work up and purification 
gave after chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 97:3), in order of elution, a 
mixture of 236 and 225 (16.1 mg, 1:2 mixture, 8% and 4%, respectively) and 235 (65.3 mg, 0.220 mmol, 
66%). 
 
2-Ethenyl-4-nitrophenyl trifluoromethanesulfonate (237). Cross coupling of 2-bromo-4-nitrophenyl 
trifluoromethanesulfonate (218)164 (102 mg, 0.29 mmol) with ethenyltributyltin (116 mg, 0.37 mmol) in 
164 
 
the presence of in the presence of PPh3 (6.5 mg, 0.03 mmol) and Pd(dba)2 (4.1 mg, 0.007 mmol) in 
dioxane (1.5 mL) was performed as described for 206 under Conditions A. Work up and chromatography 
(hexanes/EtOAc, 8:2) gave, in order of elution, a mixture of 218 and 237 (45.1 mg) followed by 2-bromo-
4-nitrophenol176 (5.2 mg, 0.02 mmol, 7%). The mixture was repurified by chromatographed 
(hexanes/EtOAc, 97:3) to afford, in order of elution, 237 (19.3 mg, 0.06 mmol, 22%) as a light pink oil 
and 218 (7.0 mg, 0.02 mmol, 7%). Analytical data for 237: 1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 2.8 
Hz, 1H), 8.20 (dd, J = 9.2, 2.8 Hz, 1H), 7.48 (d, J = 9.2 Hz, 1H), 6.94 (dd, J = 17.6, 11.2 Hz, 1H), 6.04 (d, 
J = 17.6 Hz, 1H), 5.70 (d, J = 11.2 Hz, 1H); 13C (100 MHz, CDCl3) δ 149.9, 147.2, 132.7, 127.2, 124.0, 
122.9, 122.6, 121.7, 118.5 (q, JC-F = 319 Hz); IR (ATR) 3107, 1536, 1424, 1347, 1209, 1134 cm -1; 
HRMS (ESI) calcd for C9H6NNaO5F3S (M+Na
+) 319.9811; found 319.9809.  
 
3-Bromo-4-ethenyl-nitrobenzene (238). Cross coupling of 218 (110 mg, 0.32 mmol) with 
ethenyltributyltin (138 mg, 0.43 mmol) in the presence of LiCl (42.6 mg, 1.0 mmol) and Pd(PPh3)2Cl2 
(4.5 mg, 0.006 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 85:15) to give a mixture of 218 and 238. The mixture was 
repurified by chromatography (hexanes/EtOAc, 97:3) to afford in order of elution, 238 (40.7 mg, 0.18 
mmol, 57%) as a yellow oil, 218 (8.7 mg, 0.02 mmol, 8%), and 3-bromo-4-nitrophenol (11.1 mg, 0.05 
mmol, 16%). Analytical data for 238: 1H NMR (600 MHz, CDCl3) δ 8.43 (d, J = 2.4 Hz, 1H), 8.14 (ddd, J 
= 8.4, 2.4, 0.6 Hz, 1H), 7.69 (d, J =9.0 Hz, 1H), 7.08 (dd, J =17.4, 10.8 Hz, 1H), 5.88 (d, J = 17.4 Hz, 
1H), 5.60 (dd, J = 10.8, 0.6 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 147.2, 143.7, 134.3, 128.2, 127.0, 
123.3, 122.4, 120.8; IR (ATR) 3099, 1520, 1342, 1116, 1035 cm -1; HRMS (ESI) calcd for C8H6NNaO2Br 
(M+Na+) 249.9479; found 249.9478.  
 
2-Ethenyl-4-nitrophenyl trifluoromethanesulfonate (237).  Cross coupling of 218 (89.1 mg, 0.255 
mmol) with ethenyltributyltin (105 mg, 0.331 mmol) in the presence of Pd(PPh3)2Cl2 (3.6 mg, 0.005 
mmol) in 1,4-dioxane (0.8 mL) was performed as described for 206 as described under Conditions C (100 
oC, 24 h).  Work up and purification gave after chromatography on SiO2/K2CO3 (10% K2CO3, 
hexanes/EtOAc, 98:2) gave 237 (71.4 mg, 0.240 mmol, 94%). 
 
3-Ethenyl-4-nitrophenyl trifluoromethanesulfonate (239). Cross coupling of 219 (106 mg, 0.30 mmol) 
with ethenyltributyltin (130 mg, 0.41 mmol) in the presence of in the presence of (6.4 mg, 0.02 mmol) 
and Pd(dba)2 (3.4 mg, 0.006 mmol) in dioxane (1.5 mL) was performed as described for 206 under 
Conditions A. Work up and chromatography (hexanes/EtOAc, 97:3) gave, in order of elution, 219 (4.1 
mg, 0.01 mmol, 4%) and 239 (70.0 mg, 0.24 mmol, 78%) as a colorless oil. Analytical data for 239: 1H 
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NMR (400 MHz, CDCl3) δ 8.30 (t, J = 1.6 Hz, 1H), 8.02 (t, J = 2.4 Hz, 1H), 7.60 (t, J = 2.0 Hz, 1H), 6.77 
(dd, J = 17.2, 10.8 Hz, 1H), 5.98 (d, J = 17.6 Hz, 1H), 5.60 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, 
CDCl3) δ 149.4, 149.2, 141.7, 133.2, 124.6, 120.6, 119.8, 118.6 (q, J
C-F = 319 Hz), 115.6; IR (ATR) 3103, 
1540, 1425, 1348, 1213, 1132 cm -1; HRMS (ESI) calcd for C9H7NO5F3S (M+H
+) 297.9997; found 
297.9997.  
 
3-Bromo-5-ethenyl-nitrobenzene (240). Cross coupling of 219 (109 mg, 0.31 mmol) with 
ethenyltributyltin (139 mg, 0.44 mmol) in the presence of LiCl (45.0 mg, 1.1 mmol) and Pd(PPh3)2Cl2 
(4.7 mg, 0.007 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 97:3) gave 240 (47.1 mg, 0.21 mmol, 66%) as an off-white 
solid. Analytical data for 240: mp = 37-39 oC; 1H NMR (600 MHz, CDCl3) δ 8.23 (t, J = 1.8 Hz, 1H), 
8.16 (t, J = 1.8 Hz, 1H), 7.82 (t, J = 1.8 Hz, 1H), 6.70 (dd, J = 17.4, 10.8 Hz, 1H), 5.90 (d, J = 18.0 Hz, 
1H), 5.50 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 149.0, 140.8, 134.8, 133.6, 125.3, 122.9, 
119.6, 118.5; IR (ATR) 3079, 1531, 1339, 1301, 1214 cm1; HRMS (ESI) calcd for C8H6NNaO2Br 
(M+Na+) 251.9454; found 251.9452. 
 
3-Ethenyl-5-nitrophenyl trifluoromethanesulfonate (239).  Cross coupling of 219 (104 mg, 0.296 
mmol) with ethenyltributyltin (122 mg, 0.385 mmol) in the presence of Pd(PPh3)2Cl2 (4.3 mg, 0.006 
mmol) in 1,4-dioxane (1 mL) was performed as described for 206 as described under Conditions C (100 
oC, 24 h).  Work up and purification gave after chromatography on SiO2/K2CO3 (10% K2CO3, 
hexanes/EtOAc, 98:2) gave 239 (78.5 mg, 0.264 mmol, 89%). 
 
4-Ethenyl-2-nitrophenyl trifluoromethanesulfonate (241). Cross coupling of 220 (103 mg, 0.29 mmol) 
with ethenyltributyltin (112 mg, 0.35 mmol) in the presence of in the presence of (6.8 mg, 0.03 mmol) 
and Pd(dba)2 (3.4 mg, 0.006 mmol) in dioxane (1.5 mL) was performed as described for 206 under 
Conditions A. Work up and chromatography (hexanes/EtOAc, 9:1) gave, in order of elution, a mixture of 
220 and 5-bromo-2-nitrophenol (11.3 mg) followed by 241 as a yellow oil mixed with 
dibenzylideneacetone (34.6 mg, 0.12 mmol, 41% of 241, calculated from 1H NMR spectrum).  
 
5-Bromo-2-ethenyl-nitrobenzene (242). Cross coupling of 220 (111 mg, 0.32 mmol) with 
ethenyltributyltin (131 mg, 0.41 mmol) in the presence of LiCl (44.5 mg, 0.86 mmol) and Pd(PPh3)2Cl2 
(4.2 mg, 0.006 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 9:1) gave 242 as a yellow solid (56.3 mg, 0.25 mmol, 78%). 
Analytical data for 242: mp = 40-41oC; 1H NMR (600 MHz, CDCl3) δ 8.43 (d, J = 2.4 Hz, 1H), 8.14 (ddd, 
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J = 8.4, 2.4, 0.6 Hz, 1H), 7.69 (d, J = 9.0 Hz, 1H), 7.08 (dd, J = 17.4, 10.8 Hz, 1H), 5.88 (d, J = 17.4 Hz, 
1H), 5.60 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 148.0,136..1, 132.2, 131.5, 129.7, 127.3, 
121.4, 119.7; IR (ATR) 3097, 1552, 1514, 1341, 1149 cm -1; HRMS (ESI) calcd for C8H6NNaO2Br 
(M+Na+) 251.9454; found 251.9455. 
 
             4-Ethenyl-2-nitrophenyl trifluoromethanesulfonate (241).  Cross coupling of 220 (122 mg, 0.348 
mmol) with ethenyltributyltin (162 mg, 0.511 mmol) in the presence of Pd(PPh3)2Cl2 (4.9 mg, 0.007 
mmol) in 1,4-dioxane (2.5 mL) was performed as described for 206 as described under Conditions C (100 
oC, 26 h).  Work up and purification gave after chromatography on SiO2/K2CO3 (10% K2CO3, 
hexanes/EtOAc, 98:2) gave 241 (54.5 mg, 0.311 mmol, 89%). Analytical data for 241: 1H NMR (600 
MHz, CDCl3) δ d, J=2.4 Hz, 1H), 7.72 (dd, J=8.4, 1.8 Hz, 1H), 7.41 (d, J=9.0 Hz, 1H), 6.74 (dd, J=17.4, 
10.8 Hz, 1H), 5.92 (d, J=17.4 Hz, 1H), 5.55 (d, J=10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 141.6, 
140.2, 139.2, 133.1, 132.2, 124.3, 123.8, 119.1, 118.5 (q, JC-F = 319 Hz), IR (ATR) 3117, 1581, 1519, 
1431, 1343, 1207 cm-1; HRMS (ESI) calculated for C9H7F3NO5S (M+H
+) 297.9997, found 297.9994.  
 
3-Ethenyl-6-nitrophenyl trifluoromethanesulfonate (243). Cross coupling of 3-bromo-6-nitrophenyl 
trifluoromethanesulfonate (221) (100 mg, 0.29 mmol) with ethenyltributyltin (95.1 mg, 0.30 mmol) in the 
presence of in the presence of (6.0 mg, 0.02 mmol) and Pd(dba)2 (3.3 mg, 0.006 mmol) in dioxane (1.5 
mL) was performed as described for 206 under Conditions A. Work up and chromatography 
(hexanes/EtOAc, 97:3) gave, in order of elution, a mixture of 221 and dba (17.2 mg) followed by 243 
(34.6 mg, 0.12 mmol, 41%) as a yellow oil. Analytical data for 243: 1H NMR (600 MHz, CDCl3) δ 8.15 
(d, J = 8.4 Hz, 1H), 7.55 (dd, J = 9.0, 1.8 Hz, 1H), 7.41 (d, J = 1.2 Hz, 1H), 6.75 (dd, J = 17.4, 10.8 Hz, 
1H), 5.97 (d, J = 17.4 Hz, 1H), 5.63 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 145.3, 141.9, 
139.9, 133.3, 127.1, 126.3, 121.7, 120.9, 118.5 (q, JC-F = 318 Hz); IR (ATR) 3114, 1587, 1529, 1429, 
1341, 1209 cm-1; HRMS (ESI) calcd for C9H7NO5F3S (M+H
+) 297.9997; found 297.9995.  
 
3-Ethenyl-6-nitrophenyl trifluoromethanesulfonate (243) and 4-Bromo-2-ethenyl-nitrobenzene 
(244).188 Cross coupling of 221 (99.5 mg, 0.29 mmol) with ethenyltributyltin (98.1 mg, 0.31 mmol) in the 
presence of LiCl (37.0 mg, 0.87 mmol) and Pd(PPh3)2Cl2 (4.0 mg, 0.006 mmol) in DMF (1.5 mL) was 
performed as described for 207 under Conditions B. Work up and chromatography (hexanes/EtOAc, 9:1) 
gave, in order of elution, 244 (11.0 mg, 0.05 mmol, 17%) as an off-white solid, 221 (22.9 mg, 0.07 mmol, 
22%) and 243 (19.4 mg, 0.07 mmol, 23%). Spectral data for 244 were in accordance with literature 
values.  
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3-Ethenyl-6-nitrophenyl trifluoromethanesulfonate (243) Cross coupling of 221 (96.8 mg, 0.277 
mmol) with ethenyltributyltin (114 mg, 0.360 mmol) in the presence of Pd(PPh3)2Cl2 (4.0 mg, 0.006 
mmol) in 1,4-dioxane (0.7 mL) was performed as described for 206 as described under Conditions C (100 
oC, 24 h).  Work up and purification by chromatography on SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 
19:1) gave, in order of elution, a 6:1 mixture of 227 and 244 (5.1 mg, 0.024 mmol, 9% of 227 and 0.9 mg, 
0.004 mmol, 14% of 244, calculated from 1H NMR spectrum) and 243 (60.9 mg, 0.205 mmol, 74%). 
 
2-Ethenyl-5-nitrophenyl trifluoromethanesulfonate (245). Cross coupling of 222 (74.7 mg, 0.21 
mmol) with ethenyltributyltin (83.2 mg, 0.26 mmol) in the presence of in the presence of PPh3 (5.0 mg, 
0.02 mmol) and Pd(dba)2 (2.7 mg, 0.005 mmol) in dioxane (1.5 mL) was performed as described for 206 
under Conditions A. Work up and chromatography (hexanes/EtOAc, 97:3) gave, in order of elution, 222 
(14.8 mg, 0.04 mmol, 20%) and 245 (30.2 mg, 0.10 mmol, 48%) as a yellow oil. Analytical data for 245: 
1H NMR (600 MHz, CDCl3) δ 8.24 (dd, J = 8.4, 2.4 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 7.83 (d, J = 8.4 Hz, 
1H), 6.97 (dd, J = 17.4, 11.4 Hz, 1H), 6.05 (d, J = 17.4 Hz, 1H), 5.75 (d, J = 10.8 Hz, 1H); 13C NMR (150 
MHz, CDCl3) δ 147.4, 145.9, 137.5, 127.8, 127.5, 123.2, 122.9, 118.5 (q, J
C-F = 319 Hz), 117.7; IR (ATR) 
3118, 1528, 1425, 1346, 1210, 1132 cm-1; HRMS (ESI) calcd for C9H7NO5F3S (M+H
+) 297.9997; found 
297.9994.  
 
2-Ethenyl-5-nitrophenyl trifluoromethanesulfonate (245) and 4-bromo-3-ethenyl-nitrobenzene 
(246). Cross coupling of 222 (85.9 mg, 0.25 mmol) with ethenyltributyltin (98.2 mg, 0.31 mmol) in the 
presence of LiCl (32.2 mg, 0.76 mmol) and Pd(PPh3)2Cl2 (3.6 mg, 0.005 mmol) in DMF (1.5 mL) was 
performed as described for 207 under Conditions B. Work up and chromatography (hexanes/EtOAc, 
97:3) gave, in order of elution, 246 (3.8 mg, 0.02 mmol, 7%) as an off-white solid, 222 (27.0 mg, 0.08 
mmol, 31%) and 245 (22.4 mg, 0.08 mmol, 31%). Analytical data for 246: mp = 38-40 oC; 1H NMR (400 
MHz, CDCl3) δ 8.38 (d, J = 2.8 Hz, 1H), 7.96 (dd, J = 8.8, 2.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.05 (dd, 
J = 17.2, 10.8 Hz, 1H), 5.88 (d, J = 17.2 Hz, 1H), 5.56 (d, J = 10.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 147.4, 139.0, 134.1, 133.9, 130.3, 123.1, 121.5, 119.7; IR (ATR) 3099, 2926, 1525, 1341, 1030 cm1; 
HRMS (ESI) calcd for C8H6NNaO2Br (M+Na
+) 251.9454; found 251.9452.  
 
2-Ethenyl-5-nitrophenyl trifluoromethanesulfonate (245) A solution of 222 (162 mg, 0.463 mmol) in 
dioxane (2 mL) was treated with ethenyltributyltin (191 mg, 0.602 mmol) in the presence of PdCl2(PPh3)2 
(13.0 mg, 0.019 mmol), was performed as described for 206 as described under Conditions C (100 oC, 24 
h).  Work up and purification, gave after chromatography SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 
19:1) 245 (122 mg, 0.412 mmol, 89%) as a pale yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.24 (dd, J = 
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8.4, 2.4 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 6.97 (dd, J = 17.4, 11.4 Hz, 1H), 6.05 
(d, J = 17.4 Hz, 1H), 5.75 (d, J = 10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 147.4, 145.9, 137.5, 
127.8, 127.5, 123.2, 122.9,118.5 (q, JC-F = 319 Hz), 117.7; IR (ATR) 1526, 1425, 1345, 1209, 1134, 944, 
836 cm-1; HRMS (ESI) calcd for C9H6NNaO5F3S (M+Na
+) 319.9811; found 319.9812. 
 
3-Ethenyl-6-trifluoromethanesulfonate-nitrobenzene (241), 3-Ethenyl-6-hydroxy-1-nitrobenzene 
(248), and 2,5-Diethenyl-1-nitrobenzene (230). Cross coupling of 4-iodo-6-nitrophenyl 
trifluoromethanesulfonate (247)189 (102 mg, 0.26 mmol) with ethenyltributyltin (106 mg, 0.33 mmol) in 
the presence of in the presence of PPh3 (5.8 mg, 0.02 mmol) and Pd(dba)2 (3.5 mg, 0.006 mmol) in 
dioxane (1.5 mL) was performed as described for 206 under Conditions A. Work up and chromatography 
(hexanes/EtOAc, 97:3) gave, in order of elution, a mixture of 248 and 230 (8.2 mg; 5.8 mg, 0.035 mmol, 
14% of 248 and 2.4 mg, 0.014 mmol, 5% of 230, calculated from 1H NMR spectrum) followed by 241 
(29.5 mg, 0.099 mmol, 38%) as a yellow oil.  
 
3-Ethenyl-6-trifluoromethanesulfonate-nitrobenzene (241), 3-Iodo-6-ethenyl-nitrobenzene (249) 
and 5-Iodo-2-hydroxynitrobenzene. Cross coupling of 247 (116 mg, 0.29 mmol) with ethenyltributyltin 
(120 mg, 0.38 mmol) in the presence of LiCl (39.7 mg, 0.94 mmol) and Pd(PPh3)2Cl2 (4.1 mg, 0.006 
mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work up and 
chromatography (hexanes/EtOAc, 97:3) gave in order of elution, 249 (3.2 mg, 0.01 mmol, 4%) as a 
brown oil, 5-iodo-2-hydroxynitrobenzene (8.7 mg, 0.03 mmol, 14%), and a mixture of 241 and 247 (67.1 
mg; 43.7 mg, 0.147 mmol, 50% of 241 and 23.3 mg, 0.059 mmol, 20% of 247, calculated from 1H NMR 
spectrum). Analytical data for 249: 1H NMR (600 MHz, CDCl3) δ 8.25 (d, J = 1.8 Hz, 1H), 7.89 (dd, J = 
7.8, 1.8 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.09 (dd, J = 17.4, 11.4 Hz, 1H), 5.76 (d, J = 167.4 Hz, 1H), 
5.52 (d, J = 11.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 148.0, 141.9, 133.0, 132.8, 131.6, 129.8, 119.7, 
91.8; IR (ATR) 3094, 2925, 1519, 1341, 1261, 1086 cm-1; HRMS (ESI) calcd for C8H6NNaO2I (M+Na
+) 
297.9335; found 297.9333.  
 
3-Ethenyl-6-trifluoromethanesulfonate-nitrobenzene (241) and 2,5-Diethenyl-1-nitrobenzene (230). 
Cross coupling of 247 (205 mg, 0.517 mmol) with ethenyltributyltin (213 mg, 0.671 mmol) in the 
presence of PdCl2(PPh3)2 (7.3 mg, 0.010 mmol) in dioxane (2 mL) was performed as described for 206 
under Conditions C (100 oC, 24 h).  Work up and purification gave after chromatography SiO2/K2CO3 
(10% K2CO3, hexanes/EtOAc, 19:1), in order of elution, 230 (10.0 mg, 0.057 mmol, 8%) and 241 (133 
mg, 0.449 mmol, 87%) as faint yellow oil. 
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3-Bromo-6-trifluoromethanesulfonate acetophenone (253).190 To a solution of 1-hydroxy-5-
bromoacetophenone182 (381 mg, 1.77 mmol) in CH2Cl2 (10 mL) at 0 
oC was added pyridine (275 µL, 3.41 
mmol) and Tf2O (325 µL, 1.92 mmol). The mixture was removed from the cold bath and allowed to stir at 
ambient temperature for 1 h. The resulting mixture was filtered through a small plug of silica gel and the 
solvent was removed under reduced pressure from the filtrate to give 253 (590 mg, 1.70 mmol, 96%) as a 
pale orange oil. The compound was used as such without further purification.  1H NMR (400 MHz, 
CDCl3) δ 7.90 (d, J = 2.8 Hz, 1H), 7.70 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 2.62 (s, 
3H); 13C NMR NMR (100 MHz, CDCl3) δ 195.1, 145.5, 136.4, 133.5, 133.4, 124.3, 122.0, 118.4 (d, J
C-F 
=213 Hz) 29.2; IR (ATR) 1701, 1424, 1202, 1133, 879, 796 cm-1; HRMS (ESI) calcd for C9H7BrO4F3S 
(M+H+) 348.9175; found 348.9177. 
 
3-Ethenyl-6-trifluoromethanesulfonate acetophenone (254). Cross coupling of 253 (101 mg, 0.29 
mmol) with ethenyltributyltin (116 mg, 0.37 mmol) in the presence of in the presence of PPh3 (6.4 mg, 
0.02 mmol) and Pd(dba)2 (3.8 mg, 0.007 mmol) in dioxane (1.5 mL) was performed as described for 206 
under Conditions A. Work up and chromatography (hexanes/EtOAc, 9:1) gave 254 (11.6 mg, 0.04 mmol, 
14%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ 7.78 (d, J = 2.4 Hz, 1H), 7.60 (dd, J = 8.4, 2.4 Hz, 
1H), 7.30 (d, J = 9.0 Hz, 1H), 6.73 (dd, J = 17.4, 10.8 Hz, 1H), 5.83 (d, J = 17.4 Hz, 1H), 5.44 (d, J = 
10.8 Hz, 1H), 2.65 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 196.5, 145.8, 138.1, 134.2, 132.2, 130.7, 
128.3, 122.8, 118.5 (q, JC-F = 319 Hz), 117.2, 29.4; IR (ATR) 3096, 1698, 1421, 1202, 1134 cm -1; HRMS 
(ESI) calcd for C11H10F3O4S (M+H
+) 295.0252; found 295.0249.  
 
6-Ethenyl-3-bromoacetophenone (255). Cross coupling of 253 (112 mg, 0.32 mmol) with 
ethenyltributyltin (129 mg, 0.41 mmol) in the presence of LiCl (43.5 mg, 1.03 mmol) and Pd(PPh3)2Cl2 
(4.8 mg, 0.007 mmol) in DMF (1.5 mL) was performed as described for 207 under Conditions B. Work 
up and chromatography (hexanes/EtOAc, 8:2) gave 255 (42.6 mg, 0.19 mmol, 58%) as a colorless oil. 1H 
NMR (600 MHz, CDCl3) δ 7.72 (d, J = 1.8 Hz, 1H), 7.56 (dd, J = 8.4, 2.4 Hz, 1H), 7.42 (d, J = 8.4 Hz, 
1H), 7.09 (dd, J = 17.4, 10.8 Hz, 1H), 5.63 (dd, J = 17.4, 1.2 Hz, 1H), 5.37 (dd, J = 11.4, 1.2 Hz, 1H), 
2.56 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 200.5, 138.9, 136.3, 134.7, 134.4, 131.3, 129.1, 121.1, 117.4, 
29.8; IR (ATR) 3088, 1686, 1472, 1355, 1235, 830 cm-1; HRMS (ESI) calcd for C10H10BrO (M+H
+) 
224.9915; found 224.9914.  
 
3-Ethenyl-6-trifluoromethanesulfonate acetophenone (254). Cross coupling of 253 (70.2 mg, 0.202 
mmol) with ethenyltributyltin (83.4 mg, 0.263 mmol) in the presence of PdCl2(PPh3)2 (3.0 mg, 0.004 
mmol) in dioxane (0.6 mL) was performed as described for 206 under Conditions C (100 oC, 24 h).  Work 
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up and purification gave after chromatography SiO2/K2CO3 (10% K2CO3, hexanes/EtOAc, 19:1) 254 
(33.8 mg, 0.115 mmol, 57%). 
 
3-Ethenyl-4-trifluoromethanesulfonate-1-methoxybenzene (251). Cross coupling of 3-bromo-4-
trifluoromethanesulfonate-1-methoxybenzene (250)191 (106 mg, 0.32 mmol) with ethenyltributyltin (126 
mg, 0.40 mmol) in the presence of in the presence of PPh3 (7.0 mg, 0.03 mmol) and Pd(dba)2 (3.7 mg, 
0.006 mmol) in dioxane (1.5 mL) was performed as described for 206 under Conditions A. Work up and 
chromatography (hexanes/EtOAc, 9:1) gave 251 (29.6 mg, 0.10 mmol, 33%) as a colorless oil. 1H NMR δ 
7.18 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 3.0 Hz, 1H), 6.89 (dd, J = 17.4, 11.4 Hz, 1H), 6.84 (dd, J = 9.0, 3.0 
Hz, 1H), 5.83 (d, J = 18.0 Hz, 1H), 5.49 (d, J = 11.4 Hz, 1H), 3.84 (s, 1H); 13C NMR δ 158.9, 140.5, 
132.1, 129.1, 122.6, 118.6, 118.3 (q, JC-F = 319 Hz), 114.5, 111.6, 55.7; IR (ATR) 2968, 1485, 1419, 
1206, 1137, 868 cm -1; HRMS (ESI) calcd for C10H8F3O4S (M-H) 281.0095; found 281.0100.  
 
3-Ethenyl-4-trifluoromethanesulfonate-1-methoxybenzene (251) and 3-Bromo-4-ethenylanisole 
(252).192 Cross coupling of 250 (103 mg, 0.31 mmol) with ethenyltributyltin (119 mg, 0.38 mmol) in the 
presence of LiCl (38.9 mg, 0.92 mmol) and Pd(PPh3)2Cl2 (4.5 mg, 0.006 mmol) in DMF (2 mL) was 
performed as described for 207 under Conditions B. Work up and chromatography (hexanes/EtOAc, 9:1) 
gave, in order of elution, 251 (26.3 mg, 0.12 mmol, 39%) as a faint orange oil and 252 (3.3 mg, 0.01 
mmol, 4%). Spectral data for 252 were in accordance with literature values.  
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4-Bromo-2,3-dinitrophenol (257). To a solution of 256 (730 mg, 2.24 mmol) in THF (8 mL) and H2O 
(0.5 mL) in an ACE Glass pressure tube was added NaOH (1.04 g, 26.1 mmol). The pressure tube was 
sealed with a Teflon screw cap and the solution was heated at 80 oC (18 h). The resulting brown solution 
was diluted with H2O (25 mL), acidified with HCl, and extracted with EtOAc (3x30 mL). The combined 
organic layers were dried (MgSO4), filtered, and solvents removed from the filtrate under reduced 
pressure. The crude brown oil was purified by chromatography (hexanes/EtOAc, 7:3 with 5% AcOH) to 
afford 257 (554 mg, 2.11 mmol, 94%) as a yellow solid. mp=59-61 oC; 1H NMR (400 MHz, CDCl3) δ 
7.55 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.8 Hz, 1H); 13C NMR (150 MHz, DMSO-d6) δ 151.3, 143.8, 137.6, 
132.4, 123.1, 101.9; IR (ATR) 3391, 1566, 1535, 1456, 1374 cm-1; HRMS (ESI) calcd for 
C6H3N2O5Br (M-H+) 260.9147, found 260.9148. 
 
4-Bromo-2,3-dinitrophenyltrifluoromethanesulfonate (258) To an ice-cooled solution of 257 (1003 
mg, 3.812 mmol) in CH2Cl2 (10 mL) under a nitrogen atmosphere was added pyridine (933 µL, 11.441 
mmol) followed by addition of trifluoromethanesulfonic anhydride (Tf2O, 834 µL, 4.957 mmol) and the 
solution was stirred while warming to ambient temperature over 30 minutes. Solvents were removed 
under reduced pressure and the crude product was purified by chromatography (hexane/EtOAc, 7:3) to 
afford 258 (1229 mg, 3.111 mmol, 82%) as a colorless viscous oil. mp=59-60 oC;  1H NMR (400 MHz, 
CDCl3) δ 8.06 (d, J=9.2 Hz, 1H), 7.59 (d, J=9.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 144.9, 139.8, 
138.3, 137.4, 126.3,118.3 (q, JC-F=319 Hz), 115.1, 19F NMR (376.10 MHz, CDCl3) δ -72.6; IR (ATR) 
1547, 1436, 1350, 1222, 1130 cm-1; HRMS (ESI) calcd for C7H3BrF3N2O7S (M+H
+) 394.8796 
(M+Na=416.8616), found  
 
4-Bromo-2,5-dinitrophenol (262) and 4-bromo-2,3-dinitrophenol (257). 4-Bromo-3-nitrophenol (259) 
(5.0 g, 22.94 mmol) was added to concentrated nitric acid (130 mL) and the solution was stirred at 
ambient temperature for 1 h whereby yellow solid started separating out. The mixture was quenched with 
ice-cold water (100 mL) and allowed to cool to ambient temperature. The mixture was diluted with 
EtOAc (180 mL) and the organic layer was washed with ice-cold water (100 mLx5). The organic layer 
was dried (MgSO4), filtered and was concentrated under reduced pressure. The crude was purified by 
chromatography (Hexane/EtOAc, 95:5, then, 8:2 acidified with few drops of AcOH) to give, in order of 
elution, 262 (2.25 g, 8.56 mmol, 37%) and 257 (3.06 g, 11.62 mmol, 51%) both as a yellow solid. 
Analytica data for 262: mp=113-114 oC; 1H NMR (400 MHz, CDCl3) δ 10.50 (s, 1H), 8.49 (s, 1H), 7.58 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 154.4, 154.1, 134.8, 131.1, 117.0, 103.0; IR (ATR) 3286, 1538, 
1254 cm-1; HRMS (ESI) calculated for C6H4BrN2O5 (M+H
+) 262.9304, found    
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4-Iodo-2,5-dinitrophenol (263)218 and 4-iodo-2,3-dinitrophenol (261). 4-Iodo-3-nitrophenol (260) (5.0 
g, 18.87 mmol) was added to concentrated nitric acid (HNO3, 100 mL) and the solution was stirred at 
ambient temperature for 1 h whereby yellow solid started separating out. The mixture was quenched with 
ice-cold water (150 mL) and allowed to cool to ambient temperature. The mixture was diluted with 
EtOAc (150 mL) and the organic layer was washed with ice-cold water (100 mLx5). The organic layer 
was dried (MgSO4), filtered and was concentrated under reduced pressure. The crude was purified by 
chromatography (Hexane/DCM, 7:3, acidified with few drops of AcOH) to give, in order of elution, 263 
(1.79 g, 5.77 mmol, 31%) and 261 (2.90 g, 9.36 mmol, 50%) both as a yellow solid. Analytical data for 
261: mp=139-140 oC; 1H NMR (400 MHz, CDCl3) δ 11.25 (br, s, 1H), 7.72 (d, J=9.2 Hz, 1H), 6.98 (d, 
J=8.8 Hz, 1H); 13C NMR (100 MHz, CDCl3/DMSO-d6) δ 151.8, 147.7, 142.5, 132.5, 122.6, 72.8; IR 
(ATR) 3237, 1544, 1433, 1215, 1137 cm-1; HRMS (ESI) calcd for C6H4IN2O5 (M+H
+) 310.9165, found    
 
4-Iodo-2,3-dinitrophenyltrifluoromethanesulfonate (264). Treatment of 261 (1.923 g, 6.203 mmol) 
with Tf2O (1.40 mL, 8.32 mmol) in CH2Cl2 (20 mL) in the presence of pyridine (1.50 mL, 18.39 mmol) 
under a nitrogen atmosphere, as described for 258 (0 oC -rt, 30 mins.), gave after solvent removal and 
chromatography (Hexane/EtOAc, 7:3), 264 (2.523 g, 5.707 mmol, 92%) as a yellow solid. mp=61-62 oC;  
1H NMR (400 MHz, CDCl3) δ 8.26 (d, J=8.8 Hz, 1H), 7.42 (d, J=8.8 Hz, 1H); 
13C NMR (100 MHz, 
CDCl3) δ 148.5, 144.5, 140.7, 137.2, 126.3, 118.3 (q, J
C-F=319 Hz), 86.8; 19F NMR (376.10 MHz, CDCl3) 
δ -72.5; IR (ATR) 1546, 1435, 1349, 1213, 1131 cm-1; HRMS (ESI) calculated for C7H3F3IN2O7S 
(M+H+) 442.8658 (M+Na=464.8477), found 
  
4-Bromo-2,5-dinitrophenyltrifluoromethanesulfonate (265). Treatment of a solution of 262 (1.500 g, 
5.705 mmol) with Tf2O (1.25 mL, 7.416 mmol) in CH2Cl2 in the presence of pyridine (1.40 mL, 17.114 
mmol) under a nitrogen atmosphere, as described for 258 (0 °C-rt, 30 mins.) gave after solvent removal 
and chromatography (Hexane/EtOAc, 9:1), 265 (1.803 g, 4.564 mmol, 80%) as a white solid. mp=62-63 
°C; 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 7.94 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ 152.0, 142.8, 
140.3, 133.1, 121.7, 118.4 (q, JC-F=320 Hz), 115.1; 19F NMR (376 MHz, CDCl3) δ -72.5; IR (ATR) 1539, 
1426, 1353, 1231, 1141 cm-1; HRMS (ESI) calcd for C7H3BrF3N2O7S (M+H
+) 394.8796 
(M+Na=416.8616), found.  
 
4-Iodo-2,5-dinitrophenyltrifluoromethanesulfonate (266). Treatment of 263 (1.389 g, 4.480 mmol) 
with Tf2O (0.98 mL, 5.82 mmol) in CH2Cl2 (16 mL) in the presence of pyridine (1.10 mL, 13.44 mmol) 
under a nitrogen atmosphere, as described for 258 (0 oC -rt, 25 mins.), gave after solvent removal and 
chromatography (Hexane/EtOAc, 95:5), 266 (1.596 g, 3.610 mmol, 81%) as a yellow oil. mp=60-61 oC; 
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1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 7.92 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ 155.4, 142.5, 
141.2, 139.6, 121.2, 118.4 (q, JC-F=319 Hz), 85.8; 19F NMR (376.10 MHz, CDCl3) δ -72.4; IR (ATR) 
1532, 1434, 1336, 1195, 1132 cm-1; HRMS (ESI) calcd for C7H3F3IN2O7S (M+H
+) 442.8658 
(M+Na=464.8477), found  
 
5-Bromo-2,4-dinitrophenol (270) and 3-bromo-2,6-dinitrophenol (271). Treatment of a solution of 5-
bromo-2-nitrophenol (268) (579 mg, 2.658 mmol) in DCM (2 mL) with NaNO3 (271 mg, 3.190 mmol) in 
concentrated H2SO4 (5 mL) at 0 
oC, as described for 274 and 275 (10 h), gave, after work up and 
chromatography (Hexane/EtOAc, 9:1), a mixture of 270 and 271 (693 mg, 2.634 mmol, 99%) as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 10.93 (s, 1H), 10.82 (s, 1H), 8.82 (s, 1H), 8.14 (d, J=9.2 Hz, 1H), 7.63 
(s, 1H), 7.35 (d, J=9.2 Hz, 1H); IR (ATR) 3233, 1542, 1236, 854 cm-1; HRMS (ESI) calcd for, found 
 
5-Bromo-2,5-dinitrophenyltrifluoromethanesulfonate (204) and 3-bromo-2,6-
dinitrophenyltrifluromethanesulfonate (273). Treatment of the mixture of 270 and 271 (1.700 g, 6.465 
mmol) with Tf2O (1.41 mL, 8.40 mmol) in CH2Cl2 (18 mL) in the presence of triethylamine (Et3N, 2.34 
mL, 16.81 mmol) under a nitrogen atmosphere, as described for 258 (0 oC -rt, 1 h), gave, in order of 
elution, after solvent removal and chromatography (Hexane/EtOAc, 9:1), 204 (1.458 g, 3.691 mmol, 
57%) as a yellow oil and 273 (409 mg, 1.034 mmol, 16%) as a white solid. Analytical data for 273: 
mp=93-94 oC; 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J=8.8 Hz, 1H), 7.95 (d, J=9.2 Hz, 1H); 
13C NMR 
(100 MHz, CDl3) δ 145.8, 141.4, 134.0, 133.9, 127.7, 121.4, 118.1 (q, JC-F=320 Hz); 
19F NMR (376.10 
MHz, CDCl3) δ -71.8 IR (ATR) 1534, 1437, 1350, 1218, 1131 cm
-1; HRMS (ESI) calcd for, found 
 
5-Iodo-2,4-dinitrophenol (274)215 and 3-Iodo-2,6-dinitrophenol (275). To an ice-cooled solution of 
NaNO3 (648 mg, 7.629 mmol) in concentrated H2SO4 (13 mL) was added drop wise the solution of 5-
iodo-2-nitrophenol (269) (1.264 g, 4.768 mmol) in DCM (5 mL). The resulting solution was maintained 
at 0 oC overnight (10 h). The solution was quenched with ice-cold water and allowed to cool to ambient 
temperature. The solution was extracted in EtOAc (3X30 mL), dried (MgSO4), filtered and was 
concentrated under reduced pressure. The crude oil was purified by chromatography (Hexane/DCM, 7:3, 
acidified with AcOH) to give a mixture of 274 and 275 (1.168 g, 3.768 mmol, 79%) as a yellow oil. 
Analytical data for 274 and 275 from the mixture: 1H NMR (600 MHz, CDCl3) δ 10.94 (s, 1H), 10.74 (s, 
1H), 8.79 (s, 1H), 7.79 (s, 1H), 7.95 (d, J=9.0 Hz, 1H), 7.57 (d, J=9.0 Hz, 1H); 13C NMR (150 MHz, 
CDCl3) δ 155.9, 147.0, 146.9, 144.3, 134.1, 133.9, 132.2, 130.2, 126.2, 122.6, 97.2, 96.9; IR (ATR) 3276, 
1538, 1239, 835 cm-1; HRMS (ESI) calcd. for, found 
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5-Iodo-2,5-dinitrophenyltrifluoromethanesulfonate (276) and 3-iodo-2,6-
dinitrophenyltrifluoromethanesulfonate (277). Treatment of the mixture of 274 and 275 (1.167 g, 
3.764 mmol) with Tf2O (0.86 mL, 5.08 mmol) in CH2Cl2 (12 mL) in the presence of triethylamine (Et3N, 
1.40 mL, 9.79 mmol) under a nitrogen atmosphere, as described for 258 (0 oC -rt, 30 mins.), gave, in 
order of elution, after solvent removal and chromatography (Hexane/EtOAc, 9:1), 276 (1.035 g, 2.341 
mmol, 62%) as a yellow oil and 277 (466 mg, 1.054 mmol, 28%) as a white solid. Analytical data for 
276: 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.16 (s, 1H); 151.5, 142.1, 140.9, 138.0, 123.2, 118.4 
(q, JC-F=319.5 Hz), 94.3; 19F NMR (MHz, CDCl3) δ -72.4; IR (ATR) 1527, 1433, 1343, 1197, 837 cm
-1; 
HRMS (ESI) calcd for, found  
Analytical data for 277: mp=121-122 oC; 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J=8.4 Hz, 1H), 7.98 (d, 
J=9.0 Hz, 1H); 13C NMR (100 MHz, CDl3) δ 149.6, 142.2, 140.3, 133.0, 127.8, 118.1 (q, J
C-F=319.5 Hz), 
94.3; 19F NMR (376.10 MHz, CDCl3) δ -71.9; IR (ATR) 1532, 1436, 1352, 1216, 897 cm
-1; HRMS (ESI) 
calcd for, found 
 
2-Bromo-3,6-dinitrophenol (279) and 2-Bromo-3,4-dinitrophenol (280). To an ice-cooled solution of 
NaNO3 (869 mg, 10.23 mmol) in concentrated H2SO4 (20 mL) was added drop wise the solution of 2-
bromo-3-nitrophenol (278) (1.716 g, 7.872 mmol) in DCM/MeOH (5/5 mL). The resulting solution was 
maintained at 0 oC 3 h and then was allowed to warm to ambient temperature over a period of 1 h. The 
solution was quenched with ice-cold water and allowed to cool to ambient temperature. The solution was 
extracted in EtOAc (3X20 mL), dried (MgSO4), filtered and was concentrated under reduced pressure. 
The crude oil was purified by chromatography (Hexane/EtOAc, 9:1, then, 7:3, acidified with AcOH) to 
give, in order of elution, 279 (1.263 g, 4.802 mmol, 61%) and 280 (213 g, 0.811 mmol, 10%) both as a 
yellow solid. 
Analytical data for 279: mp=92-93 oC; 1H NMR (600 MHz, CDCl3) δ 11.43 (s, 1H), 8.29 (d, J=9.0 Hz, 
1H), 7.31 (d, J=9.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.4, 153.6, 134.7, 125.2, 114.7, 107.0; IR 
(ATR) 3239, 1536, 1445, 1141, 816 cm-1; HRMS (ESI) calcd for C6H4BrN2O5 (M+H
+) 262.9304 
(M+Na=284.9123), found 
Analytical data for 280: mp=149 oC (decomposition); 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J=9.2 Hz, 
1H), 7.28 (d, J=9.2 Hz, 1H), 6.55 (br, s, 1H); 13C NMR (100 MHz, CDCl3/DMSO-d6) δ 161.8, 146.2, 
130.9, 125.9, 115.8, 103.6; IR (ATR) 3234, 1553, 1313, 1091 cm-1; HRMS (ESI) calcd for C6H4BrN2O5 
(M+H+) 262.9304 (M+Na=284.9123), found 
 
2-Bromo-3,6-dininitrophenyltrifluoromethanesulfonate (281). Treatment of a solution of 279 (1.2360 
g, 4.700 mmol) with Tf2O (1.12 mL, 6.657 mmol) in CH2Cl2 (15 mL) in the presence of Et3N (1.70 mL, 
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12.220 mmol) under a nitrogen atmosphere, as described for 258 (0 oC -rt, 30 min), gave, after solvent 
removal and chromatography (Hexane/EtOAc, 7:3), 281 (1.6934 g, 4.286 mmol, 91%) as a white solid. 
mp=108-109 oC; 1H NMR (600 MHz, CDCl3) δ 8.20 (d, J=9.0 Hz, 1H), 7.93 (d, J=9.0 Hz, 1H); 
13C NMR 
(150 MHz, CDCl3) δ 153.7, 144.7, 140.7, 126.0, 124.2, 118.3 (q, J
C-F=319.5 Hz), 113.3; 19F NMR (MHz, 
CDCl3) δ -72.3; IR (ATR) 1544, 1434, 1351, 1214, 1131 cm
-1; HRMS (ESI) calcd for C7H3BrF3N2O7S 
(M+H+) 394.8796 (M+Na=416.8616), found 
 
1,4-Diethenyl-2,3-dinitrobenzene (285). To a yellow mixture of 2,3-dinitro-1.4-dibromobenzene 256 
(538.3 mg, 1.652 mmol) and PdCl2(PPh3)2 in 1,4-dioxane (4 mL) at ambient temperature under a nitrogen 
atmosphere was added a solution of ethenyl tributyltin (282) (1153 mg, 3.634 mmol) in 1,4-dioxane (1 
mL) via syringe. The resulting solution was heated at reflux (100 oC, 21 h). The solvent was removed at 
reduced pressure and the crude product was purified by chromatography (10% K2CO3-SiO2, 
hexane/EtOAc, 95:5) to give 285 (245.1 mg, 1.113 mmol, 67%) as a yellow solid. mp=113-114 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.77 (s, 2H), 6.74 (dd, J=17.2, 11.2 Hz, 2H), 5.93 (d, J=17.2 Hz, 2H), 5.64 (d, 
J=11.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 142.0, 131.4, 129.2, 128.4, 122.1; IR (ATR) 1525, 1478, 
1352, 975, 934, 848 cm-1; HRMS (ESI) calcd for C10H8N2O4Na (M+Na
+) 243.0382, found 243.0375.  
 
2,3-Dinitro-1,4-di(1-propen-1-yl)benzene (286). To a solution of 256 (106 mg, 0.327 mmol), 
PdCl2(PPh3)2 (4.7 mg, 0.01 mmol) and PPh3 (3.4 mg, 0.01 mmol) in dioxane (3 mL), under a nitrogen 
atmosphere, was added the solution of 1-propen-1-yl tributyltin (283) (282 mg, 0.852 mmol) in dioxane 
(1 mL) via a syringe. The solution was heated at reflux (100 oC, 24 h).  The solvent was removed under 
reduced pressure and the resulting residue was purified by chromatography (10% K2CO3-SiO2, 
hexane/EtOAc, 9:1) to afford 286 (69.0 mg, 0.278 mmol, 85%, ~2:1 trans-cis/trans-trans mixture) as a 
yellow solid. mp=125-127 oC; 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.3 Hz, 1H), 7.64 (s, 1H), 7.50 
(s, 1H), 7.45 (d, J = 8.3 Hz, 1H), 6.47 – 6.33 (m, 6H), 6.06 (ddq, J = 11.5, 9.7, 7.2 Hz, 2H), 1.94 (m, 6H), 
1.78 (dd, J = 7.0, 1.6 Hz, 3H), 1.76 (dd, J = 7.0, 1.6 Hz, 3H); 13C NMR (150 MHz, DMSO-d6) δ 141.8, 
141.7, 140.5, 140.4, 135.8, 135.6, 133.8, 133.7, 133.5, 133.4, 130.4, 130.2, 129.9, 129.9, 129.8, 129.8, 
121.7, 121.7, 121.5, 18.7, 14.3; IR (ATR) 3041, 2954, 1649, 1528, 1358, 859, 820 cm-1; HRMS (ESI) 
calcd for C12H12N2O4Na (M+Na
+) 271.0689, found 271.0688. 
 
2,3-Dinitro-1,4-di(1-propen-2-yl)benzene (287). To a solution of 256 (352 mg, 1.082 mmol) and 
PdCl2(PPh3)2 (30.4 mg, 0.043 mmol) in 1,4-dioxane (3 mL), stirred for 5 min under a nitrogen 
atmosphere, was added the solution of isopropenytributyltin (284) (824 mg, 2.488 mmol) in dioxane 
(1mL) via a syringe. The solution was heated at reflux (100 oC) for 24 h.  The solvent was removed under 
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reduced pressure and the resulting crude was purified by chromatography (10% K2CO3-SiO2, 
hexane/EtOAc, 95:5) to afford 287 (189 mg, 0.761 mmol, 70%) as a white solid. mp=138-139 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.45 (s, 2H), 5.27 (s, 2H), 5.02 (s, 2H), 2.10 (s, 6H); 
13C NMR (100 MHz, 
CDCl3) δ 141.9, 139.2, 137.4, 131.5, 118.1, 23.1; IR (ATR) 3094, 2973, 1643, 1543, 1526, 1355, 911, 
847 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found xxxxxxxxxx.   
 
1,5-Diethenyl-2,4-dinitrobenzene (289). Treatment of a solution of 288 (500 mg, 1.535 mmol) with 282 
(1.071 g, 3.38 mmol) in the presence of PdCl2(PPh3)2 (43.1 mg, 0.061 mmol) in dioxane (6.5 mL), as 
described for 285 (90 oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 95:5) 
289 (247 mg, 1.121 mmol, 73%) as a white solid. mp=60-61 oC;  1H NMR (400 MHz, CDCl3) δ 8.65 (s, 
1H), 7.83 (s, 1H), 7.27 (dd, J=17.2, 10.8 Hz, 2H), 5.90 (d, J=17.2 Hz, 2H), 5.70 (d, J=11.2 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 145.6, 137.9, 131.2, 129.1, 122.4, 121.6; IR (ATR) 1578, 1517, 1340, 
940,907 cm-1; HRMS (ESI) calcd for C10H9N2O4 (M+H
+) 221.0562 (M+Na=243.0382), found 
 
2,4-Dinitro-1,5-di(1-propen-1-yl)benzene (290). Treatment of a solution of 288 (136.1 mg, 0.418 mmol) 
with 283 (360 mg, 1.086 mmol) in the presence of PdCl2(PPh3)2 (5.9 mg, 0.008 mmol) and PPh3 (4.4 mg, 
0.017 mmol) in dioxane (4 mL), as described for 285 (90 oC, 24 h), gave after solvent removal and 
chromatography (Hexane/EtOAc, 95:5) 290 (96.7 mg, 0.390 mmol, 93%) as a yellow solid. mp=98-99 
oC;  1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 8.65 (s, 1H), 8.56 (s, 1H), 7.73 (s, 1H), 7.57 (s, 1H), 7.39 
(s, 1H), 6.99-6.93 (m, 2H), 6.78-6.74 (m, 2H), 6.46-6.35 (m, 2H), 6.13-6.04 (m, 2H), 2.02-1.99 (m, 6H), 
1.79 (dd, J=7.2, 2.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 145.9, 145.5, 144.7, 144.5, 137.6, 137.2, 
137.0, 136.9, 135.9, 135.6, 135.4, 131.8, 131.3, 131.2, 128.4, 125.2, 125.0, 124.9, 124.7, 121.8, 121.7, 
121.6, 19.1, 19.0, 14.5, 14.5; IR (ATR) 1537, 1352, 1277, 938 cm-1; HRMS (ESI) calcd for C12H13N2O4 
(M+H+) 249.0875 (M+Na=271.0695), found 
 
2,4-Dinitro-1,5-di(1-propen-1-yl)benzene (290). Treatment of a solution of 204 (400.3 mg, 1.013 mmol) 
with 283 (772 mg, 2.331 mmol) in the presence of PdCl2(PPh3)2 (28.3 mg, 0.040 mmol), BHT (20.1 mg, 
0.091 mmol) and LiCl (133.1 mg, 3.140 mmol) in dioxane (3 mL), as described for 285 (90 oC, 23 h), 
gave after solvent removal and chromatography (Hexane/EtOAc, 95:5) 290 (104.2 mg, 0.420 mmol, 41%) 
as a yellow solid.  
 
2,4-Dinitro-1,5-di(1-propen-2-yl)benzene (291). Treatment of a solution of 288 (175.6 mg, 0.539 mmol) 
with 284 (464 mg, 1.401 mmol) in the presence of PdCl2(PPh3)2 (15.1 mg, 0.022 mmol) and PPh3 (11.3 
mg, 0.043 mmol) in dioxane (5 mL), as described for 285 (90 oC, 24 h), gave after solvent removal and 
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chromatography (Hexane/EtOAc, 9:1) 291 (116.5 mg, 0.469 mmol, 87%) as a white solid. mp=69-70 oC; 
1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 7.31 (s, 1H), 5.28 (s, 2H), 5.02 (s, 2H), 2.11 (s, 6H); 
13C 
NMR (100 MHz, CDCl3) δ 146.3, 143.3, 141.1, 133.0, 120.6, 117.1, 22.9; IR (ATR) 1584, 1525, 1344, 
908, 734 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found 
 
1,4-Diethenyl-2,5-dinitrobenzene (292). To a solution of 266 (310.3 mg, 0.740 mmol) in DMF (5 mL) 
under nitrogen atmosphere were added BHT (18.4 mg, 0.084 mmol), PdCl2(PPh3)2 (9.9 mg, 0.014 mmol), 
LiCl (95.3 mg, 2.248 mmol) and 282 (534.2 mg, 1.685 mmol) respectively. The reaction mixture was 
stirred at ambient temperature for 27 h. EtOAc (20 mL) was added and the mixture was washed with 
water (6X15 mL). The organic layer was dried (MgSO4), filtered and the solvent was evaporated under 
reduced pressure. The resulting residue was purified by chromatography (Hexane/EtOAc, 98:2) to give 
292 (82 mg, 0.372 mmol, 53%) as a yellow solid. mp=148-149 oC; 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 
2H), 7.09 (dd, J=17.2, 11.2 Hz, 2H), 5.90 (d, J=17.6 Hz, 2H), 5.65 (d, J=11.2 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ 149.3, 133.0, 129.9, 124.3, 121.6; IR (ATR) 1518, 1348, 1283, 937 cm
-1; HRMS (ESI) 
calcd for C10H9N2O4 (M+H
+) 221.0562 (M+Na=243.0382), found 
 
2,5-Dinitro-1,4-di(1-propen-1-yl)benzene (293). A mixture of 266 (397.6 mg, 0.899 mmol) and 283 
(774.3 mg, 2.338 mmol) in DMF (6 mL) in the presence of PdCl2(PPh3)2 (25.3 mg, 0.036 mmol), BHT 
(21.8 mg, 0.099 mmol) and LiCl (137.3 mg, 3.239 mmol) was stirred at 65 oC for 14 h. After cooling to 
ambient temperature, the solution was diluted with EtOAc (15 mL) and was washed with water (7x10 
mL). The resulting crude was purified by chromatography (10% K2CO3 silica gel, Hexane/EtOAc, 97:3) 
to give 293 (89.1 mg, 0.359 mmol, 40%) as a yellow solid. mp=114-115 oC;  1H NMR (600 MHz, CDCl3) 
δ 8.14 (s, 1H), 8.01 (s, 1H), 7.95 (s, 1H), 7.82 (s, 1H), 6.78 (dq, J=16.8, 1.2 Hz, 1H), 6.74 (dq, J=15.6, 1.8 
Hz, 1H), 6.64 (dq, J=11.4, 1.8 Hz, 1H), 6.61 (dq, J=11.4, 1.8 Hz, 1H), 6.46-6.36 (m, 2H), 6.11-6.02 (m, 
2H), 1.99 (dd, J=6.6, 1.8 Hz, 3H), 1.97 (dd, J=6.6, 1.8 Hz, 3H), 1.81 (dd, J=7.2, 1.8 Hz, 3H), 1.79 (dd, 
J=7.2, 1.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 150.0, 149.6, 148.9, 148.4, 134.6, 134.2, 132.5, 131.9, 
131.8, 131.8, 131.6, 131.2, 127.6, 127.5, 124.0, 123.9, 123.8, 123.5, 123.5, 18.9, 18.9, 14.5, 14.5; IR 
(ATR) 1519, 1350, 1270, 963 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 
(M+Na=271.0695), found 
  
2,5-Dinitro-1,4-di(1-propen-1-yl)benzene (293). Treatment of a solution of 266 (213 mg, 0.482 mmol) 
with 283 (416.5 mg, 1.258 mmol) in the presence of PdCl2(PPh3)2 (6.8 mg, 0.010 mmol), PPh3 (5.2 mg, 
0.020 mmol), BHT (12.6 mg, 0.057 mmol) and LiCl (73.5 mg, 1.734 mmol) in dioxane (2.5 mL), as 
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described for 285 (100 oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 9:1) 
293 (62.2 mg, 0.251 mmol, 52%) as a yellow solid.  
 
2,5-Dinitro-1,4-di(1-propen-1-yl)benzene (293). Treatment of a solution of 265 (313.1 mg, 0.793 mmol) 
with 283 (685 mg, 2.069 mmol) in the presence of PdCl2(PPh3)2 (11.1 mg, 0.016 mmol), PPh3 (8.3 mg, 
0.032 mmol), BHT (20.9 mg, 0.0595 mmol) and LiCl (121.6 mg, 2.855 mmol) in dioxane (3 mL), as 
described for 285 (100 oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 95:5) 
293 (124 mg, 0.500 mmol, 63%) as a yellow solid.  
 
2,5-Dinitro-1,4-di(1-propen-2-yl)benzene (294). Treatment of a solution of 266 (239.2 mg, 0.541 mmol) 
with 284 (466 mg, 1.407 mmol) in the presence of PdCl2(PPh3)2 (7.6 mg, 0.011 mmol), PPh3 (5.7 mg, 
0.022 mmol), BHT (11.9 mg, 0.054 mmol), and LiCl (78 mg, 1.840 mmol) in dioxane (5 mL), as 
described for 285 (100 oC, 30 h), gave after solvent removal and chromatography (Hexane/EtOAc, 95:5) 
294 (71.9 mg, 0.290 mmol, 54%) as a white solid. mp=118-119 oC; 1H NMR (600 MHz, CDCl3) δ 7.77 
(s, 2H), 5.29 (s, with further fine splitting, 2H), 5.05 (s, with further fine splitting, 2H), 2.11 (dd, J=2.4, 
1.2 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 149.6, 140.1, 138.5, 125.9, 117.6, 22.85; IR (ATR) 1533, 
1350, 905, 847 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found 
 
2,5-Dinitro-1,4-di(1-propen-2-yl)benzene (294). Treatment of a solution of 265 (203.4 mg, 0.515 mmol) 
with 284 (445 mg, 1.344 mmol) in the presence of PdCl2(PPh3)2 (7.3 mg, 0.010 mmol), PPh3 (5.4 mg, 
0.021 mmol), BHT (13.2 mg, 0.060 mmol) and LiCl (78.6 mg, 1.854 mmol) in dioxane (2 mL), as 
described for 285 (100 oC, 26 h), gave after solvent removal and chromatography (Hexane/EtOAc, 97:3) 
294 (81.9 mg, 0.330 mmol, 64%) as a white solid.  
 
1,2-Diethenyl-3,6-dinitrobenzene (295) Treatment of a solution  of 288 (103 mg, 0.261 mmol) with 282 
(206.6 mg, 0.652 mmol) in the presence of PdCl2(PPh3)2 (3.7 mg, 0.005 mmol), PPh3 (2.7 mg, 0.010 
mmol), BHT (6.9 mg, 0.031 mmol) and LiCl (39.8 mg, 0.940 mmol) in dioxane (1.5 mL), as described 
for 285 (100  oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 9:1) 295 (21.2 
mg, 0.096 mmol, 37%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 2H), 6.73 (dd, J=18.0, 11.6 
Hz, 2H), 5.60 (dd, J=11.2, 0.4 Hz, 2H), 5.41 (dd, J=18.0, 0.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
151.0, 133.6, 129.6, 123.3, 122.8; IR (ATR) 1523, 1350, 804, 726 cm-1; HRMS (ESI) calcd for 
C10H9N2O4 (M+H
+) 221.0562 (M+Na=243.0382), found 
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3,6-Dinitro-1,3-di(1-propen-1-yl)benzene (296) Treatment of a solution  of 288 (482.2 mg, 1.221 mmol) 
with 283 (1.0104 g, 3.051 mmol) in the presence of PdCl2(PPh3)2 (17.1 mg, 0.024 mmol), PPh3 (12.7 mg, 
0.048 mmol), BHT (32.3 mg, 0.147 mmol) and LiCl (186.2 mg, 4.396 mmol) in dioxane (4 mL), as 
described for 285 (100 oC, 20 h), gave after solvent removal and chromatography (Hexane/EtOAc, 9:1) 
296 (143.6 mg, 0.578 mmol, 47%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 7.71 (8.8 
Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 7.56 (s, 1H), 6.36-6.28 (m, 4H), 5.96-5.77 (m, 4H), 1.85 (dd, J=6.8, 1.6 
Hz, 3H), 1.82 (dd, J=6.8, 2.0 Hz, 3H), 1.43 (dd, J=6.8, 1.6 Hz, 3H), 1.41 (dd, J=7.2, 1.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 151.6, 151.3, 151.3, 151.2, 135.0, 134.5, 133.8, 133.8, 133.3, 133.0, 131.3, 
131.3, 122.9, 122.8, 122.6, 122.5, 122.5, 122.3, 122.1, 121.9, 18.9, 18.9, 14.5, 14.4; IR (ATR) 1528, 
1350, 959, 826 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found 
 
3,6-Dinitro-1,2-di-(1-propen-2-yl)benzene (297) Treatment of a solution  of 288 (400.1 mg, 1.013 
mmol) with 32 (831.6 g, 2.512 mmol) in the presence of PdCl2(PPh3)2 (14.2 mg, 0.020 mmol), PPh3 (11 
mg, 0.042 mmol), BHT (26.8 mg, 0.122 mmol) and LiCl (154.4 mg, 3.642 mmol) in dioxane (4 mL), as 
described for 285 (100  oC, 20 h), gave after solvent removal and chromatography (Hexane/EtOAc, 9:1) 
297 (121.2 mg, 0.488 mmol, 48%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.75 (s, 2H), 5.30 (s, 
2H), 4.92 (s, 2H), 2.11 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 151.1, 139.1, 138.7, 122.8, 118.7, 24.1; IR 
(ATR) 1531, 1348, 912, 735 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 
(M+Na=271.0695), found 
 
1,3-Diethenyl-2,6-dinitrobenzene (298). Treatment of a solution of 273 (463 mg, 1.172 mmol) with 282 
(929 mg, 2.930 mmol) in the presence of PdCl2(PPh3)2 (32.9 mg, 0.047 mmol), PPh3 (24.6 mg, 0.094 
mmol), BHT (28.4 mg, 0.129 mmol), and LiCl (159 mg, 3.75 mmol) in dioxane (8 mL), as described for 
285 (90 oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 95:5) 298 (82.6 mg, 
0.375 mmol, 32%) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.08 (d, J=8.4 Hz, 1H), 7.71 (d, J=9.0 
Hz, 1H), 6.89 (dd, J=17.4, 10.8 Hz, 1H), 6.61 (dd, J=17.4, 11.4 Hz, 1H), 6.50 (d, J=17.4 Hz, 1H), 5.69 (d, 
J=10.8 Hz, 1H), 5.56 (d, J=12.0 Hz, 1H), 5.46 (d, J=18.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.7, 
146.9, 134.2, 128.1, 127.3, 127.2, 126.0, 125.5, 123.4, 122.3; IR (ATR) 1516, 1346, 937, 914 cm-1; 
HRMS (ESI) calcd for C10H9N2O4 (M+H
+) 221.0562 (M+Na=243.0382), found. 
 
Scheme 7.12 Selective coupling of 258 with 282. Treatment of a solution of 258 (203.2 mg, 0.514 
mmol) with 282 (196.2 mg, 0.619 mmol) in the presence of PdCl2(PPh3)2 (7.2 mg, 0.010 mmol), PPh3 
(5.4 mg, 0.021 mmol), and BHT (10 mg, 0.045 mmol) in dioxane (4 mL), as described for 285 (100  oC, 
24 h), gave, in order of elution, after solvent removal and chromatography (Hexane/DCM, 95:5, then 9:1),  
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inseparable mixtures of 285 and 4-bromo-1-ethenyl-2,3-dinitrobenzene (285 + 299, 22.7 mg) as a white 
solid and 258 and 300 (258 + 300, 69.8 mg) as a colorless oil. 
 
4-Ethenyl-2,3-Dinitrophenyltrifluoromethanesulfonate (300). Treatment of a solution of 264 (884.1 
mg, 2.000 mmol) with 282 (761 mg, 2.400 mmol) in the presence of PdCl2(PPh3)2 (28.1 mg, 0.040 
mmol), PPh3 (21 mg, 0.080 mmol), and BHT (44 mg, 0.200 mmol) in dioxane (8 mL), as described for 
285 (98 oC, 24 h), gave in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
9:1) 285 (8.8 mg, 0.040 mmol, 2%) and 300 (444 mg, 1.297 mmol, 65%) both as a white solid. mp=58-59 
oC;  1H NMR (400 MHz, CDCl3) δ 7.93 (d, J=8.8 Hz, 1H), 7.65 (d, J=8.8 Hz, 1H), 6.75 (dd, J=17.2, 10.8 
Hz, 1H), 5.97 (d, J=17.6 Hz, 1H), 5.76 (d, J=10.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 142.3, 139.5, 
136.9, 132.6, 131.2, 127.4, 118.3 (q, JC-F =319 Hz); 19F NMR (376.10 MHz, CDCl3) δ -72.7; IR (ATR) 
1521, 1421, 1326, 1200, 1132 cm-1; HRMS (ESI) calcd for C9H6F3N2O7S (M+H
+) 342.9848 
(M+Na=364.9667), found 
 
2,3-Dinitro-4-(1-propen-1-yl)phenyltrifluoromethanesulfonate (301).  Treatment of a solution of 264 
(720 mg, 1.629 mmol) with 283 (663 mg, 2.003 mmol) in the presence of PdCl2(PPh3)2 (22.8 mg, 0.032 
mmol), PPh3 (17.1 mg, 0.065 mmol), and BHT (35 mg, 0.159 mmol) in dioxane (6 mL), as described for 
285 (100 oC, 24 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 9:1) 301 (370.2 mg, 
1.039 mmol, 64%) as a yellow solid. mp=64-65 oC; 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 9.0 Hz, 
1H), 7.67 (d, J = 8.8 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 9.0 Hz, 1H), 6.54 – 6.37 (m, 3H), 6.18 
(dq, J = 11.6, 7.2 Hz, 1H), 1.99 (d, J = 5.1 Hz, 3H), 1.79 (dd, J = 7.2, 1.8 Hz, 2H);  13C NMR (100 MHz, 
CDCl3) δ 143.1, 141.6, 138.8, 138.6, 137.9, 136.9, 136.8, 135.4, 135.2, 133.0, 132.6, 131.3, 125.4, 125.2, 
121.1, 120.6, 118.3 (q, JC-F=319 Hz, 2C), 18.9, 14.5; IR (ATR) 1547, 1436, 1350, 1233, 1137 cm-1; 
HRMS (ESI) calcd for C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
 
2,3-Dinitro-4-(1-propen-2-yl)phenyltrifluoromethanesulfonate (302). Treatment of a solution of 264 
(923.1 mg, 2.088 mmol) with 284 (830 mg, 2.506 mmol) in the presence of PdCl2(PPh3)2 (29.3 mg, 0.042 
mmol), PPh3 (21.9 mg, 0.083 mmol), and BHT (46 mg, 0.209 mmol) in dioxane (10 mL), as described for 
285 (98 oC, 24 h), gave, in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
9:1) 287 (15.4 mg, 0.062 mmol, 2%) and 302 (479 mg, 1.344 mmol, 64%) both as a white solid. mp=69-
70 oC;   1H NMR (600 MHz, CDCl3) δ 7.67 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.4 Hz, 1H), 5.34 (s, 1H), 5.08 
(s, 1H), 2.12 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 142.8, 139.2, 138.9, 138.1, 136.6, 133.7, 125.3, 
119.5, 118.3 (q, JC-F=319.5 Hz); IR (ATR) 1544, 1429, 1219, 1135, 834 cm-1; HRMS (ESI) calcd for 
C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
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Ethyl 4(-trifluoromethylsulfonyloxy)-2,3-dinitrophenylprop-2-enoate (303). Treatment of a solution 
of 264 (367.8 mg, 0.832 mmol) with ethyl 2-tributylstannyl-2-propenoate (369 mg, 0.948 mmol) in the 
presence of PdCl2(PPh3)2 (11.7 mg, 0.017 mmol), PPh3 (8.7 mg, 0.033 mmol), and BHT (20.2 mg, 0.092 
mmol) in dioxane (4 mL), as described for 285 (98 oC, 23 h), gave, after solvent removal and 
chromatography (Hexane/DCM, 6:4) 303 (170.7 mg, 0.412 mmol, 50%) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.73 (d, J=8.8 Hz, 1H), 7.67 (d, J=8.8 Hz, 1H), 6.73 (s, 1H), 6.05 (s, 1H), 4.23 (quartet, 
7.2 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.1, 142.5, 140.1, 137.6, 135.8, 
134.8, 133.2, 131.8, 125.9, 119.9, 116.7, 62.3, 13.8; 19F NMR (376.10 MHz, CDCl3) δ -72.3; IR (ATR) 
1716, 1552, 1212, 1131, 832 cm-1; HRMS (ESI) calcd for C12H10F3N2O9S (M+H
+) 415.0059 
(M+Na=436.9879), found 
 
5-Ethenyl-2,4-Dinitrophenyltrifluoromethanesulfonate (205). Treatment of a solution of 276 (112.2 
mg, 0.254 mmol) with 282 (98 mg, 0.309 mmol) in the presence of PdCl2(PPh3)2 (3.6 mg, 0.005 mmol), 
PPh3 (2.7 mg, 0.010 mmol), and BHT (6.7 mg, 0.030 mmol) in dioxane (2 mL), as described for 285 (98
 
oC, 32 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 95:5) 205 (30 mg, 0.088 
mmol, 35%) as a faint yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.80 (s, 1H), 7.74 (s, 1H), 7.26 (dd, 
J=17.4, 10.8 Hz, 1H), 6.02 (d, J=16.8 Hz, 1H), 5.87 (d, J=10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 
145.3, 143.5, 140.6, 139.6, 129.7, 124.9, 124.3, 123.9, 118.5 (q, JC-F=213 Hz); 19F NMR (MHz, CDCl3) δ 
-72.8; IR (ATR) 1536, 1434, 1338, 1210, 1131 cm-1; HRMS (ESI) calcd for C9H6F3N2O7S (M+H
+) 
342.9848 (M+Na=364.9667), found 
 
2,4-Dinitro-5-(1-propen-1-yl)phenyl trifluoromethanesulfonate (305). Treatment of a solution of 204 
(703.2 mg, 1.780 mmol) with 283 (766 mg, 2.314 mmol) in the presence of PdCl2(PPh3)2 (25 mg, 0.036 
mmol), PPh3 (18.7 mg, 0.071 mmol), and BHT (43.1 mg, 0.196 mmol) in dioxane (8 mL), as described 
for 285 (90 oC, 24 h), gave, in order of elution, after solvent removal and chromatography 
(Hexane/EtOAc, 95:5) 290 (52.6 mg, 0.212 mmol, 12%) as a yellow solid and 305 (476.3 mg, 1.337 
mmol, 75%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 8.75 (s, 1H), 7.64 (s, 1H), 7.51 
(s, 1H), 6.95 (dq, J=15.6, 2.0 Hz, 1H), 6.76 (dq, J=12.0, 2.0 Hz, 1H), 6.54 (dq, J=15.6, 6.8 Hz, 1H), 6.24 
(dq, J=12.0, 7.2 Hz, 1H), 2.06 (dd, J=6.8, 1.6 Hz, 3H), 1.84 (dd, J=7.2, 2.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 146.1, 144.8, 143.3, 142.9, 140.6, 140.2, 139.4, 139.1, 138.6, 134.4, 127.6, 123.9, 123.7, 123.7, 
123.5, 123.1, 118.5 (q, JC-F=320 Hz), 118.4 (q, JC-F=319 Hz); 19F NMR (376.10 MHz, CDCl3) δ -73.0, -
72.9; IR (ATR) 1534, 1434, 1339, 1215, 1131 cm-1; HRMS (ESI) calcd for C10H8F3N2O7S (M+H
+) 
357.0004 (M+Na=378.9824), found 
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2,4-Dinitro-5-(1-propen-2-yl)trifluoromethanesulfonate (306). Treatment of a solution of 276 (312.7 
mg, 0.707 mmol) with 284 (284 mg, 0.858 mmol) in the presence of PdCl2(PPh3)2 (9.9 mg, 0.014 mmol), 
PPh3 (7.4 mg, 0.028 mmol), and BHT (17.1 mg, 0.078 mmol) in dioxane (3 mL), as described for 285 (90
 
oC, 23 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 97:3), in order of elution, 291 
(9.9 mg, 0.040 mmol, 6%) as a white solid and 306 (129 mg, 0.362 mmol, 51%) as a colorless oil.  1H 
NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 7.44 (s, 1H), 5.38 (s, with further fine splitting, 1H), 5.11 (s, 
1H), 2.12 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 146.3, 146.3, 143.1, 139.8, 139.6, 126.7, 123.2, 118.9, 
118.5 (q, JC-F=320 Hz); 19F NMR (376.10 MHz, CDCl3) δ -72.6; IR (ATR) 1539, 1435, 1340, 1213, 1131 
cm-1; HRMS (ESI) calcd for C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
 
4-Ethenyl-2,5-dinitrophenyltrifluoromethanesulfonate (307). Treatment of a solution of 266 (782.4 
mg, 1.770 mmol) with 282 (670.5 mg, 2.114 mmol) in the presence of PdCl2(PPh3)2 (24.8 mg, 0.035 
mmol), PPh3 (18.6 mg, 0.071 mmol), and BHT (39 mg, 0.177 mmol) in dioxane (10 mL), as described for 
285 (80 oC, 24 h), gave, in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
98:2, then 95:5) 292 (12.2 mg, 0.055 mmol, 3%) as a yellow solid and 307 (463.3 mg, 1.354 mmol, 76%) 
as yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.41 (s, 1H), 8.00 (s, 1H), 7.13 (dd, J=17.4, 10.8 Hz, 1H), 
6.01 (d, J=17.4 Hz, 1H), 5.78 (d, J=10.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 149.0, 143.5, 139.7, 
134.5, 129.0, 126.7, 123.7, 120.8, 118.4 (q, JC-F=213 Hz); 19F NMR ( MHz, CDCl3) δ -72.9; IR (ATR) 
1553, 1437, 1342, 1213, 1130 cm-1; HRMS (ESI) calcd for C9H6F3N2O7S (M+H
+) 342.9848 
(M+Na=364.9667), found 
 
2,5-Dinitro-4-(1-propen-1-yl)phenyltrifluoromethanesulfonate (308). Treatment of a solution of 266 
(723 mg, 1.636 mmol) with 283 (763.2 mg, 2.305 mmol) in the presence of PdCl2(PPh3)2 (23 mg, 0.033 
mmol), and PPh3 (17.2 mg, 0.065 mmol) in dioxane (7 mL), as described for 285 (90
 oC, 24 h), gave, in 
order of elution, after solvent removal and chromatography (Hexane/EtOAc, 98:2) 293 (29.6 mg, 0.119 
mmol, 7%) as a yellow solid and 308 (406.9 mg, 1.142 mmol, 70%) as yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 8.34 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.94 (s, 1H), 6.84 (dq, J = 15.6, 1.6 Hz, 1H), 6.72 – 6.62 
(m, 1H), 6.52 (dq, J = 15.6, 6.8 Hz, 1H), 6.20 (dq, J = 11.6, 7.2 Hz, 1H), 2.03 (dd, J = 6.4, 1.6 Hz, 3H), 
1.83 (dd, J = 7.2, 1.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 150.0, 148.5, 143.3, 142.9, 139.3, 138.8, 
137.6, 134.6, 133.9, 133.6, 129.8, 126.4, 122.8, 122.4, 120.8, 120.7, 118.4 (q, JC-F=319 Hz); 19F NMR 
(376.10 MHz, CDl3) δ -72.6, -72.6; IR (ATR) 1532, 1336, 1202, 1123 cm
-1; HRMS (ESI) calcd for 
C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
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2-Ethenyl-3,6-dinitrophenyltrifluoromethanesulfonate (309). Treatment of a solution of 281 (987.8 
mg, 2.500 mmol) with 282 (961.1 mg, 3.031 mmol) in the presence of PdCl2(PPh3)2 (35.1 mg, 0.050 
mmol), PPh3 (26.2 mg, 0.100 mmol) and BHT (66.1 mg, 0.300 mmol) in dioxane (7 mL), as described for 
285 (98 oC, 24 h), gave, in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
95:5) 295 (55.6 mg, 0.253 mmol, 10%) as a yellow oil and 309 (301.2 mg, 0.880 mmol, 35%) as a faint 
yellow solid. mp=61-62 oC; 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J=8.8 Hz, 1H), 7.98 (d, J=8.8 Hz, 
1H), 6.77 (dd, J=17.6, 11.6 Hz, 1H), 5.90 (d, J=11.6 Hz, 1H), 7.75 (d, J=18.0 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 151.5, 144.8, 139.4, 131.1, 127.2, 125.4, 124.6, 123.8, 118.2 (q, J
C-F=319 Hz); 19F NMR 
(MHz, CDCl3) δ -73.0; IR (ATR) 1548, 1341, 1207, 1129, 971 cm
-1; HRMS (ESI) calcd for C9H6F3N2O7S 
(M+H+) 342.9848 (M+Na=364.9667), found 
 
3,6-dinitro-2-(1-propen-1-yl)phenyltrifluoromethanesulfonate (310). Treatment of a solution of 281 
(1.2523 g, 3.170 mmol) with 283 (1.2500 g, 3.775 mmol) in the presence of PdCl2(PPh3)2 (44.5 mg, 0.063 
mmol), PPh3 (33.3 mg, 0.127 mmol) and BHT (83.8 mg, 0.300 mmol) in dioxane (10 mL), as described 
for 285 (100 oC, 25 h), gave, in order of elution, after solvent removal and chromatography 
(Hexane/EtOAc, 96:4) 296 (48.8 mg, 0.197 mmol, 6%) and 310 (509.3 mg, 1.430 mmol, 45%) both as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J=8.8 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H), 8.03 (d, J=8.8 
Hz, 1H), 7.91 (d, J=8.8 Hz, 1H), 6.44-6.39 (m, 2H), 6.30-6.19 (m, 2H), 1.97 (dd, J=6.8, 2.0 Hz, 3H), 1.63 
(dd, J=6.8, 1.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 152.0, 151.6, 144.6, 140.3, 139.6, 139.4, 136.4, 
130.9, 129.9, 125.4, 124.7, 124.0, 123.6, 118.1 (q, JC-F=320 Hz), 118.1 (q, JC-F=319 Hz), 117.7, 117.2, 
19.0, 15.1;  19F NMR (MHz, CDCl3) δ -73.4, -73.5; IR (ATR) 1557, 1423, 1347, 1203, 839 cm
-1; HRMS 
(ESI) calcd for C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
 
3,6-Dinitro-2-(1-propen-2-yl)phenyltrifluoromethanesulfonate (311). Treatment of a solution of 281 
(1.5178 g, 3.842 mmol) with 284 (1.5100 g, 4.560 mmol) in the presence of PdCl2(PPh3)2 (53.9 mg, 0.077 
mmol), PPh3 (40.3 mg, 0.154 mmol) and BHT (101.6 mg, 0.461 mmol) in dioxane (10 mL), as described 
for 285 (100 oC, 25 h), gave, in order of elution, after solvent removal and chromatography 
(Hexane/EtOAc, 96:4) 297 (32.9 mg, 0.133 mmol, 3%) as a yellow oil and 311 (698 mg, 1.959 mmol, 
51%) as a white solid. mp=94-95 oC; 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J=8.8 Hz,1H), 7.89 (d, J=8.8 
Hz, 1H), 5.34 (s, 1H), 5.18 (s, 1H), 2.19 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 152.1, 144.5, 139.0, 
135.6, 134.5, 125.4, 123.5, 122.7, 118.1 (q, JC-F=319 Hz), 22.4;  19F NMR (MHz, CDCl3) δ -72.8; IR 
(ATR) 1548, 1419, 1336, 1197, 837 cm-1; HRMS (ESI) calcd for C10H8F3N2O7S (M+H
+) 357.0004 
(M+Na=378.9824), found 
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3-Ethenyl-2,6-dinitrophenyltrifluoromethanesulfonate (312). Treatment of a solution of 273 (803.2 
mg, 2.033 mmol) with 282 (762 mg, 2.403 mmol) in the presence of PdCl2(PPh3)2 (28.5 mg, 0.041 
mmol), PPh3 (21.3 mg, 0.081 mmol) and BHT (44.7 mg, 0.203 mmol) in dioxane (6 mL), as described for 
282 (98 oC, 24 h), gave, in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
9:1) an inseparable mixture of 298 and 3-bromo-2,6-dinitrobenzene (80.2 mg) as a colorless oil and 312 
(305.2 mg, 0.892 mmol, 44%) as white solid. mp=72-73 oC; 1H NMR (400 MHz, CDCl3) δ 8.26 (d, J=8.8 
Hz, 1H), 7.87 (d, J=8.8 Hz, 1H), 6.66 (dd, J=17.2, 11.2 Hz, 1H), 6.10 (d, J=17.2 Hz, 1H), 5.82 (d, J=10.8 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 143.0, 140.7, 137.8, 133.5, 127.6, 127.4, 126.7, 125.6, 118.1 (q, 
JC-F=320 Hz); 19F NMR (376.10 MHz, CDCl3) δ -72.3; IR (ATR) 1546, 1435, 1349, 1209, 1132 cm
-1; 
HRMS (ESI) calcd for C9H6F3N2O7S (M+H
+) 342.9848 (M+Na=364.9667), found 
 
2,6-Dinitro-3-(1-propen-2-yl)phenyltrifluoromethanesulfonate (313). Treatment of a solution of 273 
(1.126 g, 2.850 mmol) with 284 (1.213 g, 3.663 mmol) in the presence of PdCl2(PPh3)2 (40 mg, 0.057 
mmol), PPh3 (29.9 mg, 0.114 mmol) and BHT (62.8 mg, 0.285 mmol) in dioxane (7 mL), as described for 
285 (100 oC, 22 h), gave, in order of elution, after solvent removal and chromatography (Hexane/EtOAc, 
96:4), an inseparable mixture of decoupling and C-OTf coupling products along with unknown impurities 
(125.3 mg) and 313 (459 mg, 1.288 mmol, 45%) both as a yellow oil. Analytical data for 313: 1H NMR 
(400 MHz, CDCl3) δ 8.07 (d, J = 8.6 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 5.19 (s, 1H), 4.95 (s, 1H), 1.94 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 144.4, 143.4, 140.7, 138.2, 133.1, 129.6, 127.5, 119.7, 118.1 (q, J
C-
F=319 Hz), 22.5; 19F NMR (376 MHz, CDCl3) δ -72.6; IR (ATR) 1546, 1454, 1353, 1216, 1139 cm
-1; 
HRMS (ESI) calcd for C10H8F3N2O7S (M+H
+) 357.0004 (M+Na=378.9824), found 
 
4-Chloro-2,3-Dinitro-1-ethenylbenzene (314). Reaction of 300 (260 mg, 0.760 mmol) with 284 (317 
mg, 0.957 mmol) in DMF (3 mL) in the presence of PdCl2(PPh3)2 (10.6 mg, 0.015 mmol), BHT (18.4 mg, 
0.084 mmol), and LiCl (103.4 mg, 2.440 mmol), as described for 292 (rt, 16 h), gave, after work up and 
chromatography (Hexane/EtOAc, 95:5, then 9:1) 314 (109.3 mg, 0.478 mmol, 63%) as a white solid. 
mp=100-101 oC;   1H NMR (400 MHz, CDCl3) δ 7.77 (d, J=6.0 Hz, 1H), 7.68 (d, J=6.0 Hz, 1H), 6.72 
(dd, J=17.2, 10.8 Hz, 1H), 5.93 (d, J=17.2 Hz, 1H), 5.67 (d, J=11.2 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 142.5, 142.2, 133.3, 131.4, 129.8, 128.0, 126.3, 122.9; IR (ATR) 1548, 1354, 947, 841 cm
-1; 
HRMS (ESI) calcd for C8H6ClN2O4 (M+H
+) 229.0016 (M+Na=250.9836), found 
 
4-Chloro-2,5-Dinitro-1-ethenylbenzene (315). Reaction of 307 (158.3 mg, 0.463 mmol) with 284 (188.4 
mg, 0.569 mmol) in DMF (2 mL) in the presence of PdCl2(PPh3)2 (6.4 mg, 0.009 mmol), BHT (12.2 mg, 
0.056 mmol), and LiCl (57 mg, 1.345 mmol), as described for 292 (rt, 21 h), gave, after work up and 
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chromatography (Hexane/EtOAc, 98:2) 315 (56 mg, 0.245 mmol, 53%) as a white solid. mp=102-103 oC;   
1H NMR (400 MHz, CDCl3) δ 8.09 (s, 2H), 7.08 (dd, J=17.2, 10.8 Hz, 1H), 5.90 (d, J=17.2 Hz, 1H), 5.69 
(d, J=11.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.9, 148.4, 133.1, 129.5, 127.8, 126.4, 125.1, 122.4; 
IR (ATR) 1547, 1524, 1347, 1274, 851 cm-1; HRMS (ESI) calcd for C8H6ClN2O4 (M+H
+) 229.0016 
(M+Na=250.9836), found 
 
1-Ethenyl-2,5-dinitro-4-(1-propen-2-yl)benzene (316) Treatment of a solution of 315 (95 mg, 0.416 
mmol) with 284 (206 mg, 0.623 mmol) in the presence of PdCl2(PPh3)2 (5.8 mg, 0.008 mmol), PPh3 (8.7 
mg, 0.033 mmol), and BHT (11 mg, 0.050 mmol) in dioxane (4 mL), as described for 285 (90  oC, 24 h), 
gave, after solvent removal and chromatography (Hexane/EtOAc, 98:2) 316 (76.9 mg, 0.328 mmol, 79%) 
as a faint yellow solid. mp=89-90 oC;  1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.86 (s, 1H), 7.09 (dd, 
J=17.2, 10.8 Hz, 1H), 5.88 (d, J=17.2 Hz, 1H), 5.64 (d, J=11.2 Hz, 1H), 5.29 (s, with further fine 
splitting, 1H), 5.05 (s, with further fine splitting, 1H); 2.10 (dd, J=1.2, 0.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 150.2, 148.7, 140.1, 138.5, 133.0, 130.0, 126.4, 123.8, 121.5, 117.7, 22.8; IR (ATR) 1528, 
1350, 912, 853 cm-1; HRMS (ESI) calcd for C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0537), found 
 
1-Ethenyl-2,3-dinitro-4-(1-propen-1-yl)benzene (317). Treatment of a solution of 300 (203.5 mg, 0.595 
mmol) with 283 (256 mg, 0.773 mmol) in the presence of PdCl2(PPh3)2 (8.3 mg, 0.012 mmol), PPh3 (6.2 
mg, 0.024 mmol), BHT (15.7 mg, 0.071 mmol) and LiCl (95.8 mg, 2.260 mmol) in dioxane (6 mL), as 
described for 285 (98 oC, 30 h), gave after solvent removal and chromatography (Hexane/EtOAc, 85:15) 
317 (91.2 mg, 0.389 mmol, 65%) as a faint yellow solid. mp=95-97 oC;  1H NMR (400 MHz, CDCl3) δ 
7.77 (d, J=8.4 Hz, 1H), 7.71 (s, 2H), 7.52 (d, J=8.0 Hz, 1H), 6.70 (dd, J=17.2, 11.2 Hz, 1H), 6.68 (dd, 
J=17.2, 11.2 Hz, 1H), 6.49-6.35 (m, 3H), 6.07 (dq, J=14.0, 6.8 Hz, 1H), 5.93 (d, J=10.4 Hz, 1H), 5.88 (d, 
J=10.4 Hz, 1H), 5.61 (d, J=10.4 Hz, 1H), 5.58 (d, J=11.2 Hz, 1H), 1.93 (dd, J=6.0, 0.8 Hz, 3H), 1.76 (dd, 
J=7.2, 2.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.7, 142.0, 141.9, 141.4, 135.2, 133.6, 133.2, 131.6, 
131.4, 130.7, 130.2, 129.1, 128.8, 128.7, 128.4, 128.4, 122.3, 121.9, 121.8, 121.5, 18.9, 14.6; IR (ATR) 
1533, 1436, 1347, 1216, 1128, 902 cm-1; HRMS (ESI) calcd for C11H11N2O4 (M+H
+) 235.0719 
(M+Na=257.0537), found 
 
1-Ethenyl-2,3-dinitro-4-(1-propen-2-yl)benzene (318). Treatment of a solution of 300 (189.3 mg, 0.553 
mmol) with 284 (234.4 mg, 0.708 mmol) in the presence of PdCl2(PPh3)2 (7.8 mg, 0.011 mmol), PPh3 
(5.8 mg, 0.022 mmol), BHT (14.6 mg, 0.066 mmol) and LiCl (89.1 mg, 2.102 mmol) in dioxane (4.5 
mL), as described for 285 (100 oC, 28 h), gave after solvent removal and chromatography 
(Hexane/EtOAc, 9:1) 318 (83.2 mg, 0.355 mmol, 64%) as a white solid. mp=99-100 oC;  1H NMR (400 
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MHz, CDCl3) δ 7.75 (d, J=8.4 Hz, 1H), 7.48 (d, J=8.4 Hz, 1H), 6.72 (dd, J=17.2, 10.8 Hz, 1H), 5.91 (d, 
J=17.2 Hz, 1H), 5.62 (d, J=11.2 Hz, 1H), 5.25 (s, with further fine splitting, 1H), 5.02 (s, with further fine 
splitting, 1H), 2.09 (dd, J=1.6, 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.2, 141.6, 139.2, 137.8, 
131.8, 131.0, 129.0, 128.4, 122.0, 118.1, 22.9IR (ATR) 1536, 1302, 1169, 803 cm-1; HRMS (ESI) calcd 
for C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0537), found 
 
2,3-Dinitro-4-(1-propen-1-yl)-1-(1-propen-2-yl)benzene (319). Treatment of a solution  of 302 (199.8 
mg, 0.561 mmol) with 283 (232.2 mg, 0.701 mmol) in the presence of PdCl2(PPh3)2 (7.8 mg, 0.011 
mmol), BHT (13.6 mg, 0.062 mmol), and LiCl (76.1 mg, 1.795 mmol) in DMF (2.5 mL), as described for 
292 (rt, 18 h), gave after work up and chromatography (Hexane/EtOAc, 95:5) 319 (63 mg, 0.254 mmol, 
45%) as a white solid. mp=62-63 oC;  1H NMR (600 MHz, CDCl3) δ 7.67 (d, J=7.8 Hz, 1H), 7.48 (d, 
J=8.4 Hz, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 6.42-6.38 (m, 3H), 6.07 (dq, J=14.4, 7.2 
Hz, 1H), 5.26 (s, 1H), 5.24 (s, 1H), 5.03 (s, 1H), 5.01 (s, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 1.94 (dd, J=4.8, 
2.4 Hz, 3H), 1.77 (dd, J=7.2, 1.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 142.5, 142.3, 142.2, 141.3, 
139.3, 139.3, 137.1, 136.8, 134.9, 133.4, 132.9, 131.5, 131.3, 131.3, 131.0, 128.9, 122.4, 121.9, 118.1, 
117.9, 23.1, 23.0, 18.9, 14.6; IR (ATR) 1547, 1409, 1326, 1174, 837 cm-1; HRMS (ESI) calcd for 
C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0538), found 
 
Ethyl 4-(ethenyl-2,3-dinitrophenyl)prop-2-enoate (320). Treatment of a solution of 300 (403.2 mg, 
1.178 mmol) with ethyl 2-tributylstannyl-2-propenoate (531.2 mg, 1.365 mmol) in the presence of 
PdCl2(PPh3)2 (16.5 mg, 0.023 mmol), PPh3 (12.4 mg, 0.047 mmol), BHT (31 mg, 0.141 mmol) and LiCl 
(179.8 mg, 4.242 mmol) in dioxane (4 mL), as described for 285 (100 oC, 24 h), gave after solvent 
removal and chromatography (Hexane/EtOAc, 9:1) 320 (174.5 mg, 0.597 mmol, 51%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.84 (d, J=8.40 Hz, 1H), 7.50 (d, J=8.4 Hz, 1H), 6.67 (dd, J=17.2, 11.2 Hz, 
1H), 6.64 (s, 1H), 5.98 (s, 1H), 5.95 (d, J=17.2 Hz, 1H), 5.64 (d, J=11.2 Hz, 1H), 4.19 (quartet, J=7.2 Hz, 
2H), 1.24 (t, J=7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.6, 142.5, 141.8, 136.8, 133.3, 132.3, 
132.0, 130.6, 129.9, 127.9, 122.6, 61.9, 13.8; IR (ATR) 1703, 1523, 1363, 1156, 802 cm-1; HRMS (ESI) 
calcd for C13H13N2O6 (M+H
+) 293.0774 (M+Na=315.0593), found 
 
Ethyl 2,3-dinitro-4-(1-propen-1-yl)phenylprop-2-enoate (321). Treatment of a solution of 301 (360.1 
mg, 1.011 mmol) with ethyl 2-tributylstannyl-2-propenoate (444.6 mg, 1.142 mmol) in the presence of 
PdCl2(PPh3)2 (14.2 mg, 0.020 mmol), PPh3 (10.6 mg, 0.040 mmol), BHT (22.1 mg, 0.100 mmol) and LiCl 
(150 mg, 3.539 mmol) in dioxane (4 mL), as described for 285 (100 oC, 24 h), gave after solvent removal 
and chromatography (Hexane/EtOAc, 9:1) 321 (157.9 mg, 0.516 mmol, 51%) as a faint yellow oil. 1H 
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NMR (600 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 
7.43 (d, J = 8.4 Hz, 1H), 6.66 (s, 1H), 6.63 (s, 1H), 6.46 (dq, J = 15.6, 6.6 Hz, 1H), 6.40 – 6.35 (m, 2H), 
6.11 (dq, J = 11.6, 7.2 Hz, 1H), 5.99 (s, 1H), 5.95 (s, 1H), 4.21 (dq, J = 8.0, 7.2 Hz, 4H), 1.95 (dd, J = 6.6, 
1.2 Hz, 4H), 1.79 (dd, J = 7.2, 1.8 Hz, 3H), 1.26 (t, J=7.2 Hz, 3H), 1.25 (t, J=7.2 Hz, 3H); 13C NMR (150 
MHz, CDCl3) δ 163.7, 143.5, 142.1, 141.9, 141.9, 137.0, 137.0, 135.6, 134.1, 133.8, 133.0, 132.7, 132.4, 
132.1, 131.6, 131.2, 130.5, 130.3, 129.8, 122.1, 121.5, 62.0, 62.0, 19.0, 14.6, 13.9, 13.9; IR (ATR) 1708, 
1547, 1355, 1207, 1097 cm-1; HRMS (ESI) calcd for C14H15N2O6 (M+H
+) 307.0930 (M+Na=329.0750), 
found 
 
Ethyl 2,3-dinitro-4-(1-propen-1-yl)phenylprop-2-enoate (321). Treatment of a solution of 303 (100.3 
mg, 0.242 mmol) with 283 (104 mg, 0.314 mmol) in the presence of PdCl2(PPh3)2 (3.4 mg, 0.005 mmol), 
PPh3 (2.5 mg, 0.010 mmol), BHT (5.3 mg, 0.024 mmol), and LiCl (36.9 mg, 0.871 mmol) in dioxane (2 
mL), as described for 285 (100 oC, 26 h), gave after solvent removal and chromatography 
(Hexane/EtOAc, 7:3) 321 (32.1 mg, 0.105 mmol, 43%) as a faint yellow oil.  
 
Ethyl 4-(1-propen-2-yl-2,3-dinitrophenyl)prop-2-enoate (322). Treatment of a solution of 302 (465.5 
mg, 1.307 mmol) with ethyl 2-tributylstannyl-2-propenoate (661 mg, 1.698 mmol) in the presence of 
PdCl2(PPh3)2 (18.3 mg, 0.026 mmol), PPh3 (13.7 mg, 0.052 mmol), BHT (34.5 mg, 0.157 mmol), and 
LiCl (199.4 mg, 4.704 mmol) in dioxane (4 mL), as described for 285 (100 oC, 24 h), gave after solvent 
removal and chromatography (Hexane/DCM, 6:4) 322 (218.2 mg, 1.058 mmol, 55%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.53 (d, J=8.0 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 6.63 (s, 1H), 5.97 (s, 1H), 5.27 
(s, with further fine splitting, 1H), 5.02 (s, with further fine splitting, 1H), 4.20 (quartet, J=7.2 Hz, 2H), 
2.09 (s, 3H), 1.25 (t, J=7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.6, 142.7, 141.5, 138.8, 138.4, 
136.8, 133.1, 132.5, 131.8, 130.6, 118.3, 61.9, 23.1, 13.8; IR (ATR) 1650, 1534, 1372, 1169, 802 cm-1; 
HRMS (ESI) calcd for C14H15N2O6 (M+H
+) 307.0930 (M+Na=329.0750), found 
 
1-Ethenyl-2,4-dinitro-5-(1-propen-2-yl)benzene (323). Treatment of a solution of 205 (310.3 mg, 0.907 
mmol) with 284 (381.3 mg, 1.152 mmol) in the presence of PdCl2(PPh3)2 (12.7 mg, 0.018 mmol), PPh3 
(9.5 mg, 0.036 mmol), BHT (23.9 mg, 0.108 mmol) and LiCl (130.7 mg, 3.084 mmol) in dioxane (6 mL), 
as described for 285 (90 oC, 24 h), gave after solvent removal and chromatography (Hexane/EtOAc, 98:2) 
323 (135.2 mg, 0.577 mmol, 64%) as a faint yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.53 (s, 1H), 7.58 
(s, 1H), 7.23 (dd, J=17.4, 11.4 Hz, 1H), 5.89 (d, J=17.4 Hz, 1H), 5.67 (d, J=11.4 Hz, 1H), 5.29 (s, with 
further fine splitting, 1H), 5.03 (s, with further fine splitting, 1H), 2.11 (s, with further fine splitting, 3H); 
13C NMR (150 MHz, CDCl3) δ 146.4, 145.6, 143.7, 141.3, 137.5, 131.0, 131.0, 122.4, 121.2, 117.0, 22.9; 
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IR (ATR) 1582, 1522, 1344, 1265, 911, 733 cm-1; HRMS (ESI) calcd for C11H11N2O4 (M+H
+) 235.0719 
(M+Na=257.0538), found 
 
2,4-Dinitro-5-(1-propen-1-yl)-1-(1-propen-2-yl)benzene (324). Treatment of a solution of 305 (404.4 
mg, 1.135 mmol) with 284 (473.6 mg, 1.430 mmol) in the presence of PdCl2(PPh3)2 (15.9 mg, 0.023 
mmol), PPh3 (11.9 mg, 0.045 mmol), BHT (25 mg, 0.114 mmol) and LiCl (154 mg, 3.633 mmol) in 
dioxane (8 mL), as described for 285 (80  oC, 24 h), gave after solvent removal and chromatography 
(Hexane/EtOAc, 97:3) 324 (203.2 mg, 0.819 mmol, 72%) as a faint yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 8.57 (s, 1H), 8.48 (s, 1H), 7.54 (s, 1H), 7.36 (s, 1H), 6.91 (dq, J=15.6, 1.8 Hz, 1H), 6.73 (dq, 
J=11.4, 1.8 Hz, 1H), 6.45 (dq, J=15.6, 6.6 Hz, 1H), 6.08 (dq, J=11.6, 7.2 Hz, 1H), 5.27 (s, with further 
fine splitting, 1H), 5.25 (s, with further fine splitting, 1H), 5.01 (s, with further fine splitting, 1H), 4.99 (s, 
with further fine splitting, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 1.99 (dd, J=3.0, 1.2 Hz, 3H), 1.78 (dd, J=7.2, 
1.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 146.2, 145.8, 145.4, 145.2, 143.4, 143.0, 141.6, 141.2, 137.6, 
137.0, 136.0, 134.3, 131.7, 130.7, 124.7, 124.4, 121.2, 121.1, 116.9, 116.6, 22.9, 22.8, 19.0, 14.5; IR 
(ATR) 1579, 1517, 1339, 909, 832 cm-1; HRMS (ESI) calcd for C12H13N2O4 (M+H
+) 249.0875 
(M+Na=271.0695), found 
 
1-Ethenyl-2,5-dinitro-4-(1-propen-1-yl)benzene (325). Treatment of a solution of 307 (302.7 mg, 0.885 
mmol) 283 (369.5 mg, 1.116 mmol) in the presence of PdCl2(PPh3)2 (12.4 mg, 0.018 mmol), PPh3 (9.3 
mg, 0.035 mmol), BHT (23.4 mg, 0.106 mmol) and LiCl (142.6 mg, 3.364 mmol) in dioxane (4 mL), as 
described for 285 (100 oC, 30 h), gave after solvent removal and chromatography (Hexane/DCM, 9:1) 325 
(132.6 mg, 0.566 mmol, 64%) as a yellow solid. mp=111-113 oC;  1H NMR (400 MHz, CDCl3) δ 8.19 (s, 
1H), 8.08 (s, 1H), 8.06 (s, 1H), 7.90 (s, 1H), 7.10 (dd, J=17.2, 10.8 Hz, 1H), 7.07 (dd, J=17.2, 10.8 Hz, 
1H), 6.77 (dq, J=15.6, 1.2 Hz, 1H), 6.64 (dq, J=11.6, 1.6 Hz, 1H), 6.43 (dq, J=15.2, 6.8 Hz, 1H), 6.08 
(dq, J=14.4, 7.2 Hz, 1H), 5.90 (d, J=16.8 Hz, 1H), 5.86 (d, J=17.2 Hz, 1H), 5.65 (d, J=10.8, 5.61 (d, 
J=11.2 Hz, 1H), 1.98 (dd, J=6.8, 1.6 Hz, 3H), 1.80 (dd, J=7.2, 2.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 150.1, 149.2, 149.0, 148.7, 134.8, 133.0, 132.4, 132.3, 132.0, 131.8, 130.0, 127.6, 124.2, 124.1, 124.0, 
123.7, 123.4, 121.4, 121.0, 18.9, 14.5; IR (ATR) 1538, 1520, 1351, 1275, 938 cm-1; HRMS (ESI) calcd 
for C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0538), found 
 
(325). Treatment of a solution  of 307 (325.9 mg, 0.952 mmol) with 283 (387.8 mg, 1.171 mmol) in the 
presence of PdCl2(PPh3)2 (13.4 mg, 0.019 mmol), BHT (23 mg, 0.105 mmol) and LiCl (129.1 mg, 3.046 
mmol) in DMF (4 mL), as described for 292 (rt, 21 h), gave after work up and chromatography 
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(Hexane/EtOAc, 98:2) 325 (37 mg, 0.158 mmol, 17%) as a yellow solid and 315 (13.4 mg, 0.059 mmol, 
6%) as a white solid.  
 
2,5-Dinitro-4-(1-propen-1-yl)-1-(1-propen-2-yl)benzene (326). Treatment of a solution of 308 (362.2 
mg, 1.017 mmol) with 284 (424.2 mg, 1.281 mmol) in the presence of PdCl2(PPh3)2 (14.3 mg, 0.020 
mmol), BHT (26.9 mg, 0.122 mmol) and LiCl (176.8 mg, 4.171 mmol) in DMF (7 mL), as described for 
292 (rt, 21 h), gave after work up and chromatography (Hexane/EtOAc, 98:2) 326 (66.3 mg, 0.267 mmol, 
26%) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.99 (s, 1H), 7.90 (s, 1H), 7.80 (s, 1H), 7.78 (s, 1H), 
6.76 (dq, J=15.6, 1.2 Hz, 1H), 6.62 (dq, J=11.4, 1.2 Hz, 1H), 6.41 (dq, J=15.6, 2.4 Hz, 1H), 6.07 (dq, 
J=14.4, 7.2 Hz, 1H), 5.28 (s, with further splitting, 1H), 5.26 (s, with further splitting, 1H), 5.06 (s, with 
further splitting, 1H), 5.03 (s, with further splitting, 1H), 2.11 (s, with further splitting, 3H), 2.08 (s, with 
further splitting, 3H), 1.97 (dd, J=6.6, 1.8 Hz, 3H), 1.80 (dd, J=7.2, 1.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 150.0, 149.5, 148.4, 140.2, 137.9, 137.4, 134.7, 133.0, 132.3, 131.8, 127.1, 126.4, 126.3, 123.7, 
123.6, 123.4, 117.6, 117.4, 22.8, 22.8, 18.9, 14.4; IR (ATR) 1540, 1345, 1265, 733 cm-1; HRMS (ESI) 
calcd for C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found 
 
1-Ethenyl-3,6-dinitro-2-(1-propen-1-yl)benzene (327). Treatment of a solution of 309 (301 mg, 0.880 
mmol) with 283 (363.7 mg, 1.098 mmol) in the presence of PdCl2(PPh3)2 (12.9 mg, 0.018 mmol), PPh3 
(9.2 mg, 0.035 mmol), BHT (22.3 mg, 0.101 mmol) and LiCl (135.6 mg, 3.199 mmol) in dioxane (3 mL), 
as described for 285 (100 oC, 30 h), gave after solvent removal and chromatography (Hexane/EtOAc, 
97:3) 327 (130 mg, 0.555 mmol, 63%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J=8.8 Hz, 
1H), 7.70 (d, J=8.8 Hz, 1H), 7.63 (s, 2H), 6.69 (dd, J=17.6, 11.6 Hz, 1H), 6.67 (dd, J=17.6, 11.6 Hz, 1H), 
6.38-6.34 (m, 2H), 5.98-5.80 (m, 2H), 5.57 (d, J=11.6 Hz, 1H), 5.50 (d, J=11.6 Hz, 1H), 5.38 (d, J=17.6 
Hz, 2H), 1.85 (dd, J=6.8, 1.6 Hz, 3H), 1.42 (dd, J=6.8, 1.6 Hz, 3H);  13C NMR (100 MHz, CDCl3) δ 
151.3, 151.2, 151.0, 135.6, 134.1, 133.5, 133.3, 133.1, 131.7, 129.8, 129.4, 122.8, 122.8, 122.7, 122.7, 
122.6, 122.3, 122.0, 18.9, 14.6; IR (ATR) 1531, 1351, 906, 726 cm-1; HRMS (ESI) calcd for C11H11N2O4 
(M+H+) 235.0719 (M+Na=257.0538), found 
 
1-Ethenyl-3,6-dinitro-2-(1-propen-2-yl)benzene (328). Treatment of a solution of 309 (211.8 mg, 0.619 
mmol) with 284 (276.7 mg, 0.836 mmol) in the presence of PdCl2(PPh3)2 (8.7 mg, 0.012 mmol), PPh3 
(6.5 mg, 0.025 mmol), BHT (16.4 mg, 0.074 mmol) and LiCl (95 mg, 2.241 mmol) in dioxane (2.5 mL), 
as described for 285 (100 oC, 30 h), gave after solvent removal and chromatography (Hexane/EtOAc, 
95:5) 328 (93 mg, 0.397 mmol, 64%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J=8.8 Hz, 
1H), 7.70 (d, J=8.8 Hz, 1H), 6.75 (dd, J=18.0, 11.6 Hz, 1H), 5.53 (d, J=11.6 Hz, 1H), 5.44 (d, J=18.0 Hz, 
190 
 
1H), 5.26 (s, with further fine splitting, 1H), 4.90 (s, with further fine splitting, 1H), 2.05 (s, with further 
fine splitting, 3H) 13C NMR (100 MHz, CDCl3) δ 151.0, 150.8, 139.2, 139.0, 132.9, 128.8, 122.8, 122.7, 
118.2, 23.2; IR (ATR) 1531, 1349, 804, 726 cm-1; HRMS (ESI) calcd for C11H11N2O4 (M+H
+) 235.0719 
(M+Na=257.0538), found 
 
3,6-Dinitro-1-(1-propen-1-yl)-2-(1-propen-2-yl)benzene (329). Treatment of a solution of 311 (303.1 
mg, 0.851 mmol) with 283 (366.3 mg, 1.106 mmol) in the presence of PdCl2(PPh3)2 (11.9 mg, 0.017 
mmol), PPh3 (8.9 mg, 0.034 mmol), BHT (22.5 mg, 0.102 mmol) and LiCl (1299 mg, 3.064 mmol) in 
dioxane (3 mL), as described for 285 (100 oC, 30 h), gave after solvent removal and chromatography 
(Hexane/EtOAc, 97:3) 329 (106 mg, 0.427 mmol, 50%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.77 (s, 2H), 7.67 (d, J=8.8 Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 6.41-6.34 (m, 2H), 5.95-5.85 (m, 2H), 5.25-
5.24 (m, 1H), 5.18-5.16 (m, 1H), 4.88-4.87 (m, 1H), 4.82 (m, 1H), 2.05-2.04 (m, 6H), 1.83 (dd, J=6.4, 1.6 
Hz, 3H), 1.42 (dd, J=6.8, 1.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 151.7, 151.3, 150.9, 150.8, 
139.9,139.7, 139.5, 138.9,134.8, 132.6, 132.6, 131.6, 122.8, 122.6, 122.5, 122.1, 122.0, 121.9, 117.9, 
116.8, 23.0, 22.8, 18.9, 14.6;  IR (ATR) 1537, 1435, 1341, 1216, 1332, 793 cm-1; HRMS (ESI) calcd for 
C12H13N2O4 (M+H
+) 249.0875 (M+Na=271.0695), found 
 
3-Ethenyl-2,6-dinitro-1-(1-propen-2-yl)benzene (330). Treatment of a solution of 313 (415.8 mg, 
0.1.167 mmol) with 282 (666.2 mg, 2.101 mmol) in the presence of PdCl2(PPh3)2 (16.4 mg, 0.023 mmol), 
PPh3 (12.2 mg, 0.047 mmol), BHT (25.7 mg, 0.117 mmol) and LiCl (178 mg, 4.199 mmol) in dioxane 
(3.5 mL), as described for 285 (100 oC, 24 h), gave after solvent removal and chromatography 
(Hexane/DCM, 95:5) 330 (122.7 mg, 0.524 mmol, 45%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
8.05 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.90 (dd, J = 17.8, 11.6 Hz, 1H), 5.55 (dd, J = 11.6, 0.5 
Hz, 1H), 5.44 (dd, J = 17.8, 0.5 Hz, 1H), 5.31 (s, 1H), 5.07 (s, 1H), 2.10 (d, J=0.4 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 149.7, 146.8, 140.9, 138.8, 128.7, 127.3, 127.1, 125.2, 122.2, 118.7, 23.2; IR (ATR) 
1546, 1387, 1178, 837 cm-1; HRMS (ESI) calcd for C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0538), 
found 
 
1-Ethenyl-2,6-dinitro-3-(1-propen-2-yl)benzene (331). Treatment of a solution of 312 (293.1 mg, 0.856 
mmol) with 284 (357.2 mg, 1.079 mmol) in the presence of PdCl2(PPh3)2 (12 mg, 0.017 mmol), PPh3 (9 
mg, 0.034 mmol), BHT (18.8 mg, 0.086 mmol) and LiCl (130.7 mg, 3.083 mmol) in dioxane (4 mL), as 
described for 285 (100 oC, 24 h), gave after solvent removal and chromatography (Hexane/DCM, 85:15) 
331 (54.8 mg, 0.234 mmol, 27%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J=8.4 Hz, 1H), 
7.46 (d, J=8.4 Hz, 1H), 6.60 (dd, J=17.2, 11.2 Hz, 1H), 6.00 (d,  J=17.2 Hz, 1H), 5.68 (d, J=11.2 Hz, 1H), 
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2.11 (dd, J=1.6, 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 149.8, 146.7, 136.8, 134.2, 132.0, 128.4, 
125.9, 125.8, 123.3, 118.7, 23.3; IR (ATR) 1546, 1397, 1179, 836 cm-1; HRMS (ESI) calcd for 
C11H11N2O4 (M+H
+) 235.0719 (M+Na=257.0538), found 
 
1H,6H-Pyrrolo[2,3-g]indole (336). A solution of 285 (35.2 mg, 0.160 mmol), palladium (II) acetate 
(Pd(OAc)2, 2.9 mg, 0.013 mmol), and 1,10-phenanthroline (2.4 mg, 0.013 mmol) was prepared in 
anhydrous N,N-dimethylformamide (DMF, 2 mL) in a threaded ACE glass pressure tube. The tube was 
fitted with a pressure head, the solution was saturated with carbon monoxide (four cycles of 6 atm of CO). 
The reaction mixture was stirred at 120 oC for 93 h. The solution was concentrated under reduced pressure 
at 80 oC and the resulting crude was purified by chromatography (Hexane/EtOAc, 7:3) to give 336 (17.5 
mg, 0.112 mmol, 70%) as a white solid. mp=199-200 oC (decomposition); 1H NMR (400 MHz, CDCl3) δ 
7.43 (s, 2H), 6.88 (br, s, 2H), 6.79 (t, J=2.8 Hz, 2H), 6.64 (dd, J=3.2, 2.0 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 123.1, 121.9,121.7, 113.8, 103.2; IR (ATR) 3353,1516, 1135, 1053, 754 cm
-1; HRMS (ESI) 
calcd for C10H9N2 (M+H
+) 157.0766 (M+Na=179.0585), found 
 
1H,6H-Pyrrolo[3,2-g]indole (336). Reaction of a solution of 285 (14.1 mg, 0.064 mmol), 
bis(dibenzylideneacetone)palladium (0) (Pd(dba)2, 3.8 mg, 0.007 mmol), and triphenylphosphine (6.8 mg, 
0.026 mmol) in DMF (1.2 mL), as described for 336 above (pCO = 6 atm, 120 oC, 126 h), gave after 
solvent removal and chromatography (Hexane/EtOAc, 7:3) 336 (6.4 mg, 0.041 mmol, 64%) as a white 
solid.  
   
6-Ethenyl-7-nitroindole (337). Reaction of a solution of 285 (27.8 mg, 0.126 mmol), Pd(OAc)2 (2.8 mg, 
0.012 mmol), and 1,3-bis(diphenylphosphino)propane (dppp, 5.2 mg, 0.013 mmol) in DMF (1.5 mL), as 
described for 336 (pCO = 6 atm, 120 oC, 94 h), gave after solvent removal and chromatography 
(Hexane/EtOAc, 7:3) 337 (11.4 mg, 0.061 mmol, 48%) as a yellow solid. mp=90-91 oC;   1H NMR (400 
MHz, CDCl3) δ 9.93 (br, s, 1H), 7.87 (d, J=8.0 Hz, 1H), 7.56 (dd, J=17.2, 11.2 Hz, 1H), 7.37 (dd, J=2.8, 
0.4 Hz, 1H), 7.33 (d, J=8.4 Hz, 1H), 6.67 (dd, J=3.2, 2.0 Hz, 1H), 5.72 (dd, J=17.2, 1.2 Hz, 1H ), 5.49 
(dd, J=10.8, 0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 135.2, 135.2, 131.5, 130.9, 130.0, 127.6, 126.6, 
120.7, 117.9, 103.9; IR (ATR) 3407, 1330, 1265, 1092 cm-1; HRMS (ESI) calcd for C10H9N2O2 (M+H
+) 
189.0664 (M+Na=211.0483), found 
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2,5-Dimethyl-1H,6H-pyrrolo[2,3-g]indole (338). Reaction of a solution of 286 (45.5 mg, 0.183 mmol), 
Pd(OAc)2 (4.1 mg, 0.018 mmol), and 1,10-phen (3.3 mg, 0.018 mmol) in DMF (1.5 mL), as described for 
336 (pCO =6 atm, 120 oC, 144 h), gave after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
338 (22.6 mg, 0.119 mmol, 67%) as a white solid. mp=209 oC (decomposition);   1H NMR (400 MHz, 
CDCl3) δ 7.24 (s, 2H), 7.11 (br, s, 2H), 6.25 (dd, J=2.0, 1.2 Hz, 2H), 2.27 (s, 3H); 
13C NMR (100 MHz, 
CDCl3) δ 131.9, 123.9, 121.7, 112.6, 101.5, 13.5; IR (ATR) 3354, 1547, 1432, 1333, 1234 cm
-1; HRMS 
(ESI) calcd for C12H13N2 (M+H
+) 185.1079, found 
 
2-Methyl-7-nitro-6-(1-propen-1-yl)indole (339). Reaction of a solution of 286 (46.7 mg, 0.188 mmol), 
Pd(OAc)2 (4.2 mg, 0.019 mmol), and dppp (7.8 mg, 0.019 mmol) in DMF (2 mL), as described for 336 
(pCO = 6 atm, 120 oC, 57 h), gave, in orde of elution, after solvent removal and chromatography 
(Hexane/EtOAc, 7:3) 339 (28.1 mg, 0.130 mmol, 69%) as a yellow solid and 338 (3.1 mg, 0.017 mmol, 
9%) as a white solid. mp=116-117 oC;   1H NMR (600 MHz, CDCl3) δ 9.72 (br, s, 1H), 9.63 (br, s, 1H), 
7.70 (d, J=8.4 Hz, 1H), 7.66 (d, J=7.8 Hz, 1H ), 7.23 (d, J=18.6 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 7.02 (d, 
J=7.8 Hz, 1H), 6.96 (d, J=11.4 Hz, 1H), 6.33 (d, J=1.2 Hz, 1H), 6.30 (d, J=1.2 Hz, 1H), 6.18 (dq, J=15.6, 
6.6 Hz, 1H), 5.91 (dq, J=14.4, 7.2 Hz, 1H), 2.52 (s, 3H), 2.50 (s, 3H), 1.98 (dd, J=6.6, 1.2 Hz, 3H), 1.75 
(dd, J=7.2, 1.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 137.7, 137.4, 131.4, 131.3, 131.3, 130.5, 130.4, 
130.3, 129.8, 129.1, 128.9, 128.8, 126.5, 126.2, 125.7, 123.2, 120.5, 101.5, 101.4, 18.9, 14.5, 13.7; IR 
(ATR) 3399, 1507, 1333, 1217, 764 cm-1; HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
2,5-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (338). Reaction of a solution of 286 (42.7 mg, 0.172 mmol), 
Pd(OAc)2 (9.9 mg, 0.017 mmol), and dppp (7.1 mg, 0.017 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 48 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 85:15) 
338 (11.4 mg, 0.062 mmol, 36%) as a white solid.  
     
3,6-Dimethyl-1H,6H-pyrrolo[2,3-g]indole (340). Reaction of a solution of 287 (29.2 mg, 0.118 mmol), 
Pd(OAc)2 (2.6 mg, 0.012 mmol), and 1,10-phen (2.6 mg, 0.014 mmol) in DMF (1.5 mL), as described for 
336 (pCO = 6 atm, 120 oC, 98 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
340 (11.7 mg, 0.061 mmol, 54%) as a white solid. mp=245 oC (decomposition);   1H NMR (400 MHz, 
Acetone-d6) δ 9.73 (br, s, 2H), 7.19 (s, 2H), 6.92 (m, 2H), 2.32 (d, J=1.2 Hz, 6H); 
13C NMR (100 MHz, 
Acetone-d6) δ 124.9, 124.3, 119.5, 112.4, 111.4, 10.3;  IR (ATR) 3367, 1548, 1433, 1323, 1232 cm
-1; 
HRMS (ESI) calcd for C12H13N2 (M+H
+) 185.1079, found 
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3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (340). Reaction of a solution of 287 (39.6 mg, 0.160 mmol), 
Pd(dba)2 (9.2 mg, 0.016 mmol), dppp (6.6 mg, 0.016 mmol), and 1,10-phen (5.7 mg, 0.032 mmol) in 
DMF (1.5 mL), as described for 336 (pCO = 6 atm, 120 oC, 110 h), gave, after solvent removal and 
chromatography (Hexane/EtOAc, 7:3) 340 (19.6 mg, 0.106 mmol, 67%) as a white solid.  
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (340). Reaction of a solution of 287 (34.6 mg, 0.139 mmol), 
Pd(dba)2 (8 mg, 0.014 mmol), and PPh3 (14.7 mg, 0.056 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 60 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 340 
(15.8mg, 0.086 mmol, 62%) as a white solid.  
 
3-Methyl-7-nitro-6-(1-propen-2-yl)indole (341). Reaction of a solution of 287 (21.3 mg, 0.086 mmol), 
Pd(OAc)2 (1.3 mg, 0.006 mmol), and dppp (2.5 mg, 0.006 mmol) in DMF (1 mL), as described for 336 
(pCO = 6 atm, 120 oC, 72 h), gave, in order of elution, after solvent removal and chromatography 
(Hexane/EtOAc, 9:1) 341 (14.5 mg, 0.067 mmol, 78%) as a yellow oil) and  340 (2.6 mg, 0.014 mmol, 
16%) as a white solid. Analytical data for 341: mp=179 oC (decomposition); 1H NMR (400 MHz, CDCl3) 
δ 9.62 (br, s, 1H), 7.78 (d, J=7.6 Hz, 1H), 7.12 (s, with further fine splitting, 1H), 7.01 (d, J=7.6 Hz, 1H), 
5.19 (s, with further fine splitting, 1H), 4.93 (s, with further fine splitting, 1H), 2.35 (s, with further fine 
splitting, 3H), 2.13 (s, with further fine splitting, 3H); 13C NMR (100 MHz, CDCl3) δ 145.4, 136.7, 131.1, 
130.3, 125.5, 123.8, 121.7, 113.7, 112.9, 23.7, 9.4; IR (ATR) 3330, 1493, 1301, 1268, 1096, 894 cm-1; 
HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (342). Reaction of a solution of 317 (56 mg, 0.239 mmol), 
Pd(OAc)2 (4.3 mg, 0.019 mmol), and 1,10-phen (3.5 mg, 0.019 mmol) in DMF (3 mL), as described for 
336 (pCO = 6 atm, 120 oC, 100 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
342 (25.7 mg, 0.151 mmol, 63%) as a white solid. mp=179 oC (decomposition);   1H NMR (400 MHz, 
CDCl3) δ 7.38 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 6.67 (br, s, 1H), 6.65-6.63 (m, 1H), 6.59-6.58 
(m, 1H), 6.55 (br, s, 1H), 6.32-6.31 (m, 1H), 2.33 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 132.5, 124.0, 
122.6, 121.7, 121.6, 121.5, 113.3, 113.1, 102.9, 101.3, 13.5; IR (ATR) 3356, 1532, 1473, 1302, 1272 cm-
1; HRMS (ESI) calcd for 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (342). Reaction of a solution of 317 (31 mg, 0.132 mmol), 
Pd(OAc)2 (1.5 mg, 0.007 mmol), and PPh3 (6.9 mg, 0.026 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 31 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3), 342 
(5.7 mg, 0.033 mmol, 25%) as a white solid. 
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3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (343). Reaction of a solution of 318 (52.3 mg, 0.223 mmol), 
Pd(OAc)2 (3 mg, 0.013 mmol), and 1,10-phen (2.4 mg, 0.013 mmol) in DMF (3 mL), as described for 336 
(pCO = 6 atm, 120 oC, 98 h), gave, after solvent removal and chromatography (Hexane/DCM, 3:7) 343 
(24.5 mg, 0.144 mmol, 65%) as a white solid. mp=181 oC (decomposition);   1H NMR (400 MHz, CDCl3) 
δ 7.43 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 6.74-6.73 (m, 1H), 6.63 (m, 2H), 6.55 (s, 1H), 6.45 (br, 
s, 1H), 2.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 123.4, 123.1, 121.9, 121.9, 121.7, 119.4, 113.1, 
112.3, 112.0, 103.0, 10.0; , IR (ATR) 3380, 1548, 1403, 1375, 1205 cm-1; HRMS (ESI) calcd for 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (344). Reaction of a solution of 319 (41.3 mg, 0.166 mmol), 
Pd(OAc)2 (2.7 mg, 0.012 mmol), and 1,10-phen (2.1 mg, 0.012 mmol) in DMF (2 mL), as described for 
336 (pCO = 6 atm, 120 oC, 100 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 8:2) 
344 (20.6 mg, 0.112 mmol, 67%) as a white solid. mp=210 oC (decomposition);   1H NMR (400 MHz, 
CDCl3/DMSO-d6) δ 10.36 (br, s, 1H), 9.92 (br, s, 1H), 7.01 (s, 2H), 6.87-6.86 (m, 1H), 6.10-6.09 (m, 1H), 
2.41 (d, J=0.8 Hz, 3H), 2.25 (d, J=0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3/DMSO-d6) δ 130.5, 123.4, 
122.5, 122.5, 122.2, 118.3, 111.2, 110.5, 110.2, 100.3, 13.3, 9.9; IR (ATR) 3396, 1601, 1406, 1343, 1263 
cm-1; HRMS (ESI) calcd for C12H13N2 (M+H
+) 185.1979, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (345). Reaction of a solution of 320 (79.8 mg, 0.273 mmol), 
Pd(OAc)2 (3.7 mg, 0.016 mmol), and 1,10-phen (3 mg, 0.017 mmol) in DMF (3 mL), as described for 336 
(pCO = 6 atm, 120 oC, 109 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 6:4) 345 
(42.1 mg, 0.184 mmol, 68%) as a white solid. mp=199 oC (decomposition);   1H NMR (400 MHz, 
DMSO-d6) δ 11.45 (br, s, 1H), 10.68 (br, s, 1H), 7.94 (d, J=2.8 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.35 (d, 
J=8.8 Hz, 1H), 7.27 (t, J=2.8 Hz, 1H), 6.51 (dd, J=2.8, 2.0 Hz, 1H), 4.29 (quartet, J=7.2 Hz, 2H), 1.34 (t, 
J=7.2 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 128.7, 123.6, 123.0, 122.3, 122.3, 120.6, 114.8, 
112.5, 108.0, 102.5, 58.8, 14.5; IR (ATR) 3325, 1642, 1433, 1175 cm-1; HRMS (ESI) calcd for 
C13H13N2O2 (M+H
+) 229.0977, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (346). Reaction of a solution of 321 (59.2 mg, 0.193 mmol), 
Pd(OAc)2 (3.1 mg, 0.014 mmol), and 1,10-phen (2.5 mg, 0.014 mmol) in DMF (3 mL), as described for 
336 (pCO = 6 atm, 120 oC, 108 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 1:1) 
346 (34.2 mg, 0.141 mmol, 73%) as a white solid. mp=235 oC (decomposition);   1H NMR (400 MHz, 
DMSO-d6) δ 11.16 (br, s, 1H), 10.56 (br, s, 1H), 7.89 (d, J=3.2 Hz, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.22 (d, 
J=8.4 Hz, 1H), 6.19 (s, with further fine splitting, 1H), 4.28 (quartet, J=7.2 Hz, 2H), 2.44 (s, 3H), 1.34 (t, 
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J=7.2 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 131.9, 128.7, 124.3, 122.6, 122.0, 120.2, 114.1, 
112.1, 107.9, 100.6, 58.8, 14.5, 13.4; IR (ATR) 3343, 1651, 1403, 1313, 1170, 803 cm-1; HRMS (ESI) 
calcd for C14H15N2O2 (M+H
+) 243.1134, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (347). A solution of 322 (85.3 mg, 0.279 mmol), Pd(OAc)2 
(3.2 mg, 0.014 mmol), and 1,10-phen (2.5 mg, 0.014 mmol) in DMF (3 mL) was stirred under CO (pCO 
= 6 atm) at 120 oC for 110 h. After coling to ambient temperature, pressure was released and the reaction 
mixture was diluted with EtOAc (30 mL). The organic layer was washed with brine (6x10 mL), dried 
(MgSO4) and was filtered. The filtrate was concentrated and the resulting crude was purified by 
chromatography (Hexane/EtOAc, 1:1) to give 347 (50.2 mg, 0.207 mmol, 74%) as a white solid. mp=233 
oC (decomposition); 1H NMR (400 MHz, DMSO-d6) δ 11.43 (br, s, 1H), 10.33 (br, s, 1H), 7.93 (d, J=2.8 
Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.29 (d, J=8.4 Hz, 1H), 7.04 (s, with further fine splitting, 1H), 4.28 
(quartet, J=7.2 Hz, 2H), 2.29 (s, 3H), 1.34 (t, J=7.2 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 
128.7, 123.8, 123.0, 122.5, 120.8, 119.8, 113.0, 111.8, 110.7, 107.9, 58.8, 14.5, 9.9; IR (ATR) 3350, 
1644, 1428, 1184, 1133 cm-1; HRMS (ESI) calcd for C14H15N2O2 (M+H
+) 243.1134, found 
 
2-Methyl-6-nitro-5-(1-propen-1-yl)indole (348). Reaction of a solution of 290 (35.9 mg, 0.145 mmol), 
Pd(OAc)2 (2.3 mg, 0.010 mmol), and 1,10-phen (1.8 mg, 0.010 mmol) in DMF (1.5 mL), as described for 
336 (pCO = 6 atm, 120 oC, 46 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 
85:15) 348 (11.6 mg, 0.054 mmol, 37%) as a yellow solid. mp=118-119 oC;  1H NMR (400 MHz, CDCl3) 
δ 8.29 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 8.03 (s, 1H), 7.56 (s, 1H), 7.37 (s, 1H), 7.03 – 6.94 (m, 1H), 6.87 
– 6.81 (m, 1H), 6.30-6.27 (m, 2H), 6.09 (dq, J = 15.6, 6.8 Hz, 1H), 5.86 (dq, J = 11.6, 7.2 Hz, 1H), 2.51 
(d, J = 0.8 Hz, 3H), 2.49 (d, J = 0.8 Hz, 3H), 1.93 (dd, J = 6.8, 2.0 Hz, 3H), 1.74 (dd, J = 7.2, 2.0 Hz, 3H); 
13C NMR (100 MHz, DMSO-d6) δ 143.4, 143.3, 141.3, 141.0, 133.6, 133.5, 132.9, 132.4, 128.3, 126.6, 
125.1, 124.8, 122.9, 120.8, 117.9, 108.1, 107.7, 100.5, 100.4, 18.5, 14.1, 13.7, 13.6; IR (ATR) 3353, 
1490, 1437, 1297 cm-1; HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (348). Reaction of a solution of 290 (35.6 mg, 0.143 mmol), 
Pd(dba)2 (6.6 mg, 0.010 mmol), and PPh3 (12 mg, 0.046 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 92 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 348 
(19.9 mg, 0.092 mmol, 64%) as a yellow solid.  
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3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (349). Reaction of a solution of 291 (45.6 mg, 0.184 mmol), 
Pd(dba)2 (5.3 mg, 0.009 mmol), dppp (3.8 mg, 0.009 mmol), and 1,10-phen (3.3 mg, 0.018 mmol) in 
DMF (2 mL), as described for 347 (pCO = 6 atm, 120 oC, 82 h), gave, after solvent removal and 
chromatography (Hexane/EtOAc, 7:3) 349 (18.1 mg, 0.098 mmol, 53%) as a white solid. mp=200 oC 
(decomposition);   1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.57 (br, s, 2H), 7.19 (s, 1H), 6.93 (s, 2H), 
2.41 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 135.2, 124.7, 121.1, 111,0, 106.7, 90.9, 10.0; IR (ATR) 
3329, 1474, 1301, 1092 cm-1; HRMS (ESI) calcd for C12H13N2 (M+H
+) 185.1079, found 
 
3-Methyl-6-nitro-5-(1-propen-2-yl)indole (350). Reaction of a solution of 291 (56.5 mg, 0.228 mmol), 
Pd(OAc)2 (3.1 mg, 0.014 mmol), and 1,10-phen (2.5 mg, 0.014 mmol) in DMF (2 mL), as described for 
336 (pCO = 6 atm, 120 oC, 50 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
350 (9.7 mg, 0.045 mmol, 20%) as a yellow solid. mp=117-118 oC;   1H NMR (600 MHz, CDCl3) δ 8.29 
(br, s, 1H), 8.08 (s, 1H), 13C NMR (150 MHz, CDCl3) δ 145.2, 143.2, 133.7, 131.6, 131.2, 127.4, 120.0, 
114.0, 112.7, 108.5, 24.1, 9.5; IR (ATR) 3335, 1206, 1100, 896 cm-1; HRMS (ESI) calcd for C12H13N2O2 
(M+H+) 217.0977, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (350). Reaction of a solution of 291 (51.7 mg, 0.208 mmol), 
Pd(dba)2 (7.1 mg, 0.012 mmol), and PPh3 (13.1 mg, 0.050 mmol) in DMF (2 mL), as described for 336 
(pCO = 6 atm, 120 oC, 121 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 350 
(38.1 mg, 0.176 mmol, 85%) as a yellow solid.  
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (351). Reaction of a solution of 292 (29.3 mg, 0.133 mmol), 
Pd(OAc)2 (2.1 mg, 0.009 mmol), and 1,10-phen (1.7 mg, 0.009 mmol) in DMF (1 mL), as described for 
336 (pCO = 6 atm, 120 oC, 48 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
351 (12.5 mg, 0.080 mmol, 60%) as a white solid. mp=239 oC (decomposition); 1H NMR (600 MHz, 
CDCl3) δ 7.91 (br, s, 2H), 7.58 (s, 2H), 
13C NMR (100 MHz, CDCl3) δ 133.2, 126.0, 125.0, 101.4, 100.0; 
IR (ATR) 3336, 1156, 1053, 756 cm-1; HRMS (ESI) calcd for C10H9N2 (M+H
+) 157.0766, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (XX). Reaction of a solution of 292 (29.3 mg, 0.133 mmol), 
Pd(dba)2 (4.6 mg, 0.008 mmol), and PPh3 (8.5 mg, 0.032 mmol) in DMF (1 mL), as described for 336 
(pCO = 6 atm, 120 oC, 64 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) XX 
(14 mg, 0.074 mmol, 56%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7
13C NMR (100 MHz, 
CDCl3) δ 1IR (ATR) cm
-1; HRMS (ESI) calcd for 
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2-Methyl-5-nitro-6-(1-propen-1-yl)indole (352). Reaction of a solution of 293 (39 mg, 0.157 mmol), 
Pd(OAc)2 (2.5 mg, 0.011 mmol), and 1,10-phen (2 mg, 0.011 mmol) in DMF (2 mL), as described for 336 
(pCO = 6 atm, 120 oC, 49 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 352 
(10.5 mg, 0.049 mmol, 31%) as a yellow solid. mp=111-112 oC;   1H NMR (600 MHz, CDCl3) δ 8.31 (s, 
1H), 8.18 (s, 1H), 8.18 (br, s, 1H), 8.15 (br, s, 1H), 7.32 (s, 1H), 7.15 (s, 1H), 6.97 (d, J=15.6 Hz, 1H), 
6.84 (d, J=11.4 Hz, 1H), 6.34 (s, 1H), 6.29 (s, 1H), 6.07 (dq, J=15.6, 6.0 Hz, 1H), 5.85 (dq, J=11.4, 6.6 
Hz, 1H), 2.48 (s, 3H), 2.47 (s, 3H), 1.93 (d, J=6.6 Hz, 3H), 1.72 (d, J=6.6 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 142.3, 142.0, 138.8, 138.7, 138.5, 138.0, 128.5, 128.2, 127.8, 127.8, 127.4, 127.4, 126.1, 126.1, 
117.6, 117.2, 112.4, 109.2, 102.1, 102.0, 18.6, 14.3, 13.8; IR (ATR) 3321, 1462, 1285, 823 cm-1; HRMS 
(ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (352). Reaction of a solution of 293 (45.6 mg, 0.184 mmol), 
Pd(dba)2 (6.4 mg, 0.011 mmol), and PPh3 (11.6 mg, 0.044 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 72 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 352 
(39.7 mg, 0.184 mmol, 100%) as a yellow solid.  
 
3-Methyl-5-nitro-6-(1-propen-2-yl)indole (353). Reaction of a solution of 294 (45.2 mg, 0.182 mmol), 
Pd(dba)2 (6.3 mg, 0.011 mmol), and PPh3 (11.5 mg, 0.044 mmol) in DMF (2 mL), as described for 347 
(pCO = 6 atm, 120 oC, 72 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 9:1) 353 
(28.7 mg, 0.133 mmol, 73%) as a yellow solid. mp=114-115 oC;   1H NMR (400 MHz, CDCl3) δ 8.34 (br, 
s, 1H), 8.30 (s, 1H), 7.20 (s, 1H), 7.10 (s, 1H), 5.14 (s, 1H), 4.95 (s, 1H), 2.34 (s, 3H), 2.11 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 145.1, 141.5, 138.1, 133.9, 126.8, 124.7, 117.0, 114.0, 113.8, 112.2, 23.8, 9.5; 
IR (ATR) 3337, 1208, 1113, 836 cm-1; HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (YY). Reaction of a solution of 294 (24.9 mg, 0.100 mmol), 
Pd(dba)2 (3.5 mg, 0.006 mmol), and PPh3 (6.3 mg, 0.024 mmol) in DMF (1.5 mL), as described for 336 
(pCO = 6 atm, 120 oC, 68 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) YY 
(4.8 mg, 0.026 mmol, 26%) as a white solid. mp=214 oC (decomposition); 1H NMR (400 MHz, 
CDCl3/DMSO-d6) δ 9.88 (br, s, 2H), 7.25 (s, 2H), 6.91 (s, 2H), 2.25 (s, 3H); 
13C NMR (100 MHz, 
CDCl3/DMSO-d6) δ 132.9, 125.9, 122.2, 107.6, 97.4, 9.8; IR (ATR) 3315, 1476, 1300, 1175 cm
-1; HRMS 
(ESI) calcd for C12H13N2 (M+H
+) 185.1079, found 
 
4-Ethenyl-5-nitroindole(354). A solution of 295 (81.4 mg, 0.370 mmol), Pd(OAc)2 (4.2 mg, 0.018 
mmol), and 1,10-phen (3.4 mg, 0.019 mmol) in DMF (3 mL) was stirred under CO (pCO = 6 atm) at 120 
198 
 
oC for 120 h. After coling to ambient temperature, pressure was released and the reaction mixture was 
concentrated under reduced pressure via bulb-to-bulb distillation. The resulting crude was purified by 
chromatography (Hexane/EtOAc, 7:3) to give 354 (30.1 mg, 0.160 mmol, 43%) as a yellow solid solid. 
mp=143-144 oC; 1H NMR (400 MHz, CDCl3/DMSO-d6) δ 11.35 (br, s, 1H), 7.77 (d, J=9.2 Hz, 1H), 7.33 
(d, J=9.2 Hz, 1H), 7.32 (dd, J=5.6, 2.8 Hz, 1H), 7.20 (dd, J=17.6, 11.2 Hz, 1H), 6.72-6.71 (m, 1H), 5.66 
(dd, J=17.6, 1.6 Hz, 1H), 5.60 (dd, J=11.6, 1.6 Hz, 1H); 13C NMR (100 MHz, CDCl3/DMSO-d6) δ 139.4, 
137.9, 132.4, 127.8, 127.5, 126.0, 119.3, 117.5, 110.4, 103.4; IR (ATR) 3323, 1311, 929, 739 cm-1; 
HRMS (ESI) calcd for C10H9N2O4 (M+H
+) 189.0664, found 
 
(354). Reaction of a solution of 295 (71.1 mg, 0.323 mmol), Pd(dba)2 (9.5 mg, 0.016 mmol), and PPh3 
(16.9 mg, 0.065 mmol) in DMF (2.5 mL), as described for 354 (pCO = 6 atm, 120 oC, 110 h), gave, after 
solvent removal and chromatography (Hexane/EtOAc, 7:3) 354 (41.1 mg, 0.218 mmol, 68%) as a yellow 
solid.  
 
2-Methyl-5-nitro-4-(1-propen-1-yl)indole(355). Reaction of a solution of 296 (70.4 mg, 0.284 mmol), 
Pd(OAc)2 (3.3 mg, 0.015 mmol), and 1,10-phen (2.7 mg, 0.015 mmol) in DMF (3 mL), as described for 
336 (pCO = 6 atm, 120 oC, 70 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
355 (45.3 mg, 0.209 mmol, 74%) as a yellow solid. mp=101-103 oC;  1H NMR (600 MHz, CDCl3) δ 8.34 
(br, s, 2H), 7.93 (d, J=9.0 Hz, 1H), 7.82 (d, J=9.0 Hz, 1H), 7.22 (d, J=9.0 Hz, 1H), 7.16 (d, J=9.0 Hz, 1H), 
6.98 (dq, J=16.2, 1.8 Hz, 1H), 6.85 (dq, J=11.4, 1.8 Hz, 1H), 6.50-6.49 (m, 1H), 6.24-6.18 (m, 2H), 5.97 
(dq, J=13.8, 7.2 Hz, 1H), 2.47 (m, 6H), 2.01 (dd, J=7.2, 1.8 Hz, 3H), 1.50 (dd, J=6.6, 1.8 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) δ 141.1, 140.6, 138.1, 137.9, 137.7, 137.7, 132.0, 128.5, 128.0, 127.9, 127.8, 
126.8, 126.4, 125.4, 118.3, 118.3, 108.9, 108.7, 103.1, 102.9, 19.0, 15.1, 13.8, 13.7; IR (ATR) 3351, 
1508, 1316, 1172 cm-1; HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
(355). Reaction of a solution of 296 (34.5 mg, 0.139 mmol), Pd(dba)2 (4 mg, 0.007 mmol), and PPh3 (7.3 
mg, 0.028 mmol) in DMF (2 mL), as described for 336 (pCO = 6 atm, 120 oC, 72 h), gave, after solvent 
removal and chromatography (Hexane/EtOAc, 8:2) 355 (20.9 mg, 0.097 mmol, 70%) as a yellow solid. 
 
3-Methyl-5-nitro-4-(1-propen-2-yl)indole(356). Reaction of a solution of 297 (80.3 mg, 0.323 mmol), 
Pd(OAc)2 (3.7 mg, 0.016 mmol), and 1,10-phen (3.0 mg, 0.017 mmol) in DMF (3 mL), as described for 
354 (pCO = 6 atm, 120 oC, 100 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
356 (60.3 mg, 0.279 mmol, 86%) as a yellow solid. mp=98-99 oC;  1H NMR (400 MHz, CDCl3) δ 8.43 
(br, s, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.28 (d, J=8.8 Hz, 1H), 7.09-7.08 (m, 1H), 5.32-5.30 (m, 1H), 4.91-
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4.90 (m, 1H), 2.38 (d, J=0.8 Hz, 3H), 2.30-2.29 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 141.3, 140.9, 
138.6, 134.3, 125.2, 124.8, 118.7, 115.1, 114.8, 110.0, 25.3, 11.6; IR (ATR) 3369, 1406, 799 cm-1; 
HRMS (ESI) calcd for C12H13N2O2 (M+H
+) 217.0977, found 
 
(356). Reaction of a solution of 297 (57.7 mg, 0.232 mmol), Pd(dba)2 (6.7 mg, 0.012 mmol), dppp (4.8 
mg, 0.012 mmol), and 1,10-phen (4.2 mg, 0.023 mmol) in DMF (2.5 mL), as described for 354 (pCO = 6 
atm, 120 oC, 91 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 356 (25.7 mg, 
0.119 mmol, 51%) as a yellow solid. 
 
5-Nitro-4-(1-propen-1-yl)indole (357) and 4-ethenyl-2-methyl-5-nitroindole (358). Reaction of a 
solution of 327 (75.2 mg, 0.321 mmol), Pd(dba)2 (11.1 mg, 0.019 mmol), dppp (7.9 mg, 0.019 mmol), 
and 1,10-phen (6.9 mg, 0.038 mmol) in DMF (3 mL), as described for 336 (pCO = 6 atm, 120 oC, 74 h), 
gave, after solvent removal and chromatography (Hexane/EtOAc, 85:15) an inseparable mixture of 357 
and 358 (28.9 mg, 0.143 mmol, 45%, 357/358, 1:1) as a yellow oil. 
 
5-Nitro-4-(1-propen-2-yl)indole (359) and 4-ethenyl-3-methyl-5-nitroindole (360). Reaction of a 
solution of 328 (83.9 mg, 0.358 mmol), Pd(OAc)2 (4.8 mg, 0.021 mmol), and 1,10-phen (3.9 mg, 0.022 
mmol) in DMF (3 mL), as described for 336 (pCO = 6 atm, 120 oC, 96 h), gave, after solvent removal and 
chromatography (Hexane/EtOAc, 8:2) an inseparable mixture of 359 and 360 (51 mg, 0.252 mmol, 70%, 
359/360, 1:1) as a yellow oil. 
 
5-Nitro-3-methyl-4-(1-propen-1-yl)indole (361) and 5-nitro-2-methyl-4-(1-propen-2-yl)indole (362). 
Reaction of a solution of 329 (81.5 mg, 0.328 mmol), Pd(OAc)2 (5.2 mg, 0.023 mmol), and 1,10-phen 
(4.2 mg, 0.023 mmol) in DMF (3 mL), as described for 336 (pCO = 6 atm, 120 oC, 122 h), gave, after 
solvent removal and chromatography (Hexane/EtOAc, 8:2) an inseparable mixture of 361 and 362 (54.6 
mg, 0.253 mmol, 77%, 361/362, 1:1) as a yellow oil. 
 
3,6-Dimethyl-1H,6H-pyrrolo[3,2-g]indole (363) and (364). Reaction of a solution of 298 (78.5 mg, 
0.357 mmol), Pd(OAc)2 (4.8 mg, 0.021 mmol), and 1,10-phen (3.9 mg, 0.022 mmol) in DMF (3 mL), as 
described for 336 (pCO = 6 atm, 120 oC, 101 h), gave, in order of elution, after solvent removal and 
chromatography (Hexane/DCM, 1:1) 364 (13.7 mg, 0.073 mmol, 20%) as a yellow solid and 363 (28 mg, 
0.179 mmol, 50%) as a white solid. Analytical data for 363: mp=138-139 oC; 1H NMR (400 MHz, 
CDCl3/DMSO-d6 ) δ 11.06 (br, s, 1H), 10.89 (br, s, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.13 (t, J = 2.8 Hz, 1H), 
7.07 (d, J = 8.8 Hz, 1H), 7.05 (t, J=2.8 Hz, 1H), 6.62 (t, J = 2.4 Hz, 1H), 6.40 (dd, J = 2.8, 2.0 Hz, 1H). 
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 13C NMR (100 MHz, CDCl3/DMSO-d6) δ 132.4, 128.6, 121.6, 120.0, 119.6, 114.2, 113.4, 104.9, 101.9, 
97.9; IR (ATR) 3426, 3363, 1389, 718 cm-1; C10H9N2 (M+H
+) 157.0766, found cm-1; HRMS (ESI) calcd 
for Analytical data for 364: mp=97-98 oC; 1H NMR (400 MHz, CDCl3) δ 8.58 (br, s, 1H), 7.59 (d, J=8.4 
Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.38 (t, J=2.4 Hz, 1H), 7.25 (dd, J=17.2, 10.8 Hz, 1H), 6.92 (s, with 
further fine splitting, 1H), 5.73 (d, J=17.2 Hz, 1H), 5.43 (d, J=10.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 140.0, 136.8, 133.3, 127.7, 126.5, 122.2, 121.4, 117.0, 116.0, 102.6; IR (ATR) 3461, 1520, 1264, 731 
cm-1; HRMS (ESI) calcd for C10H9N2O2 (M+H
+) 189.0664, found 
 
7-Ethenyl-6-nitroindole (364). Reaction of a solution of 298 (45.6 mg, 0.207 mmol), Pd(dba)2 (7.1 mg, 
0.012 mmol), and PPh3 (13 mg, 0.050 mmol) in DMF (2 mL), as described for 354 (pCO = 6 atm, 120 
oC, 
126 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 364 (19.2 mg, 0.102 mmol, 
49%) as a yellow solid.  
 
5-Ethenyl-3-methyl-4-nitroindole (365). Reaction of a solution of 331 (49.1 mg, 0.210 mmol), 
Pd(OAc)2 (2.4 mg, 0.011 mmol), and 1,10-phen (1.9 mg, 0.011 mmol) in DMF (2.5 mL), as described for 
354 (pCO = 6 atm, 120 oC, 71 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 
365 (31 mg, 0.153 mmol, 73%) as a yellow sticky oil. mp=64-65 oC;   1H NMR (400 MHz, CDCl3) δ 8.23 
(br, s, 1H), 7.41 (s, 2H), 7.04 (m, 1H), 6.81 (dd, J=17.2, 10.8 Hz, 1H), 5.77 (dd, J=17.2, 0.8 Hz, 1H), 5.38 
(dd, J=10.8, 0.8 Hz, 1H), 2.18 (d, J=0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.1, 137.6, 130.4, 
125.1, 121.5, 119.4, 118.6, 116.8, 113.7, 110.4, 9.8; IR (ATR) 3392, 1504, 1331, 807 cm-1; HRMS (ESI) 
calcd for C11H11N2O2 (M+H
+) 203.0821, found 
 
4-Nitro-5-(1-propen-2-yl)indole (366). Reaction of a solution of 330 (57.8 mg, 0.247 mmol), Pd(OAc)2 
(4.4 mg, 0.020 mmol), and 1,10-phen (3.6 mg, 0.020 mmol) in DMF (2 mL), as described for 354 (pCO = 
6 atm, 120 oC, 108 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 366 (30.3 
mg, 0.150 mmol, 61%) as a yellow solid. mp=100-101 oC; 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 
7.56 (d, J = 8.4 Hz, 1H), 7.39 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.89 (s, 1H), 5.17 (s, 1H), 4.95 (s, 1H), 
2.15 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 143.8, 139.7, 136.4, 132.2, 127.9, 123.3, 122.0, 115.5, 114.7, 
101.9, 23.8; IR (ATR) 3387, 1488, 1333, 814 cm-1; HRMS (ESI) calcd for C11H11N2O2 (M+H
+) 203.0821, 
found 
 
4-Nitro-5-(1-propen-2-yl)indole (366) and pyrroloindole (367). Reaction of a solution of 330 (62.8 mg, 
0.268 mmol), Pd(dba)2 (9.3 mg, 0.016 mmol), dppp (6.6 mg, 0.016 mmol) and 1,10-phen (5.8 mg, 0.032 
mmol) in DMF (2 mL), as described for 354 (pCO = 6 atm, 120 oC, 72 h), gave, after solvent removal and 
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chromatography (Hexane/EtOAc, 8:2) an inseparable mixture of 366 and 367 (27.5 mg, 367 nearly 8% of 
the mixture) as a yellow oil. 
 
1-Acetoxy-2-methyl-5-nitro-6-(1-propen-1-yl)indole(368). A solution of 352 (35.6 mg, 0.165 mmol), 
acetic anhydride ((CH3CO)2O, (0.6 mL, 6.347 mmol), 4-dimethylaminopyridine (77 mg, 0.630 mmol), 
and Et3N (0.7 mL, 5.019 mmol) in 1,2-dichloroethane (DCE, 2 mL) was stirred at 75 
oC under a nitrogen 
atmosphere for 18 h. After cooling to ambient temperature, the mixture was diluted with water and was 
extracted in EtOAc (2x10 mL). The organic layer was dried (MgSO4), filtered and was concentrated 
under reduced pressure. The resulting crude was purified by chromatography (Hexane/EtOAc, 8:2) to 
give 368 (42.4 mg, 0.164 mmol, 100%) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.29 (s, 1H), 8.16 
(s, 1H), 8.08 (s, 1H), 8.03 (s, 1H), 6.94 (dd, J = 15.5, 1.7 Hz, 1H), 6.82 (dd, J = 11.5, 1.5 Hz, 1H), 6.47 (d, 
J = 0.8 Hz, 1H), 6.43 (d, J = 0.8 Hz, 1H), 6.21 (dq, J = 15.3, 6.6 Hz, 1H), 5.93 (dq, J = 11.4, 7.1 Hz, 1H), 
2.74 (d, J = 3.5 Hz, 6H), 2.67 (dd, J = 8.3, 1.0 Hz, 6H), 1.95 (dd, J = 6.7, 1.7 Hz, 3H), 1.78 (dd, J = 7.1, 
1.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.04, 170.0, 144.4, 143.9, 139.9, 139.7, 139.0, 138.4, 
129.8, 129.6, 128.2, 128.1, 128.0, 127.6, 127.5, 127.3, 118.0, 116.4, 116.1, 114.9, 109.7, 109.6, 27.2, 
27.2, 18.7, 17.6, 17.6, 14.3; IR (ATR) 1710, 1510, 1365, 1295 cm-1; HRMS (ESI) calcd for C14H15N2O3 
(M+H+) 259.1083, found 
 
2-Methyl-5-nitro-6-(1-propen-1-yl)indole(352). Reaction of a solution of 368 (33.4 mg, 0.129 mmol), 
Pd(dba)2 (3.7 mg, 0.006 mmol), dppp (2.7 mg, 0.007 mmol), and 1,10-phen (2.3 mg, 0.013 mmol) in 
DMF (2 mL), as described for 354 (pCO = 6 atm, 120 oC, 36 h), gave, after solvent removal and 
chromatography (Hexane/EtOAc, 7:3) 352 (11 mg, 0.051 mmol, 39%) as a yellow solid. 
 
1-Acetoxy-2-methyl-5-nitro-4-(1-propen-2-yl)indole (369). Treatment of a solution of 356 (50 mg, 
0.231 mmol) with (CH3CO)2O (0.84 mL, 8.996 mmol) in the presence of Et3N (0.98 mL, 7.030 mmol), 
and DMAP (108 mg, 0.883 mmol) in DCE (3 mL) under nitrogen atmosphere, as described for 368 (75 
°C, 18 h), gave after work up and chromatography (Hexane/EtOAc, 8:2) 369 (56.3 mg, 0.218 mmol, 
94%) as a white solid. mp=189-190 oC; 1H NMR (600 MHz, CDCl3) δ 8.49 (d, J = 9.1 Hz, 1H), 7.87 (d, J 
= 9.1 Hz, 1H), 7.29 (s, 1H), 5.33 (s, 1H), 4.91 (s, 1H), 2.62 (s, 3H), 2.35 (s, 3H), 2.26 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 168.3, 144.3, 140.1, 138.0, 132.8, 128.3, 125.5, 121.1, 119.4, 116.6, 115.5, 25.5, 
23.9, 11.9; IR (ATR) 1718, 1533, 1371, 1303 cm-1; 
 
3-Methyl-5-nitro-4-(1-propen-2-yl)indole (356). Reaction of a solution of 369 (27.5 mg, 0.106 mmol), 
Pd(dba)2 (3.1 mg, 0.005 mmol), dppp (2.2 mg, 0.005 mmol), and 1,10-phen (1.9 mg, 0.011 mmol) in 
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DMF (2 mL), as described for 354 (pCO = 6 atm, 120 oC, 48 h), gave, after solvent removal and 
chromatography (Hexane/EtOAc, 7:3) a mixture of 356 and the pyrroloindole (7.2 mg). 
3-Methyl-5-nitro-4-(1-propen-2-yl)-1-tosylindole (370). To a slurry of NaH (60%, 84.5 mg, 2.112 
mmol) in DMF (2 mL) at 0 °C under a nitrogen atmosphere was added the solution of 356 (228.3 mg, 
1.056 mmol) in DMF (2 mL) via a syringe and the red solution was allowed to stir for 20 min. A solution 
of p-toluenesulfonyl chloride (TsCl, 241.6 mg, 1.267 mmol) in DMF (2 mL) was added drop wise via a 
syringe at the same temperature. The orange solution was allowed to warm to ambient temperature. After 
8 h, the reaction mixture was quenched with saturated solution of NaHCO3 and diluted with EtOAc (20 
mL). The organic layer was washed with water (6X10 mL), dried (MgSO4) and filtered. The filtrate was 
concentrated under reduced pressure and purified by chromatography (Hexane/EtOAc, 8:2) to afford 370 
(306 mg, 0.826 mml, 78%) as a white solid. mp=154-155 oC ; 1H NMR (600 MHz, CDCl3) δ 8.00 (d, J = 
9.1 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.47 (s, 1H), 7.27 (d, J = 8.2 Hz, 2H), 5.29 
(s, 1H), 4.85 (s, 1H), 2.35 (s, 3H), 2.32 (s, 3H), 2.21 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 145.5, 144.0, 
139.7, 136.9, 134.7, 133.4, 130.0, 128.4, 126.8, 126.2, 120.3, 119.3, 116.5, 112.3, 25.24, 21.44, 11.63; IR 
(ATR) 1518, 1341, 1176, 906, 728 cm-1; 
 
(371). Reaction of a solution of 370 (53.6 mg, 0.145 mmol), Pd(dba)2 (4.3 mg, 0.008 mmol), dppp (3.2 
mg, 0.008 mmol), and 1,10-phen (2.7 mg, 0.015 mmol) in DMF (2 mL), as described for 336 (pCO=6 
atm, 120 oC, 48 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 371 (43.2 mg, 
0.128 mmol, 88%) as an off white solid. mp=147-148 oC ; 1H NMR (600 MHz, CDCl3) δ 8.07 (s, 1H), 
7.88 (d, J = 8.9 Hz, 1H), 7.68 (d, J = 8.1 Hz, 2H), 7.35 (s, 1H), 7.22 (d, J = 8.9 Hz, 1H), 7.07 (d, J = 8.0 
Hz, 2H), 6.92 (s, 1H), 2.51 (s, 3H), 2.49 (s, 3H), 2.21 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 144.3, 
135.3, 133.9, 130.6, 129.5, 126.5, 124.3, 123.1, 122.9, 120.3, 118.8, 111.1, 108.9, 108.5, 21.34, 14.97, 
14.89; IR (ATR) 3417, 1353, 1165, 1087 cm-1; 
 
(372). Treatment of 350 (119.6 mg, 0.553 mmol) with TsCl (137 mg, 0.719 mmol) in DMF (4 mL) in the 
presence of NaH (60%, 44.3 mg, 1.108 mmol), as described for 370 (0 °C -ambient temperature, 8 h), 
gave after work up and chromatography 372 (158.2 mg, 0.427 mmol, 77%) as a white solid. mp=177-178 
oC ; 1H NMR (600 MHz, CDCl3) δ 8.57 (s, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.53 (s, 1H), 7.36 (s, 1H), 7.26 
(d, J = 8.3 Hz, 2H), 5.16 (s, 1H), 4.92 (s, 1H), 2.36 (s, 3H), 2.28 (d, J = 0.7 Hz, 3H), 2.09 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ 145.5, 145.1, 143.6, 134.7, 134.6, 134.3, 132.7, 130.1, 127.6, 126.7, 120.7, 
118.2, 114.9, 110.2, 23.6, 21.5, 9.4; IR (ATR) 1516, 1370, 1175, 906 cm-1; 
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(373). Treatment of 348 (58.3 mg, 0.270 mmol) with TsCl (66.9 mg, 0.351 mmol) in DMF (3 mL) in the 
presence of NaH (60%, 21.6 mg, 0.540 mmol), as described for 370 (0 °C-ambient temperature, 8 h), 
gave after work up and chromatography 373 (69.4 mg, 0.187 mmol, 69%) as a faint yellow solid. 
mp=181-182 oC ; 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.76 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.70 
(d, J = 8.4 Hz, 2H), 7.49 (s, 1H), 7.30 (d, J = 11.2 Hz, 1H), 7.27 – 7.23 (m, 3H), 6.88 (dd, J = 15.5, 1.4 
Hz, 1H), 6.75 (dd, J = 11.4, 1.1 Hz, 1H), 6.39 (s, 1H), 6.36 (s, 1H), 6.18 – 6.08 (m, 1H), 5.89 (dq, J = 
11.5, 7.0 Hz, 1H), 2.64 (s, 3H), 2.62 (s, 3H), 2.38 (s, 3H), 2.37 (s, 3H), 1.92 (dd, J = 6.6, 1.6 Hz, 3H), 
1.71 (dd, J = 7.0, 1.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 145.6, 145.5, 144.7, 144.2, 142.8, 142.8, 
135.5, 134.5, 134.4, 133.3, 132.8, 130.2, 130.2, 129.3, 129.6, 128.1, 127.5, 127.2, 126.9, 126.6, 126.5, 
122.2, 119.1, 111.5, 111.2, 108.9, 108.8, 21.6, 18.7, 15.8, 14.3; IR (ATR) 1518, 1341, 1175, 1096, 811 
cm-1; 
 
(374). Treatment of 353 (159.2 mg, 0.736 mmol) with TsCl (168.4 mg, 0.883 mmol) in DMF (4 mL) in 
the presence of NaH (60%, 58.8 mg, 1.472 mmol), as described for 370 (0 °C-ambient temperature, 8 h), 
gave after work up and chromatography 374 (197.5 mg, 0.533 mmol, 72%) as a white solid. mp=169-170 
oC ; 1H NMR (600 MHz, CDCl3) δ 8.05 (s, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.44 (s, 1H), 7.26 
(d, J = 8.2 Hz, 2H), 5.21 (s, 1H), 4.95 (s, 1H), 2.36 (s, 3H), 2.27 (s, 3H), 2.12 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ 145.5, 144.3, 143.5, 136.6, 135.8, 134.7, 130.4, 130.0, 126.7, 125.7, 118.7, 116.3, 115.3, 
114.7, 23.6, 21.5, 9.4; IR (ATR) 1513, 1338, 1175, 905, 726 cm-1; 
 
(375). Treatment of 352 (127 mg, 0.587 mmol) with TsCl (146.5 mg, 0.768 mmol) in DMF (4 mL) in the 
presence of NaH (60%, 47.2 mg, 1.180 mmol), as described for 370 (0 °C-ambient temperature, 8 h), 
gave after work up and chromatography (Hexane/EtOAc, 9:1), 375 (154.7 mg, 0.418 mmol, 71%) as a 
faint yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.32 (s, 1H), 8.11 (d, J = 11.8 Hz, 2H), 7.95 (s, 1H), 7.67 
(dd, J = 8.2, 3.2 Hz, 4H), 7.26 (d, J = 7.8 Hz, 4H), 6.91 (d, J = 15.4 Hz, 1H), 6.80 (d, J = 11.5 Hz, 1H), 
6.43 (s, 1H), 6.38 (s, 1H), 6.26 (dq, J = 13.3, 6.7 Hz, 1H), 5.94 (dq, J = 14.1, 7.0 Hz, 1H), 2.63 (s, 3H), 
2.60 (s, 3H), 2.37 (s, 6H), 1.97 (d, J = 5.8 Hz, 3H), 1.78 (dd, J = 6.8, 0.9 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 145.5, 145.5, 144.7, 144.3, 140.7, 140.6, 139.0, 138.4, 135.7, 130.1, 130.1, 129.4, 128.1, 127.9, 
127.8, 127.2, 127.0, 126.4, 126.3, 116.8, 116.6, 116.4, 113.3, 109.1, 109.1, 21.5, 18.7, 15.7, 14.3; IR 
(ATR) 1521, 1342, 1165, 1096, 843 cm-1; 
 
(376). Treatment of 354 (41.6 mg, 0.221 mmol) with TsCl (50.6 mg, 0.265 mmol) in DMF (4 mL) in the 
presence of NaH (60%, 10.6 mg, 0.442 mmol), as described for 370 (0 °C-ambient temperature, 12 h), 
gave after work up and chromatography (Hexane/EtOAc, 9:1) 376 (58.5 mg, 0.171 mmol, 77%) as a 
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white solid. mp=148-149 oC ; 1H NMR (600 MHz, CDCl3) δ 8.03 – 7.96 (m, 2H), 7.79 (d, J = 8.3 Hz, 
2H), 7.71 (d, J = 3.7 Hz, 1H), 7.28 (d, J = 8.1 Hz, 2H), 7.17 (dd, J = 17.6, 11.4 Hz, 1H), 6.94 (d, J = 3.7 
Hz, 1H), 5.69 (d, J = 11.4 Hz, 1H), 5.58 (d, J = 17.7 Hz, 1H), 2.37 (s, 3H); 13C NMR (150 MHz, CDCl3) 
δ 145.8, 143.1, 136.7, 134.6, 131.3, 130.2, 130.0, 128.9, 128.6, 126.9, 121.4, 120.9, 112.5, 109.3, 21.6; IR 
(ATR) 1513, 1374, 1168, 823 cm-1; 
 
(377). Treatment of 355 (128.7 mg, 0.595 mmol) with TsCl (147.5 mg, 0.774 mmol) in DMF (5 mL) in 
the presence of NaH (60%, 47.6 mg, 1.190 mmol), as described for 370 (0 °C-ambient temperature, 10 h), 
gave after work up and chromatography (Hexane/EoOAc, 8:2), 377 (174.4 mg, 0.471 mmol, 79%) as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 9.2 Hz, 1H), 7.98 (d, J = 
9.2 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.70 (dd, J = 8.2, 5.5 Hz, 3H), 7.26 (dd, J = 8.1, 4.1 Hz, 3H), 6.82 
(dd, J = 15.9, 1.5 Hz, 1H), 6.71 (dd, J = 11.4, 1.1 Hz, 1H), 6.60 (s, 1H), 6.34 (s, 1H), 6.00 (ddq, J = 20.8, 
11.5, 6.8 Hz, 2H), 2.62 (s, 6H), 2.36 (d, J = 2.7 Hz, 6H), 1.95 (dd, J = 6.6, 1.6 Hz, 3H), 1.42 (dd, J = 7.0, 
1.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 145.5, 145.5, 143.7, 143.1, 139.9, 139.6, 138.6, 138.2, 135.6, 
135.5, 133.3, 130.1, 130.0, 129.3, 129.1, 128.9, 127.0, 126.3, 126.3, 125.9, 124.7, 123.8, 120.0, 119.9, 
113.0, 112.6, 109.7, 109.6, 21.4, 18.8, 15.6, 14.9; IR (ATR) 1518, 1365, 1176, 1095, 810 cm-1; 
 
(378). Treatment of 366 (50.8 mg, 0.251 mmol) with TsCl (57.4 mg, 0.301 mmol) in DMF (4 mL) in the 
presence of NaH (60%, 20 mg, 0.502 mmol), as described for 370 (0 °C-ambient temperature, 8 h), gave 
after work up and chromatography (Hexane/EtOAc, 9:1), 378 (69 mg, 0.194 mmol, 77%) as a white solid. 
mp=128-129 oC ; 1H NMR (600 MHz, CDCl3) δ 8.14 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 8.3 Hz, 2H), 7.72 
(d, J = 3.7 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 3.6 Hz, 1H), 5.17 (s, 
1H), 4.92 (s, 1H), 2.36 (s, 3H), 2.10 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 145.7, 142.4, 140.4, 134.7, 
134.4, 130.2, 129.3, 126.9, 126.0, 124.9, 117.1, 115.8, 106.9, 23.5, 21.6; IR (ATR) 1512, 1373, 1161, 
1128, 662 cm-1; 
 
(379). Treatment of 337 (39.8 mg, 0.211 mmol) with TsCl (52.4 mg, 0.275 mmol) in DMF (3 mL) in the 
presence of NaH (60%, 16.9 mg, 0.422 mmol), as described for 370 (0 °C-ambient temperature, 10 h), 
gave after work up and chromatography (Hexane/EtOAc, 8:2) 379 (58.2 mg, 0.170 mmol, 81%) as a 
colorless oil. 1H NMR (600 MHz, CDCl3) δ 7.72-7.70 (m, 3H), 7.60 (d, J = 8.3 Hz, 1H), 7.48 (d, J = 8.3 
Hz, 1H), 7.25 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 3.7 Hz, 1H), 6.70 (dd, J=16.8, 10.8 Hz, 1H), 5.80 (d, J = 
17.2 Hz, 1H), 5.45 (d, J = 11.0 Hz, 1H), 2.36 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 145.3, 137.6, 134.8, 
133.8, 130.8, 130.2, 129.7, 127.2, 127.0, 123.9, 123.6, 121.8, 119.6, 109.4, 21.6; IR (ATR) 1593, 1514, 
1344, 1161, 662 cm-1; 
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(380). Reaction of a solution of 372 (76.4 mg, 0.206 mmol), Pd(dba)2 (7.1 mg, 0.012 mmol), dppp (5.1 
mg, 0.012 mmol), and 1,10-phen (4.5 mg, 0.025 mmol) in DMF (2 mL), as described for 336 (pCO=6 
atm, 120 oC, 24 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3), 380 (55.4 mg, 
0.164 mmol, 79%) as an off white solid. mp=143-144 oC ; 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 
7.94 (s, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.49 (s, 1H), 7.22 (d, J = 0.8 Hz, 1H), 7.08 (d, J = 8.1 Hz, 2H), 6.98 
(s, 1H), 2.33 (s, 3H), 2.28 (d, J = 0.6 Hz, 3H), 2.23 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.2, 135.4, 
135.0, 133.0, 129.5, 126.8, 126.6, 126.3, 122.6, 122.1, 119.6, 111.0, 107.9, 95.9, 21.4, 10.0, 9.8; IR 
(ATR) 3417, 1444, 1353, 1165, 1087 cm-1; 
 
(381). Reaction of a solution of 373 (41.1 mg, 0.111 mmol), Pd(dba)2 (3.8 mg, 0.007 mmol), dppp (2.7 
mg, 0.007 mmol), and 1,10-phen (2.4 mg, 0.013 mmol) in DMF (2 mL), as described for 336 (pCO=6 
atm, 120 oC, 24 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 8:2) 381 (26.4 mg, 
0.078 mmol, 70%) as an off white solid. mp=153oC (dec.) ; 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 
7.88 (s, 1H), 7.59 (d, J = 8.5 Hz, 2H), 7.41 (s, 1H), 7.11 (d, J = 8.0 Hz, 2H), 6.35 (s, 1H), 6.19 (dt, J = 
1.9, 0.9 Hz, 1H), 2.57 (d, J = 1.2 Hz, 3H), 2.44 (d, J = 0.9 Hz, 3H), 2.28 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 144.2, 136.2, 136.1, 136.0, 134.7, 134.0, 129.6, 127.0, 126.1, 124.7, 110.7, 109.0, 99.5, 96.5, 
21.5, 16.1, 13.9; IR (ATR) 3418, 1353, 1165, 1086 cm-1; 
 
(382). Reaction of a solution of 374 (61.2 mg, 0.165 mmol), Pd(dba)2 (6.7 mg, 0.012 mmol), dppp (4.8 
mg, 0.012 mmol), and 1,10-phen (4.2 mg, 0.023 mmol) in DMF (2 mL), as described for 336 (pCO=6 
atm, 120 oC, 24 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 382 (49.4 mg, 
0.146 mmol, 88%) as an off white solid. mp=179-180 oC ; 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 
7.78 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 1.0 Hz, 1H), 7.19 (s, 1H), 7.07 (d, J = 8.2 Hz, 2H), 6.97 
(s, 1H), 2.38 (s, 3H), 2.22 (s, 3H), 2.20 (d, J = 0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 144.1, 135.1, 
134.3, 131.0, 129.5, 129.1, 127.4, 126.6, 123.1, 119.1, 111.5, 103.0, 99.8, 21.4, 9.9, 9.9; IR (ATR) 3436, 
1349, 1166, 734 cm-1; 
 
(383). Reaction of a solution of 375 (58.2 mg, 0.157 mmol), Pd(dba)2 (6.3 mg, 0.011 mmol), dppp (4.5 
mg, 0.011 mmol), and 1,10-phen (4 mg, 0.022 mmol) in DMF (2 mL), as described for 336 (pCO=6 atm, 
120 oC, 25 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 8:2) 383 (40.5 mg, 0.120 
mmol, 76%) as a faint yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.28 (s, 1H), 7.71 (s, 1H), 7.62 (d, J = 
8.0 Hz, 2H), 7.11 (s, 1H), 7.08 (d, J = 8.0 Hz, 2H), 6.31 (s, 1H), 6.28 (s, 1H), 2.61 (s, 3H), 2.41 (s, 3H), 
2.25 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 144.1, 136.7, 136.2, 136.1, 134.2, 133.0, 129.5, 127.3, 126.1, 
125.8, 110.4, 104.7, 100.5, 99.6, 21.4, 16.2, 13.8; IR (ATR) 3436, 1359, 1166 cm-1; 
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(384). Reaction of a solution of 376 (52.5 mg, 0.153 mmol), Pd(dba)2 (5.3 mg, 0.010 mmol), dppp (3.8 
mg, 0.010 mmol), and 1,10-phen (3.3 mg, 0.018 mmol) in DMF (2 mL), as described for 336 (pCO=6 
atm, 120 oC, 25 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3), 384 (42.4 mg, 
0.137 mmol, 89%) as a faint yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 7.87 (d, J = 9.0 Hz, 
1H), 7.72 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 3.6 Hz, 1H), 7.30 (d, J = 9.0 Hz, 1H), 7.18 (t, J = 2.8 Hz, 1H), 
7.11 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 3.4 Hz, 1H), 6.70 – 6.64 (m, 1H), 2.24 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 144.6, 135.3, 132.1, 129.6, 129.5, 126.6, 125.3, 123.9, 123.2, 120.2, 108.7, 108.4, 108.0, 100.8, 
21.4; IR (ATR) 3401, 1348, 1160, 1102, 777 cm-1; 
 
(385). Reaction of a solution of 377 (85.4 mg, 0.230 mmol), Pd(dba)2 (8.0 mg, 0.014 mmol), dppp (5.7 
mg, 0.014 mmol), and 1,10-phen (5.0 mg, 0.028 mmol) in DMF (2.5 mL), as described for 336 (pCO=6 
atm, 120 oC, 26 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 8:2), 385 (60.4 mg, 
0.178 mmol, 77%) as an off white solid. mp=134-135 oC ; 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 9.1 
Hz, 1H), 7.98 (s, 1H), 7.62 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 9.0 Hz, 1H), 7.10 (d, J = 8.2 Hz, 2H), 6.56 (s, 
1H), 6.31 (s, 1H), 2.66 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.2, 136.3, 
136.0, 134.8, 132.5, 131.5, 129.6, 126.0, 121.4, 120.4, 108.9, 108.5, 106.9, 98.7, 21.4, 16.1, 13.7; IR 
(ATR) 3401, 1348, 1160, 1102 cm-1; 
 
(386). Reaction of a solution of 378 (59.9 mg, 0.168 mmol), Pd(dba)2 (4.9 mg, 0.010 mmol), dppp (3.5 
mg, 0.010 mmol), and 1,10-phen (3.1 mg, 0.20 mmol) in DMF (2 mL), as described for 336 (pCO=6 atm, 
120 oC, 26 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 8:2), 386 (47.6 mg, 
0.147 mmol, 87%) as an off white solid. mp=137 oC (dec.); 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 
7.83 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 3.6 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.14 
(d, J = 8.1 Hz, 2H), 6.90 (s, 1H), 6.77 (d, J = 3.5 Hz, 1H), 2.35 (s, 3H), 2.27 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 144.7, 135.1, 131.7, 129.7, 128.5, 126.7, 124.8, 123.7, 119.8, 116.0, 115.9, 112.5, 106.1, 105.3, 
21.4, 9.8; IR (ATR) 3415, 1353, 1165, 1087 cm-1; 
 
(379). Reaction of a solution of 379 (52.7 mg, 0.154 mmol), Pd(dba)2 (5.3 mg, 0.010 mmol), dppp (3.8 
mg, 0.010 mmol), and 1,10-phen (3.3 mg, 0.018 mmol) in DMF (3 mL), as described for 336 (pCO=6 
atm, 120 oC, 36 h), gave, after solvent removal and chromatography (Hexane/EtOAc, 7:3) 379 (37.1 mg, 
0.108 mmol, 70%) as a colorless oil. 
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(379). Reaction of a solution of 379 (31 mg, 0.091 mmol), Pd(OAc)2 (2.1 mg, 0.009 mmol) and 1,10-phen 
(1.7 mg, 0.009 mmol) in DMF (2 mL), as described for 354 (pCO=6 atm, 120 oC, 50 h), gave, after 
solvent removal and chromatography (Hexane/EtOAc, 7:3) 379 (30.2 mg, 0.088 mmol, 82%) as a 
colorless oil. 
 
 
208 
 
References and Footnotes 
1. a) Bao, B.; Sun, Q.; Yao, X.; Hong, J.; Lee, C.-O.; Cho, H. Y.; Jung, J. H. J. Nat. Prod. 2007, 70, 2-
8. b) Jung, J. H.; Shinde, P. B.; Hong, J.; Liu, Y.; Sim, C. J. Biochem. System. Ecol. 2007, 35, 48-
51. c) Bao, B.; Sun, Q.; Yao, X.; Hong, J.; Lee, C. O.; Sim, C. J.; Im, K. S.; Jung, J. H. J. Nat. 
Prod. 2005, 68, 711-715. d) Oh, K.-B.; Mar, W.; Kim, S.; Kim, J.-Y.; Oh, M.-N.; Kim, J.-G.; Shin, 
D.; Sim, C. J.; Shin, J. Bioorg. Med. Chem. Lett. 2005, 15, 4927-2931.  e) Casapullo, A.; Bifulco, 
G.; Bruno, I.; Riccio, R. J. Nat. Prod. 2000, 63, 447-451. f) Gunasekera, S. P.; McCarthy, P. J.; 
Kelly-Borges, M. J. J. Nat. Prod. 1994, 57, 1437-1441. 
2. a) Capon, R. J.; Rooney, F.; Murray, L. M.; Collins, E.; Sim, A. T. R.; Rostas, J. A. P.; Butler, M. 
S.; Carroll, A. R. J. Nat. Prod. 1998, 61, 660-662. b) Wright, A. E.; Pomponi, S. A.; Cross, S. S.; 
McCarthy, P. J. Org. Chem. 1992, 57, 4772-4775. c) Morris, S. A.; Andersen, R. J. Tetrahedron 
1990, 46, 715-720. d) Kohmoto, S.; Kashman, Y.; McConnell, O. J.; Rinehart Jr., K. L.; Wright, A.; 
Koehn, F. J. Org. Chem. 1988, 53, 3116-3118.  
3. a) Shin, J.; Seo, Y.; Cho, K. W.; Rho, J.-R.; Sim, C. J. J. Nat. Prod. 1999, 62, 647-649. b) Morris, 
S. A.; Andersen, R. J. Tetrahedron 1990, 46, 715-720. f) Morris, S. A.; Andersen, R. J. Can. J. 
Chem. 1989, 67, 677-681. c) Tsujii, S.; Rinehart, K. L.; Gunasekera, S. P.; Kashman, Y.; Cross, S. 
S.; Lui, M. S.; Pomponi, S. A.; Diaz, M. C.  J. Org. Chem. 1988, 53, 5446-5453. d) Bartic, K.; 
Braekman, J. C.; Daloze, D.; Stoller, C.; Huysecom, J.; Vandevyver, G.; Ottinger, R. Can. J. Chem. 
1987, 65, 2118-2121. 
4. Sakemi, S.; Sun, H. H. J. Org. Chem. 1991, 56, 4304-4307. 
5. Sato, H.; Tsuda, M.; Watanabe, K.; Kobayashi, J. Tetrahedron 1998, 54, 8687-8690.  
6. For a recent extensive review of indoles isolated from marine organisms, see: Netz, N.; Opatz, T. 
Mar. Drugs 2015, 13, 4814-4914. 
7. Oh, K.-B.; Mar, W.; Kim, S.; Kim, J.-Y.; Lee, T.-H.; Kim, J.-G.; Shin, D.; Sim, C. J.; Shin, J. Biol. 
Pharm. Bull. 2006, 29, 570-573. 
8. Alvarado, S.; Roberts, B. F.; Wright, A. E.; Chakrabarti, D. Antimicrob. Agents Ch. 2013, 57, 2362-
2364. 
9. Zhu, L.-h.; Chen, C.; Wang, H.; Ye, W.-e.; Zhou, G.-x. Chem. Pharm. Bull. 2012, 60, 670-673. 
10. Endo, T.; Tsuda, M.; Fromont, J.; Kobayashi, J. J. Nat. Prod. 2007, 70, 423-424. 
11. Lee, Y.-L.; Lee, D.-G.; Rho, H. S.; Krasokhin, V. B.; Shin, H. J.; Lee, J. S.; Lee, H.-S. J. 
Heterocycl. Chem. 2013, 50, 1400-1404. 
12. Kim, S. H.; Sperry, J. J. Nat. Prod. 2015, 78, 3080-3082. 
209 
 
13. Kim, S. H.; Sperry, J. Tetrahedron Lett. 2015, 56, 5914-5915. 
14. Tasch, B. O. A.; Merkul, E.; Müller, T. J. J. Eur. J. Org. Chem. 2011, 4532-4535. 
15. Mosquera, A.; Riveiros, R.; Sestelo, J. P.; Sarandeses, L. A. Org. Lett. 2008, 10, 3745-3748. 
16. For leading references see: a) Kuethe, J. T.; Davies, I. W. Tetrahedron 2006, 62, 11381-11390. b) 
Clawson Jr., R. W.; Deavers III, R. E.; Akhmedov, N. G.; Söderberg, B. C. G. Tetrahedron 2006, 
62, 10829-10834. c) Akazome, M.; Kondo, T.; Watanabe, Y. J. Org. Chem. 1994, 59, 3375-3380.  
d) Tollari, S.; Cenini, S, Crotti, C.; Gianella, E. J. Mol. Catal.  1994, 87, 203-214. 
17. Kuethe, J. T.; Wong, A.; Davies, I. W. Org. Lett. 2003, 5, 3721-3723. 
18. Scott, T. L.; Söderberg, B. C. G. Tetrahedron 2003, 59, 6323-6332. 
19. Dantale, S. W.; Söderberg, B. C. G. Tetrahedron 2003, 59, 5507-5514. 
20. Scott, T. L.; Yu, X.; Gorunatula, S. P.; Carrero-Martínez, G.; Söderberg, B. C. G. Tetrahedron 
2006, 62, 10835-10842. 
21. Söderberg, B. C.; Chisnell, A. C.; O’Neil, S. N.; Shriver, J. A. J. Org. Chem. 1999, 64, 9731-9734. 
22. Zhang, Y.; Hubbard, J. W.; Akhmedov, N. G.; Petersen, J. L.; Söderberg, B. C. G. J. Org. Chem. 
2015, 80, 4783-4790. 
23. a) Hamze, A.; Le Menez, P.; Provot, O.; Morvan, E.; Brion, J.-D.; Alami, M. Tetrahedron 2012, 66, 
8698-8706. b) Hamze, A.; Veau, D.; Provot, O.; Brion, J.-D.; Alami, M. J. Org. Chem. 2009, 74, 
1337. c) Alami, M.; Liron, F.; Gervais, M.; Peyrat, J.-F.; Brion, J.-D. Angew. Chem., Int. Ed. 2002, 
41, 1578–1580. d) Liron, F.; Le Garrec, P.; Alami, M. Synlett 1999, 246-248. 
24. Barlow, A. J.; Compton, B. J.; Weavers, R. T. J. Org. Chem. 2005, 70, 2470-2475. 
25. For a review, see: Nikishkin, N. I.; Huskens, J.; Verboom, W. Org. Biomolec. Chem. 2013, 11, 
3583-3602. 
26. Pieterse, K.; Lauritsen, A.; Schenning, A. P. H. J.; Vekemans, J. A. J. M.; Meijer, E. W. Chem. Eur. 
J. 2003, 9, 5597-5604. 
27. a) Lanoe, P.-H.; Tong, C. M.; Harrington, R. W.; Probert, M. R.; Clegg, W.; Williams, J. A. G.; 
Kozhevnikov, V. N. Chem. Commun. 2014, 50, 6831-6834. b) Hao, Q.; Yu, S.; Li, S.; Chen, J.; 
Zeng, Y; Yu, T.; Yang, G.; Li, Y. J. Org. Chem. 2014, 79, 459-464. c) Williams, J. D.; Bguyen, S. 
T.; Gu, S.; Ding, X.; Butler, M. M.; Tashjian, T. F.; Opperman, T. J.; Panchal, R. G.; Bavari, S.; 
Peet, N. P.; Moir, D. T.; Bowlin, T. L. Bioorg. Med. Chem. 2013, 21, 7790-7806.  
28. Hasan, K.; Donato, L.; Shen, Y.; Slinker, J. D.; Zysman-Colman, E. Dalton Trans. 2014, 43, 
13672-13682. 
29. Pieterse, K.; Vekemans, J. A. J. M.; Kooijman, H.; Spek, A. L.; Meijer, E. W. Chem. Eur. J. 2000, 
6, 4597-4603. 
210 
 
30. Garg, N. K.; Stolz, B. M. Tetrahedron Lett. 2005, 46, 2423-2426. 
31. Yang, C.-G.; Liu, G.; Jiang, B. J. Org. Chem. 2002, 67, 9392-9396. 
32. For examples, see: a) Yoshida, H.; Shinke, A.; Kawano, Y.; Takai, K. Chem. Commun. 2015, 51, 
10616-10619. b) Jeong, S.; Chen, X.; Harran, P. G. J. Org. Chem. 1998, 63, 8640-8641. 
33. a) Jacqemard, U.; Dias, N.; Lansiaux, A.; Bailly, C.; Loge, C.; Robert, J.-M.; Lozach, O.; Meijer, L. 
Bioorg. Med. Chem. 2008, 16, 4932-4953. b) Krompiec, S.; Krompiec, M.; Ignasiak, H.; 
Lapkowski, M.; Baj, S.; Grabarczyk, D. Catal. Commun. 2007, 8, 1457-1462. c) Liu, C.-M.; Chen, 
B.-H.; Liu, W.-Y.; Wu, X.-L.; Ma, Y.-X. J. Organomet. Chem. 2000, 598, 348-352. 
34. For a review of cine substitution, see: Peng, Y.; Li, W.-D. Z. Eur. J. Org. Chem. 2010, 6703-6718. 
35. Chen, S.-H. Tetrahedron Lett. 1997, 38, 4741-4744. 
36. Tanaka, K.; Kobayashi, T.; Mori, H.; Katsumura, S. J. Org. Chem. 2004, 69, 5906-5925. 
37. Faye, D.; Vybornyi, M.; Boeda, F.; Legoupy, S. Tetrahedron 2013, 69, 5421-5425. 
38. Solberg, J.; Undheim, K. Acta Chem. Scand. 1989, 43, 62–68. 
39. For NMR data for 1-phenyl-1-(2-pyrimidyl)ethene, see: Itoh, M.; Hirano, K.; Satoh, T.; Miura, M. 
Org. Lett. 2014, 16, 2050-2053. 
40. For related double Sonogashira reactions of 2,5-dibromopyridine, see: a) Miguel, D.; Alvarez de 
Cienfuegos, L.; Martin-Lasanta, A.; Morcillo, S. P.; Zotti, L. A.; Leary, E.; Burkle, M.; Asai, Y.; 
Jurado, R.; Cardenas, D. J.; Rubio-Bollinger, G.; Agrait, N.; Cuerva, J. M.; Gonzalez, M. T. J. Am. 
Chem. Soc. 2015, 137, 13818-13826. b) Wang, C.; Jung, G.-Y.; Batsanov, A. S.; Bryce, M. R.; 
Petty, M. C. J. Mat. Chem. 2002, 12, 173-180. 
41. Compound 14 has been described in a patent but only a very cursory 1H NMR was reported. 
Piotrowski, D. W.; Rogers, B. N.; McWhorter, W. W., Jr.; Walker, D. P.; Corbett, J. W.; Groppi, V. 
E., Jr.; Rudmann, D. G. PCT Int. Appl. WO 2003093250 [CAN139:395938]. 
42. The compound is commercially available however it was prepared in two steps from 4-
bromopyrimidine according to: Maji, A.; Hazra, A.; Maiti, D. Org. Lett. 2014, 16, 4524-4527. 
43. Cadogan, J. I. G.; Cameron-Wood, M. Proc. Chem. Soc. 1962, 361. 
44. Sundberg, R. J. J. Org. Chem. 1968, 33, 487-490. 
45. For recent applications of this type of cyclization in total synthesis of indole alkaloids, see: a) 
Zhang, Y.; McArdle, I. W.; Hubbard, J. W.; Akhmedov, N. G.; Söderberg, B. C. G. Tetrahedron 
Lett. 2016, 57, 2865-2867. b) Cummings, M. M.; Clawson, R. W.; Sharma, S. B.; Byerly, R. A.; 
Akhmedov, N. G.; Söderberg, B. C. G. Tetrahedron 2011, 67, 4753-4757. c) Clawson, R. W.; 
Dacko, C. A.; Deavers, R. E.; Akhmedov, N. G.; Söderberg, B. C. G. Tetrahedron 2009, 65, 8786-
8793. 
211 
 
46. Lowinger, T. B.; Chu, J.; Spence, P. L.  Tetrahedron Lett.  1995, 36, 8383-8386. 
47. For reported spectral data see: Hudkins, D. L.; Diebold, J. L.; Marsh, F. D.  J. Org. Chem. 1995, 60, 
6218-6220. 
48. Kumaran, E.; Leong, W. K. Tetrahedron Lett. 2014, 55, 5495-5498. 
49. Arcadi, A.; Bianchi, G.; Marinelli, F. Synthesis 2004, 610-618. 
50. a) Lopez, M. S.; Choy, J. W.; Peters, U.; Sos, M. L.; Morgan, D. O.; Shokat, K. M. J. Am. Chem. 
Soc. 2013, 135, 18135-18159. b) Lin, C-I.; Selvi, S.; Fang, J.-M.; Chou, P.-T.; Lai, C.-H.; Cheng, 
Y.-M. J. Org. Chem. 2007, 72, 3537-3542. 
51. Parvatkar, P. T.; Kadam, H. K.; Parameswaran, P. S.; Tilve, S. G. Asian J. Chem. 2012, 24, 2213-
2215. 
52. Koza, D. J.; Euler, W. B. Heterocycl. Commun. 1999, 5, 399-402. 
53. Bergman, J.; Koch, E.; Pelcman, B. Tetrahedron 1995, 51, 5631-5642. 
54. TMB = 2,4,6-trimethylbenzoate; TMphenanthroline = 3,4,7,8-tetramethylphenanthroline. 
55. Tolari, S.; Cenini, S.; Crotti, C.; Gianelli, E.  J. Mol. Catal.  1994, 87, 203-214. 
56. Davies, I. W.; Smitrovich, J. H.; Qu, C. PCT Int. Appl. 2005, WO 2005000804. 
57. Araki, T.; Manabe, Y.; Fujioka, K.; Yokoe, H.; Kanematsu, M.; Yoshida, M.; Shishido, K. 
Tetrahedon Lett. 2013, 54, 1012-1014. 
58. Ansari, N. H.; Söderberg, B. C. G. Tetrahedron 2016, 72, 4214-4221. 
59. Spectral data for this compound has been reported, see: Berens, U.; Brown, J. M.; Long, J.; Selke, 
R.  Tetrahedron Asymm.  1996, 7, 285-292. 
60. a) Tanaka, J.; Higa, T.; Bernardinelli, G.; Jefford, C. W. Tetrahedron 1989, 45, 7301-7310. b) El-
Gamal, A. A.; Wang, W.-L.; Duh, C.-Y. J. Nat. Prod. 2005, 68, 815-817. c) Kubota, N. K.; 
Iwamoto, H.; Fukuzawa, Y.; Uchio, Y. Hetercycles 2005, 65, 2675-2682. d) Fang, H.-Y.; Chiou, 
S.-F.; Uvarani, C.; Wen, Z.-H.; Hsu, C.-H.; Wu, Y.-C.; Wang, W.-L.; Liaw, C.-C.; Sheu, J.-H. Bull. 
Chem. Soc. Jpn. 2014, 87, 1278-1280. 
61. Su, H.; Yuan, Z. H.; Li, J.; Guo, S. J.; Deng, L. P.; Han, L. J.; Zhu, X. B.; Shi, D. Y. Chin. Chem. 
Lett. 2009, 20, 456-458. 
62. Norton, R. S.; Wells, R. J. J. Am. Chem. Soc. 1982, 104, 3628-3635. 
63. Shi, D. Y.; Han, L. J.; Sun, J.; Li, S.; Wang, S. Y.; Yang, Y. C.; Fan, X.; Shi, J. G. Chinese Chem. 
Lett. 2005, 16, 777-780. 
64. Bertinetti, B. V.; Rodriguez, M. A.; Godeas, A. M.; Cabrera, G. M. J. Antibiot. 2010, 63, 681-683. 
65. Tasch, B. O. A.; Antovic, D.; Merkul, E.; Müller, T. J. J. Eur. J. Org. Chem. 2013, 4564-4569. 
66. Nakhai, A.; Bergman, J. Heterocycles 2014, 88, 309-318. 
212 
 
67. Li, Y.; Wang, W.-H.; Yang, S.-D.; Li, B.-J.; Feng, C.; Shi, Z.-J. Chem. Commun. 2010, 46, 4553-
4555. 
68. Piers, E.; Gladstone, P. L.; Yee, J. G. K.; McEachern, E. J. Tetrahedron 1998, 54, 10609-10626. 
69. Ghosal, S.; Luke, G. P.; Kyler, K. S. J. Org. Chem. 1987, 52, 4296-4298. 
70. Kang, S.-K.; Baik, T.-G.; Jiao, X. H.; Lee, Y.-T. Tetrahedron Lett. 1999, 40, 2383-2384. 
71. Following the procedure: Lo, C.; Kumar, M. P.; Chang, H.; Lush, S.; Liu, R.  J. Org. Chem. 2005, 
70, 10482-10487. 
72. Harrowven, D. C.; Curran, D. P.; Kostiuk, S. L.; Wallis-Guy, I. L.; Whiting, S.; Stenning, K. J.; 
Tang, B.; Packard, E.; Nanson, L. Chem. Commun. 2010, 46, 6335-6337. 
73. For a synthesis of unsymmetrical 3,3’-biindoles, see: Ramesh, C.; Kavala, V.; Kuo, C.-W.; Raju, B. 
R.; Yao, C.-F. Eur. J. Org. Chem. 2010, 3796-3801. 
74. Alford, P. E.; Fu, L.; Kubert, J. K.; Wang, L.; Gribble, G. W. Tetrahedron Lett. 2011, 52, 2642-
2644. 
75. Bocchi, V.; Palla, G. Tetrahedron 1986, 42, 5019-5024. 
76. For a very recent example and references to previously reported reactions, see: Guo, T.; Han, S.-L.; 
Liu, Y.-C.; Liu, Y.; Liu, H.-M. Tetrahedron Lett. 2016, 57, 1097-1099. 
77. a) Racemosine B: Liu, D.-Q.; Mao, S.-C.; Zhang, H.-Y.; Yu, X.-Q.; Feng, M.-T.; Wang, B.; Feng, 
L.-H.; Guo, Y.-W. Fitotherapia. 2013, 91, 15-20. b) Asteropusazole A and B: Russell, F.; 
Harmody, D.; McCarthy, P. J.; Pomponi, S. A.; Wright, A. E. J. Nat. Prod. 2013, 76, 1989-1992. c) 
Ancorinazole: Meragelman, K. M.; West, L. M.; Northcote, P. T.; Pannell, L. K.; McKee, T. C.; 
Boyd, M. R. J. Org. Chem. 2002, 67, 6671-6677. 
78. Tanaka, H.; Murakami, Y.; Torii, S. Bull. Chem. Soc. Jpn. 1989, 62, 4061-4062. 
79. Blanc, A.; Bochet, C. G.  J. Org. Chem. 2003, 68, 1138-1141. 
80. Murray, M. M.; Kaszynski, P.; Kaisaki, D. A.; Chang, W.; Dougherty, D. A.  J. Am. Chem. Soc. 
1994, 116, 8152-8161. 
81. Umeda, R.; Morishita, S.; Nishiyama, Y. Heteroatom Chem. 2011, 22, 571-575. 
82. Hayashi, K.; Choshi, T.; Chikaraishi, K.; Oda, A.; Yoshinaga, R.; Hatae, N.; Ishikura, M.; Hibino, 
S. Tetrahedron 2012, 68, 4274-4279. 
83. a) Bassoli, A.; Cenini, S.; Farina, F.; Orlandi, M.; Rindone, B. J. Mol. Catal. 1994, 89, 121-142. b) 
Tollari, S.; Cenini, S.; Crotti, C.; Gianella, E. J. Mol. Catal. 1994, 87, 203-214. c) Crotti, C.; 
Cenini, S. Bassoli, A.; Rindone, B.; Demartin, F. J. Mol. Catal. 1991, 70, 175-187. 
84. Crotti, C.; Cenini, S.; Rindone, B.; Tollari, S.; Demartin, F. J. Chem. Soc., Chem. Commun. 1986, 
784-786. 
213 
 
85. For a related alkyne hydrostannation cross coupling, see: Hamze, A.; Veau, D.; Provot, O.; Brion, 
J.-D.; Alami, M. J. Org. Chem. 2009, 74, 1337-1340. 
86. Kim, H. S.; Kim, Y. B.; Lee, C. J.; Shin, J. Y.; La, J. G.; Kim, T. H.; Baek, Y. M. Repub. Korean 
Kongkae Taeho Kongbo, KR 2015119653, 2015. [CAN163:649442]. 
87. Kumar, S.; Rathore, V.; Verma, A.; Prasad, C. D.; Kumar, A.; Yadav, A.; Jana, S.; Sattar, M.; 
Meenakshi, Kumar, S. Org. Lett. 2015, 17, 82-85. 
88. Franck, P.; Hostyn, S.; Dajka-Halasz, B.; Polonka-Balint, A.; Monsieurs, K.; Matyus, P.; Maes, B. 
U. W. Tetrahedron 2008, 64, 6030-6037. 
89. Kanaoka, Y.; Itoh, K. Synthesis 1972, 36. 
90. Li, Z.; Wang, W.; Zhang, X.; Hu, C.; Zhang, Wei. Synlett 2013, 24, 73-78. 
91. Li, Y.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. Tetrahedron 2015, 71, 2927-2935. 
92. Clemo, G. R.; Felton, D. G. I. J. Chem. Soc. 1951, 671-677. 
93. One carbon resonance was missing in the spectrum. 
94. Compound 6 is commercially available however, it was prepared for this study according to: 
Hughes, I.; Raphael, R. A. Tetrahedron Lett. 1994, 24, 1441-1444. 
95. Hudkins, D. L.; Diebold, J. L.; Marsh, F. D. J. Org. Chem. 1995, 60, 6218-6220. 
96. Compound 17 is commercially available however, it was prepared for this study according to: 
Coffman, K. C.; Palazzo, T. A.; Hartley, T. P.; Fettinger, J. C.; Tantillo, D. J.; Kurth, M. J. Org. 
Lett. 2013, 15, 2062-2065. 
97. Prepared as described by :Jadhav, A. M.; Bhunia, S.; Liao, H.-Y.; Liu, R. S.; J. Am. Chem. Soc. 
2011, 133, 1769-1771. 
98. Bai, H.; Zhao, X.; Gong, Y.; Zhong, J.; Zhu, Q.; Liu, Z.; Liu, L.; Zhou, Q. PCT Int. Appl. 2012, 
WO 2012058866. 
99. Yamakawa, T.; Ideue, E.; Iwaki, Y.; Sato, A.; Tokuyama, H.; Shimokawa, J.; Fukuyama, T. 
Tetrahedron, 2011, 67, 6547-6560. 
100. The chromatography was performed using silica gel/K2CO3 (10% K2CO3). 
101. Li, Y.; Wang, W.-H.; Yang, S.-D.; Li, B.-J.; Feng, S.; Shi, Z.-J. Chem. Commun. 2010, 46, 4553-              
4555. 
102. Prepared as described by: Cikotiene, I. Eur. J. Org. Chem. 2012, 2012, 2766-2773. 
103. Yamakawa, T.; Ideue, E.; Iwaki, Y.; Sato, A.; Tokuyama, H.; Shimokawa, J.; Fukuyama, T.       
Tetrahedron 2011, 67, 6547-6560. 
104. Prasitpan, N.; Patel, J. N.; De Croos, P. Z.; Stockwell, B. L.; Manavalan, P.; Kar, L.; Johnson, M. 
E.; Currie, B. L. J. Heterocycl. Chem. 1992, 29, 335-341. 
105. Tanaka, H.; Murakami, Y.; Torii, S. Bull. Chem. Soc. Jpn. 1989, 62, 4061-4062. 
214 
 
106. Chen, Y.-L.; Chung, C.-H.; Chen, I.-L.; Chen, P.-S.; Jeng, H.-Y. Bioorg. Med. Chem. 2002, 10, 
2705-2712. 
107. Blanc, A.; Bochet, C. G. J. Org. Chem. 2003, 68, 1138-1141. 
108. For recent syntheses and complete analytical data, see: a) Li, Z.; Wang, W.; Zhang, X.; Hu, C.; 
Zhang, W. Synlett 2013, 24, 73-78. b) Putey, A.; Popowycz, F.; Do, O.-T.; Bernard, P.; Talapatra, 
S. K.; Kozielski, F.; Galamaini, C. M.; Joseph, B. J. Med. Chem. 2009, 52, 5916-5925. 
109. Norton, R. S.; Wells, R. J. J. Am. Chem. Soc. 1982, 104, 3628-3635. 
110. Hodder, A. R.; Capon, R. J. J. Nat. Prod. 1991, 54, 1616-1663. 
111. Su, H.; Yuan, Z. H.; Li, J. Chin. Chem. Lett. 2009, 20, 456-458. 
112. Guo, S.; Su, H.; Li, X.; Zhu, X. Faming Zhuanli Shenqing, CN 103833624, A 20140604, 2014. 
113. Ansari, N. H.; Dacko, C. A.; Akhmedov, N. G.; Björn, C. G. S. J. Org. Chem. 2016, 81, 9337-9349. 
114. Carter, M. D.; Hadden, M.; Weaver, D. F.; Jacobo, S. M. H.; Lu, E. PCT Int. Appl. WO 
2006125324 [CAN146:45396]. 
115. Zhang, P.; Liu, R.; Cook, J. M. Tetrahedron Lett. 1995, 36, 3103-3106. 
116. Suarez-Castillo, O. R.; Sanchez-Zavala, M.; Melendez-Rodrigues, M.; Aquino-Torres, M. S.; 
Morales-Rios, M. S.; Joseph-Nathan, P. Heterocycles 2007, 71, 1539-1551. 
117. Mistry, A. G.; Smith, K.; Bye, M. R. Tetrahedron Lett. 1986, 27, 1051-1054. 
118. Hino, T.; Tonuzka, M.; Nakagawa, M. Tetrahedron 1974, 30, 2123-2133. 
119. Miyake, F. Y.; Yakushijin, K.; Horne, D. A. Org. Lett. 2004, 6, 4249-4251. 
120. Da Settimo, A.; Santerini, V.; Primofore, G.; Biagi, G.; Veneziano, C. Gazz. Chim. Ital. 1977, 107, 
367-372. 
121. Loudon, V. J. D.; Tennant, G. J. Chem. Soc. 1963, 4268-4269. 
122. a) Stacey, G. W.; Ettling, B. V.; Papa, A. J. J. Org. Chem. 1964, 29, 1537-1540. b) McNab, H.;   
Smith, D. M. J. Chem. Soc., Perkin Trans. 1 1973, 1310-1314. c) Machin, J.; Mackie, R. K.; 
McNab, H.; Reed, G. A.; Sagar, A. J. G.; Smith, D. M. J. Chem. Soc., Perkin Trans. 1 1976, 394-
399. 
123. a) Gardiner, J. M.; Loyns, C. R. Synth. Commun. 1995, 25, 819-827. b) Gardiner, J. M.; Loyns, C. 
R.; Schwalbe, C. H.; Barrett, G. C.; Lowe, P. L. Tetrahedron 1995, 51, 4101-4110. c) Gardiner, J. 
M.; Lyons, C. R.; Burke, A.; Khan, A.; Mahmood, N. Bioorg. Med Chem. Lett. 1995, 5, 1251-1254. 
d) Evans, T. M.; Gardiner, J. M.; Mahmood, N.; Smis, M. Bioorg. Med Chem. Lett. 1997, 7, 409-
412. e) Gardiner, J. M.; Procter, Tetrahedron Lett. 2001, 42, 5109, 5111. f) Gardiner, J. M.; Goss, 
A. D.; Majid, T.; Morley, A. D.; Pritchard, R. G.; Warren, J. E. Tetrahedron Lett. 2002, 43, 7707-
7710. g) Gardiner, J. M.; Goss, A. D.; Majid, T.; Morley, A. D. Tetrahedron Lett. 2003, 44, 511-
513. 
215 
 
124. For a cyclization in the absence of an alkylating reagents, see: Popov, I. I.; Kryshtalyuk, O. V. 
Khim. Geterotsilikl. 1991, 997-998. 
125. See for example, Bowser, T. E.; Bartlett, V. J.; Grier, M. C.; Verma, A. K.; Warchol, T.; Levy,S. 
B.; Alekshun, M. N. Bioorg. Med. Chem. Lett. 2007, 17, 5652-5655. 
126. a) Grochowski, E.; Kwastowa, E. J. Chem. Res., Synop. 1978, 300-301. b) Grochowski, E.; 
Stepowska, H. Synthesis 1988, 795-797. 
127. Aguirre, G.; Boiani, M.; Cerecetto, H.; Gerpe, A.; Gonzales, M.; Sainz, Y. F.; Denicola, A. de 
Ortiz, C. O.; Nogal, J. J.; Montero, S.; Escario, J. A. Arch. Pharm. 2004, 337, 259-270. 
128. Commercially available. For spectral data, see: Deiters, E.; Song, B.; Chauvin, A.-S.; Vandevyver, 
C. D. B.; Gumy, F.; Bünzli, J.-C. Chem. Eur. J. 2009, 15, 885-900. 
129. Nazer, M. Z.; Haddadin, M. J.; Petridou, J. P.; Issidorides, C. H. Heterocycles 1977, 6, 541-545. 
130. Nyerges, M.; Viranyi, A.; Zhang, W.; Groundwater, P. W.; Blasko, G.; Toke, L. Tetrahedron 2004, 
60, 9937–9944. 
131. Nyerges, M.; Somfai, B.; Toth, J.; Toke, L.; Dancso, A.; Blasko, G. Synthesis 2005, 2039-2045. 
132. Banini, S. R.; Turner, M. R.; Cummings, M. M.; Söderberg, B. C. G. Tetrahedron 2011, 67, 3603-
3611. 
133. Compound 12 is known but only the 1H NMR was reported. Chen Y. I.; Helberg, K.; Guarino, K.;  
et al. J. Antibiot. 1991, 44, 870-884. 
134. Söderberg, B. C. G.; Wallace, J. M.; Tamariz, J. Org. Lett. 2002, 4, 1339-1342. 
135. NaH (80%) in mineral oil without removal of oil was used in all experiments. The amount of NaH 
shown in each experimental procedure represents the mass of NaH and not the total mass of NaH  
plus mineral oil. 
136.  Ansari, N. H.; Jordan, A. L.; Sderberg, B. C. G. Tetrahedron, 2017, 73, 4811-4821. 
137.  Takahashi, S.; Kanio, H. Chem. Pharm. Bull. 1964, 12, 282-291. 
138. Echavarren, A, M.; Stille, J. K. J. Am. Chem. Soc. 1987, 109, 5478-5486. 
139. For the same substrate and selectivity, see: Saa, J. M.; Martorell, G. J. Org. Chem. 1993,      58, 
1963-1966.  
140. For iodo-selective Kosugi-Migita-Stille reactions, see also: a) DeBoos, G. A.; Fullbrook, J. J.; 
Percy, J. M. Org. Lett. 2001, 3, 2859-2861. b) Takayuki, D.; Inoue, H.; Tokita, M.; Watanabe, J.; 
Takahashi, T. J. Comb. Chem. 2008, 10, 135-141. 
141. This catalyst system was used as a convenient substitute for 1.5% Pd2(dba)3-3.0% P(t-Bu)3, since 
Pd2(dba)3 and Pd(P(t-Bu)3)2 are more easily handled and stored. 
142. Littke, A. F.; Schwartz, L.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 6343-6348. 
216 
 
143. For additional examples of the C-Cl vs C-OTf selectivity in Suzuki-Miyaura and Kosugi-Migita-
Stille reactions, see: a) Littke, A. F.; Dai, C.; Fu, G. C. J. Am. Chem. Soc. 2000, 122, 4020-4028. b) 
Proutiere, F.; Schoenebeck, F. Angew. Chem. In. Ed. 2011, 50, 8192-8195. 
144. Jutand, A.; Mosleh, A. Organometallics 1995, 14, 1810-18-17.  
145. For the same conclusion, see: Casado, A. L.; Espinet, P.; Gallego, A. M.  J. Am. Chem. Soc. 2000, 
122, 11771-11782. 
146. Verbeeck, S.; Meyers, C.; Franck, P.; Jutand, A.; Maes, M. U. W. Chem. Eur. J. 2010, 16, 12831-
12837. 
147. Casado, A. L.; Espinet, P. J. Am. Chem. Soc. 1998, 120, 8978-8985. 
148. Echavarren, A, M.; Stille, J. K. J. Am. Chem. Soc. 1988, 110, 1557-1565. 
149. Related C-OTf specific carbonylations of 1 and similar compounds containing both a C-OTf and a 
C-Br bond have been reported. a) Dolle, R. E.; Schmidt, S. J.; Kruse, L. I. J. Chem. Soc., Chem. 
Commun. 1987, 904-905. b) Cacchi, S.; Ciattini, P. G.; Morera, E.; Ortar, G. Tetrahedron Lett. 
1986, 27, 3931-3934. c) Holt, D. A.; Levy, M. A.; Ladd, D. L.; Oh, H.-J.; Erb, J. M.; Heaslip, J. I.; 
Brandt, M.; Metcalf, B. W. J. Med. Chem. 1990, 33, 937-942. d) Brennfuehrer, A.; Neumann, H.; 
Beller, M. Synlett 2007, 2537-2540. 
150. a) Chen, S.; Williams, R. M. Tetrahedron 2006, 62, 11572-11579. b) Huang, C.-W.; 
Shanmugasundaram, M.; Chang, H.-M.; Cheng, C.-H. Tetrahedron 2003, 59, 3635-3641. c) 
Takemura, S.; Hirayama, A.; Tokunaga, J.; Kawamura, F.; Inigaki, K.; Hashimoto, K.; Nakata, M. 
Tetrahedron Lett. 1999, 40, 7501-7505. 
151. It has been shown that an increase in temperature from ambient to 70 oC resulted in erosion of C-
OTf versus C-Br selectivity in Suzuki couplings. Wang, B., Sun, H.-X.; Sun, Z.-H. Eur. J. Org. 
Chem. 2009, 3688-3692. 
152. Espino, G.; Kurbangalieva, A.; Brown, J. M. Chem. Commun. 2007, 1742-1744. 
153. Molander, G. A.; Petrillo, D. E.; Landzberg, N. R.; Rohanna, J. C.; Biolatto, B. Synlett 2005, 1763-
1766.  
154. Hassan, Z.; Hussein, M.; Villinger, A.; Langer, P. Tetrahedron 2012, 68, 6305-6313. 
155. Fu, J. M.; Snieckus, V. Tetrahedron Lett. 1990, 31, 1665-1668. 
156. Eleya, N.; Mahal, A.; Hein, M.; Villinger, A.; Langer, P. Adv. Synth. Catal. 2011, 353, 2761-2774. 
157. Abid, O.; Ibad, M. F.; Nawaz, M.; Ali, A.; Sher, M.; Rama, N. H.; Villinger, A.; Langer, P. 
Tetrahedron Lett. 2010, 51, 1541. 
158. Nawaz, M.; Farooq Ibad, M.; Obaid-Ur-Rahman, A.; Khera, R. A.; Villinger, A.; Langer, P. Synlett. 
2010, 150. 
159. Oh-e, T.; Miyaura, N.; Suzuki, A. J. Org. Chem. 1993, 58, 2201-2208. 
217 
 
160. Finke, A. D.; Elleby, E. C.; Boyd, M. J.; Weissman, H.; Moore, J. S. J. Org. Chem. 2009, 74, 8897-
8900. 
161. Mio, M. J.; Kopel, L. C.; Braun, J. B.; Gadzikwa, T. L.; Hull, K. L.; Brisbois, R. G.; Markworth, C. 
J.; Grieco, P. A. Org. Lett. 2002, 4, 3199-3202. 
162. Kamikawa, T.; Hayashi, T. J. Org. Chem. 1998, 63, 8922-8925. 
163. Fujita, T.; Ichitsuka, T.; Fuchibe, K.; Ichiwara, J. Chem. Lett. 2011, 40, 986-988. 
164. Herbert, J. M.; Kohler, A. D.; Le Strat, F.; Whitehead, D. J. Label. Compd. Radiopharm. 2007, 50, 
440-441. 
165. Kamikawa, T.; Hayashi, T. Tetrahedron Lett. 1997, 38, 7087-7090. 
166. Jutand, A.; Mosleh, A. Organometallics 1995, 14, 1810-18-17. 
167. Dong, Z.-B.; Manolikakes, G.; Shi, L.; Knochel, P.; Maye, H. Chem. Eur. J. 2010, 16, 248-253. 
168. Kim, Y. M.; Yu, S. J. Am. Chem. Soc. 2003, 125, 1696-1697. 
169. Bahmanyar, S.; Borer, B. C.; Kim, Y. M.; Kurtz, D. M.; Yu, S. Org. Lett. 2005, 7, 1011-1014. 
170. Fürstner, A.; Ackerstaff, J. Chem. Commun. 2008, 2870-2872. 
171. Tada, A.; Tokoro, Y.; Fukuzawa, S.-i. J. Org. Chem. 2014, 79, 7905-7909. 
172. Xiaoquing, S.; Hyde, A. M.; Buckwald, S. L. J. Am. Chem. Soc. 2010, 132, 14076-14078. 
173. We were unable to obtain a HRMS of this compound. 
174. Li, D.; Zhao, B.; Sim, S.; Li, T.; Liu, A.; Liu, L. F.; LaVoie, E. J. Bioorg. Med. Chem. 2003, 11, 
521-528. 
175. Hodgson, H. H.; Moore, F. H. J. Chem. Soc. 1926, 155-161. 
176. Habibi, D.; Zolfigol, M. A.; Shiri, M.; Sedaghat, A. S. Afr. J. Chem., 2006, 59, 93-96. 
177. Lee, Y.; Kelly, M. J. Tet. Lett. 2006, 47, 4897-4901. 
178. Ghorbani-Choghamarani, A.; Nikoorazm, M.; Goudarziafshar, H.; Naserifar, Z.; Zamani, P. 
Chinese. J. Chem. 2011, 29, 731-734. 
179. Suresh, P.; Annalakshmi, S.; Pitchumani, K. Tetrahedron 2007, 63, 4959-4967. 
180. Hu, J.; Hirao, H.; Li, Y.; Zhou, J. Angew. Chem. Int. Ed. 2013, 52, 8676-8680.  
181. Matsumura, K.; Shimizu, H.; Saito, T.; Kumobayashi, H. Adv. Synth. Catal. 2003, 345, 180-184. 
182. Commercially available. 
183. Krolski, M. E.; Renaldo, A. F.; Rudisill, D. E.; Stille, J. K. J. Org. Chem. 1988, 53, 1170-1176. 
184. Rudisill, D.; Stille, J. K. J. Org. Chem. 1989, 54, 5856-5866. 
185. Eloy, N.; Pasquinet, E.; Grech, E.; David-quillot, F.; Besnard, O.; Poullain, D. Synthesis 2008, 
1805-1807. 
186. Jarkas, N.; McConathy, J.; Voll, R. J.; Goodman, M. M. J. Med. Chem. 2005, 48, 4254-4265. 
218 
 
187. Harrington, P. J.; Hegedus, L. S. J. Org. Chem., 1984, 49, 2657-2662. 
188. Oda, N.; Yoshida, Y.: Nagai, S.; Ueda, T.; Sakakibara, J. Chem. Pharm. Bull. 1987, 35, 1796-1802. 
189. Rottaelander, M.: Palmer, N.; Knochel, P. Synlett 1996, 573-575. 
190. The compound has been prepared previously but no analytical data were reported. Murugesan, N.; 
Tellew, J. E.; Macor, J. E.; Gu, Z. U.S. Pat Appl. (2002) US 20020143024. 
191. Dai, M.; Wang, Z.; Danishefsky, S. J. Tetrahedron Lett. 2008, 49, 6613-6616. 
192. Grigg, R. D.; Van Hoveln, R.; Schomaker, J. M. J. Am. Chem. Soc. 2012, 134, 16131-16134. 
193. a) Samsoniya, S. A.; Trapaidze, M. V.; Targamadze, N. L; Chikvaidze, I. S.; Suvorov, R. R.; 
Ershova, N. N.; Chernov Soobshch. Akad. Nauk Gruz. SSR, 1980, 337, 100. b) Samsoniya, S. A.; 
Medvedev, B. A.; Kadzhrishvili, D. O.; Tabidze, D. M.; Mashkovskii, M. D.; Suvorov, N. N. 
Khim.-Farm. Zh. 1982, 1335. c) Samsoniya, S. A.; Lomtatidze, Z. S.; Dolidze, S. V.; Suvorov, N. 
N. Khim.-Farm. Zh. 1984, 1452. 
194. Lee, S. M.; Li, X. F.; Jiang, H.; Cheng, J. G.; Seong, S.; Choi, H. D.; Son, B. W. Tetrahedron Lett. 
2003, 44, 7707-7710. 
195. Wang, C.; Sperry, J. Org. Lett. 2011, 13, 6444-6447. 
196. Yudina, L. N.; Bergman, J. Tetrahedron, 2003, 59, 1265-1275. 
197. Boudreault, P-L. T.; Wakim S.; Bloun, N.; Simard, M.; Tassier, C.; Tao, Y.; Leclerc, M. J. Am. 
Chem. Soc. 2007, 129, 9125-9136. 
198. Wu, Y.; Li, Y.; Gardner, G.; Ong, B. S. J. Am. Chem. Soc. 2005, 127, 614-618. 
199. a) Giuliano, R.; Leonardi, G. Ric. Sci. 1957, 27, 1843. b) Samsoniya, S. A.; Targamadze, N. L.; 
Tret’yakova, L. G.; Efimova, T. K.; Turchin, K. G.; Gverdtsiteli, I. M.; Suvorov, N. N. Khim. 
Geterotskl. Soedin. 1977, 938. c) Ruggli, P.; Petitjean, C. Helv. Chim. Acta 1936, 19, 928. d) Katti, 
H. A.; Siddappa, S. Ind. J. Chem. 1983, 228, 1205. 
200. Baird, D. B.; Baxter, V.; Cameron, D. W.; Phillips, W. R. J. Chem. Soc. Perkin Trans. 1 1973, 832. 
201. Ruggli, P.; Straub, O. Helv. Chim Acta 1936, 19, 326. 
202. Ruggli, P.; Straub, O. Helv. Chim. Acta 1938, 21, 1084. 
203. Berlin, A.; Bradamante, S.; Ferraccioli, R.; Pagani, G. A.; Sannicolo, F. J. Chem. Soc., Chem. 
Commun. 1987, 1176. 
204. Chunchatprasert, L.; Shannon, P. V. R. J. Chem. Soc., Perkin Trans. 1 1996, 1787-1795. 
205. Samsoniya, S. A.; Kadzhrishvili, D. O.; Chikvaidze, I. S. Pharm. Chem. J. 2011, 45, 22-25. 
206. Samsoniya, S. A.; Kadzhrishvili, D. O.; Chikvaidze, I. S.; Targamadze, N. L. Heterocycl. Compd. 
2010, 99-118. 
207. Yoshikai, N.; Wei, Y. U.S. Pat. Appl. (2015), US 20150005494 A1 20150101. 
208. Suzuki, Y.; Ohta, Y.; Oishi, S.; Fujii, N.; Ohno, H. J. Org. Chem. 2009, 74, 4246-4251. 
219 
 
209. Clentsmith, G. K. B.; Field, L. D.; Messerle, B. A.; Shasha, A.; Turner, P. Tetrahedron Lett. 2009, 
50, 1469-1471. 
210. Prepared from 1,4-dibromobenzene according to: Sunde, C. J.; Johnson, G.; Kade, C. F. J. Org. 
Chem. 1939, 4, 548-554. 
211. Prepared from 4-amino-3-nitrophenol according to: Gim, H. J.; Li, H.; Eun, L.; Ryu, J.-H.; Jeon, R. 
Bioorg. Med. Chem. Lett. 2013, 23, 513-517. 
212. Prepared from 3-nitrophenol according to: Smith, C. J.; Ali, A.; Chen, L.; Hammond, M. L.; 
Anderson, M. S.; Chen, Y.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; 
Wright, S. D.; Sinclair, P. J. Bioorg. Med. Chem. Lett. 2010, 20, 346-349. 
213. Olah, G. A.; Wang, Q.; Sandford, G.; Prakash, G. K. S. J. Org. Chem. 1993, 58, 3194-3195. 
214. Prepared from 3-iodophenol according to: Banwell, M. G.; Jones, M. T.; Loong, D. T. J.; Lupton, 
D. W.; Pinkerton, D. M.; Ray, J. K.; Willis, A. C. Tetrahedron 2010, 66, 9252-9262. 
215. Hodgson, H. H.; Moore, F. H. J. Chem. Soc. 1927, 630-635. 
216. Prepared according to: Kawakami, T.; Suzuki, H. Tetrahedron Lett. 2000, 41, 7093-7096. 
217. Mundla, S. R. Tetrahedron Lett. 2000, 41, 6319-6321. 
218. Previously prepared by iodination of 2,5-dinitrophenol: Hajipour, A. R.; Adibi, H. J. Chem. Res. 
2004, 4, 294-295 
 
 
220 
 
 
 
Figure 1.2 1H and 13C NMR of compound 2 
BnO
NO2
TMS
2
BnO
NO2
TMS
2
221 
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Figure 1.5 1H and 13C NMR of compound 6 
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Figure 1.6 1H and 13C NMR of compound 7 
225 
 
 
 
Figure 1.7 1H and 13C NMR of compound 8 
N
N
N
N
H
H
BnO
BnO
8
N
N
N
N
H
H
BnO
BnO
8
226 
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Figure 1.13 1H and 13C NMR of scalaridine A 
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Figure 1.17 1H and 13C NMR of compound 19 
N N
19
N N
19
236 
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 Figure 1.21 1H and 13C NMR of hyrtinadine A 
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Figure 1.25 1H and 13C NMR of hyrtinadine B 
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Figure 2.2 1H and 13C NMR of compound 28 
245 
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Figure 2.17 1H and 13C NMR of compound 49 
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Figure 2.18 1H and 13C NMR of compound 50 
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Figure 2.19 1H and 13C NMR of compound 51 
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Figure 2.20 1H and 13C NMR of compound 52 
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Figure 2.22 1H and 13C NMR of compound 54 
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Figure 2.24 1H and 13C NMR of compound 56 
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Figure 2.25 1H and 13C NMR of compound 57 
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Figure 2.28 1H and 13C NMR of compound 60 
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Figure 2.29 1H and 13C NMR of compound 62 
 
272 
 
 
 
Figure 2.30 1H and 13C NMR of compound 63 
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Figure 2.31 1H and 13C NMR of compound 64 
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Figure 2.32 1H and 13C NMR of compound 66 
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Figure 2.33 1H and 13C NMR of compound 67 
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Figure 2.34 1H and 13C NMR of compound 68 
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Figure 2.35 1H and 13C NMR of compound 69 
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Figure 2.35 1H and 13C NMR of compound 71 
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Figure 2.37 1H and 13C NMR of compound 72 
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Figure 2.38 1H and 13C NMR of compound 73 
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Figure 2.39 1H and 13C NMR of compound 74 
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Figure 2.40 1H and 13C NMR of compound 75 
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 Figure 2.41 1H and 13C NMR of compound 76 
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Figure 2.42 1H and 13C NMR of compound 77 
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Figure 2.43 1H and 13C NMR of compound 78 
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Figure 2.44 1H and 13C NMR of compound 81 
287 
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Figure 3.13 1H and 13C NMR of compound 121 
314 
 
 
 
Figure 4.1 
1
H and 
13
C NMR of compound 124 
315 
 
 
 
Figure 4.2
 1
H and 
13
C NMR of compound 125 
316 
 
 
 
Figure 4.3 
1
H and 
13
C NMR of compound 125 
317 
 
 
 
Figure 4.4 
1
H and 
13
C NMR of compound 128 
318 
 
 
 
Figure 4.5 
1
H and 
13
C NMR of compound 129 
319 
 
 
 
Figure 4.6 
1
H and 
13
C NMR of compound 130 
320 
 
 
 
Figure 4.7 
1
H and 
13
C NMR of compound 132 
321 
 
 
 
Figure 4.8 
1
H and 
13
C NMR of compound 133 
322 
 
 
 
Figure 4.9 
1
H and 
13
C NMR of compound 134 
323 
 
 
 
Figure 4.10 
1
H and 
13
C NMR of compound 135 
324 
 
  
 
Figure 4.11 
1
H and 
13
C NMR of compound 136 
325 
 
 
 
Figure 4.12 
1
H and 
13
C NMR of compound 137 
326 
 
  
 
Figure 4.13 
1
H and 
13
C NMR of compound 139 
327 
 
 
 
Figure 4.14 
1
H and 
13
C NMR of compound 140 
328 
 
 
 
Figure 4.15 
1
H and 
13
C NMR of compound 141 
329 
 
  
 
Figure 4.16 
1
H and 
13
C NMR of compound 143 
330 
 
 
 
Figure 4.17 
1
H and 
13
C NMR of compound 145 
331 
 
 
 
Figure 4.18 
1
H and 
13
C NMR of compound 146 
332 
 
  
 
Figure 4.19 
1
H and 
13
C NMR of compound 148 
333 
 
 
 
Figure 4.20 
1
H and 
13
C NMR of compound 149 
334 
 
 
 
Figure 4.21 
1
H and 
13
C NMR of compound 150 
335 
 
  
 
Figure 4.22 
1
H and 
13
C NMR of compound 151 
336 
 
 
 
Figure 4.23 
1
H and 
13
C NMR of compound 152 
337 
 
 
 
Figure 4.24 
1
H and 
13
C NMR of compound 153 
338 
 
 
 
Figure 4.25 
1
H and 
13
C NMR of compound 154 
339 
 
 
 
Figure 4.26 
1
H and 
13
C NMR of compound 155 
340 
 
 
 
Figure 4.27 
1
H and 
13
C NMR of compound 156 
341 
 
 
 
Figure 4.28 
1
H and 
13
C NMR of compound 158 
342 
 
 
 
Figure 4.29 
1
H and 
13
C NMR of compound 159 
 
343 
 
 
 
Figure 4.30 
1
H and 
13
C NMR of compound 160 
344 
 
 
 
Figure 4.31 
1
H and 
13
C NMR of compound 161 
345 
 
 
 
Figure 4.32 
1
H and 
13
C NMR of compound 162 
346 
 
  
 
Figure 4.33 
1
H and 
13
C NMR of compound 163 
347 
 
 
 
Figure 4.34 
1
H and 
13
C NMR of compound 164 
348 
 
 
 
Figure 4.35 
1
H and 
13
C NMR of compound 165 
349 
 
 
 
Figure 4.36 
1
H and 
13
C NMR of compound 166 
350 
 
 
 
Figure 4.37 
1
H and 
13
C NMR of compound 167 
351 
 
 
 
Figure 4.38 
1
H and 
13
C NMR of compound 169 
352 
 
 
 
Figure 4.39 
1
H and 
13
C NMR of compound 171 
353 
 
 
 
Figure 4.40 
1
H and 
13
C NMR of compound 172 
354 
 
 
 
Figure 4.41 
1
H and 
13
C NMR of compound 173 
355 
 
 
Figure 4.42 
1
H and 
13
C NMR of compound 174 
 
356 
 
 
 
Figure 4.43 
1
H and 
13
C NMR of compound 175 
357 
 
  
 
Figure 4.44 
1
H and 
13
C NMR of compound 176 
358 
 
 
 
Figure 4.45 
1
H and 
13
C NMR of compound 177 
359 
 
 
 
Figure 4.46 
1
H and 
13
C NMR of compound 178 
360 
 
 
 
Figure 4.47 
1
H and 
13
C NMR of compound 179 
361 
 
 
 
Figure 4.48 
1
H and 
13
C NMR of compound 180 
362 
 
 
 
Figure 4.49 
1
H and 
13
C NMR of compound 181 
363 
 
 
 
Figure 4.50 
1
H and 
13
C NMR of compound 182 
364 
 
  
 
Figure 4.51 
1
H and 
13
C NMR of 4-carbomethoxy-N-methyl-N-(2-methyl-1-propen-1-yl)-2-nitroaniline 
MeO2C NO2
N
MeO2C NO2
N
365 
 
 
 
Figure 4.52 
1
H and 
13
C NMR of 2,4-dinitro-N-methyl-N-(2-methyl-1-propen-1-yl)aniline 
N
O2N NO2
N
O2N NO2
366 
 
 
 
Figure 4.53 
1
H and 
13
C NMR of 5-chloro-N-(2-methyl-1-propen-1-yl)-2-nitroaniline 
Cl N
NO2
Cl N
NO2
367 
 
 
 
Figure 5.1 
1
H and 
13
C NMR of compound 190 
368 
 
 
Figure 5.2 
1
H and 
13
C NMR of compound 191 
369 
 
 
 
Figure 5.3 
1
H and 
13
C NMR of compound 192 
370 
 
 
 
Figure 5.4 
1
H and 
13
C NMR of compound 193 
371 
 
 
 
Figure 5.5 
1
H and 
13
C NMR of compound 195 
372 
 
 
 
Figure 5.6 
1
H and 
13
C NMR of compound 196 
373 
 
 
 
Figure 5.7 
1
H and 
13
C NMR of compound 197 
374 
 
 
 
Figure 5.8 
1
H and 
13
C NMR of compound 198 
375 
 
 
 
Figure 5.9 
1
H and 
13
C NMR of compound 199 
376 
 
 
 
Figure 5.10 
1
H and 
13
C NMR of compound 200 
377 
 
 
 
Figure 5.11 
1
H and 
13
C NMR of compound 201 
378 
 
Figure 6.2 
1
H of compound 204 
TfO
O2N
Br
NO2
204
379 
 
 
 
Figure 6.3 
13
C and 
19
F NMR of compound 204 
TfO
O2N
Br
NO2
204
TfO
O2N
Br
NO2
204
380 
 
 
Figure 6.4 
1
H NMR of compound 205 
205
OTf
NO2O2N
381 
 
 
 
Figure 6.5 
13
C and 
19
F NMR of compound 205 
205
OTf
NO2O2N
205
OTf
NO2O2N
382 
 
 
 
Figure 6.6 
1
H and 
13
C NMR of compound 211 
TfO
211
TfO
211
383 
 
 
 
Figure 6.7 
1
H and 
13
C NMR of compound 215 
215
TfO
Br
NO2
215
TfO
Br
NO2
384 
 
 
Figure 6.8 
1
H of compound 216 
216
NO2
TfO Br
385 
 
 
 
Figure 6.9 
13
C and 
19
F NMR of compound 216 
216
NO2
TfO Br
216
NO2
TfO Br
386 
 
 
Figure 6.10 
1
H of compound 217 
217
NO2
TfO
Br
387 
 
 
 
Figure 6.11 
13
C and 
19
F NMR of compound 217 
217
NO2
TfO
Br
217
NO2
TfO
Br
388 
 
 
 
Figure 6.12 
1
H and 
13
C NMR of compound 219 
O2N Br
OTf
219
O2N Br
OTf
219
389 
 
 
 
Figure 6.13 
1
H and 
13
C NMR of compound 222 
222
O2N
OTf
Br
222
O2N
OTf
Br
390 
 
 
 
Figure 6.14 
1
H and 
13
C NMR of compound 224 
224
Br
NO2
224
Br
NO2
391 
 
 
 
Figure 6.15 
1
H and 
13
C NMR of compound 225 
225
NO2
225
NO2
392 
 
 
 
Figure 6.16 
1
H and 
13
C NMR of compound 226 
226
OTf
NO2
226
OTf
NO2
393 
 
 
 
Figure 6.17 
1
H and 
13
C NMR of compound 227 
227
NO2
227
NO2
394 
 
 
Figure 6.18 
1
H of a mixture of compounds 226 and 228 
 
226
OTf
NO2
Br
NO2
228
+
395 
 
 
 
Figure 6.19 
1
H and 
13
C NMR of compound 229 
OTf
NO2
229
OTf
NO2
229
396 
 
 
 
Figure 6.20 
1
H and 
13
C NMR of compound 232 
NO2
232
OTf
NO2
232
OTf
397 
 
 
 
Figure 6.21 
1
H and 
13
C NMR of compound 233 
NO2
233
Br
NO2
233
Br
398 
 
 
 
Figure 6.22 
1
H and 
13
C NMR of compound 234 
234
NO2
234
NO2
399 
 
 
 
Figure 6.23 
1
H and 
13
C NMR of compound 235 
235
NO2
OTf
235
NO2
OTf
400 
 
 
 
Figure 6.24 
1
H and 
13
C NMR of compound 237 
237
TfO
NO2
237
TfO
NO2
401 
 
 
 
Figure 6.25 
1
H and 
13
C NMR of compound 238 
238
Br
NO2
238
Br
NO2
402 
 
 
 
Figure 6.26 
1
H and 
13
C NMR of compound 239 
239
NO2TfO
239
NO2TfO
403 
 
 
 
Figure 6.27 
1
H and 
13
C NMR of compound 240 
240
NO2Br
240
NO2Br
404 
 
 
 
Figure 6.28 
1
H and 
13
C NMR of compound 241 
241
OTf
NO2
241
OTf
NO2
405 
 
 
 
Figure 6.29 
1
H and 
13
C NMR of compound 242 
242
Br
NO2
242
Br
NO2
406 
 
 
 
Figure 6.30 
1
H and 
13
C NMR of compound 243 
243
NO2
OTf
243
NO2
OTf
407 
 
 
 
Figure 6.31 
1
H and 
13
C NMR of compound 245 
245
NO2
OTf
245
NO2
OTf
408 
 
 
 
Figure 6.32 
1
H and 
13
C NMR of compound 246 
Br
O2N
246
Br
O2N
246
409 
 
 
 
Figure 6.33 
1
H and 
13
C NMR of compound 249 
249
I
NO2
249
I
NO2
410 
 
 
 
Figure 6.34 
1
H and 
13
C NMR of compound 253 
OTf
O
Br
253
OTf
O
Br
253
411 
 
 
 
Figure 6.35 
1
H and 
13
C NMR of compound 254 
254
TfO
O
254
TfO
O
412 
 
 
 
Figure 6.36 
1
H and 
13
C NMR of compound 255 
255
Br
O
255
Br
O
413 
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Figure 7.103 1H and 13C NMR of compound 363 
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Figure 7.107 1H and 13C NMR of compound 368 
N
Ac
O2N
368
N
Ac
O2N
368
519 
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